,nct_id,primaryOutcomes,secondaryOutcomes,otherOutcomes,startDate,status,study_type,phases
0,NCT00759109,Number of Participants With the Development of Hepatocellular Carcinoma (HCC),Change in the Proliferating Cell Nuclear Antigen Labeling Index (PCNA-LI),Proliferating Cell Nuclear Antigen Labeling Index (PCNA-LI) at Baseline,2002-03,COMPLETED,INTERVENTIONAL,['PHASE3']
1,NCT05626309,1-year disease-free survival rate,Percentage of Participants With Adverse Events,,2022-10-01,RECRUITING,INTERVENTIONAL,['NA']
2,NCT04249739,ORR (objective response rate) per RECIST 1.1,Genomic analysis,,2020-09-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3,NCT03789162,Blood-based biomarkers associated with genetic and epigenetic alterations,,,2018-12-20,RECRUITING,OBSERVATIONAL,['NA']
4,NCT02017509,Correlation of the number of infiltrating leukocytes within a biopsy sample with pathologic response,,,2014-01-24,COMPLETED,OBSERVATIONAL,['NA']
5,NCT03110068,Presence of microvascular invasion,,,2017-04-10,UNKNOWN,OBSERVATIONAL,['NA']
6,NCT04731428,Use of analgesic (See Table 1)(postoperative 3rd day),Postoperative serum cortisol levels (3rd. assessment),,2018-03-15,COMPLETED,INTERVENTIONAL,['NA']
7,NCT02270554,Incidence of pancreatic fistula grade B/C,Incidence of pancreatic fistula stratified based on thickness of pancreas parenchyma,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2']
8,NCT00066430,,,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE1']
9,NCT03199989,3-year disease free survival,Major adverse events,,2017-06-01,RECRUITING,INTERVENTIONAL,['PHASE3']
10,NCT00359333,Tumor response,Time to tumor progression Overall survival Quality of life,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE2']
11,NCT01479465,Progression Free Survival (PFS),Objective Response Rate (ORR),,2011-12,TERMINATED,INTERVENTIONAL,['PHASE2']
12,NCT03785743,5-year overall survival,intraoperative indicators,,2019-03-01,RECRUITING,INTERVENTIONAL,['NA']
13,NCT05640726,progression free survival,objective response rate,,2023-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
14,NCT04685525,PRO-CTCAE questionnaire scores,,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
15,NCT03575806,Recurrence-free Survival (RFS) Time,Overall Survival (OS) Rate at 24 Months,,2017-01-09,COMPLETED,INTERVENTIONAL,['PHASE2']
16,NCT02188901,False referral rate of HCC,,,2014-10-15,COMPLETED,INTERVENTIONAL,['NA']
17,NCT00000764,,,,na,COMPLETED,INTERVENTIONAL,['PHASE1']
18,NCT05095714,Incremental cost / QALY ratio,Compliance,,2021-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
19,NCT05534087,3-year disease-free survival rate,EORTC QLQ-C30 scale,,2022-12-15,RECRUITING,INTERVENTIONAL,['PHASE3']
20,NCT00072748,,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
21,NCT03620643,Percentage of Basket Cohort Participants With Objective Response Assessed Using RECIST v1.1,Assessment of overall survival in each cohort,,2019-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
22,NCT04384601,Total Percentage of Patients With Pathological Complete Tumor Regression (TRG1a) and Sub-total Tumor Regression (TRG1b) in the Primary Tumour,Disease free survival (DFS),,2021-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
23,NCT04455932,HCC detection with US surveillance versus aNC-MRI surveillance,,,2022-01,RECRUITING,INTERVENTIONAL,['NA']
24,NCT00313872,Second progress-free survival,"Toxicity, overall survival",,2003-05,COMPLETED,INTERVENTIONAL,['PHASE3']
25,NCT03992664,Through a randomized feasibility clinical trial to investigate the effectiveness of an educational intervention in conjunction with routine management of rash in patients receiving EGFRI therapy.,Assessing the quality of life in relation to the rash through the QLQI questionnaire.,,2019-01-01,UNKNOWN,INTERVENTIONAL,['NA']
26,NCT04770896,Overall Survival (OS),Serum Concentration of Atezolizumab,,2021-04-26,RECRUITING,INTERVENTIONAL,['PHASE3']
27,NCT00593723,The study will evaluate the feasibility of using helical tomotherapy to deliver IMRT in patients with unresectable esophagus cancer.,Evaluate overall survival rates,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE1']
28,NCT03568630,"Result of MMTT which may indicate type 3c diabetes, which may be a risk factor for pancreas cancer.",,,2018-07-26,RECRUITING,OBSERVATIONAL,['NA']
29,NCT00989469,disease control,overall survival,,2009-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
30,NCT01627080,Evaluation of Cardiac Biomarker Elevation with Radiation Therapy,Incidence of Adverse Cardiac Outcomes,,2014-04,WITHDRAWN,OBSERVATIONAL,['NA']
31,NCT03937453,Early Stage Pancreatic Cancer or Precursor Lesions,Relative Risk of Pancreatic Cancer Among Individuals with Detiorating diabetes,,2018-01-19,RECRUITING,OBSERVATIONAL,['NA']
32,NCT00492999,Resectability rate,Survival,,2007-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
33,NCT02401815,Part 2e: To identify the recommended phase 2 dose (RP2D) of PLX9486 in combination with sunitinib for further evaluation,Part 2: To determine the progression-free survival of PLX9486 treatment in combination with PLX3397 or sunitinib.,,2015-03-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
34,NCT00659113,Response rate,Initial squamous cell carcinoma antigen and C-reactive protein correlation with response and survival,,2008-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
35,NCT04048421,Postoperative complications,Overall survival,,2019-12-20,RECRUITING,INTERVENTIONAL,['NA']
36,NCT03821909,The difference of the exosomes acquisited from portal venous blood between patients with pancreatic cancer and benign pancreatic diseases,The difference of the exosomes between portal venous and peripheral blood,,2018-08-01,UNKNOWN,OBSERVATIONAL,['NA']
37,NCT05643417,ORR,OS,,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
38,NCT05320497,"Intubation rates of bile duct ends, cystic duct openings, and left and right hepatic duct bifurcations",Biopsy accuracy,,2022-04-14,UNKNOWN,INTERVENTIONAL,['NA']
39,NCT03695250,Objective Response Rate (ORR),Overall Survival (OS),,2018-10-16,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
40,NCT04646928,5-year Cumulative hepatocellular carcinoma incidence,Incidence of cirrhosis regression,,2017-03-17,UNKNOWN,OBSERVATIONAL,['NA']
41,NCT01671449,Progression-free survival,Number of Adverse Events,,2012-12,COMPLETED,INTERVENTIONAL,['PHASE3']
42,NCT00687778,Uptake of C11-Acetate and F18-FDG in tumor will be measured in SUV PET units,,,2008-05,UNKNOWN,OBSERVATIONAL,['NA']
43,NCT05056116,Objective response rate(ORR),Overall survival (OS),,2021-09-01,RECRUITING,INTERVENTIONAL,['NA']
44,NCT02750657,The feasibility of prospectively identifying subgroups of patients with advanced PDAC who have distinct genomic characteristics for better treatment selection while undergoing 1st-line chemotherapy using next generation sequencing.,Correlation with tumor molecular characteristics and toxicities to treatment using next generation sequencing.,,2015-12,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
45,NCT00016965,,,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE2']
46,NCT00081315,- Acute radiochemotherapy-induced esophagitis will be assessed from the time of randomization through up to 3 months after completion of radiochemotherapy treatment.,- Acute radiochemotherapy-induced pneumonitis will be assessed until 6 months after the last dose of XRT.,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE2']
47,NCT05657743,Safety - Adverse events,Efficacy-Alpha DaRT seeds,Urine radioactivity measurements,2023-08-16,RECRUITING,INTERVENTIONAL,['NA']
48,NCT04767503,Metabolomics,I-FEED scoring,,2021-02-20,UNKNOWN,INTERVENTIONAL,['NA']
49,NCT05631613,Deposition of of lipiodol-idarubicin emulsion,Visibility of lipiodol-idarubicin emulsion under X-ray: image quality,,2022-12-28,RECRUITING,OBSERVATIONAL,['NA']
50,NCT01285102,Overall Survival,,,2010-10,TERMINATED,INTERVENTIONAL,['PHASE1']
51,NCT01633411,Esophageal Stricture,Presence of Residual Barrett's Esophagus,,2011-12,COMPLETED,OBSERVATIONAL,['NA']
52,NCT00270543,high-dose 5-FU/leucovorin chemotherapy for patients with inoperable advanced gastric cancer.,Overall survival.,,na,UNKNOWN,INTERVENTIONAL,['PHASE2']
53,NCT06085365,the incidence of chemotherapy related adverse reactions,changes in immune microenvironment,,2023-07-24,RECRUITING,INTERVENTIONAL,['PHASE3']
54,NCT02207465,Number of Adverse Events,,,2014-07,RECRUITING,INTERVENTIONAL,['PHASE1']
55,NCT02551250,sensitivity for detecting HCC,false referral rate for HCC,,2015-09,UNKNOWN,OBSERVATIONAL,['NA']
56,NCT00489671,Risk of pancreatic cancer as determined by urine cadmium levels,"Predictive value of urinary cadmium alone, CA 19-9 alone, and both tests together on development of pancreatic cancer",,2003-06,COMPLETED,OBSERVATIONAL,['NA']
57,NCT04077372,Difference in proportions of patients with documented goals of care,Overall comparison of QOL survey,,2019-09-16,TERMINATED,INTERVENTIONAL,['NA']
58,NCT00878215,The Number of Participants Who Have Complete Ablation According to Early Post-ablative Imaging Studies as Well as no Recurrence of the Tumor Within 6 Months (Phase 4 Portion of the Study),,,2002-10-24,TERMINATED,INTERVENTIONAL,['PHASE2']
59,NCT04940286,Incidence of adverse events,,Change in circulating tumor deoxyribonucleic acid (ctDNA) levels,2021-09-28,RECRUITING,INTERVENTIONAL,['PHASE2']
60,NCT03355443,Adenoma miss rate in the proximal colon (AMR),Adenoma Detection Rate in the proximal colon (ADR),,2017-12,UNKNOWN,INTERVENTIONAL,['NA']
61,NCT00392899,Disease-free survival,Types and severities of adverse events,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
62,NCT01790035,Safety (phase I safety lead-in),Serum citrulline,,2014-08-19,TERMINATED,INTERVENTIONAL,['PHASE1']
63,NCT03283540,Average intra-balloon pressure,Low Anterior Resection Syndrome score (LARS),,2017-09-25,RECRUITING,OBSERVATIONAL,['NA']
64,NCT06041425,Pain intensity at 24hours after the end of TACE.,Nausea and vomiting scale,,2023-08-07,COMPLETED,INTERVENTIONAL,['PHASE4']
65,NCT00109031,Number of Participants With Severe Oral Mucositis (WHO Grade 3 and 4),Number of Participants With WHO Grade 4 Oral Mucositis,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE3']
66,NCT00005843,,,,2000-05,COMPLETED,INTERVENTIONAL,['PHASE2']
67,NCT05889949,Progression-Free Survival (PFS),Adverse events,,2019-06-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
68,NCT03878472,Immunotherapy-related biomarkers,R0 resection rate,,2019-04-01,RECRUITING,INTERVENTIONAL,['PHASE2']
69,NCT01499576,Percent Agreement Between Acetic Acid Chromoendoscopy and Endoscopic Biopsy,Number of Participants With Adverse Events,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
70,NCT01892527,Study of Tivantinib (ARQ 197) plus Cetuximab in EGFR inhibitor-Resistant MET High Subjects with Locally Advanced or Metastatic Colorectal Cancer with Wild-Type KRAS,Tivantinib (ARQ 197) plus Cetuximab in EGFR inhibitor-Resistant MET High Subjects,,2013-03,COMPLETED,INTERVENTIONAL,['PHASE2']
71,NCT06268379,RFS,,,2010-02-15,COMPLETED,OBSERVATIONAL,['NA']
72,NCT01435525,Number of Adverse Drug Reactions,Rate of H.Pylori eradication,,2011-09,COMPLETED,OBSERVATIONAL,['NA']
73,NCT06283576,Cancer detection,Overall survival,,2024-03-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
74,NCT05495685,The sensitivity and specificity of multi-cancer early detection by the combined model in cancer arm and benign disease arm,Sensitivity and specificity of the blood miRNA-based model in detecting pancreatic cancer.,,2022-03-24,RECRUITING,OBSERVATIONAL,['NA']
75,NCT05688761,Gastric adenocarcinoma,Esophageal cancer,,2019-01-01,COMPLETED,OBSERVATIONAL,['NA']
76,NCT02378948,Functional recovery,Quality of life,,2015-10,COMPLETED,INTERVENTIONAL,['NA']
77,NCT04611711,Overall response rate (ORR),Overall survival (OS),,2020-11-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
78,NCT04432870,Interest in colon cancer screening,Risk perception on COVID-19,,2020-06-09,COMPLETED,OBSERVATIONAL,['NA']
79,NCT04797624,Comparison of the clinical staging and pathologic TNM staging of the patients,Comparison of the demographic data,,2021-01-15,COMPLETED,OBSERVATIONAL,['NA']
80,NCT02584998,The Number of Participants Who Completed the Mailed FIT Test Screening Within 6 Months,The Number of Participants Who Received Any Colorectal Cancer Screening Test in the 6-month Period After Enrollment Into the Study.,,2017-01-01,COMPLETED,INTERVENTIONAL,['NA']
81,NCT02452021,Rate of CTCAE acute grade 3 or higher adverse effects possibly attributed to neoadjuvant CRT,Assessment of early cardiac toxicity after CRT using cardiac MRI,,2015-07,COMPLETED,OBSERVATIONAL,['NA']
82,NCT03620877,Evaluation of coordinated transmission,Adherence to personalized intervention,,2018-09-24,UNKNOWN,INTERVENTIONAL,['NA']
83,NCT03208283,The mean independently performed flexible sigmoidoscopy completion rate in each study group,Patients' satisfaction,,2014-10-28,COMPLETED,INTERVENTIONAL,['NA']
84,NCT05844865,Development of individual patient-derived peritoneal carcinomatosis (pdPC) vascularized micro-tumor (VMT),Overall Survival (OS),,2023-05-04,RECRUITING,INTERVENTIONAL,['NA']
85,NCT06281886,Progression free survival rate,Distant metastasis-free survival,,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2']
86,NCT05713994,Number of Patients Amendable to Curative Surgical Interventions,Quality of Life (QoL) after treatment,,2020-05-19,RECRUITING,OBSERVATIONAL,['NA']
87,NCT03854890,The positive number of lymph nodes retrieved,Detection rate of indocyanine green-positive para-aortic lymph node,,2019-07-01,UNKNOWN,INTERVENTIONAL,['NA']
88,NCT04714814,recurrence or metastasis provened by imageologic diagnosis (PFS),,,2021-06-01,UNKNOWN,OBSERVATIONAL,['NA']
89,NCT02741401,Change from baseline in anxiety and depression as assessed by Hospital Anxiety and Depression Scale (HADS) questionnaire,Patients' opinion and need about hand-foot massage's utility as assessed by questionnaire,,2016-03,UNKNOWN,INTERVENTIONAL,['NA']
90,NCT00586235,"Primary Endpoints: Global Fiducial Registration Error (FRE) of real-time US and fused CT images, Target Registration Error (TRE) and distance between lesional epicenters of real-time US and fused CT images.",Secondary Endpoint: Number of coregistration attempts to realize separation of lesional epicenters of real-time US and fused CT images of ≤2 cm and the number of attempts to realize a separation of ≤0.3 cm.,,2007-02,COMPLETED,OBSERVATIONAL,['NA']
91,NCT05275985,Overall Survival (OS),,,2022-03-01,UNKNOWN,INTERVENTIONAL,['NA']
92,NCT01395030,Number of Participants Comprising Two Distinct PET/CT Imaging Phenotypes (High FCH Uptake vs. Low FCH Uptake) Between the Different Tumor Sub-classes,,,2011-08-15,COMPLETED,INTERVENTIONAL,['PHASE2']
93,NCT05592886,The incidence of metachronous recurrent colorectal adenoma at year 1 (local or at other sites),Changes in the levels of bacterial gene markers,,2022-12-15,RECRUITING,INTERVENTIONAL,['NA']
94,NCT04597710,Proportion of patients for whom clinically-actionable data is provided by whole genome sequencing at the time of surgery.,Proportion of patients for whom actionable biomarkers of drug sensitivity are identified with WGS.,,2021-02-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
95,NCT01355302,Time to Maximum Concentration (Tmax) of Golvatinib,Time to Progression (TTP),,2011-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
96,NCT03930368,the change of glycated albumin,the change of uric acid,,2019-04-15,UNKNOWN,INTERVENTIONAL,['NA']
97,NCT04260191,Number of Participants Who Experienced a Treatment-emergent AE (TEAE),Overall Survival,,2020-06-29,TERMINATED,INTERVENTIONAL,['PHASE1']
98,NCT06147492,urinary retention,,,2016-01-30,COMPLETED,INTERVENTIONAL,['NA']
99,NCT04709445,anastomotic leak,Length of hospital stay,,2020-03-01,UNKNOWN,INTERVENTIONAL,['NA']
100,NCT02267343,Overall survival,Safety will be analyzed through the incidence of laboratory abnormalities,,2014-10,COMPLETED,INTERVENTIONAL,['PHASE3']
101,NCT04913480,Progression-free survival at 1 year,Changes in PD-L1 and PD-1 positive circulating tumor cells before and after stereotactic body radiation therapy and durvalumab,,2020-10-15,RECRUITING,INTERVENTIONAL,['PHASE2']
102,NCT01914744,Incidence rate of HBV reactivation,Incidence rate and median time of HBV DNA level normalization,Incidence of drug resistance of viral variants,2013-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
103,NCT03791398,Progression Free Survival,,,2019-11-15,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
104,NCT01413295,Progression Free Survival,Overall Survival,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2']
105,NCT03730948,Adverse events experienced by subjects (i.e. safety of DC vaccine in subjects with surgically resected hypermutated CRC),Percentage of CD8+ cells in primary tumor tissue,,2019-03-12,TERMINATED,INTERVENTIONAL,['PHASE1']
106,NCT00718211,,,,2006-05,COMPLETED,OBSERVATIONAL,['NA']
107,NCT02797197,"number of handgrip strength test measures per patient, number of handgrip test measures compared to the number of day hospitalisations, number of patients who had all of the measures, between 50 and 100% of measures, less than 50% of measures",to study the association between the evolution of hand grip strength test and the evolution of nutritional indices (anthropometric and biologic),,2016-05-18,COMPLETED,INTERVENTIONAL,['NA']
108,NCT00746161,The %body weight ratio,"preoperative complication, PNI and QOL score",,2002-04,COMPLETED,INTERVENTIONAL,['PHASE3']
109,NCT00529984,determine the safety of immunization with CEA(6D) VRP,evaluate CEA-specific immune response to immunizations,,2007-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
110,NCT02571036,Expansion Phase: Assess Antitumor Activity of DCC-2618 in all diseases,Escalation Phase: Assess Antitumor Activity of DCC-2618 in patients with advanced malignancies,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE1']
111,NCT01465464,Overall Survival(OS),Time to Transcatheter Arterial Chemoembolization (TACE) Failure,,2010-12,TERMINATED,INTERVENTIONAL,['PHASE3']
112,NCT03233711,Disease free survival,Incidence of toxicities,,2018-07-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
113,NCT03236051,Numeric rating scales (NRS) score with 24 hours after the surgery,Prealbumin,,2017-02-10,UNKNOWN,INTERVENTIONAL,['NA']
114,NCT06162468,The proportion of patients in whom EUS-PCA was completed as planned.,The IPMN complete response rate in the injected lesion(s) on imaging 3 months post-EUS-PCA.,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
115,NCT02423811,Progression-free survival,,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE2']
116,NCT06015035,Primary Endpoints: pCR,,,2021-04-01,COMPLETED,INTERVENTIONAL,['PHASE2']
117,NCT05622825,Image Assessment,Quality of life assessment.,,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
118,NCT03385018,3 year relapse-free survival,Quality of life(EORTC QLC STO22),,2018-04-05,RECRUITING,INTERVENTIONAL,['NA']
119,NCT05659381,Progression-free survival,Residual Disease,,2024-03-01,RECRUITING,INTERVENTIONAL,['PHASE3']
120,NCT03057288,Success rate evaluation of the placement of two fiducial markers,The presence of the markers at the end of the radiotherapy,,2017-02-03,COMPLETED,INTERVENTIONAL,['NA']
121,NCT00819208,Disease-free survival,Predictors of physical activity adherence as assessed by Social Cognitive Determinants of Exercise questionnaire,,2009-06-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
122,NCT05436275,Nasal Congestion Score (NCS),Anti-drug antibodies (ADA),,2022-08-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
123,NCT06105515,Severe complication,Health-related quality of life,,2024-06,RECRUITING,INTERVENTIONAL,['NA']
124,NCT03742453,Diagnostic performance of CEUS for diagnosing HCC,Diagnostic performance of gadoxetic-acid liver MRI for diagnosing HCC using KLCSG-NCC guidelinev2018,,2018-10-16,UNKNOWN,INTERVENTIONAL,['NA']
125,NCT00332280,Improvement in clinical benefit response,Safety and tolerability,,2006-05,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
126,NCT03879395,Overall survival,Complications according to Clavien-Dindo within 90 days.,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
127,NCT05251038,Objective Response Rate (ORR),Overall Survival (OS),,2022-09-13,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
128,NCT00103142,Recurrence-free Survival at 2 Years,Positive Immune Response as Measured by (Enzyme-linked Immunosorbent Spot) ELISpot Assay,,2005-02,COMPLETED,INTERVENTIONAL,['PHASE2']
129,NCT04634357,The recommended phase 2 dose (RP2D) regimen of ET140203 T cell therapy primarily based on DLT,Determine the pharmacokinetics of ET140203 T cells after infusion.,,2022-07-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
130,NCT05431621,Establish and evaluate the non-invasive early detection model for hepatocellular carcinoma,,,2020-11-15,COMPLETED,OBSERVATIONAL,['NA']
131,NCT00003018,Overall Survival,Resectability of patents who respond to this regimen,,1997-09,COMPLETED,INTERVENTIONAL,['PHASE2']
132,NCT04587310,endoscopy performed on patients,,,2008-10-01,COMPLETED,OBSERVATIONAL,['NA']
133,NCT03937830,"To evaluate the 6-month PFS in patients with BTC and HCC BCLC stage C treated with bevacizumab, durvalumab and tremelimumab","To determine the safety and feasibility of bevacizumab, durvalumab, tremelimumab in patients with advanced BTC",,2021-03-10,RECRUITING,INTERVENTIONAL,['PHASE2']
134,NCT06318793,Concentration of C-reactive protein (CRP),,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
135,NCT05573282,Progress Free Survival,Tumor Response,,2022-10-16,RECRUITING,OBSERVATIONAL,['NA']
136,NCT05578287,Feasibility,Overall Survival (OS),,2023-07-18,RECRUITING,INTERVENTIONAL,['PHASE2']
137,NCT04704661,Differential pharmacodynamic (PD) profile of tumor tissue (DNA damage & repair) (Dose expansion phase),PD markers,"Association of TP53, ATM, and RAS mutations with ORR",2021-08-09,RECRUITING,INTERVENTIONAL,['PHASE1']
138,NCT01575574,hepatocellular carcinoma diagnosed,magnetic resonance imaging sensitivity,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE4']
139,NCT06191185,Colonoscopy completion,Scheduled by GI for colonoscopy,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
140,NCT04951804,Change in Likert pain scores,Difference in Global Rating Scale of Change at T3 vs all other follow-up time points,,2021-10-07,RECRUITING,INTERVENTIONAL,['NA']
141,NCT00316745,PFS of 1st line treatment,safety,,2006-04,SUSPENDED,INTERVENTIONAL,['PHASE3']
142,NCT02547480,Area Under the Curve (AUC),Technical success - total dose delivered,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
143,NCT03771508,Prospective collection of PillCam SB3 videos,,,2018-12-13,RECRUITING,OBSERVATIONAL,['NA']
144,NCT03795311,Number of Participants with Acute toxicities as a Measure of treatment specific Safety and Tolerability,,,2018-11-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
145,NCT06252142,International Prostate Symptom Score (IPSS),Treatment-related toxicities,,2024-02-19,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
146,NCT06301386,objective response rate (ORR),advert events,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
147,NCT00250822,"Response Rate ( CR + PR rate); namely, to determine response rate to the Gemcitabine and Oxaliplatin combination administered to patients with hepatocellular cancer. Furthermore, patients who achieve a response leading to tumor respectability.",,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2']
148,NCT04761172,Primary tumor detection,Tumor to background ratio,,2020-06-17,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
149,NCT01617382,To improve the prognosis/survival of patients with malignancies localized on the peritoneal surface.,,,2012-05,RECRUITING,OBSERVATIONAL,['NA']
150,NCT06266832,Organ retention rate,QoL,,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
151,NCT03595540,Quantification of FMD-emergent adverse events,,,2017-11-22,COMPLETED,INTERVENTIONAL,['NA']
152,NCT02788214,Bacterial DNA sequence,,,2016-07-27,TERMINATED,OBSERVATIONAL,['NA']
153,NCT00896467,Adjustment strategies and emotional regulation as assessed by the WCC and ERQ questionnaires,,,2007-09,TERMINATED,OBSERVATIONAL,['NA']
154,NCT04599179,Quality of life (QoL) after endoscopic or surgical treatment,,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
155,NCT04650451,Maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE),Antitumor activity of BPX-603,,2020-12-07,SUSPENDED,INTERVENTIONAL,['PHASE1']
156,NCT04823793,Sensitivity and specificity of methylation biomarker and FIT for adenoma and colorectal cancer screening,,,2021-03-31,UNKNOWN,OBSERVATIONAL,['NA']
157,NCT01443481,Pharmacokinetic (PK) parameter of AUCinf following a single dose of TKI258,Pharmacokinetics and Hepatic Function Abnormalities,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
158,NCT01524848,Disease control rate,Overall response rate,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2']
159,NCT03174444,Colorectal Cancer Screening,,,2017-08-15,COMPLETED,INTERVENTIONAL,['NA']
160,NCT00379782,subject satisfaction with navigation,,,2006-10,COMPLETED,INTERVENTIONAL,['NA']
161,NCT02188342,VO2 peak,Quality of life,,2015-01,COMPLETED,INTERVENTIONAL,['NA']
162,NCT02473003,Change in Fatigue,Treatment completion rate,,2015-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
163,NCT03690921,Acute Toxicity,Complete Response at 24 Weeks,,2018-11-08,COMPLETED,INTERVENTIONAL,['PHASE2']
164,NCT04961138,1-year disease free survival,objective response rate,,2021-08,UNKNOWN,INTERVENTIONAL,['NA']
165,NCT02989922,6-month Overall Survival Rate,Overall Survival,,2016-11-15,COMPLETED,INTERVENTIONAL,['PHASE2']
166,NCT03428958,"Number of patients with treatment-emergent clinically significant changes in laboratory parameters, ECG changes, or changes in physical examinations",Tolerability of NUC-3373 in each combination cohort measured by dose intensity in Cycle 1,,2018-10-16,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
167,NCT06001268,Participant Rating on Ease of Use the Mobile Application - Usability,Malnutrition -Nutritional Status,,2023-08-14,RECRUITING,INTERVENTIONAL,['NA']
168,NCT04915807,Progression-free survival,Adverse events of special interest,,2021-06,UNKNOWN,OBSERVATIONAL,['NA']
169,NCT02753127,Overall Survival (OS),Number of Patients With Adverse Events in the General Population,,2016-06,COMPLETED,INTERVENTIONAL,['PHASE3']
170,NCT01641458,Predefined fluoropyrimidine-related (index) toxicity,Progression-free survival,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE4']
171,NCT03154983,progress-free survival time,disease control rate,,2017-05-20,UNKNOWN,INTERVENTIONAL,['PHASE2']
172,NCT01904890,Receipt of CRC Screening,CRC screening Intention,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
173,NCT01995591,number of sentinel lymph nodes identified in pieces of colectomy from patients with colon cancer with Indocyanine Green,,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
174,NCT01765582,Progression-Free Survival During First-Line Therapy (PFS1),Percentage of Participants With Adverse Events,,2013-01-23,TERMINATED,INTERVENTIONAL,['PHASE2']
175,NCT02900248,Time to Treatment Progression,To determine rate of enrollment into existing and future therapeutic clinical trials.,,2017-10-02,TERMINATED,OBSERVATIONAL,['NA']
176,NCT03551470,Operative time,,,2012-10,UNKNOWN,OBSERVATIONAL,['NA']
177,NCT00041197,Recurrence-free survival (RFS),Relationship between genetic and phenotypic characteristics of GIST and clinical outcomes,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE3']
178,NCT04808466,overall survival,The positive rate of cancer cells of participants by exfoliative cytology examination,,2021-09-18,RECRUITING,INTERVENTIONAL,['PHASE2']
179,NCT03652467,Progression Free Survival (PFS) in Participants With Unresectable Hepatocellular Cancer,Number of Participants With Drug-Related Treatment-Emergent Adverse Events,,2018-09-01,UNKNOWN,INTERVENTIONAL,['PHASE1']
180,NCT05661643,Objective respone rate in SDH deficiency wild type GIST,,,2023-06-28,RECRUITING,INTERVENTIONAL,['PHASE2']
181,NCT03639792,Postoperative Morbidity and mortality,Overall survival,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
182,NCT03756051,Psychosocial Harms,Physical Harms,,2018-04-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
183,NCT04131426,Recruitment and Retention,Porportion of subjects with improved cachexia-related symptoms 3 months,,2020-04-24,COMPLETED,INTERVENTIONAL,['PHASE1']
184,NCT01696630,Variation of intraoperative Mean Arterial Pressure (MAP),Delay to intestinal transit recovery,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2']
185,NCT03009461,Overall survival,,,2017-06-01,COMPLETED,INTERVENTIONAL,['PHASE2']
186,NCT01768104,En bloc resection,Quality of life,,2011-12,UNKNOWN,INTERVENTIONAL,['NA']
187,NCT01211210,3-year disease free survival,quality of life,,2010-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
188,NCT05965466,Number of gallstone patients,Number of patients with bile duct stones,,2023-07-21,RECRUITING,INTERVENTIONAL,['NA']
189,NCT02502630,Overall Survival (OS),Treatment related adverse events,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
190,NCT01224652,progression-free survival,Overall survival,,na,UNKNOWN,INTERVENTIONAL,['PHASE3']
191,NCT01678027,Gastric cancer incidence,All-cause mortality,,2004-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
192,NCT04247958,Number of SureForm™ Stapler fires and reload colors,Incidence of peri-operative and short term outcomes,,2020-01-30,COMPLETED,OBSERVATIONAL,['NA']
193,NCT04192565,Complication rate (%),,,2020-09-09,COMPLETED,INTERVENTIONAL,['NA']
194,NCT02643498,maximum tolerated dose (MTD) of SBRT,,,2015-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
195,NCT00333788,Occurrence of at Least One Study-emergent Adverse Event During the Study (Maximum 164 Weeks),Occurrence of at Least 1 Concurrent Medical Procedure During the Overall Period,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
196,NCT00920803,To characterize the pharmacokinetic profile of SRT501 in blood and normal and malignant metastatic tissues when administered once daily for 14 days.,To examine the pharmacodynamics of SRT501 activity in both normal and malignant tissue samples and blood.,,2008-08-19,COMPLETED,INTERVENTIONAL,['PHASE1']
197,NCT04871204,Weight change in percent (%),Number of patients completing treatment,,2021-06-16,RECRUITING,INTERVENTIONAL,['PHASE2']
198,NCT04813432,time-point of highest enhancement difference between a pancreatic lesion and background pancreatic parenchyma,,,2018-09-10,UNKNOWN,OBSERVATIONAL,['NA']
199,NCT02110953,"Maximum tolerated dose of irinotecan-eluting beads, determined by dose limiting toxicities, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",Time to progression,,2016-01-29,TERMINATED,INTERVENTIONAL,['PHASE1']
200,NCT00632515,Psychosocial + External factors influencing CRC patients' communication with FDRs about CRC risk & screening information,,,2008-01-29,COMPLETED,OBSERVATIONAL,['NA']
201,NCT02173080,Polycystic Liver Disease-specific patient reported outcomes questionnaire (PLD-Q) total score,Total kidney volume,,2014-06,RECRUITING,OBSERVATIONAL,['NA']
202,NCT03977233,Best disease control rate by Pancreatic ductal adenocarcinoma (PDAC) subtype,proportion of patients whose tumor/stroma subtype changes after treatment with FOLFIRINOX,,2019-06-12,RECRUITING,INTERVENTIONAL,['PHASE2']
203,NCT01652079,Progression Free Survival,Analysis of biopsies,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2']
204,NCT00729482,Progression-free Survival Rate at 4-month (16 Weeks),Number of Participants With Adverse Events,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2']
205,NCT04931394,Disease free time,Concordance between radiosensitivity test results and patients' treatment response (descriptive statistics).,,2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE3']
206,NCT05029869,The specificity of MRD detection using ctDNA as the biomarker,Mutation profile of gastric cancer,,2021-10-04,RECRUITING,OBSERVATIONAL,['NA']
207,NCT00551057,,,,2007-10,UNKNOWN,OBSERVATIONAL,['NA']
208,NCT01742806,Time to drain removal,total amount of exudate drainage,Time to discharge after surgery and postoperative complication,2012-10,UNKNOWN,INTERVENTIONAL,['NA']
209,NCT06006338,R0 resection rate,Blood loss,,2023-09-15,RECRUITING,INTERVENTIONAL,['PHASE1']
210,NCT02969681,Progression Free Survival,Assessment of treatment-related adverse events,,2017-01,COMPLETED,INTERVENTIONAL,['PHASE3']
211,NCT00005094,"Percentage of patients with adenomas, aspirin use at baseline, and covariates",Adverse events coded using the MedRA dictionary,,2000-03,COMPLETED,INTERVENTIONAL,['PHASE3']
212,NCT02288507,Safety and tolerability of concurrent sorafenib and yttrium-90 transarterial radioembolization (TARE) for patients with advanced hepatocellular cancer as measures by Adverse events,"Efficacy of concurrent sorafenib and yttrium-90 transarterial radioembolization (TARE) for patients with advanced hepatocellular cancer as measured by response rate, time to progression (TTP), progression free survival (PFS), overall survival (OS)",,2014-11,WITHDRAWN,INTERVENTIONAL,['PHASE1']
213,NCT05060471,cCR rate,overall sruvival,,2021-09-08,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE2']
214,NCT04823403,Maximum Tolerated Dose (MTD),,,2020-11-13,RECRUITING,INTERVENTIONAL,['PHASE1']
215,NCT03793335,Colorectal cancer prevention,,,2019-04-14,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
216,NCT02923622,Overall survival,Number of participants with treatment-related adverse events as assessed by Chinese version of CTCAE v4.0,,2016-09,UNKNOWN,OBSERVATIONAL,['NA']
217,NCT05663203,Attentional Function Index,Short Form Health Survey,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA']
218,NCT04005690,Proportion of all pharmacodynamic feasibility-evaluable participants within a study arm that have a measurable change in post-treatment tumor biology from baseline,Incidence of >= grade 3 toxicities for each assigned window treatment (as described in sub-protocol),,2019-08-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
219,NCT01689376,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
220,NCT03707444,Change in Average pain as assessed by Brief Pain Inventory Question 3,Change in opioid use,,2018-10-01,WITHDRAWN,OBSERVATIONAL,['NA']
221,NCT00753441,Serum bilirubin,Procedure-related complications,,2009-02-01,TERMINATED,INTERVENTIONAL,['NA']
222,NCT01379807,Objective response rate,Exploratory Objectives,,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
223,NCT00004210,"Assessment of cancer risk perception, cancer screening practices, views regarding genetic services, and family communication about HNPCC / Lynch syndrome by family members",,,2000-02,COMPLETED,INTERVENTIONAL,['NA']
224,NCT01533311,,,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
225,NCT02565667,anastomotic leak rate,30-day mortality rate,,2015-09,UNKNOWN,INTERVENTIONAL,['NA']
226,NCT05182762,Clavien-Dindo Grade,Age comparison,,2020-02-01,COMPLETED,OBSERVATIONAL,['NA']
227,NCT03086291,maximum tolerated dose,,,2018-01-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
228,NCT05783076,Overall survival will be determined,Quality of life will be determined,,2023-06-25,RECRUITING,INTERVENTIONAL,['PHASE2']
229,NCT03636308,Objective response rate,The incidence of treatment related emergent adverse events（Safety and Tolerance）,,2018-07-17,UNKNOWN,INTERVENTIONAL,['PHASE2']
230,NCT06005974,To evaluate the preliminary anti-tumor activity of REC-4881 as measured by Objective Response Rate (ORR),To assess the anti-tumor activity of REC-4881 as measured by to other efficacy endpoints,,2024-01-15,RECRUITING,INTERVENTIONAL,['PHASE2']
231,NCT05585073,surgery complicated,,,2022-01-01,COMPLETED,OBSERVATIONAL,['NA']
232,NCT05931445,HRQoL EORTC Quality of Life of Cancer Patients (QLQ-C30) global health status score,Communication between patients and healthcare providers (EORTC QLQ-COMU26 score),,2021-01-26,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
233,NCT00330915,Feasibility of Pemetrexed Prior to Surgery,Number of Participants Receiving Sphincter Saving Surgery,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
234,NCT02785146,Disease-free survival (DFS),Metastasis-free survival (MFS),The effects of Huaier Granule on adverse events of adjuvant chemotherapy.,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
235,NCT02895464,Adverse events,Discharge destination,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
236,NCT06257264,Part 2: Objective Response Rate,Part 2: Plasma concentrations for BG-68501,,2024-02-28,RECRUITING,INTERVENTIONAL,['PHASE1']
237,NCT00383149,Percentage of Participants Surviving at 6 Months,Change From Baseline in FHSI-8 Total Score by Time-point,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2']
238,NCT01718821,"Changes in pain, assessed by BPI-SF.","Changes in neuropathic pain. Neuropathic pain, assessed by DN4 questions.",,2012-09,COMPLETED,OBSERVATIONAL,['NA']
239,NCT02424864,The estimation of tumor size of the primary esophageal tumor on 4Dvs 3D FDG PET,"Measurement of SUV max, SUV mean, and SUV peak in 4D versus 3D images of esophageal cancer and lymph nodes and number of suspected involved lymph nodes",,2014-08,COMPLETED,INTERVENTIONAL,['NA']
240,NCT02671890,Maximum tolerated dose (MTD) (Cohort I),Changes in fist-grip strength as measured by hand dynamometer (Cohort II),Changes in muscle messenger ribonucleic acid (mRNA) levels via real-time polymerase chain reaction,2016-02-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
241,NCT03958500,Rate of anastomotic leakage,Timing of anastomosis leakage,,2019-04-01,COMPLETED,INTERVENTIONAL,['NA']
242,NCT04459754,Disease-free Survival,,,2020-06-29,RECRUITING,INTERVENTIONAL,['PHASE2']
243,NCT02066259,"Number of participants in each of the clinicaly defined groups (0,1 and 2).",,,2014-08,UNKNOWN,OBSERVATIONAL,['NA']
244,NCT05771480,Number of participants with Grade 3 or 4 possibly related adverse event (PRAE),EORTC QLQ-BIL21 Score,,2023-08-16,RECRUITING,INTERVENTIONAL,['PHASE3']
245,NCT05913583,Graft rejection,Early allograft dysfunction (EAD),pDC to mDC ratio,2023-04-01,RECRUITING,OBSERVATIONAL,['NA']
246,NCT06250166,Change from baseline in mean platelet-lymphocyte ratio at 12 weeks,Change in mean daily energy and protein intake at 12 weeks,,2023-06-15,RECRUITING,INTERVENTIONAL,['NA']
247,NCT03723720,correlation between ADR and PDR for all and screening colonoscopies,,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
248,NCT01836432,Overall Survival,Immune Response,,2013-05,TERMINATED,INTERVENTIONAL,['PHASE3']
249,NCT00808379,Side effects and other adverse effects in the two groups during radiotherapy and up to 2 years post radiotherapy.,Comparison of pathological downstaging between the two groups who undergo surgery.,,2006-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
250,NCT05650918,Incidence of Dose Limiting Toxicities (DLTs) as assessed by CTCAE v5.0,Radiological response rate as defined by RECIST version 1.1 and iRECIST,,2021-08-30,COMPLETED,INTERVENTIONAL,['PHASE1']
251,NCT00003139,Acute salivary gland toxicity,Effects of continuing pilocarpine out to 6 months from the start of treatment,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE3']
252,NCT06034977,Overall survival,,,2023-12-01,RECRUITING,INTERVENTIONAL,['PHASE2']
253,NCT02606994,Oral mucositis changes,Quality of life changes,,2018-05-29,TERMINATED,INTERVENTIONAL,['PHASE2']
254,NCT01523431,"Incidence of toxicity, especially neutropenia and diarrhea","Pharmacokinetics of irinotecan and its metabolites, SN-38 and SN-38G.",,2012-03-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
255,NCT01448655,Disease-free survival time (DFS).,"Number of patients with unexpected adverse events (UAE) contributed to conventional oncological therapy (radio-, chemo-, targeted therapy).",,2010-09,UNKNOWN,OBSERVATIONAL,['NA']
256,NCT03109041,Safety & Toxicity of Delivering Primary Radiation Therapy with CivaSheet using the CTCAE 4.0 scale,,,2017-09-06,COMPLETED,INTERVENTIONAL,['PHASE1']
257,NCT04094454,incidence and grade of vaginal fibrosis,assessment of quality of life,,2019-10-01,RECRUITING,INTERVENTIONAL,['NA']
258,NCT00423150,Tumor Responses (Complete and Partial Response),,,2007-01-26,TERMINATED,INTERVENTIONAL,['PHASE2']
259,NCT01271582,Association between UGT1A1 polymorphism and grade 3/4 neutropenia after 1st cycle of FOLFIRI treatment,Progression-free survival,,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
260,NCT03013010,Disease free survival,Proportion of patients with surgery-related complication,,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
261,NCT03511170,time to failure of strategy（TFS）,time to failure of strategy（TFS）,,2018-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
262,NCT02164916,Progression-free Survival,Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug,Overall Response Rate in Patients Who Register to Arm 3 (Crossover) After Disease Progression on Arm 1,2014-11,COMPLETED,INTERVENTIONAL,['PHASE2']
263,NCT00107536,Proportion of Patients Demonstrating Objective Response (PR+CR) as Defined by RECIST,Expression Profile and Mutations of Genes Critical for EGFR and ERBB2 Signaling Pathways,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2']
264,NCT03176264,Overall Response Rate (ORR) per investigator assessment using RECIST v1.1,Antidrug antibodies (ADA),,2017-09-25,TERMINATED,INTERVENTIONAL,['PHASE1']
265,NCT00079833,Control is defined as gastric acid secretory rate below 10 mEq/h or below 5 meq/h for patients with prior gastric acid reducing Surgery,"The following safety variables will be assessed at Month 6 and Month 12: adverse events, clinical laboratory results (ie, chemistry, hematology, urinalysis), physical examinations, and EGDs.",,2003-11,COMPLETED,INTERVENTIONAL,['PHASE3']
266,NCT00006269,,,,1999-12,TERMINATED,INTERVENTIONAL,['PHASE3']
267,NCT04264702,Determine the rate of recurrence of patients diagnosed with CRC while asymptomatic using SIGNATERA™,Examine the number of Stage I CRC patients that have recurrent disease detected post-surgery based on SIGNATERA™ test results,,2020-04-24,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
268,NCT05729867,Technical success rate,Stent dysfunction rate,,2020-04-27,RECRUITING,INTERVENTIONAL,['NA']
269,NCT05275075,Proportion of African American pancreatic cancer patients with weight loss and cachexia.,"Differences in cachexia-associated RNA signatures in African American pancreatic cancer patients, and other racial groups.",,2022-12-07,RECRUITING,OBSERVATIONAL,['NA']
270,NCT02938195,Percentage of patients completing adjuvant chemoradiotherapy and surgery,Percentage of pathological complete response,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
271,NCT01323166,Health Related Quality of life after rectal cancer surgery - possible differences due to choice of procedure,Impact of rectal cancer surgery and the level of intrusive thoughts,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
272,NCT06048146,3 year disease free survival,,,2022-10-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
273,NCT01007617,Mucositis scale - World Health Organization (WHO),Psychological impact,,2009-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
274,NCT04296019,PFS,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2021-02-01,RECRUITING,INTERVENTIONAL,['PHASE2']
275,NCT04707482,Difference of protein expression,,,2021-06-01,UNKNOWN,OBSERVATIONAL,['NA']
276,NCT00591461,The primary outcome will be the interobserver variability in the presence of columnar epithelium as well as the measured lengths.,variables that predict endoscopic interobserver agreement and path-confirmation,,2007-12,TERMINATED,OBSERVATIONAL,['NA']
277,NCT04481659,The damage degree of anal function,Local recurrence,,2020-07-19,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
278,NCT04428437,Response rate (RR),Adverse Events,,2022-07-02,TERMINATED,OBSERVATIONAL,['NA']
279,NCT01025882,Tumor samples for RNA and protein harvesting (when possible) from pretreatment biopsies and surgical specimens,,,2009-10,TERMINATED,INTERVENTIONAL,['PHASE1']
280,NCT04965311,Rate of clinically relevant postoperative pancreatic fistula (POPF),Rate of any POPF,,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE2']
281,NCT03033186,Everolimus TDM to predict long-term toxicity,Everolimus TDM to predict dose reductions,,2017-05-16,UNKNOWN,OBSERVATIONAL,['NA']
282,NCT03613168,Adverse events,Overall survival,,2019-06-01,COMPLETED,INTERVENTIONAL,['PHASE2']
283,NCT01226719,Overall Response Rate (ORR),Overall Survival (OS),,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2']
284,NCT04239781,HCC patients' willingness and expectation for post-operative treatment.,,,2020-01,UNKNOWN,OBSERVATIONAL,['NA']
285,NCT03734627,Area under the curve for paracetamol at 30 minutes after a 400kcal mixed meal stimulus,EORTC health related quality of life,Duodenal enteroendocrine cell mRNA expression profile,2016-07-01,COMPLETED,OBSERVATIONAL,['NA']
286,NCT04278222,objective response rate,adverse events,,2020-02-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
287,NCT00699569,,,,2008-07,UNKNOWN,INTERVENTIONAL,['NA']
288,NCT03215459,Survival at 6 months (followed up for 12mths),Time-to-event endpoints,,2021-02-01,UNKNOWN,OBSERVATIONAL,['NA']
289,NCT02056041,Safety of surgery for HCC,Score systems HCC,,2004-01,COMPLETED,OBSERVATIONAL,['NA']
290,NCT06291779,Urine,,,2022-11-30,RECRUITING,OBSERVATIONAL,['NA']
291,NCT05183958,Progression-free survival (PFS),Adverse Events (AEs),Duration of Response (DoR),2021-12-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
292,NCT04452266,Correlation between endometrial cancer and predictif factors,Correlation between endometrial cancer and predictif factors in post menopausal woman,,2020-08-14,COMPLETED,OBSERVATIONAL,['NA']
293,NCT01767857,Overall Survival (OS),Percentage of Participants With Disease Control,,2013-03-31,TERMINATED,INTERVENTIONAL,['PHASE3']
294,NCT00445549,Number of Participants With Clinical Efficacy,The Number of Participants With Adverse Events,,2007-01,TERMINATED,INTERVENTIONAL,['PHASE2']
295,NCT02102789,Complete resection rates (R0 resection rates) (defined as no macroscopic or microscopic residual tumor) of both arms,"Number of participants with surgical complications, AES and SAEs as a measure of safety",,2014-03,RECRUITING,INTERVENTIONAL,['PHASE3']
296,NCT03601234,operation time,hospitalization expenses,,2018-04-16,UNKNOWN,INTERVENTIONAL,['NA']
297,NCT06307938,Inflammatory bowel disease,Treatment response,,2025-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
298,NCT04888546,Overall response rate (ORR),The incidence and severity of SAE,,2021-04-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
299,NCT01044420,adverse events,response rate,,2009-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
300,NCT04883450,Incidence of pancreatic ductal adenocarcinoma (PDAC) in the high predicted risk group,,,2021-02-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
301,NCT05202600,NNT of IA for the appendiceal neoplasm,NNT of IA for the death due to appendicits in elderly,Definition of the elderly group for the complicated appendicitis or death,2022-02-01,UNKNOWN,OBSERVATIONAL,['NA']
302,NCT04524871,Objective Response Rate (ORR),Percentage of Participants With Adverse Events During Stage 2,,2020-11-02,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
303,NCT04714957,"genetic and epigenetic data available for 20 ""multiplets"" biospecimens (peritoneal carcinomatosis + healthy tissue + primary tumor + tissue from other tumor metastasis - when applicable and available- )",,,2020-09-01,RECRUITING,OBSERVATIONAL,['NA']
304,NCT02860546,Immune-Related Overall Response Rate (irORR),Overall Survival (OS),,2016-08-29,COMPLETED,INTERVENTIONAL,['PHASE2']
305,NCT01035229,Overall Survival (OS),Pharmacokinetics Assessments - Cmax,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE3']
306,NCT00529113,Phase II - To determine if treatment with RTA 402 in combination with gemcitabine can increase the progression-free survival versus gemcitabine plus placebo in patients with unresectable metastatic pancreatic cancer.,"Phase II - To determine the changes in quality of life (Functional Assessment of Chronic Illness Therapy (Fatigue), [FACIT-F]).",,2007-09-30,TERMINATED,INTERVENTIONAL,['PHASE1']
307,NCT03531320,"Part 2: Incidence of Dose Modifications, Including Dose Reduction, Interruption, or Discontinuation of Study Drug",Part 2: PK- AUC,,2018-08-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
308,NCT00467142,Percentage of Participants in Objective Response (Partial or Complete Responses),Median Duration of Response,,2007-01-23,COMPLETED,INTERVENTIONAL,['PHASE2']
309,NCT00190541,Relapse-free survival,Incidence of sexual and urinary dysfunction,,2003-06,COMPLETED,INTERVENTIONAL,['PHASE3']
310,NCT01793805,To characterize common genetic/molecular profiles associated with colorectal cancer (CRC),To conduct further analysis of tumor samples for the discovery of new potential targets and mechanisms of drug resistance,,2013-02,COMPLETED,OBSERVATIONAL,['NA']
311,NCT01457846,Median Progression Free Survival,Percentage of Patients Without Progressive Disease at 8 Weeks,,2011-11,TERMINATED,INTERVENTIONAL,['PHASE2']
312,NCT01773785,Progression free survival,Safety of SPI-1620 when administered in combination with docetaxel,,2013-04,TERMINATED,INTERVENTIONAL,['PHASE2']
313,NCT00099294,Overall Survival,Performance Status,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
314,NCT04525326,Conversion liver resection rate,overall survival,,2020-10-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
315,NCT02272504,Biomarker assays exceeding threshold,Surveillance until HCC development and detection,,2014-08,UNKNOWN,OBSERVATIONAL,['NA']
316,NCT03791905,clinical complete response,Chemoradiotherapy-related toxicity,,2019-01-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
317,NCT05323890,Pathologic complete response rate,Incidence of Treatment-related Adverse Events,,2022-04-20,RECRUITING,INTERVENTIONAL,['PHASE2']
318,NCT00515866,To establish the maximum tolerated dose (MTD) or a tolerable and effective dose of KU 0059436 in combination with gemcitabine,To identify the dose-limiting toxicity of the combination therapy,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
319,NCT04354064,Freedom from progression,Distant-metastasis-free survival,,2019-05-29,RECRUITING,OBSERVATIONAL,['NA']
320,NCT01204177,Disease Control Rate (DCR),Biomarkers,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE2']
321,NCT02251782,Comparison of Adherence to Screening for Each Group,Diagnostic yield of colonoscopy:,,2014-10,COMPLETED,OBSERVATIONAL,['NA']
322,NCT04561336,overall survival,,,2018-08-10,COMPLETED,INTERVENTIONAL,['PHASE2']
323,NCT04145193,ctDNA clearance,Number of subjects with detectable anti-drug antibody (ADA) to novel agents in combination with mFOLFOX6,,2020-10-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
324,NCT02487225,Change in Interleukin-8 (IL-8) Levels From Admission Baseline at One Week.,,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE3']
325,NCT01867892,"the response rate, disease control rate, overall survival, and patients' quality of life.",,,2013-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
326,NCT01178944,Overall Response Rate,Time to Progression (TTP),MicroRNA Expression - miR-215-5p,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2']
327,NCT03816774,Adequate bowel preparation rate,Tolerability to the bowel cleansing regimen:questionnaire,Patients characteristics questionnaire,2019-06-15,COMPLETED,INTERVENTIONAL,['NA']
328,NCT00522405,Survival rate- calculated from the start of TACE,"a) Tumor response on dual phase CECT b) Patient tolerance c) Childs' status of cirrhosis- will be ascertained at one and two years of follow up depending upon the Childs' scoreScore <6- Childs'A, 7-9 Childs'B and >10 Childs'C",,2007-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
329,NCT03037034,Complete resection rate,Tumor status after endoscopic resection,,2015-01-01,COMPLETED,INTERVENTIONAL,['NA']
330,NCT04044430,Incidence of treatment-related grade 3 or higher adverse events (AEs),Disease control rate (DCR),,2020-08-31,TERMINATED,INTERVENTIONAL,['PHASE1']
331,NCT00332696,Number of Participants With Treatment Success From Day 10 to Day 13,Participant's Quality of Life Using the Edmonton Scale,,2005-09,COMPLETED,INTERVENTIONAL,['PHASE2']
332,NCT04275557,Radiogenomic Analyses,Progression Free Survival,,2020-02-18,RECRUITING,OBSERVATIONAL,['NA']
333,NCT03079596,Afebrile status without major complications,Time to first bowel motion,,2019-10-01,UNKNOWN,INTERVENTIONAL,['NA']
334,NCT06215677,the rate of R0 resection,Safety and tolerability of Camrelizumab administered,,2024-01-01,RECRUITING,INTERVENTIONAL,['NA']
335,NCT00731445,Phase II : Assess the objective tumor response rate in patients according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria,Phase II: Determine the PFS,,2008-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
336,NCT00311610,Objective response rate,Overall survival,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2']
337,NCT00431756,early predictors of esophageal cancer,,,2002-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
338,NCT01646593,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
339,NCT04390399,Progression Free Survival (PFS),Quality of Life (QoL),,2020-07-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
340,NCT05709886,Effectiveness analysis,Alpha-fetoprotein levels,,2023-02-28,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
341,NCT01037049,"The primary endpoint will be the difference in the proportion of patients in each arm, downstaged according to T stage [on MRI].",Radiotherapy related toxicity rates.,,2009-10-16,UNKNOWN,INTERVENTIONAL,['PHASE2']
342,NCT06254300,Aerobic capacity,Length of hospital stay,,2022-03-23,RECRUITING,INTERVENTIONAL,['NA']
343,NCT04057274,Cell viability (%),Concentration of Insulin-like growth factor 1 (ng/ml),,2019-09-23,UNKNOWN,INTERVENTIONAL,['NA']
344,NCT05203120,Number of participants with Radiation-induced liver disease (RILD),Reduction in mean liver dose,,2022-04-01,RECRUITING,INTERVENTIONAL,['NA']
345,NCT01861912,Time to Progression,Safety,Recurrence Rate,2013-06,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
346,NCT05444478,Over-all survival (OS) rate at 36 months,Complication rate,,2022-07-01,RECRUITING,INTERVENTIONAL,['NA']
347,NCT01237990,The number of accepted liver registrations associated with laparoscopically acquired surface data compared with the number of accepted liver registrations associated with open liver acquired surface data.,Comparison of registration errors from the full and half sufflation pressures to determine an impact of insufflation pressure on registration accuracy.,,2010-08,COMPLETED,OBSERVATIONAL,['NA']
348,NCT01191385,"Evaluation of patient demographics, disease characteristics, methods of patient evaluation, diagnosis and follow-up of patients with HCC, regionally and globally (collection of data on demographics, medical history, diagnostic measurements, follow-up)",To evaluate the comorbidities in patients with HCC and their influence on treatment options and outcome (collection of data on concomitant diseases),,2010-11,WITHDRAWN,OBSERVATIONAL,['NA']
349,NCT05733598,Overall Response Rate per modified RECIST 1.1,Overall Survival,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
350,NCT01346280,,,,2011-04-16,COMPLETED,OBSERVATIONAL,['NA']
351,NCT01589419,Determine the maximum tolerated dose (MTD) and/or establish the recommended phase two dose (RPTD),Assess the pharmacokinetic profile by area under the curve vs. dose of veliparib,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE1']
352,NCT02454686,Accuracy of Fibroscan in predicting complication after hepatectomy,,,2012-02,COMPLETED,OBSERVATIONAL,['NA']
353,NCT02759588,Overall Response Rate (ORR) by RECIST 1.1 (Phase 2),Clinical Benefit Rate,,2016-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
354,NCT02551471,Clinical resection rates in both countries,Analyses of semi-structured interviews,,2015-05-01,COMPLETED,OBSERVATIONAL,['NA']
355,NCT05587725,Prevalence of type-specific HPV types,,,2023-01-01,RECRUITING,OBSERVATIONAL,['NA']
356,NCT02175654,Progression free survival rate at 6 months,Changes in ECOG performance status over time from baseline,Biomarkers associated with cell and tumour growth and/or the mechanism of action of regorafenib and their correlation with patients' clinical progression for efficacy and safety parameters.,2014-06,TERMINATED,INTERVENTIONAL,['PHASE2']
357,NCT04220242,Validation of predictive accuracy biophysics-visualisation model,Realtime delineation display of tumour area including margins,,2019-12-30,UNKNOWN,OBSERVATIONAL,['NA']
358,NCT03612531,Incidence of adverse events,Improvement in tongue innervation on Electromyography (EMG) findings,,2018-08-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
359,NCT04032392,Overall survival (OS),Patients-based Quality of Life Evaluation,,2019-07-23,UNKNOWN,INTERVENTIONAL,['PHASE1']
360,NCT01589471,Efficacy of intra-rectal Botox-A injection on anorectal function as documented with standardized Wexner score,Safety of intra-rectal Botox-A injections as documented with adverse events monitoring,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2']
361,NCT01446874,Adherence to the Pre-operative Toothbrushing Regimen,Incidence of Fever,,2011-09-22,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
362,NCT01283204,progression free survival(PFS),,,2010-03-09,COMPLETED,INTERVENTIONAL,['PHASE2']
363,NCT06287749,3-year Disease-free survival (DFS),Time to molecular recurrence,,2024-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
364,NCT04029857,Patient well-being improvement,,,2019-03-14,WITHDRAWN,INTERVENTIONAL,['PHASE3']
365,NCT02316340,Efficacy Based on Progression Free Survival of Vorinostat and Hydroxychloroquine Compared to Regorafenib,Median Overall Survival (mOS),,2015-02-11,COMPLETED,INTERVENTIONAL,['PHASE2']
366,NCT01483027,Hepatic Progression-Free Survival (HPFS),Overall Survival,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
367,NCT06084780,Overall Rate of Survival,Overall Rate of Mortality,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
368,NCT04108481,Determine the maximum tolerated dose (MTD) of Yttrium-90 radioembolization combined with immunotherapy durvalumab to treat liver-predominant metastatic colorectal cancer (mCRC),Determine duration of response,Abscopal effects,2020-10-05,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
369,NCT02309632,Detection rate of PC and precancerous lesion,,,2015-11,WITHDRAWN,INTERVENTIONAL,['NA']
370,NCT00699816,Recurrence Free Survival(RFS) Rate,Cancer-specific Survival Rate,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3']
371,NCT02112357,The percentage of patients in whom a currently actionable molecular alteration was detected by genetic sequencing.,The number needed to enroll into the trial to identify one patient with a targetable genetic alteration and the number needed to enroll into the trial to treat one patient with a targeted agent.,Duration of response for patients who received a targeted treatment as a result of genetic sequencing.,2014-02,UNKNOWN,OBSERVATIONAL,['NA']
372,NCT03092128,Progression free survival,Number of patients with objective response and adverse events,,2014-06,UNKNOWN,OBSERVATIONAL,['NA']
373,NCT01531595,Efficacy,Response,,2012-02,RECRUITING,INTERVENTIONAL,['PHASE2']
374,NCT05748145,Impact of metronidazole on F.n. loads in CRC tissues.,Potential effects of metronidazole on the intestinal metabolic profile,,2023-09-11,RECRUITING,INTERVENTIONAL,['PHASE2']
375,NCT03573791,Comparing gene expression differences between poor response group and complete response group by using RNA sequencing.,Progression Free Survival(PFS),,2018-05-21,RECRUITING,OBSERVATIONAL,['NA']
376,NCT01737827,Time to progression using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1,Plasma pharmacokinetic parameter: Racc,,2013-03-25,TERMINATED,INTERVENTIONAL,['PHASE2']
377,NCT00920751,Primary outcome - success of cecal intubation without sedation,"Diagnostic yield, patients' current experience, willingness to repeat future colonoscopy, turn around time, and staff rating of satisfaction, and medication-related complications.",,2009-03,UNKNOWN,INTERVENTIONAL,['NA']
378,NCT01303159,Change From Baseline in Bile Duct Stricture Diameter,Number of Participants With Adverse Events,,2010-03,TERMINATED,INTERVENTIONAL,['NA']
379,NCT02292641,To change R0 resection rates for locally recurrent rectal cancers with the use of the proposed staging system.,To map original radiotherapy volumes (including integrated boosts) against types of recurrence,,2014-09-25,RECRUITING,INTERVENTIONAL,['NA']
380,NCT03756636,Rate of adverse events (according to the lexiconA ASGE).,,,2018-06-01,COMPLETED,INTERVENTIONAL,['NA']
381,NCT02365480,Number of Participants With Organ Toxicity Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version (v.) 4.0,Severity of Histologic Inflammation,,2016-06-16,COMPLETED,INTERVENTIONAL,['PHASE1']
382,NCT00220116,Objective response rates,Number undergoing liver resections/curative resection (Ro) rate,,2002-08,COMPLETED,INTERVENTIONAL,['PHASE2']
383,NCT04751396,Decisional conflict scale,Patient's perception of usefulness of the tool,,2022-04-20,RECRUITING,OBSERVATIONAL,['NA']
384,NCT02885142,Number of complete excision for TEM compare to number of complete excision for ESD in rectal carcinomas staged usT1N0 and rectal adenomas.,,,2016-11,TERMINATED,INTERVENTIONAL,['NA']
385,NCT01403883,Evolution of Psychological anxiety score (STAI/Beck),Specific stoma related morbidity,,2011-10,UNKNOWN,INTERVENTIONAL,['NA']
386,NCT04811833,Comparison of anastomosis leakage rate at different timepoints in postoperative course,Assessment of suture material handling parameters,,2022-07,WITHDRAWN,OBSERVATIONAL,['NA']
387,NCT04879979,Symbol Digit Modalities Test (SDMT),PROMIS Short Form: Pain 3a.,,2021-01-12,RECRUITING,INTERVENTIONAL,['NA']
388,NCT02992886,2-year disease-free survival probability (%),QOL,Exploratory endpoints,2016-09,COMPLETED,INTERVENTIONAL,['PHASE2']
389,NCT03468712,Postoperative overall morbidity rate,Completion rate of laparoscopic surgery,,2018-03-31,UNKNOWN,INTERVENTIONAL,['NA']
390,NCT02838186,number of additional identified polyps with right colon scope retroflexion,Rate of retroflexion-related adverse events.,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
391,NCT04660929,Assess the safety and tolerability of CT-0508 in combination with pembrolizumab by estimating the frequency and severity of adverse events in subjects with HER2 overexpressing solid tumors (CT-0508 and pembrolizumab substudy only),Estimate progression-free survival (PFS).,,2021-02-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
392,NCT06331273,Tumor recurrence rate,,,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
393,NCT06108596,cCR,Disease-free survival (DFS) and overall survival (OS),,2023-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
394,NCT03485209,Confirmed ORR per blinded independent central review (BICR) (Part E),Incidence of anti-therapeutic antibodies (ATAs),,2018-06-25,RECRUITING,INTERVENTIONAL,['PHASE2']
395,NCT04715633,Clinical complete response or pathological complete response,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2020-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
396,NCT05092113,Overall incidence of chemotherapy-induced diarrhea ≥ grade 1,Overall incidence of grade 3/4 gastrointestinal adverse events,Changes of fecal flora and enteritis-associated inflammatory factors,2021-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3']
397,NCT01284231,Evaluate the safety profile in adult subjects with advanced gastrointestinal (GI) adenocarcinomas who have no available standard or curative treatments.,Immunogenicity of MED-565,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE1']
398,NCT04405206,OPR(organ preservation rate),SFS(stoma-free survival),,2020-05-25,UNKNOWN,OBSERVATIONAL,['NA']
399,NCT00003001,,,,1997-04,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
400,NCT03763266,Bowel preparation,Withdrawal time,,2018-12-06,COMPLETED,INTERVENTIONAL,['NA']
401,NCT00014651,,,,2001-03,TERMINATED,INTERVENTIONAL,['PHASE3']
402,NCT01127555,Response rate,To estimate overall survival,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2']
403,NCT03223662,BH3 Profiling of Pre-neoadjuvant Tumor Biopsy and Outcome of Pathological Complete Response After Neoadjuvant Chemoradiotherapy in Patients With Esophageal Adenocarcinoma or Squamous Cell Carcinoma,Overall Survival (OS) in Esophageal Adenocarcinoma (EAC) and Esophageal Squamous Cell Carcinoma (ESCC) Patients Undergoing Neoadjuvant Chemoradiotherapy (nCRT) and Esophagectomy,,2017-10-31,TERMINATED,INTERVENTIONAL,['PHASE2']
404,NCT06241703,Rate of urinary dysfunction,International Prostate Symptom Score,,2024-03-20,RECRUITING,INTERVENTIONAL,['NA']
405,NCT00384176,Progression Free Survival,Time to Worsening of Health Related Quality of Life (QOL) Based on the FACT Colorectal Symptom Index (FCSI),,2006-08-30,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
406,NCT01160926,To determine the MTD (maximum tolerated dose) of AZD6244 or AZD2171 when combined with pre-operative capecitabine and radiotherapy in patients with locally advanced rectal cancer.,To explore biological and radiological markers of response or toxicity,,2010-07,TERMINATED,INTERVENTIONAL,['PHASE1']
407,NCT04863144,plasma concentrations of 3'-p-hydroxypaclitaxel,Incidence of adverse effects,,2020-08-01,UNKNOWN,OBSERVATIONAL,['NA']
408,NCT01227746,,,,2011-09,UNKNOWN,OBSERVATIONAL,['NA']
409,NCT02230176,To determine the 12 months PFS,Best response,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
410,NCT01452295,Gather data,,,2010-06,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
411,NCT00202800,To evaluate the response rate,To describe the toxicity profile,,2002-03,COMPLETED,INTERVENTIONAL,['PHASE2']
412,NCT04528745,Thrombocytopenia,Hospitalization,Other adverse event(s) added by patient,2020-05-04,COMPLETED,OBSERVATIONAL,['NA']
413,NCT01526239,Communication with primary care physicians about CRC screening,,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
414,NCT05473325,Signal to Noise,,,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
415,NCT00555672,Number of Participants With First-cycle Dose Limiting Toxicities (DLTs),Progression-Free Survival (PFS),,2008-08,COMPLETED,INTERVENTIONAL,['PHASE1']
416,NCT05604378,EBV positive gastric cancer is associated with increased Ki-67 and decreased EGFR.,,,2022-08-03,COMPLETED,OBSERVATIONAL,['NA']
417,NCT00601406,"Correlation of association between common genetic variations, reported by single nucleotide polymorphisms (SNP) in relevant candidate genes, with individual patient variability in normal tissue radiation response and toxicity","PRS analyses against tumor control probability (TCP), using survival as a surrogate for TCP where necessary, and normal tissue complications vs tumor control probability",,2006-03,UNKNOWN,INTERVENTIONAL,['NA']
418,NCT01811277,Objective response rate for SOX sequential S-1,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,2010-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
419,NCT02199236,maximum tolerated dose (MTD),tumor response,,2014-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
420,NCT04475640,Impact of germline genetic testing on both therapeutic management and targeted cancer prevention,,,2019-12-13,RECRUITING,INTERVENTIONAL,['NA']
421,NCT00639509,Best Overall Response Rate (ORR),Median Overall Survival,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
422,NCT00923299,Objective response rate as assessed by RECIST criteria (Phase II),Overall survival,,2008-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
423,NCT03508180,Evaluation of nausea and vomiting,Body image,,2018-06-14,COMPLETED,INTERVENTIONAL,['NA']
424,NCT01904955,data concerning evolving relapse,,,2010-09,COMPLETED,OBSERVATIONAL,['NA']
425,NCT02047188,NBI prediction for lesion histology and invasion,immunohistochemical outcome of microvessel count and MMP-7,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
426,NCT01606098,Overall survival,Overall survival in patients in whom treatment according to protocol was initiated,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE3']
427,NCT00615056,Progression Free Survival (PFS),"Change From Baseline in MDASI-D Symptom Interference Score at Day 1 of Cycles 2-5, Day 1 of Every Odd-numbered Cycle Throughout the Study and End of Treatment (Cycle 65) or Withdrawal",,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
428,NCT00727441,"Change in the Number and Function of Peripheral Mesothelin-specific CD8+ T Cells and CD4+, FoxP3+, and GITR+ Tregs",Disease Free Survival,,2008-07-02,COMPLETED,INTERVENTIONAL,['PHASE2']
429,NCT04536077,Amount of intratumoral conventional dendritic cells (cDCs),,,2021-08-13,TERMINATED,INTERVENTIONAL,['PHASE2']
430,NCT05997056,Efficacy of nab-sirolimus,Overall survival,,2023-11-07,RECRUITING,INTERVENTIONAL,['PHASE2']
431,NCT06324097,negative predictive value,intra-observer agreement,,2024-04-01,RECRUITING,OBSERVATIONAL,['NA']
432,NCT04791735,The primary objective of the study will be to demonstrate the superiority of the laparoscopic approach over the open approach in reducing postoperative morbidity in HCC patients.,Overall and disease free survivals.,,2021-05-21,RECRUITING,INTERVENTIONAL,['NA']
433,NCT05233358,Progression Free Survival,The incidence of adverse events and serious adverse events,,2022-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
434,NCT00814619,Pathological complete or near-complete response (Dworak grade 3 and 4),Adverse events,,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2']
435,NCT01534546,3 year Disease Free Survival,Adverse Event,,2012-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
436,NCT04181645,ORR：Objective Response Rate by IRC,OS: overall survival,,2019-06-29,COMPLETED,INTERVENTIONAL,['NA']
437,NCT02626312,Maximum dose constraint,Overall survival,Tumor biomarker expression in serum,2016-02-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
438,NCT00216437,Dose-limiting toxicity.,,,2004-12,TERMINATED,INTERVENTIONAL,['PHASE1']
439,NCT05687318,PMR,AMR,,2022-09-20,COMPLETED,INTERVENTIONAL,['NA']
440,NCT02745483,Cumulative 3-year LTP rate,3-year Recurrence free survival rate,Technical success rate,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
441,NCT05466565,recurrence-free survival time,Dynamic changes of cccDNA,,2021-12-01,RECRUITING,OBSERVATIONAL,['NA']
442,NCT05131958,Perception measure,,,2021-12,UNKNOWN,OBSERVATIONAL,['NA']
443,NCT03750669,Disease-free survival,Serious adverse events incidence,,2018-10-20,RECRUITING,INTERVENTIONAL,['PHASE2']
444,NCT02459041,Strain histogram and contrast enhancement during EUS in pancreatic masses and lymph nodes,,,2015-01,COMPLETED,OBSERVATIONAL,['NA']
445,NCT03878524,Feasibility of implementing an individualized treatment strategy (number of participants to receive first dose),Time to decline (TTD),,2020-04-01,TERMINATED,INTERVENTIONAL,['PHASE1']
446,NCT05634720,Feasibility of HA Chemotherapy for PDAC,Overall Survival,,2024-01-02,RECRUITING,INTERVENTIONAL,['PHASE4']
447,NCT00667628,Time to Appearance of New Lesions (TTNL),Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs),,2008-04-24,TERMINATED,INTERVENTIONAL,['PHASE2']
448,NCT02268435,Maximal tolerated dose and recommended dose,"Imatinib and dovitinib plasma concentrations vs time profile, and basic pharmacokinetics parameters",,2015-03,WITHDRAWN,INTERVENTIONAL,['PHASE1']
449,NCT01196390,Disease-free Survival (DFS),Number of Participants With Any Cardiac Adverse Events Regardless of Attribution,,2011-02-14,COMPLETED,INTERVENTIONAL,['PHASE3']
450,NCT02316834,Change in ribonucleic acid (RNA) protein expression,Change in RNA protein expression,,2015-06-02,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
451,NCT02597465,"Progression Free Survival (PFS) of subjects treated with SPARC1507 versus IC, per Response Evaluation Criteria in Solid Tumors version 1.1",Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2018-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE3']
452,NCT05983367,Overall Response Rate,Disease Control Rate,,2023-10-10,RECRUITING,INTERVENTIONAL,['PHASE2']
453,NCT03812796,Main Phase IIB (efficacy) phase: Objective response rate using RECIST 1.1 criteria,Duration of objective response according to RECIST 1.1,,2019-01-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
454,NCT02931890,Event-Free survival,Toxicity,,2017-12-21,RECRUITING,INTERVENTIONAL,['PHASE2']
455,NCT00003137,response rate,survival,,1997-12,COMPLETED,INTERVENTIONAL,['PHASE2']
456,NCT06202066,PFS (Part 2),Incidence of adverse events (Part 2),,2024-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
457,NCT02584400,"Quantification of tumor hypoxia with [18F] HX4 PET imaging, evaluated by the measurement of a tumor-to-background (T/B) ratio on the [18F]HX4 PET/CT",Spatial correlation of [18F] HX4-PET with imaging three months after treatment using a correlation coefficient,,2016-05,TERMINATED,INTERVENTIONAL,['PHASE2']
458,NCT04124991,TTP,Number of participants with treatment-related adverse events,,2020-06-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
459,NCT06239870,pCR,TRG,,2023-04-01,RECRUITING,INTERVENTIONAL,['PHASE2']
460,NCT00154804,Clinical and pathological response rates,Toxicity,,2001-08,COMPLETED,INTERVENTIONAL,['PHASE2']
461,NCT01071655,progression-free survival,Evaluation of KRAS status as a molecular marker,,2010-02,COMPLETED,INTERVENTIONAL,['PHASE2']
462,NCT05743049,"To create a comprehensive system to collect, catalogue and store blood specimens from subjects with pancreatic cancer for future research use.",To integrate the data and specimens to permit the most informative clinical-biologic research platform.,,2023-02-27,RECRUITING,OBSERVATIONAL,['NA']
463,NCT02404363,Response to treatment based on RECIST 1.1 criterion,Bleedings,,2016-01-11,TERMINATED,INTERVENTIONAL,['PHASE3']
464,NCT00533975,,,,2007-09,UNKNOWN,OBSERVATIONAL,['NA']
465,NCT05902988,Dose Expansion: Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1,Dose Escalation & Dose Expansion: Increase in Micronuclei in Circulating Tumor Cells,,2023-10-18,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
466,NCT01845467,Evaluating the additive benefit of Secretin MRCP in differentiating focal AIP and Pancreatic malignancy,Efficacy of Secretin MRCP in monitoring therapeutic improvement in AIP patients on steroid trial,,2013-02,WITHDRAWN,OBSERVATIONAL,['NA']
467,NCT05718492,Progress Free Survival (PFS),Adverse Events (AEs),,2022-10-18,RECRUITING,INTERVENTIONAL,['NA']
468,NCT01372202,Pathological Complete Response,Esophageal Tumor CHFR Methylation and Detection in Plasma,,2011-06,TERMINATED,INTERVENTIONAL,['PHASE2']
469,NCT04880772,Inflammatory cytokines,Quality of life measure (Mental Adjustment to Cancer Scale),,2021-07-15,COMPLETED,INTERVENTIONAL,['NA']
470,NCT06053996,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,Overall survival (OS),,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
471,NCT06271291,Follow subjects longitudinally and collect biospecimens and follow-up data and record medical outcomes,,,2024-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
472,NCT00427310,Survival,,,1984-03,COMPLETED,INTERVENTIONAL,['PHASE3']
473,NCT00640692,,,,2007-12,WITHDRAWN,OBSERVATIONAL,['NA']
474,NCT05111795,Lung shunt prediction,Number of patients downstaged to liver resection or liver transplantation,,2022-01-17,COMPLETED,OBSERVATIONAL,['NA']
475,NCT03464968,6 months overall survival rate,Number of Participants With Treatment-Related Adverse Events as Assessed by NCI CTC version 4.0,,2015-07-29,COMPLETED,INTERVENTIONAL,['PHASE2']
476,NCT05665348,Overall survival (Phase III),Objective response rate (OR) under treatment (Phase III),,2023-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
477,NCT04224636,24-months survival rate,Adverse Events,,2020-06-10,RECRUITING,INTERVENTIONAL,['PHASE2']
478,NCT01998230,Postoperative complication,Length of postoperative stay,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3']
479,NCT02564666,Drug compliance for patients with HCC who is taking Sorafenib compliance,Duration of dosing period,The satisfaction with Information about Medicines Scale (SIMS) score,2015-10,UNKNOWN,INTERVENTIONAL,['NA']
480,NCT00768157,Overall survivals,Recurrence rate,,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
481,NCT00910572,Time to progression (TTP),Time-to-symptomatic progression (TTSP),,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
482,NCT05241249,R0 resection rate,Ki-67 expression in tumor cells,,2022-02-01,RECRUITING,INTERVENTIONAL,['PHASE2']
483,NCT02677038,Objective response rate (defined as complete response or partial response) assessed using Response Evaluation Criteria in Solid Tumors 1.1,Incidence of unacceptable toxicity,,2016-11-11,COMPLETED,INTERVENTIONAL,['PHASE2']
484,NCT02494687,,,,na,AVAILABLE,EXPANDED_ACCESS,['NA']
485,NCT03163992,Overall Response Rate,Progression-free Survival (PFS) and Overall Survival (OS),,2017-12-26,COMPLETED,INTERVENTIONAL,['PHASE2']
486,NCT04733963,Progression Free Survival,QoL,Exploratory Endpoint,2021-03-01,RECRUITING,INTERVENTIONAL,['PHASE2']
487,NCT05008809,Progression-free survival (PFS) time,Quality of life (QoL),,2021-12-06,RECRUITING,INTERVENTIONAL,['PHASE3']
488,NCT05144854,Overall survival (OS),Adverse event,,2021-11-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
489,NCT01857141,Heart rate variability analysis,Epidural injection,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
490,NCT03693378,Validation of IMMray™ PanCan-d test,Evaluation of the IMMray™ PanCan-d test performance,,2016-01-19,COMPLETED,OBSERVATIONAL,['NA']
491,NCT03208777,presence of telomeric abnormalities,,,2017-08-01,UNKNOWN,OBSERVATIONAL,['NA']
492,NCT05191498,Average tumour dose by SPECT imaging,Tumor response by RECIST 1.1,,2021-12-13,COMPLETED,INTERVENTIONAL,['NA']
493,NCT00855634,Overall survival,Quality of life Perioperative morbidity and mortality 1-year survival and 2-year survival,,2009-08,TERMINATED,INTERVENTIONAL,['NA']
494,NCT05559229,To evaluate the efficacy of measuring value of AFP for patients with gallbladder cancer.,,,2021-01-15,COMPLETED,OBSERVATIONAL,['NA']
495,NCT05777707,Disease-free survival (DFS),Overall survival (OS),,2020-10-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
496,NCT05514769,Gastroesophagus reflux disease apprised by questionnaire,Long-term outcome,,2021-01-01,RECRUITING,INTERVENTIONAL,['NA']
497,NCT04299048,Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities,Serum Total Ctrough of PF-06946860,,2020-11-17,COMPLETED,INTERVENTIONAL,['PHASE1']
498,NCT01691391,The predictive value of 18F-FDG-PET for the absence of response compared to the lack of clinical benefit at convential CT at 2 months,Grade of skin toxicity,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
499,NCT04932187,Rate of adverse events as assessed by CTCAE v5.0,Duration of response,,2021-08-01,RECRUITING,INTERVENTIONAL,['PHASE1']
500,NCT01106261,Feasibility of recruitment,Survival,,2010-12-02,COMPLETED,INTERVENTIONAL,['NA']
501,NCT05702684,Patient experience,,,2023-07-31,RECRUITING,OBSERVATIONAL,['NA']
502,NCT01945177,Detection rate of intestinal metaplasia,Aggregate detection rate of focal gastric lesions,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
503,NCT00580021,The overall objective of the protocol is to examine the hypothesis that hereditary cancers are distinct in clinical characteristics and outcome from those that arise in the absence of a known predisposition.,,,2006-01,WITHDRAWN,OBSERVATIONAL,['NA']
504,NCT03969576,Objective response rate,Duration of response,,2020-09-15,UNKNOWN,INTERVENTIONAL,['NA']
505,NCT03178409,Survival analysis,,,2004-01-01,COMPLETED,OBSERVATIONAL,['NA']
506,NCT05819099,Accuracy,,,2023-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
507,NCT03077334,Clinical PET type assessed by surgeons from preoperatively preformed PET imaging,Number of patients with recurrence of cancer or mortality from cancer following operation,,2014-10-07,COMPLETED,OBSERVATIONAL,['NA']
508,NCT04654403,DOR,ORR,,2022-01-01,UNKNOWN,INTERVENTIONAL,['NA']
509,NCT03511222,Recommended phase II dose (RP2D) of vorolanib plus nivolumab,Safety and toxicity of vorolanib plus nivolumab as measured by the number and type of adverse events experienced by participant,,2018-09-11,TERMINATED,INTERVENTIONAL,['PHASE1']
510,NCT04718909,Progression free survival (PFS) assessed by investigators according to Response Evalutaion Criteria in Solid Tumors (RECIST) v1.1 and immune-related RECIST (irRECIST),DCR assessed by investigators according to mRECIST.,,2021-01-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
511,NCT03198338,opioid consumption up to 24 hours,sedation score,,2017-07-01,UNKNOWN,INTERVENTIONAL,['NA']
512,NCT05213221,Objective reponse rate (ORR),Safety of treatment,,2022-03-14,COMPLETED,INTERVENTIONAL,['PHASE2']
513,NCT03418428,Intestinal microbiome composition,Serum DAO,,2018-04-01,COMPLETED,OBSERVATIONAL,['NA']
514,NCT01291407,"To define dose limited toxicities(DLT) of S-1, peroral BID, in treatment days concurrently with radiation therapy (RT) in locally advanced or recurrent gastric cancer.","To define maximum tolerated dose(MTD) of S-1, peroral BID, in treatment days concurrently with radiation therapy",,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
515,NCT00366457,Time to Tumor Progression,Overall Survival,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2']
516,NCT00077259,,,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2']
517,NCT05661110,"Relationship between the status, numerical changes of ctDNA during HIPEC combined with PD1/PDL1 inhibitor conversion therapy and postoperative R0 resection rate.",Genomic changes of ctDNA and see if they are predictive of relapse-Free Survival.,Genetic and transcriptional profiling results.,2023-01-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
518,NCT05937295,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of the peptide vaccine in combination with anti-PD-L1 immune checkpoint inhibition,,,2023-09-26,RECRUITING,INTERVENTIONAL,['PHASE1']
519,NCT04689594,Proportion of subjects without stenosis,,,2021-02-04,TERMINATED,INTERVENTIONAL,['PHASE3']
520,NCT01934829,Prophylactic topical application of ointment to reduce the hand-foot skin reactions in patients with hepatocellular carcinoma treated with sorafenib,The percentage of patients discontinuing treatment,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2']
521,NCT01851941,"clinical response rate as assessed using RECIST criteria, with computed tomography (CT) scans at baseline and after 4cycles of chemotherapy",overall survival,Pharmacologic Genetic Marker,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2']
522,NCT01086683,psychosocial well-being (as assessed by the EORTC-QLQ C30 Quality of life core questionnaire by the European Organization of Research and Treatment in Cancer (EORTC-QLQ C30) and the Profile of Mood States Short form (POMS-SF),self-efficacy as measured with the General Self-Efficacy Scale (GSE),,2004-05,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
523,NCT04202523,DFS,OS,,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
524,NCT00002475,Survival (patients without evaluable disease),,,1991-04,COMPLETED,INTERVENTIONAL,['PHASE2']
525,NCT03794440,Progression-free survival (PFS),EORTC QLQ-HCC18,,2019-02-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
526,NCT03332433,Incidence of hypoxia,Other adverse events,,2017-11-10,COMPLETED,INTERVENTIONAL,['NA']
527,NCT04193696,Objective response rate,Abscopal effects rate,,2020-01-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
528,NCT01322178,Resection rate (R0),Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
529,NCT02344810,Progression-free survival (Phase II),Evaluation of MET amplification and MET expression as determined by DAKO IHC (Phase II),,2015-03-06,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
530,NCT00002716,Time to progression,,,1996-01,COMPLETED,INTERVENTIONAL,['PHASE3']
531,NCT00614653,"Highest Tolerated Dose of Capecitabine, Erlotinib Hydrochloride, and Bevacizumab + Radiation",Response Rate of Addition of Bevacizumab and Erlotinib to Capecitabine-Based Chemoradiation,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE1']
532,NCT00508443,Patient Response (Pain Relief),,,2002-10-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
533,NCT02964455,Maximum tolerated dose,Dynamic plasma concentration of docetaxel and nedaplatin,,2016-11,COMPLETED,INTERVENTIONAL,['PHASE1']
534,NCT01909856,Complete Response(CR) within 24-120 hours after chemotherapy,Incidence of Adverse events,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2']
535,NCT04693754,"Rate of patient report of symptoms related to procedure (Acute pancreatitis, abdominal pain, infection/abscess, venous thrombosis, & fever)",,,2020-07-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
536,NCT00819780,Progression-free Survival (PFS),Number of Participants With Adverse Events (AEs),,2009-04-24,COMPLETED,INTERVENTIONAL,['PHASE2']
537,NCT03375281,1 year local tumor progression,,,2017-11-20,COMPLETED,INTERVENTIONAL,['NA']
538,NCT00699881,time to progression,toxicity,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE2']
539,NCT01318447,Local recurrence-free survival,Local recurrence-free survival,,2011-01,TERMINATED,INTERVENTIONAL,['PHASE2']
540,NCT01416688,Psychometric properties of the FACT-EGFRI 18,"Feasibility as measured by accrual, time to specified accrual, time to complete forms",,2011-11-15,COMPLETED,OBSERVATIONAL,['NA']
541,NCT01178801,the relationship between the clinical data and the decision of treatment strategies,,,2010-03,UNKNOWN,OBSERVATIONAL,['NA']
542,NCT01869088,Overall survival time,Tumor response,,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
543,NCT00422877,Response Rate,Survival,,2007-01,TERMINATED,INTERVENTIONAL,['PHASE2']
544,NCT04129177,Surgical site infection rate,,,2018-10-01,COMPLETED,OBSERVATIONAL,['NA']
545,NCT03279289,Progression-free survival,VES-13 score (Vulnerable Elders Survey) as the utility measure for health deterioration,Biomarkers in serum and tumour tissue associated with cell and tumour growth and/or involved in the mechanism of action of FOLFIRI+aflibercept and their correlation with efficacy parameters,2017-10-25,COMPLETED,INTERVENTIONAL,['PHASE2']
546,NCT04941300,Colonoscopy after abnormal FIT (primary),Follow-up process,Repeat screening (exploratory outcome),2021-06-08,ENROLLING_BY_INVITATION,INTERVENTIONAL,['PHASE3']
547,NCT02242786,oral morphine equivalent doseresponse criteria,Quality of Life,,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
548,NCT05448677,Progression-Free Survival (PFS),Objective response rate (ORR),,2022-12-15,RECRUITING,INTERVENTIONAL,['PHASE2']
549,NCT04602026,Health-related quality of life (composite measure),,,2020-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
550,NCT01560533,Body representations,,,2011-11,COMPLETED,INTERVENTIONAL,['NA']
551,NCT04522908,Treatment discontinuation rate due to treatment-related adverse events,"Correlation of biomarkers potentially associated with clinical efficacy (OS, PFS and ORR)",,2020-10-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
552,NCT02580422,"The number of patients who have changes in echocardiography, pulmonary function or one or more part of their functional evaluation tests",Change in levels of cytokines,,2015-10-01,TERMINATED,OBSERVATIONAL,['NA']
553,NCT00336856,Response Rate (RR),Overall Survival,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
554,NCT05607186,Correlation between mrTRG and pTRG,Prognostic value of mrTRG on survival outcomes of rectal cancer patients,,2011-01-01,COMPLETED,OBSERVATIONAL,['NA']
555,NCT06003673,recurrence-free survival (RFS),Overall Survival (OS),,2023-07-01,RECRUITING,INTERVENTIONAL,['PHASE4']
556,NCT03852238,exposure to Viral hepatitis B,exposure to viral hepatitis C,fats,2010-08-18,COMPLETED,OBSERVATIONAL,['NA']
557,NCT03013153,5-years overall survival rate,Sexual function scoring,,2016-12,UNKNOWN,INTERVENTIONAL,['NA']
558,NCT05873972,response rate,overall survival,,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
559,NCT02728219,overall survival,,,2012-05,COMPLETED,INTERVENTIONAL,['NA']
560,NCT01031628,Evaluation of Lesions for Progression or Response Via RECIST Criteria,,,2010-01,TERMINATED,INTERVENTIONAL,['PHASE3']
561,NCT00350142,Rate of Local Control,Median Overall Survival Time,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
562,NCT04898426,Bowel preparation quality,Polyp detection rate,,2021-08-13,UNKNOWN,INTERVENTIONAL,['NA']
563,NCT04401787,oncological outcome,early locoregional recurrence,,2016-12-11,COMPLETED,INTERVENTIONAL,['NA']
564,NCT03659292,Overall survival (OS),Blood levels of ropivacaine and sufentanil,,2018-09,UNKNOWN,INTERVENTIONAL,['NA']
565,NCT04535492,"Rate of successful completion of colorectal cancer screening noted via electronic health record having colonoscopy, fecal occult blood, or non invasive screening option result for the patient.",Average score of clinician experience and satisfaction as assessed via Likert scale survey.,,2022-01-04,WITHDRAWN,INTERVENTIONAL,['NA']
566,NCT05059665,Evaluate the performance (sensitivity/specificity) of the HelioLiver Test for all stage HCCs,,,2020-04-20,COMPLETED,OBSERVATIONAL,['NA']
567,NCT01248299,Overall survival,Cost analysis,,2011-01,TERMINATED,INTERVENTIONAL,['PHASE2']
568,NCT05176834,Proportion of patients performing at least 50% of expected daily treatments during radiotherapy period.,The proportion of the patients that will experience severe oral mucositis,,2022-01-31,UNKNOWN,INTERVENTIONAL,['NA']
569,NCT04288661,POD of intra-abdominal complication detection,Readmissions,,2020-02-28,RECRUITING,INTERVENTIONAL,['NA']
570,NCT01930383,Numbers of circulating tumor cells,Clinical characteristics,,2013-10,UNKNOWN,OBSERVATIONAL,['NA']
571,NCT00513461,Change in Serum AFP Levels,Changes in Quality of Life - Mental Score,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2']
572,NCT00069121,Disease-Free Survival (DFS) [Time to Event],Number of Participants With at Least One Adverse Event by Most Severe Intensity,,2003-04-18,COMPLETED,INTERVENTIONAL,['PHASE3']
573,NCT02009423,Recurrence Free Survival (RFS),Overall Survival (OS),,2015-07,TERMINATED,INTERVENTIONAL,['PHASE3']
574,NCT01097265,Percentage of successful sentinel lymph node mapping procedures using multivariate analysis (stage 2),Stratified analysis of DFS and OS according to total harvested lymph nodes per resected specimen and chemotherapy regimen (capecitabine and oxaliplatin versus capecitabine alone) (stage 2),,2010-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
575,NCT04168931,Frequency of HER2 expression,,,2020-01-01,TERMINATED,INTERVENTIONAL,['PHASE2']
576,NCT01434069,Maximum Tolerated Dose (MTD),Number of Participants With Tumor Response,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE1']
577,NCT04131062,MyCode enrollment decision,,,2019-11-01,COMPLETED,INTERVENTIONAL,['NA']
578,NCT01652833,Proportion of oncologists who administer Vectibix simultaneously with oxaliplatin-containing chemotherapy in mCRC patients with mutant KRAS tumors or patients with tumor KRAS status unknown,,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
579,NCT03259828,Interfraction sigmoid colon organ motion,Setup errors,,2017-12-06,COMPLETED,INTERVENTIONAL,['NA']
580,NCT00002783,,,,1996-05,COMPLETED,INTERVENTIONAL,['PHASE2']
581,NCT01774786,Overall Survival,Cmin of Trastuzumab,,2013-06-10,COMPLETED,INTERVENTIONAL,['PHASE3']
582,NCT02013089,Overall survival,Response rate,Disease control rate,2013-12,UNKNOWN,INTERVENTIONAL,['NA']
583,NCT00155272,The primary endpoint is the feasibility and tolerability of thalidomide plus radiotherapy.,The secondary end point is correlation of parameters of tumor perfusion assessed by DCEMRI and serum cytokine levels with objective tumor response.,,2005-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
584,NCT01008917,Maximum tolerated dose,"Incidence of progression-free survival, overall survival, and disease control rate",,2009-11-17,COMPLETED,INTERVENTIONAL,['PHASE1']
585,NCT02507765,"Feasibility of SBRT in combination with TACE, measured by the number of patients able to tolerate all study procedures",Progression-free survival,Change in plateau signal intensity calculated from the DCE curve,2015-07,COMPLETED,INTERVENTIONAL,['PHASE1']
586,NCT03239184,Relief degree of tumors,Overall survival（OS）,,2017-09-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
587,NCT05065515,Degree of tumor regression,The relative abundance of species,Species richness,2021-10-01,RECRUITING,OBSERVATIONAL,['NA']
588,NCT00427570,,,,1977-09,COMPLETED,INTERVENTIONAL,['PHASE3']
589,NCT01112046,Short-term morbidity,Local recurrence,,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
590,NCT01298999,Number of Participants That Experienced Change in Any Biomarker Expression,Number of Participants That Experienced Adverse Events,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE2']
591,NCT01376453,Maximum Tolerated Dose (MTD),Number of Participants With Serious Adverse Events (SAEs),,2011-06,COMPLETED,INTERVENTIONAL,['PHASE1']
592,NCT06019702,Dose-limiting Toxicity (DLT),Cytokines Level [immunogenicity],,2023-09-08,RECRUITING,INTERVENTIONAL,['PHASE1']
593,NCT05446558,Overall survival,Cost of tests during hospitalization,,2022-02-28,RECRUITING,INTERVENTIONAL,['NA']
594,NCT04525807,Objective response rate,Overall survival,,2020-09-01,UNKNOWN,OBSERVATIONAL,['NA']
595,NCT00828594,Time to disease progression assessed when 60 events have been observed,Pharmokinetics of RAD001 at pre-dose and 1 hour and 2 hours post-dose,,2008-12,TERMINATED,INTERVENTIONAL,['PHASE1']
596,NCT01771146,Progression Free Survival (PFS) as defined by the length of time that a patient survives without any signs or symptoms of that cancer or any other type of cancer,• R0 resection as defined as microscopically negative margins,,2012-10,UNKNOWN,INTERVENTIONAL,['NA']
597,NCT03641313,Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 response criteria,Overall survival (OS),Presence of other deoxyribonucleic acid (DNA) damage response defects (DDRD),2020-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
598,NCT01085617,Event-free survival,Mucositis score in patients treated with palifermin,,2010-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
599,NCT02845479,Feasibility of study protocol,Feasibility of recruitment,Natural kill cell activation,2018-12-07,COMPLETED,INTERVENTIONAL,['PHASE3']
600,NCT00491855,Maximum Tolerated Dose (MTD),,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE1']
601,NCT03592641,Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1),Months of Progression-Free Survival (PFS),,2019-07-25,TERMINATED,INTERVENTIONAL,['PHASE2']
602,NCT02450656,Progression Free Survival (Phase II),"Efficacy (Phase II) (Overall response rate (ORR), duration of response (DOR) , time to response (TTR) and overall survival (OS) per RECIST v1.1)",Pharmacogenetics profiling to assess predictors of response and resistance- inducing mutations,2015-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
603,NCT01352728,Two-year survival rate,Tissue and Serum Biomarkers,,2011-05-18,COMPLETED,INTERVENTIONAL,['PHASE2']
604,NCT05361538,Comparison of progression-free survival between MSA and traditional MWA in HCC,Comparison of the complications rate of MSA and traditional MWA in HCC,,2022-06-22,RECRUITING,INTERVENTIONAL,['NA']
605,NCT00192088,The primary objective of this study is to determine the response rate of Pemetrexed plus oxaliplatin as first-line therapy in patients with advanced gastric carcinoma.,"Determinants of efficacy and toxicity of the treatment with pemetrexed and oxaliplatin in the patient population by means of pharmacogenomic and pharmacogenetics investigations: Quantitative analysis of TS, DHFR, GARFT, RFC, MRP5, DPD, TP, FPGS and ERCC1",,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2']
606,NCT02877368,sarcopenia,Imatinib-induced toxicities,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
607,NCT05422547,Tumour recurrence,Possible economic impact,,2022-04-01,RECRUITING,OBSERVATIONAL,['NA']
608,NCT05530343,Diagnostic yield of intestinal metaplasia (Screening population only),Diagnostic yield of dysplasia (Screening population only),,2022-10-03,RECRUITING,INTERVENTIONAL,['NA']
609,NCT00121745,To determine the dose limiting toxicity and maximum tolerated dose of Rexin-G administered as intravenous infusions; To evaluate pharmacokinetics of Rexin-G,To assess anti-tumor activity of intravenously administered Rexin-G and obtain preliminary data on biochemical markers of tumor response,,2005-07,TERMINATED,INTERVENTIONAL,['PHASE1']
610,NCT01381913,,,,2005-10,COMPLETED,OBSERVATIONAL,['NA']
611,NCT03871790,Identification of tumor specific mutations on the genomic level,Identification of neo-antigens epitopes at protein level,,2019-04-01,COMPLETED,OBSERVATIONAL,['NA']
612,NCT00027495,,,,2001-12,COMPLETED,INTERVENTIONAL,['PHASE1']
613,NCT05679674,Median Progression Free Survival (PFS),Chemotherapy-Free Interval,,2023-09-21,RECRUITING,INTERVENTIONAL,['NA']
614,NCT02994888,Track and validate specific known mechanisms of resistance/response to anti-EGFR therapies through,Identify novel biomarkers of resistance to anti-EGFR therapies through whole exome sequencing,,2012-11,COMPLETED,OBSERVATIONAL,['NA']
615,NCT05724992,Presence - absence of predisposing mutations,Correlation of genetic mutations with familial oncological history,,2022-12-20,RECRUITING,INTERVENTIONAL,['NA']
616,NCT01171924,Number of Participants With Adverse Events,,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1']
617,NCT03349398,the incidence of Roux stasis syndrome,the quility of life according to the RGB standards,,2017-11-10,UNKNOWN,INTERVENTIONAL,['NA']
618,NCT03083951,Total number of lymph nodes and lymph node ratio.,Survival,Defecatory dysfunction assessed by FSFI and erectile dysfunction questionnaires,2017-09-01,COMPLETED,INTERVENTIONAL,['NA']
619,NCT04347772,Length of hospital stay,Nutritional status - Dietary Intake,,2021-05-01,UNKNOWN,INTERVENTIONAL,['NA']
620,NCT03002064,Progression free survival,Quality of life--Score of the questionnaire,,2016-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
621,NCT01669044,Cardiac output,Stroke Volume,Systemic Venous Resistance Index,2012-05,UNKNOWN,OBSERVATIONAL,['NA']
622,NCT00125034,Best Overall Response Rate - Independent Review Committee (IRC),Safety - Number of Patients Experiencing Any Adverse Event,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2']
623,NCT01770275,Overall survival,Survival distinction,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
624,NCT05385900,"Pathological complete response, pCR","major pathologic response, MPR",,2022-06-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
625,NCT01123876,Determine the MTD and establish the recommended phase 2 dose of Veliparib in combination with two different FOLFIRI regimens that include a reduced regimen (150 mg/m2 irinotecan) and the standard regimen (180 mg/m2) in subjects with advanced solid tumors,"To assess the safety and tolerability, pharmacokinetic profile of the combination at each of the FOLFIRI regimens.",,2010-03,COMPLETED,INTERVENTIONAL,['PHASE1']
626,NCT01749722,Number of adverse events,,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
627,NCT01651832,proportion of eligible patients undergoing adjuvant chemo therapy,Quality of inpatient care,,2012-07,COMPLETED,INTERVENTIONAL,['NA']
628,NCT02371135,"association of the gut microbiome and dietary factors (To validate said associations, individual questions from the Brief Diet and Lifestyle Questionnaire will be primarily used in the overall analyses)",,,2015-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
629,NCT04170257,"Negative predictive value (NPV) of WLE, NBI and ISE in the diagnosis of mild, moderate, severe dysplasia and above lesions in esophagus",Discrimination of visualized abnormal features,,2019-10-18,UNKNOWN,INTERVENTIONAL,['NA']
630,NCT00193128,"Pathologic Complete Response Rate (PCRR), the Percentage of Patients Who Have No Evidence of Cancer in Their Surgical Specimen Following Surgery",Overall Survival (OS),,2004-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
631,NCT00769405,Overall survival,"Morbidity from surgical complications (abdominal, extra-abdominal, aplasia)",,2008-02,COMPLETED,INTERVENTIONAL,['PHASE3']
632,NCT06029010,"Descriptive analysis of biomarkers of patients with mCRC who had a long-term response to regorafenib monotherapy, as indicated by a treatment duration of ≥5 months","Descriptive analysis of biomarkers of patients with mCRC who had a long-term response to regorafenib monotherapy, as indicated by a treatment duration of ≥4 months",,2023-08-31,COMPLETED,OBSERVATIONAL,['NA']
633,NCT01210235,Completion of colorectal cancer screening by eligible patients within 3 months of their flu shot,,,2009-10,COMPLETED,INTERVENTIONAL,['NA']
634,NCT02576509,Overall Survival (OS),Efficacy Based on PD-L1 Expression - ORR,,2015-12-07,COMPLETED,INTERVENTIONAL,['PHASE3']
635,NCT04017455,clinical complete and near-complete response rate,local recurrence rate at 1 year follow-up,,2019-10-22,RECRUITING,INTERVENTIONAL,['PHASE2']
636,NCT01944137,Change from baseline (i.e. first chemotherapy administration visit) in patient-reported symptoms as measured by the Memorial Symptom Assessment Scale-Short Form.,"Frequency of urgent outpatient Cancer Center visits, emergency department visits, and hospital admissions during six months post-baseline",,2013-09,COMPLETED,INTERVENTIONAL,['NA']
637,NCT00030862,,,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE2']
638,NCT05511116,Inter-observer reproducibility,Tumor response on morphological imaging vs. tumor response grade on pathology,,2022-07-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
639,NCT00155727,,,,2000-01,UNKNOWN,OBSERVATIONAL,['NA']
640,NCT02301481,R0 resection rate,Overall survival,Comparison of dosimetric differences between radiation techniques,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2']
641,NCT03158779,Overall survival,Progression free-survival of treated patients,,2017-05-10,COMPLETED,INTERVENTIONAL,['PHASE2']
642,NCT02442583,Change in number of minutes per day of bouts of sedentary behaviors.,"Covariation between baseline use of an ActiGraph, and self-reporting of sedentary behaviors",,2015-05,COMPLETED,INTERVENTIONAL,['NA']
643,NCT05431530,Frequency of major LARS after surgery,EOTC QLQ-C30,,2022-06-22,RECRUITING,OBSERVATIONAL,['NA']
644,NCT00721916,Progression free survival (PFS),Safety,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE2']
645,NCT04462354,Postoperative pancreatic fistula rate (PPF),Other complications.,,2020-06-04,UNKNOWN,INTERVENTIONAL,['NA']
646,NCT04140318,ORR,OS,,2019-11-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
647,NCT01675505,,,,2012-05,UNKNOWN,OBSERVATIONAL,['NA']
648,NCT02157246,Group B Percentage change in FMISO-PET SUVmax and uptake volume,Comparison of changes in T1/T2* MRI,Radiotherapy planning feasibility study,2013-10,COMPLETED,INTERVENTIONAL,['NA']
649,NCT01459757,Mutational status data retrospectively accessed correlated with A6181036 clinical outcomes data in GIST subjects treated with sunitinib,,,2011-10,COMPLETED,OBSERVATIONAL,['NA']
650,NCT05807984,local control,progression free survival,,2023-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
651,NCT05451719,Progression-free Survival (PFS),The incidence of adverse events,,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
652,NCT06068127,GCSI score,Pyloric distensibility,,2023-10-12,RECRUITING,OBSERVATIONAL,['NA']
653,NCT03273686,postoperative complication,Length of postoperative stay,,2017-09-15,UNKNOWN,INTERVENTIONAL,['PHASE3']
654,NCT02811666,muscle strength using a hand gauge,,,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
655,NCT04502082,The recommended phase 2 dose (RP2D) regimen of ET140203 T-cell therapy primarily based on DLT,Determine the pharmacokinetics of ET140203 T cells after infusion.,,2021-04-14,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
656,NCT05317819,Overall Survival (OS),Progression free survival,,2022-03-14,RECRUITING,INTERVENTIONAL,['PHASE3']
657,NCT06070740,Objective Response Rate,Adverse events,,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE2']
658,NCT06144762,the integration of in vivo and ex vivo MRI with histology and molecular caracteristic in order to increase the pancreatic cancer detection and therapeutic response monitoring,Correlate MRI results with hematological molecular biology results.,,2023-12-19,RECRUITING,INTERVENTIONAL,['NA']
659,NCT00455247,,,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE3']
660,NCT05216133,36-Item Short Form Survey Instrument (SF-36),,,2023-03-22,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
661,NCT01216644,median overall survival,R0-Resection rate,,2010-08,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
662,NCT06277531,Patient is diagnosed with malignant disease from biliary system,,,2024-03-01,RECRUITING,OBSERVATIONAL,['NA']
663,NCT02579460,Change in esophageal mucosal inflammation using histopathological assessment from baseline to 14 days,change in HIF expression from baseline to 14 days,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
664,NCT04324294,"The results obtained by EUS versus contrast EUS to diagnose pancreas cystic lesions, mass lesion, and origin of pancreatitis.",Quantitative Parameters of Pancreas Lesions,,2020-02-26,RECRUITING,INTERVENTIONAL,['PHASE1']
665,NCT05220800,Changes in T-cell function - mRNA expression analysis,5 year cancer free survival,,2022-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
666,NCT03164486,Assessment of safe administration of 18F-αvβ6-BP,Level of αvβ6-BP expression in tumors,,2016-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
667,NCT04835246,Sensitivity of Spectra IMDx system,Accuracy of Spectra IMDx system,,2019-10-07,UNKNOWN,INTERVENTIONAL,['NA']
668,NCT03976999,Proportion of patients who gave their consent to participate in the study,,,2017-07-05,RECRUITING,INTERVENTIONAL,['NA']
669,NCT00331682,Objective Response Rate as Measured by RECIST Criteria,Overall Survival,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2']
670,NCT00553696,Number of Participants With First Cycle Dose-limiting Toxicities (DLTs),Time to Progression (TTP),,2007-11,COMPLETED,INTERVENTIONAL,['PHASE1']
671,NCT06331260,Tumor recurrence rate,,,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
672,NCT00941967,Progression-free survival,,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
673,NCT03541629,Data accuracy,,,2018-07-26,COMPLETED,OBSERVATIONAL,['NA']
674,NCT00030524,,,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2']
675,NCT01082419,The elasticity parameter will be for each patient the median of ten ARFI values (m/s) in the right liver.,Median (m/s) of ARFI values between before and after effective treatment for liver reversible disease,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
676,NCT00637390,safety & maximally tolerated dose,Alemtuzumab effect on patients' response rates to chemotherapy given after the discontinuation of chemotherapy.,,2008-03,TERMINATED,INTERVENTIONAL,['PHASE1']
677,NCT01394159,Compare the Median Number of Passes Required to Establish a Diagnosis,Technical Failure,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
678,NCT03581435,The expression of protein A in the circulating exosomes from patients,,,2018-01-01,UNKNOWN,OBSERVATIONAL,['NA']
679,NCT02562716,Overall Survival (OS),Disease-free Survival From the Time of R0 or R1 Resection.,,2016-01-06,COMPLETED,INTERVENTIONAL,['PHASE2']
680,NCT06046794,Percentage of alive GemCore+ patients treated with Gemcitabine,Progression-free survival,Overall survival of GemCore- patients,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
681,NCT01468389,Progression free survival,adverse events,,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
682,NCT03827967,Primary Immunologic Endpoint-Per Dosing Cohort Immunoscore of the tumor microenvironment,Secondary Endpoint-CD4+ and regulatory T cells expression comparison within the Tumor Microenvironment,,2019-07-20,COMPLETED,INTERVENTIONAL,['PHASE1']
683,NCT03017326,Response in HCC is defined as complete (CR) or partial (PR) response according to RECIST version 1.1 criteria,Adherence to surgical guidelines,,2017-08-24,RECRUITING,INTERVENTIONAL,['PHASE3']
684,NCT01885884,perceived effectiveness,patient quality of life,caregiver depressive symptoms,2013-07,COMPLETED,INTERVENTIONAL,['NA']
685,NCT04155242,Diagnostic accuracy of methylation panel for diffuse IM at the GOJ,Safety of Cytosponge,,2020-09-01,RECRUITING,INTERVENTIONAL,['NA']
686,NCT05840341,Overall survival (OS),Disease Free Survival,,2023-05-01,RECRUITING,INTERVENTIONAL,['PHASE3']
687,NCT05843955,Non-alcoholic fatty liver disease (NAFLD) grade,,,2015-09-01,COMPLETED,OBSERVATIONAL,['NA']
688,NCT00003994,Toxicity rates assessed using National Cancer Institute (NCI) Common Toxicity Criteria (CTC),,,1999-03,COMPLETED,INTERVENTIONAL,['PHASE3']
689,NCT04135781,3 years Diseases-free Survival rate(3 years-DFS),Safety as measured by number and grade of adverse events,,2020-03-01,RECRUITING,INTERVENTIONAL,['PHASE3']
690,NCT05034692,The incidence of early complications,pain score,,2022-03-21,RECRUITING,INTERVENTIONAL,['NA']
691,NCT05747716,Progression free survival,Toxicities,,2023-02-28,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
692,NCT05532319,Progression-free survival,objective response rate,,2022-02-01,COMPLETED,INTERVENTIONAL,['PHASE2']
693,NCT00782886,"The overall purpose of this NIH-funded study is to evaluate the effectiveness of image-guided liver surgery by measuring variables before, during and following surgery.",,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
694,NCT03669237,Postoperative bowel function of 1 year after surgery,Postoperative bowel function of the long stable result,,2018-10-12,COMPLETED,INTERVENTIONAL,['NA']
695,NCT04201717,surgical site infection，SSI,hospital stay,,2020-06-12,RECRUITING,INTERVENTIONAL,['NA']
696,NCT02784028,Maximum tolerated dose (MTD),,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
697,NCT03299036,Tumor response in patients with hepatoma who received Taiwan ACE beads (TACE) microspheres embolization evaluated with mRECIST criteria,Serum Level of AFP,,2017-06-01,COMPLETED,INTERVENTIONAL,['NA']
698,NCT06024837,Comparison of hepatic lesion mapping between spectral scanning and conventional scanning,Evaluation of response to chemotherapy in Radiomics,,2023-06-07,RECRUITING,OBSERVATIONAL,['NA']
699,NCT02030769,Detection rate of high grade dysplasia and carcinoma in iodine void lesion,overall detection rate of iodine void lesion,observation time for esophagus,2014-01,COMPLETED,INTERVENTIONAL,['NA']
700,NCT05724563,Objective Response rate of combination zimberelimab and domvanalimab.,Number of participants with Adverse Events (AEs) (serious / non-serious) as defined by CTCAE v5.0,,2023-06-01,RECRUITING,INTERVENTIONAL,['PHASE2']
701,NCT04008030,"PFS by BICR (arm B vs C, 1L, centrally confirmed)","ORR by BICR (crossover cohort, centrally confirmed)",,2019-08-05,RECRUITING,INTERVENTIONAL,['PHASE3']
702,NCT03775473,progastrin rate,,,2019-02-07,TERMINATED,INTERVENTIONAL,['NA']
703,NCT03782831,Progression Free Survival (PFS),Adverse Events,,2018-12-11,WITHDRAWN,INTERVENTIONAL,['PHASE2']
704,NCT00390364,Response Rate: The Total Number of Participants With Progression of Disease,,,2006-10,TERMINATED,INTERVENTIONAL,['PHASE2']
705,NCT02934984,Rates of recurrence in pancreatic cancer patients,Rates of death in pancreatic cancer patients,,2016-07,UNKNOWN,OBSERVATIONAL,['NA']
706,NCT06005883,Recurrence of tumor,,,2021-04-10,COMPLETED,OBSERVATIONAL,['NA']
707,NCT04888299,Feasibility of Raman spectroscopy to identify mucosal healing in IBD and IBD-related dysplasia against the gold standard of histopathology,Diagnostic performance of Raman spectroscopy for assessment of mmucosal healing in IBD and IBD-related dysplasia against the gold standard of histopathology,,2021-04-14,UNKNOWN,INTERVENTIONAL,['NA']
708,NCT04407416,Breath analysis sensitivity,,,2020-05-02,UNKNOWN,INTERVENTIONAL,['NA']
709,NCT04661046,Progression Free Survival,,,2020-11-30,UNKNOWN,INTERVENTIONAL,['NA']
710,NCT04620538,"Determine the diagnostic accuracy of breath test for detection of fibrosis, cirrhosis or hepatocellular carcinoma.",,,2021-04-01,RECRUITING,OBSERVATIONAL,['NA']
711,NCT03658772,Define the recommended phase 2 dose (RP2D) of grapiprant combined with pembrolizumab,Observed accumulation ratio,,2018-09-20,COMPLETED,INTERVENTIONAL,['PHASE1']
712,NCT01418391,amount of post-operative morphine consumption,evaluation of post-operative pain status using visual analog scale (VAS) and superimposed face pain severity scale,,2011-06,UNKNOWN,INTERVENTIONAL,['NA']
713,NCT00683631,,,,2004-01,COMPLETED,OBSERVATIONAL,['NA']
714,NCT05913661,Objective Response Rate,Overall Survival,,2023-07,RECRUITING,INTERVENTIONAL,['PHASE2']
715,NCT05184946,3 years disease free survival rate,overall survival time,,2021-10-09,RECRUITING,INTERVENTIONAL,['PHASE2']
716,NCT03986294,Progression free survival of NaI-IRI with S1,Quality of life QoL (QLQ-C30),ctDNA,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
717,NCT00192842,time to tumor progression,toxicity,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2']
718,NCT00976612,nilotinib pharmacokinetics,,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
719,NCT00956072,Progression-free survival,Quality of life as measured by EORTC QLQ-C30,,2009-05,TERMINATED,INTERVENTIONAL,['PHASE3']
720,NCT04447443,Therapeutic effect on the chemotherapy-related grade 2 to 4 diarrhea,Gut microbiota changes in response to intervention,,2020-06-30,WITHDRAWN,INTERVENTIONAL,['NA']
721,NCT00318370,Serologic Response (Change in Cancer Antigen [CA-125] Level),Percentage of Participants Who Had a Prolongation of Remission,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
722,NCT01571284,Number of Participants With Cycle Delay and/or Dose Modification,Change From Baseline in HRQL EQ-5D-3L VAS Score,,2012-05-30,COMPLETED,INTERVENTIONAL,['PHASE3']
723,NCT02764944,En bloc resection,successful closure of resection site,,2015-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
724,NCT03391687,Incidence of Pancreatic Fistula,The mortality of Grade B and C Pancreatic Fistula,,2017-12-01,UNKNOWN,OBSERVATIONAL,['NA']
725,NCT05524974,Objective response rate,"The prediction performance of Exosome contents (including proteins, nucleic acids)",,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
726,NCT05616390,Overall survival (OS),Quality of Life (QoL),,2022-11-09,RECRUITING,INTERVENTIONAL,['PHASE2']
727,NCT05354388,1-year Progression free survival rate,Duration of continuous medication before surgery,,2021-10-01,UNKNOWN,OBSERVATIONAL,['NA']
728,NCT04764006,Objective response rate (ORR),Assess the anti-tumor activity:DCR,,2021-10-13,UNKNOWN,INTERVENTIONAL,['PHASE2']
729,NCT01821729,Number of Participants With R0 Resection,To Measure Utilization of Health Services,,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
730,NCT03722511,Effect of amino acids in tightening the intestinal barrier and protecting from antigenic translocation by evaluating plasma circulating cytokine levels in peripheral blood sample.,Evaluation of increased bacterial translocation and systemic inflammation.,,2018-12-06,COMPLETED,INTERVENTIONAL,['PHASE2']
731,NCT05319639,The maximum dose tolerated,Overall survival,,2023-02-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
732,NCT01342354,Identify the appropriate dose for treatment of unresected carcinoma of the ampulla or pancreas,Change in patient reported outcomes using FACT-Hepatobiliary (FACT-Hep) quality of life questionnaire.,,2009-04-14,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
733,NCT02917759,Number of successful xenografts established,,,2014-02,RECRUITING,OBSERVATIONAL,['NA']
734,NCT03462524,Global health-related quality of life (HR-QL) score as assessed by Eastern Co-operative Oncology Group QLQ-C30 questionnaire,Overall survival,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
735,NCT03948958,TIVAD function,Catheter tip and port chamber culture,Patient-reported outcome measure,2019-06-28,COMPLETED,INTERVENTIONAL,['NA']
736,NCT00165594,Response rate based on Response Evaluation Criteria in Solid Tumors (RECIST),Adverse drug reaction.,,2005-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
737,NCT03699111,Stratification Tools,,,2018-09-19,COMPLETED,OBSERVATIONAL,['NA']
738,NCT04868773,Recommended Phase 2 Dose [RP2D],Number of Participants with Objective Response Rate,,2021-07-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
739,NCT04906954,"Step 2 : Number of patients with improvement of 10 points between baseline and week 8, assessed using the EORTC QLQ-C30 physical functioning scale",Overall Survival (OS),,2021-06-29,UNKNOWN,INTERVENTIONAL,['NA']
740,NCT05376423,Recurrence-free survival rate,,,2022-06-02,RECRUITING,INTERVENTIONAL,['PHASE2']
741,NCT06190782,Progression-free survival difference of PD-1 inhibitor+radiotherapy and PD-1 inhibitor alone,local control rate,,2022-09-27,RECRUITING,INTERVENTIONAL,['PHASE3']
742,NCT00881816,maximum tolerated dose,dose limiting toxicity,,2009-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
743,NCT02955069,Overall Response Rate (ORR) by RECIST 1.1 and as Per Blinded Independent Central Review (BIRC).,PDR001 ADA Incidence On-treatment,,2017-02-14,COMPLETED,INTERVENTIONAL,['PHASE2']
744,NCT04293835,the height of sigmoid take-off,"The distances of the sacral promontory, third sacral segment, and superior, inferior margin of cancers, and anterior peritoneal reflection from the anal verge.",,2019-06-01,COMPLETED,OBSERVATIONAL,['NA']
745,NCT05750290,Best objective response rate,,,2022-12-01,RECRUITING,INTERVENTIONAL,['PHASE2']
746,NCT02148406,Changes in fatigue (recalled),Regulation of psychological stress (daily and recalled) as assessed by Positive and Negative Affect Schedule-Expanded Form and Cancer Behavior Inventory,Changes in circadian disruption (daily and recalled) as assessed by actigraphy and the Godin's Leisure Score Index,2014-08,COMPLETED,INTERVENTIONAL,['NA']
747,NCT04452396,study arm 2 - using Continuous Glucose Monitoring of interstitial fluid as a proxy marker of blood glucose to optimise hypoglycaemia treatment in patients with an established diagnosis of spontaneous or reactive hypoglycaemia,assessing concordance between CGMS and lab/finger prick glucose testing,,2019-12-01,TERMINATED,INTERVENTIONAL,['NA']
748,NCT01387555,Survival,Time-to-symptomatic-progression,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
749,NCT06194981,Overall Survival,Adverse Events,,2024-01-11,RECRUITING,OBSERVATIONAL,['NA']
750,NCT02151448,"Adverse Events Possibly, Probably or Definitely Related to Study Treatment",Tumor Necrosis Factor (TFNα) Cytokine Levels,,2014-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
751,NCT03329495,number of lymph nodes retrieved,operative time,,2018-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
752,NCT01439594,Feasibility of OFDI Imaging as Determined by Number of Successful Imaging Sessions,,,2008-10,COMPLETED,INTERVENTIONAL,['NA']
753,NCT01058655,Progression-Free Survival (PFS) [Phase II],Overall Survival (OS) [Phase II],,2010-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
754,NCT00822718,,,,2005-01,COMPLETED,OBSERVATIONAL,['NA']
755,NCT00081848,,,,2004-04-20,COMPLETED,INTERVENTIONAL,['PHASE1']
756,NCT00974389,Disease-control rate,Safety,,2009-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
757,NCT00066651,,,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE1']
758,NCT01853059,Functional quality of life after chemoradiotherapy for anal cancer,Patient-reported treatment-related toxicity after chemoradiotherapy for anal cancer,,2013-10,UNKNOWN,OBSERVATIONAL,['NA']
759,NCT01156142,Total Pain Reduction (Mouth and Throat),Patient Preference for Continuing Therapy With Oral Doxepin Hydrochloride,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE3']
760,NCT03406299,6-month progression-free survival rate,Biomarker study,,2018-04-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
761,NCT03041532,Proximal retroflexion improve adenoma detection rate in colorectal cancer screening,Pre-procedure factors,,2017-10-01,COMPLETED,INTERVENTIONAL,['NA']
762,NCT00763646,To determine the impact of chemotherapy on the ability of your surgeon to completely remove the cancer as well as the impact on your survival.,,,2007-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
763,NCT00115765,Objective Tumor Response Through Week 12 (Irinotecan),Time to Treatment Failure (Irinotecan),,2005-06-01,COMPLETED,INTERVENTIONAL,['PHASE3']
764,NCT03362684,Prognostic and predictive value of miR-31-3p expression on Disease Free Survival (DFS),Prognostic and predictive value of miR-31-3p expression on SAR,Distribution of miR-31-5p expression,2005-11,COMPLETED,INTERVENTIONAL,['PHASE3']
765,NCT02340949,Number of Patients Achieving Pathologic Complete Response (pCR).,Disease Free Survival (DFS) Rate at 3 Years,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2']
766,NCT02754180,Disease free survival,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2016-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
767,NCT02361320,Correlation Between Local Control and Changes in Mass Transport by Computed Tomography (CT),,,2015-03-09,RECRUITING,INTERVENTIONAL,['NA']
768,NCT03685708,Number of Participants With HEPLISAV-B Seroprotective Titer (Anti-HBs 10mIU/mL),Number of Participants That Did Not Complete Study Due to Intolerance of the HEPLISAV-B Vaccine Among CLL Patients.,,2018-12-07,COMPLETED,INTERVENTIONAL,['PHASE2']
769,NCT01143545,Tabulation of toxicity type and grade,"To determine if metronomic oral CP and celecoxib reduce the number, percentage and function of CD4+ CD25+ Fox P3+ regulatory T cells (T reg) in peripheral blood of thoracic oncology patients.",,2010-12-07,TERMINATED,INTERVENTIONAL,['PHASE1']
770,NCT05185505,Proportion of Patients Receiving Liver Transplant Experiencing Acute Rejection,Immune Cell Biomarkers,,2023-01-30,RECRUITING,INTERVENTIONAL,['PHASE4']
771,NCT05944809,The highest grade of thrombocytopenia (CTCAE 4.0) during the radiotherapy and 1 month after the radiotherapy.,"The highest grade of leukopenia, neutropenia,anemia (CTCAE 4.0) during the radiotherapy and 1 month after the radiotherapy.",,2023-07-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
772,NCT05961982,Efficacy of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA),Safety of EUS-guided RFA of pancreatic cystic neoplasms at one year,,2023-04-24,RECRUITING,INTERVENTIONAL,['NA']
773,NCT00234429,Determine the progression free survival,Determine objective tumor response,,2003-11,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
774,NCT03985072,Incidence of treatment-emergent adverse events (TEAEs) through stages 1 and 2 of the study,Incidence of Andes-1537 anti-drug antibodies (ADAs) in the plasma,Evaluate the exploratory response of tumor markers,2019-04-26,COMPLETED,INTERVENTIONAL,['PHASE1']
775,NCT02314117,Progression-free Survival (PFS),PK: Minimum Concentration (Cmin) of Ramucirumab,,2015-01-20,COMPLETED,INTERVENTIONAL,['PHASE3']
776,NCT05342350,GALAD performance for liver cancer early detection,Establishment of a bio-repository of longitudinally collected from patients with cirrhosis to be used for future studies,,2022-04-15,RECRUITING,OBSERVATIONAL,['NA']
777,NCT02121366,Safety of EUS-guided ethanol ablation,Technical feasibility,,2014-03,UNKNOWN,INTERVENTIONAL,['NA']
778,NCT01900002,Median Progression Free Survival (PFS),"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0",,2013-09-13,COMPLETED,INTERVENTIONAL,['PHASE2']
779,NCT04235660,Feasibility of Recruitment (Recruitment Rate),Objective Response Rate,,2020-07-22,TERMINATED,INTERVENTIONAL,['NA']
780,NCT02748798,Signal to Noise Ratio,Correlation with PFTs,,2020-11-10,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
781,NCT04158349,"Assess the maximum tolerated dose of intraperitoneal (IP) oxaliplatin with systemic IV 5-fluorouracil, leucovorin, and irinotecan (mFOLFIRI) every 2 weeks in patients with unresectable peritoneal carcinomatosis of colorectal or appendiceal origin",The efficacy of IP oxaliplatin plus systemic mFOLFIRI in patients with peritoneal carcinomatosis of colorectal or appendiceal origin will be measured.,,2021-03-22,TERMINATED,INTERVENTIONAL,['PHASE1']
782,NCT01461525,Quality of life outcome,Anal function,,2011-10,UNKNOWN,INTERVENTIONAL,['NA']
783,NCT03956940,Detection rate of total circulating free deoxyribonucleic acid (cfDNA) concentration at the baseline.,Overall Survival,,2019-10-04,TERMINATED,INTERVENTIONAL,['NA']
784,NCT01043484,Rate complete pathologic responses,Rate of sphincter preservation,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE2']
785,NCT03685799,Influence of histological concordance on the risk of recurrence,Identification of histological factors of recurrence.,,2016-05,COMPLETED,OBSERVATIONAL,['NA']
786,NCT00005021,,,,1996-07,COMPLETED,INTERVENTIONAL,['PHASE1']
787,NCT02509143,Number of patients who experience moderate or severe level nausea or vomiting,Serious adverse events,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
788,NCT04257526,Improvement in lifestyle score assessed via lifestyle questionnaires,,,2022-03-23,RECRUITING,INTERVENTIONAL,['NA']
789,NCT01351220,Change from Baseline in receipt of CRC screening at 6 months and 24 months,Change from Baseline in frequency of patient provider communication at 6 months and 24 months,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
790,NCT03743883,Incidence rates of oesophageal cancer and stomach cancer with use of low-dose ASA by sex-specific compared to non-use,Incidence of oesophageal cancer and stomach cancer among new users of low-dose ASA for primary or secondary cardiovascular prevention,,2018-10-30,COMPLETED,OBSERVATIONAL,['NA']
791,NCT05726097,Adequate cleanliness rate,Assessment of patient tolerance of the bowel preparations,,2023-02-01,COMPLETED,INTERVENTIONAL,['PHASE3']
792,NCT05872841,disease control rate (DCR),overall survival(OS),,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
793,NCT02780700,Progression Free Survival (PFS),Percentage of Patients With Grade 3 or Worse Adverse Events,,2016-07-05,TERMINATED,INTERVENTIONAL,['PHASE2']
794,NCT00183833,To determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of Gleevec in combination with a fixed dose of Xeloda po bid daily in patients with colon cancer.,Toxicity.,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE1']
795,NCT03024684,3-year cumulative incidence of recurrent HCC between the intervention group and control counterpart,occurrence of clinical complications related to hepatic decompensation,,2017-01-03,RECRUITING,INTERVENTIONAL,['PHASE4']
796,NCT01749332,ctDNA differences,collect preliminary data,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
797,NCT04980443,Sensitivity of CELTiC,C-statistic of CELTiC,Association between CELTiC test score and FIT concentration,2021-08-03,COMPLETED,INTERVENTIONAL,['NA']
798,NCT01359397,Progression free survival,Overall survival,,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
799,NCT05881746,relapse-free survival,postoperative mortality,,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
800,NCT02119026,Efficacy Duration of Disease Control by Tumor Assessment (CT/MRI/Clinical Examination),Tumour Assessments (Based on RECIST Criteria) in 2nd-line,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2']
801,NCT04308837,Pathological Response,Peritoneal Disease-free Survival,,2018-12-03,RECRUITING,INTERVENTIONAL,['PHASE2']
802,NCT03954548,Adenoma miss rate [AMR],Polyp Miss Rate [PMR],,2020-02-17,COMPLETED,INTERVENTIONAL,['NA']
803,NCT04847297,rate of serious complications,Mortality,,2021-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
804,NCT04724226,Objective response rate (ORR) by RECIST 1.1 and mRECIST,Median overall survival time (mOS),Treatment-related adverse events,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE2']
805,NCT01432314,Time to tumor progression,Best tumor response by modified RECIST (mRECIST) and RECIST criteria,,2011-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
806,NCT05846594,Median Time to Diagnosis,Incidence and Severity of Liquid Biopsy Sample Collection-Related Adverse Events,,2023-09-14,RECRUITING,INTERVENTIONAL,['PHASE4']
807,NCT04182386,Future liver remnant hypertrophy,Effect of sarcopenia on hypertrophy,,2012-08-01,UNKNOWN,OBSERVATIONAL,['NA']
808,NCT00023634,toxicity,,,2001-06,TERMINATED,INTERVENTIONAL,['PHASE1']
809,NCT02887612,Positive Predictive Value,prognostic molecular markers,,2016-09,UNKNOWN,OBSERVATIONAL,['NA']
810,NCT06219096,Fluorescence imaging effect of the live,Postoperative hospital stay,Disease-free survival,2023-12-10,RECRUITING,INTERVENTIONAL,['NA']
811,NCT03869892,Progression-free Survival (PFS),Time to treatment failure (TTF),,2019-03-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
812,NCT05319431,Progression-free survival (PFS),Number of participants with adverse events (AEs),,2022-06-28,RECRUITING,INTERVENTIONAL,['PHASE2']
813,NCT02859753,Time to disease progression according to American Society of Interventional Radiology criteria,,,2014-01-15,COMPLETED,INTERVENTIONAL,['NA']
814,NCT03401814,"Quantify tissue mechanical properties of the liver and liver tumor using MRE in patients receiving radiation therapy + immunotherapy at baseline, mid-treatment and time of followup imaging determined by standard of care to assess response to therapy",,,2018-08-02,COMPLETED,OBSERVATIONAL,['NA']
815,NCT02517554,Completion of Surveys,,,2015-08,COMPLETED,OBSERVATIONAL,['NA']
816,NCT05958433,duration of hospital stay,assess the effects of preoperative education using stoma appliance on quality of life in colorectal cancer patients with a stoma,,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
817,NCT05967533,Natural killer (NK) cell killing activity,Immunologic effects of FWG (Immune Correlates): serum cytokines analysis,,2023-06-02,RECRUITING,INTERVENTIONAL,['PHASE1']
818,NCT02198898,incidence of adhesive intestinal obstruction,,,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE3']
819,NCT00576940,The ratio of postoperative complications (infectious and surgical),assessment of visceral protein turnover,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE4']
820,NCT04514484,Incidence of dose limiting toxicities (DLTs),Human immunodeficiency virus (HIV) viral loads,Change in infiltrating immune cell markers,2021-11-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
821,NCT04164602,incidence of pancreatic ductal adenocarcinoma in patients with new-onset diabetes,Cost-benefit analysis,,2019-10-09,RECRUITING,OBSERVATIONAL,['NA']
822,NCT00081900,To establish the MTD and dose limiting toxicities of DENSPM intravenous infusion in patients with unresectable HCC.,To evaluate the pharmacokinetics of DENSPM in plasma and HCC tissue in patients unresectable HCC.,,2004-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
823,NCT05955833,"89Zr-trastuzumab uptake (standard uptake values (SUVmean, %ID/kg) in normal organs/tissues and bloodpool in historical controls with HER2+ breast cancer (n = 20) who underwent 89Zr-trastuzumab PET imaging.",HER2 expression measured by IHC on tumor biopsies,,2023-06-26,RECRUITING,INTERVENTIONAL,['PHASE1']
824,NCT03255811,Evaluation of apatinib mesylate tablets as first-line maintenance treatment for advanced gastric or gastroesophageal junction progression free survival site adenocarcinoma,,,2017-03-25,UNKNOWN,INTERVENTIONAL,['NA']
825,NCT00976898,Median Overall Survival,Patterns of Failure,,2009-08,COMPLETED,INTERVENTIONAL,['NA']
826,NCT03041129,Hepatic Fat Fraction,Hepatic Phosphate Concentrations,,2017-04-14,COMPLETED,OBSERVATIONAL,['NA']
827,NCT00096070,1-year survival rate,Time to treatment failure,,2004-12,COMPLETED,INTERVENTIONAL,['PHASE2']
828,NCT00280332,The prevalence of advanced colonic adenoma in the re-screening population,The time to adenoma adenoma development according to different baseline characteristics of patients and colonoscopy findings,,2006-03,COMPLETED,OBSERVATIONAL,['NA']
829,NCT00569309,Number of Participants Experiencing Immune Reconstitution,Collection of Baseline Immune Reconstitution and Quality of Life Pilot Data for Comparison in Future Post-transplant Immunotherapy Trials,,2007-12-12,COMPLETED,INTERVENTIONAL,['NA']
830,NCT04301557,Pathological Complete Response(pCR),3 year disease free survival,,2020-07-31,RECRUITING,INTERVENTIONAL,['PHASE2']
831,NCT06067620,Time to first passage of faeces,Incidence of incisional hernia,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
832,NCT02366819,R0 (analysis will be performed evaluating the R0 rate),Progression free survival,Change in SUVmax for the primary esophageal tumor,2014-12-11,RECRUITING,INTERVENTIONAL,['PHASE4']
833,NCT05519319,Overall survival (OS),Progression-free survival(PFS),,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
834,NCT02243358,Frequency of R0 Resection,,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2']
835,NCT04751773,Serious adverse events,Surgical stress: Noradrenaline,LPS-induced TNF-a production of whole blood,2021-03-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
836,NCT04690972,Surgery for a hepato-bilio-pancreatic issue,,,2020-12-20,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
837,NCT03598166,Percentage of Participants Who Undergo Screening Within 6 Months of Outreach,Self-reported Most Common Reasons for Refusing Blood Test on Questionnaire in Intervention Group,,2018-10-11,COMPLETED,INTERVENTIONAL,['NA']
838,NCT01908322,"Characteristics of patients with intermediate stage HCC (BCLC-B) treated with Nexavar will be determined by evaluating demographic data, medical history, previous treatment of HCC, specific concomitant conditions (amongst others).",Safety variables will be summarized using descriptive statistics based on adverse events collection.,,2013-08,COMPLETED,OBSERVATIONAL,['NA']
839,NCT02125929,Pancreatic fistula rate,Mortality rate,Hospital stay time,2014-04,COMPLETED,INTERVENTIONAL,['NA']
840,NCT01222689,Survival at 24 Weeks,Number of Patients With Dose Modifications and Reason for Dose Modification.,Plasma Biomarkers Potentially Predictive of Dual MEK/EGFR Inhibition,2010-11,COMPLETED,INTERVENTIONAL,['PHASE2']
841,NCT04454099,Develop a predictive model of CRC or advanced colorectal neoplasm which includes qFIT.,Explore the effect of aspirin or other anticoagulants to the diagnose accuracy of qFIT,,2020-07-01,COMPLETED,OBSERVATIONAL,['NA']
842,NCT05448846,Change in functional capacity,Rate of mortality,Colorectal Surgery Procedure,2022-04-08,RECRUITING,INTERVENTIONAL,['NA']
843,NCT00559741,Improvement of hematologic and gastrointestinal tolerance to therapy,Time to progression,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2']
844,NCT05414461,Durable clinical benefit,,,2019-03-10,COMPLETED,INTERVENTIONAL,['PHASE2']
845,NCT00355212,Sustained complete response at one year after the treatment.,costs.,,2001-01,TERMINATED,INTERVENTIONAL,['PHASE3']
846,NCT02118077,Number of Participants with Serious and Non-Serious Adverse Events,Objective tumor response,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE3']
847,NCT03766633,Accuracy of the LiverVision® software volumetric measurements,Comparison,,2018-04-29,UNKNOWN,OBSERVATIONAL,['NA']
848,NCT03465202,Area under the curve (AUC) of capecitabine and metabolites,Time of maximum plasma concentration (Tmax) of capecitabine and metabolites,,2016-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
849,NCT04476329,Overall Survival,FACIT FACT-Hep Quality of Life Measurements,,2021-01-21,TERMINATED,INTERVENTIONAL,['PHASE2']
850,NCT06184594,Colorectal Cancer (CRC) Screening completion,The Colorectal Cancer Screening Beliefs Instrument Score,,2024-01-24,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
851,NCT06114082,Objective response rate (ORR),Treatment-related serious adverse event,,2023-04-28,RECRUITING,INTERVENTIONAL,['PHASE2']
852,NCT05493358,5 year disease-free survival by Kaplan Mayer,The percentage of pattern of recurrence/metastasis,,2013-01-01,COMPLETED,OBSERVATIONAL,['NA']
853,NCT05534841,Complete response MRI criterion,MRI accuracy,,2022-04-01,COMPLETED,OBSERVATIONAL,['NA']
854,NCT01032291,Percentage of Participants With a Response to Treatment During the Proof of Concept Period,Participants With Treatment-Emergent Adverse Events (TEAE),,2009-12,TERMINATED,INTERVENTIONAL,['PHASE2']
855,NCT00291473,adverse events,immune responses including HER2 and NY-ESO-1 specific IgG and T cells,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE1']
856,NCT04600466,To identify environmental and clinicopathological factors in Hispanics associated with specific molecular changes,,,2021-01-22,RECRUITING,OBSERVATIONAL,['NA']
857,NCT03614546,Overall Survival(OS),Minimal volume of liver free from radiation,,2018-10-10,UNKNOWN,INTERVENTIONAL,['NA']
858,NCT02182804,Accuracy,,,2013-02,COMPLETED,INTERVENTIONAL,['NA']
859,NCT02583815,Number of Participants Who Use PAM Device,Brief Fatigue Inventory (BFI),,2015-08,COMPLETED,OBSERVATIONAL,['NA']
860,NCT03870607,Response rate (clinical and radiological),Variation of systemic immune parameters,,2019-03-13,RECRUITING,INTERVENTIONAL,['PHASE2']
861,NCT01754636,Inclusion in at least one Clinical trial (amendment n°3 -02/2014),Invitation to participate in in at least one Clinical trial (amendment n°3 -02/2014),,2012-11,COMPLETED,OBSERVATIONAL,['NA']
862,NCT00382811,The primary efficacy end-point is progression-free survival (PFS). PFS is the time from randomization until disease progression or death,The secondary efficacy end-point is overall survival (OS),,2006-10,COMPLETED,INTERVENTIONAL,['PHASE3']
863,NCT06111274,Objective Response Rate (ORR),The Minimum Concentration of ABSK021,,2023-10-17,RECRUITING,INTERVENTIONAL,['PHASE2']
864,NCT03077594,Mucosal Impedance as measured by an endoscopic probe,Volumetric Laser Endomicroscopy,,2016-09-26,COMPLETED,OBSERVATIONAL,['NA']
865,NCT06220617,Sensitivity and specificity of the screening test with comparison to colonoscopy,,,2024-01-11,RECRUITING,OBSERVATIONAL,['NA']
866,NCT00577889,Six Month Survival Rate,Confirmed Response Rate,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
867,NCT04518449,incidence of diarrhea,,,2022-12-01,WITHDRAWN,OBSERVATIONAL,['NA']
868,NCT04641923,Incidence of peri-hepatic adhesions at the time of repeat liver surgery,30-day mortality and morbidity,,2022-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
869,NCT02648386,Safety and Tolerability assessed by Adverse Events,Maximum Flow Rate (Qmax),,2016-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
870,NCT05791136,Progression-free survival (PFS),Time to death or distant metastasis (TTDM),,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
871,NCT04812743,Increase in knowledge and intentions related to biospecimen donation and clinical trial participation.,,,2020-01-10,TERMINATED,INTERVENTIONAL,['NA']
872,NCT00209638,objective tumor response,"Response duration, time to progression, overall survival, and safety will also be assessed.",,2000-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
873,NCT00003354,,,,1996-07,COMPLETED,INTERVENTIONAL,['PHASE3']
874,NCT05028231,Pathologic Complete Response,Objective Response Rate,Intestinal flora,2021-06-05,RECRUITING,OBSERVATIONAL,['NA']
875,NCT00686543,Participants With a Mean POS Plasma Concentration ≥/<350 ng/mL on Day 8 and ≥/<700 ng/mL on Day 15,,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE4']
876,NCT02985944,Adenoma detection rate,Factors affecting the withdrawal time,,2016-06,COMPLETED,OBSERVATIONAL,['NA']
877,NCT01497457,Determination of the distance between a rectal tumor and the pouch of Douglas,,,2011-12,COMPLETED,INTERVENTIONAL,['NA']
878,NCT02377232,Colon Cancer Screening Intent,Colon Cancer Screening Completed,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
879,NCT05635630,Relapse-free survival (RFS) time,The rate of achieving NED status when relapses happen.,,2022-06-24,RECRUITING,INTERVENTIONAL,['NA']
880,NCT02076906,Toxicity,Immune Markers,,2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
881,NCT05800080,The pathological complete response;,"major pathologic response, MPR",,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
882,NCT06276764,"The number of pancreatic ductal adenocarcinomas or their precursor lesions, dysplasia, identified only with LINFU® will be compared to standard screening methods",Determine the number of patients with early pancreatic ductal adenocarcinomas and their noninvasive precursor lesions identified only with LINFU® that require medical or surgical intervention.,Yearly survival rate of patients with early pancreatic ductal adenocarcinomas or their noninvasive precursor lesions identified only with LINFU®,2024-04-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
883,NCT06314646,Rate of anastomotic leak,Cancer recurrence,,2024-05-31,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
884,NCT00002930,,,,1996-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
885,NCT03040453,Immunological response,"Number of participants with complete radiological response at follow up 3, 6, 9 and 12 months.",,2017-01-01,WITHDRAWN,INTERVENTIONAL,['NA']
886,NCT03957564,The relationship between tumor response and mutation of ctDNA pre- and post-neoadjuvant chemotherapy and after operation.,Types of tumor-associated DNA in tumor tissues after operation.,,2019-05-28,RECRUITING,INTERVENTIONAL,['PHASE2']
887,NCT00544349,Efficacy: objective tumor response rate (RECIST criteria),Tumor progression rate,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2']
888,NCT01999478,Early cancer changes in the colon,,,2008-02,COMPLETED,OBSERVATIONAL,['NA']
889,NCT05674097,Six pattens of blood flow and AMCA based on the preoperative observation,,,2020-06-08,COMPLETED,OBSERVATIONAL,['NA']
890,NCT01480128,,,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA']
891,NCT00172861,,,,2005-01,UNKNOWN,OBSERVATIONAL,['NA']
892,NCT05604716,scores of digestive physiological and social psychological functions,progressive-free survival,,2001-01-01,RECRUITING,OBSERVATIONAL,['NA']
893,NCT00016198,,,,2001-05,COMPLETED,INTERVENTIONAL,['PHASE2']
894,NCT05095831,Clinical condition at one-year follow-up,,,2021-10-01,UNKNOWN,OBSERVATIONAL,['NA']
895,NCT04791293,MELD-Na score difference between the groups,,,2020-12-01,COMPLETED,OBSERVATIONAL,['NA']
896,NCT02273752,Incidence of Stomatitis,Response Rate Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST) Criteria,,2014-11,TERMINATED,INTERVENTIONAL,['PHASE2']
897,NCT01741038,Overall Survival,Health-Related Quality of Life (HRQoL),Longitudinal changes in tumor burden,2017-12,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
898,NCT01117428,Number of Participants With Adverse Events (AEs),Terminal Half-Life (T½),,2010-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
899,NCT02428270,"Percentage of patients who experience complete response, partial response, or stable disease",Interval between the first date of CR or PR and the earliest date of disease progression or death due to any cause.,,2016-04,COMPLETED,INTERVENTIONAL,['PHASE2']
900,NCT00704600,phase I: Incidence of any grade 3 or higher non-hematological or grade 4 or higher hematological toxicity (CTCAE v3.0) and of grade 4 or higher postoperative toxicity within 30 days post-surgery phase II:rate of pathological complete remission,,,2008-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
901,NCT05316103,Accuracy of pCLE-targeted optical biopsy,Complications of biopsy,,2021-11-04,RECRUITING,INTERVENTIONAL,['NA']
902,NCT05953662,DFS rate,3 years OS Rate,,2023-09-15,RECRUITING,INTERVENTIONAL,['NA']
903,NCT04613570,Carcinoma,Advanced gastric cancer,,2021-01-02,RECRUITING,INTERVENTIONAL,['NA']
904,NCT00086762,Quality of life as measured by Functional Assessment of Cancer Therapy,"Immune suppression as measured by cytotoxicity, stimulated release of IL-12, -4, -10, intracellular cytokines and lymphocyte phenotype",,2004-06,COMPLETED,INTERVENTIONAL,['NA']
905,NCT03261791,recurrence-free survival,safety: the potential side effects,,2017-07-20,UNKNOWN,INTERVENTIONAL,['PHASE2']
906,NCT03675243,Fecal incontinence quality of life scale,Sphinctrometry,,2018-04-01,COMPLETED,OBSERVATIONAL,['NA']
907,NCT06036563,specificity,,,2023-09,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
908,NCT05602792,"In part III, Evaluate the safety of multiple dose IT T3011 in the following indications,including sarcoma, Malignant head and neck tumor, breast cancer, esophagus cancer, lung cancer and non-melanoma skin cancer.","In part III,Overall Survival (OS)","In part II and part III,Exploring the proliferation and activity of immune cells in blood after IT T3011",2020-04-21,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
909,NCT00623883,"number, size, and location of ACF identified","complications of stain-enhanced, magnification colonoscopy",,1999-01,COMPLETED,INTERVENTIONAL,['NA']
910,NCT01210027,"Measure of Liver Function Before, During and After Radiation",Association Between Liver Perfusion and Changes in Tumor and Clinical Outcomes,,2007-03,RECRUITING,OBSERVATIONAL,['NA']
911,NCT04988971,Overall incidence of chemotherapy-induced diarrhea ≥ grade 1,Overall incidence of grade 3/4 gastrointestinal adverse events,Changes of fecal flora and enteritis-associated inflammatory factors,2021-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3']
912,NCT01339754,Progression-free survival (PFS) rate at 6 months,Impact of pharmacogenomic and pharmacokinetic profile on anti-tumor activity,,2011-02,COMPLETED,INTERVENTIONAL,['PHASE2']
913,NCT01957852,Reoperation rate for intra-abdominal bleeding after CRS and HIPEC,Length of hospital stay,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
914,NCT05543304,Objective response rate,Progression free survival,,2018-12-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
915,NCT05609253,Itraconazole drug and blood levels,Effects of itraconazole on angiogenesis,,2022-09-14,RECRUITING,INTERVENTIONAL,['PHASE1']
916,NCT03435666,AUC0-t,AUC_%Extrap_obs,,2018-05,UNKNOWN,INTERVENTIONAL,['PHASE1']
917,NCT03126058,occurrence rate of severe complications,Procalcitonin,,2017-06-21,UNKNOWN,INTERVENTIONAL,['NA']
918,NCT03741517,Protocol adherence,,Safety of core needle biopsy: NCI Common Terminology Criteria,2019-01-30,RECRUITING,OBSERVATIONAL,['NA']
919,NCT00003769,,,,1999-02,COMPLETED,INTERVENTIONAL,['PHASE2']
920,NCT04069949,Incidence of Treatment-Emergent Adverse Event,Duration of response,,2019-12-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
921,NCT02938481,Distribution of metastatic LNs,Prognostic outcomes according to the central radicality,,2013-05-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
922,NCT02882659,Safety of DKC as assessed by laboratory examinations,Efficacy of DKC as assessed by change in quality of life,,2014-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
923,NCT05042336,MPR,ORR,,2021-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
924,NCT05151068,The change of sleep,,,2021-01-01,UNKNOWN,INTERVENTIONAL,['NA']
925,NCT01796782,overall survival (OS),Number of adverse events of QYHJ Formula,,2013-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
926,NCT05911217,Disease free survival (DFS),The immunogenicity in subjects receiving CT041 infusion in this study,,2023-07-11,RECRUITING,INTERVENTIONAL,['PHASE1']
927,NCT01492127,Variation of plasma proteasome,Variation of plasma proteasome,,2011-12,UNKNOWN,INTERVENTIONAL,['NA']
928,NCT01356628,Time to Disease Progression,Response Rate (RR),,2011-05-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
929,NCT00072787,,,,2003-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
930,NCT04552236,Predicting early HCC recurrence after treatment by Ultrasound elastography,,,2021-01,UNKNOWN,OBSERVATIONAL,['NA']
931,NCT02607540,"overall survival, OS","disease control rate,DCR",,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
932,NCT03380858,fistula incidence,infection,,2017-11-02,UNKNOWN,OBSERVATIONAL,['NA']
933,NCT05543863,platelet function testing at 5 days,postoperative complications,,2022-08-20,RECRUITING,OBSERVATIONAL,['NA']
934,NCT00606385,Recurrence rate,Survival,,2007-12,UNKNOWN,INTERVENTIONAL,['NA']
935,NCT05451862,confirmed Objective Response Rate (ORR) by localized mRECIST,Quality of Life using EQ-5D-5L questionnaire,,2023-08-21,RECRUITING,INTERVENTIONAL,['NA']
936,NCT02624895,"average relative dose intensity of every drug""",Questionnaire score,,2015-12-30,COMPLETED,OBSERVATIONAL,['NA']
937,NCT00588367,"A reproducible technique to measure CT perfusion parameters may provide a method for non-invasively monitoring tumor response during treatment, or differentiating between autoimmune and chronic pancreatitis.",,,2006-04,COMPLETED,OBSERVATIONAL,['NA']
938,NCT03285867,The change of LSM(kpa) measured by FibroScan(a kind of external harmless ultrasonoscope),,,2018-06-25,UNKNOWN,OBSERVATIONAL,['NA']
939,NCT01103128,BRCA1 vs. BRCA2 mutations,Interaction of other cancer genes with BRCA1 and BRCA2,,2009-03,TERMINATED,OBSERVATIONAL,['NA']
940,NCT06208397,Radiological assessment of CRLM,,,2023-12-24,RECRUITING,OBSERVATIONAL,['NA']
941,NCT06121700,Overall survival (OS),Surgical mortality,,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
942,NCT04500990,Objective Response Rate,Overall survival,,2020-09,UNKNOWN,OBSERVATIONAL,['NA']
943,NCT05097911,Evaluable Non-Target Disease Response,Evaluation of Best Overall Response,,2021-08-02,RECRUITING,INTERVENTIONAL,['PHASE1']
944,NCT05371197,Pathological complete response (pCR) rates,Drug feasibility,,2022-05-05,RECRUITING,INTERVENTIONAL,['PHASE2']
945,NCT06126406,Obtained the recommended dose and infusion regimen of CAR-T cells for the treatment of patients with CEA-positive advanced malignancies[Safety and Tolerability],Pharmacodynamics of CEA CAR-T cells[Cell dynamics],Overall survival(OS)of CEA CAR-T treatment in patients with CEA-positive advanced malignancies[Effectiveness],2023-11-06,RECRUITING,INTERVENTIONAL,['PHASE1']
946,NCT03473574,Objective response rate (ORR),Quality of Life,,2018-05-02,COMPLETED,INTERVENTIONAL,['PHASE2']
947,NCT01243619,Feasibility: Determined by the Number of Participants Who Had All Three Sets of Completed Serial PET Scans That Were Imported for Analysis,,"Analyze Correlation Between FDG and FLT PET Scans, and the Correlation Between Both Types of PET Scan and the Response to Treatment.",2010-08,COMPLETED,INTERVENTIONAL,['NA']
948,NCT06221878,Short-term outcome,Long-term Oncologic outcome,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
949,NCT02233374,Predictive value of PET/CT and MRI 2 weeks into chemo-irradiation for developing a pathologic complete response at surgery.,Impact of pCR rates on long term disease control,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
950,NCT02178436,Overall Survival (Phase II),Progression Free Survival (Phase II),"Change in Gene Expression (Including Forkhead Box Protein O, I-kappaB, Cyclin-dependent Kinase Inhibitor 1B, Par4 and Phosphorylated Signal Transducer and Activator of Transcription 3) (Phase II)",2014-10-31,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
951,NCT00891878,Comparison of Progression-free Survival,Duration of Response,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2']
952,NCT05862792,Postoperative Dysphagia with Dysphagia Survey,Postoperative Pain Medication Usage,,2023-06-01,RECRUITING,OBSERVATIONAL,['NA']
953,NCT06123117,cumulative opioid consumption during the stay at the recovery,cumulative opioid consumption (emergency and inpatient surgery),pain-control failure & possible causes,2024-01-16,RECRUITING,INTERVENTIONAL,['NA']
954,NCT00084643,"MTD of the combination of GTI-2040, oxaliplatin and capecitabine based on the incidence of dose-limiting toxicity (DLT) as assessed by CTCAE version 3.0",Change in biochemical and molecular correlates,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE1']
955,NCT00617708,Progression-Free Survival,Toxicity,,2008-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
956,NCT05697198,The percent adoption of the OmniSeq next generation sequencing (NGS) testing platform in an advanced cancer patient population compared to baseline over a 2 year period,,,2021-04-19,RECRUITING,OBSERVATIONAL,['NA']
957,NCT03223779,The Duration of Local Control,Serial ctDNA,,2017-10-13,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
958,NCT03114631,Number of Participants Who Survived at 1 Year,Number of Participants Who Survived at 3 Years or more,,2017-01-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
959,NCT03950609,Objective response rate,Incidence of adverse events,,2019-07-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
960,NCT01005199,Progression-free survival,Correlation between vitamin B12 and overall survival,,2009-11,COMPLETED,INTERVENTIONAL,['PHASE2']
961,NCT05176223,Time to progression,,,2022-01-25,RECRUITING,INTERVENTIONAL,['PHASE2']
962,NCT05320029,Number of Participants With Anastomosis Success,,,2018-08-30,COMPLETED,INTERVENTIONAL,['NA']
963,NCT05755594,Rate of long-term Survival,Incidence of postoperative complications,,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
964,NCT06283303,Treatment Emergent Adverse Event（TEAE）,Progression-free survival (PFS),,2024-04-02,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
965,NCT01836913,"Preventable locoregional recurrence by the use of PET/CT-based treatment planning, instead of CT-based",Cost-effectivity analyses,,2009-05,COMPLETED,OBSERVATIONAL,['NA']
966,NCT02428907,patient perception of colonoscopy,Staff perception of teamwork,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
967,NCT03491878,R0 rescetion rate,,,2018-05-01,UNKNOWN,INTERVENTIONAL,['NA']
968,NCT04093141,2-year survival proportion from 1) diagnosis and 2) IRE,Nutritional status assessment (PG-SGA-SF),,2019-05-01,RECRUITING,INTERVENTIONAL,['NA']
969,NCT00578396,Expression and cellular localization of beta-catenin in intestinal mucosa: localization of β-catenin. Expression of Wnt pathway target genes in intestinal mucosa: Wnt target gene expression,Monitor resveratrol content of grapes throughout the course of the study. Grapes will be obtained from the same source as participants monthly throughout the study and the content of resveratrol will be measured.,,2007-12,WITHDRAWN,INTERVENTIONAL,['PHASE1']
970,NCT04341012,Utility of breath profiles for disease diagnosis or prognosis,,,2019-09-10,COMPLETED,OBSERVATIONAL,['NA']
971,NCT02148549,Number of participants with toxicity of FIRINOX therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.,The optimal treatment schedule of FIRINOX therapy as neoadjuvant chemotherapy for borderline resectable pancreatic cancer.,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1']
972,NCT05593458,Major Pathological Response rate,pathological Complete Response rate,,2023-04-01,RECRUITING,INTERVENTIONAL,['PHASE3']
973,NCT01133990,Phase 1b: Number of Participants With Clinically Significant Change From Baseline in Electrocardiograms (ECGs) Parameter,Phase 2: Overall Survival (OS),,2010-03-04,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
974,NCT00713128,frequency of delayed emesis (vomiting/retching),"Freq. of mild-severe nausea D 2-6 Freq. use of antiemetics D 2-6, Pts.with complete response(no emesis/use of rescue antiemtics)D 1, Pts. with total control (no:emesis,nausea, use of rescue antiemetics)D 2-6, Overall satisfaction",,2008-04,COMPLETED,OBSERVATIONAL,['NA']
975,NCT04843215,Disease Free Survival(DFS),Overall Survival(OS),Postoperative morbidity,2021-01-01,RECRUITING,INTERVENTIONAL,['NA']
976,NCT00111761,Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 1),Time to Initial Objective Tumor Response (Part 1),,2002-07,COMPLETED,INTERVENTIONAL,['PHASE2']
977,NCT00834236,Number of Participants With Accurate Diagnosis for Gastric Cancer,,,2008-03,COMPLETED,INTERVENTIONAL,['NA']
978,NCT06078982,Objective response rate (ORR),Drug-related safety indicators,,2023-06-06,RECRUITING,INTERVENTIONAL,['PHASE1']
979,NCT05823987,Objective Response Rate (ORR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2023-05-16,RECRUITING,INTERVENTIONAL,['PHASE2']
980,NCT01912222,Number of Participants Reporting Clinically Significant Change From Baseline in Vital Signs,,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1']
981,NCT05854368,"Characterization and validation of a signature combining plasmatic proteins related to inflammation and carcinogenesis process, associated with the presence of gastric mucosal dysplasia lesions compared with an H. pylori negative control group.","Characterization of the plasma levels of the proteins biomarker composing these signatures specific for the different stages of gastric cancer cascade, between the different studied pathology groups",,2023-07-03,RECRUITING,INTERVENTIONAL,['NA']
982,NCT02399228,"Patients Achieving Less Than or Equal to ""2"" RTOG Score At Visit 9",NRPS (Numerical Rating Pain Scale),Safety Will be Assessed Based on the Frequency and Severity of Adverse Events.,2015-10-04,COMPLETED,INTERVENTIONAL,['PHASE2']
983,NCT01471132,Overall Survival,Safety,,2011-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
984,NCT05677113,The primary outcome will be the 2-year Progression-Free Survival (PFS) rate,Five-year overall survival,,2023-08-30,RECRUITING,INTERVENTIONAL,['PHASE2']
985,NCT02672657,Changes in burden of patients' caregivers as assessed by the Zarit burden inventory questionnaire,"Prognostic value of baseline HRQoL measurements on patient's functional decline, defined as any decrease in the ADL scale",,2016-02,UNKNOWN,OBSERVATIONAL,['NA']
986,NCT02450032,Change in Subject's World Health Organization Performance Status,Adverse Events,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2']
987,NCT04076761,Median progression-free survival (PFS),Quality of life: European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30,,2019-12-11,TERMINATED,INTERVENTIONAL,['PHASE2']
988,NCT03521765,WHOQOL-BREF(the World Health Organization Quality of Life-BREF),Barthel Index (BI),,2017-07-01,COMPLETED,INTERVENTIONAL,['NA']
989,NCT01542294,chemotherapy complete rate,overall survival(OS),,2011-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
990,NCT00902291,Survival rate at 6 months,Disease Control (Stable Disease or better per RECIST criteria),,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
991,NCT03748134,OS in PD-L1 positive population,PFS - PD-L1 positive,,2018-12-24,COMPLETED,INTERVENTIONAL,['PHASE3']
992,NCT04338763,Determination of the maximum tolerated dose (MTD) and the recommended dose for phase II of RP72 monotherapy and RP72 in combination with Gemcitabine,,,2021-04-19,RECRUITING,INTERVENTIONAL,['PHASE1']
993,NCT02651987,Median Progression Free Survival (PFS),Mean Change From Baseline in PanNet Specific Tumour Biomarkers: Glucagon,,2015-12-15,COMPLETED,INTERVENTIONAL,['PHASE2']
994,NCT05796700,Progession-free survival,,,2008-01-01,COMPLETED,INTERVENTIONAL,['NA']
995,NCT00436774,Quality of life (QOL) as measured by pediatric cancer quality-of-life inventory or Short Form 36 questionnaires,,,2006-06,UNKNOWN,OBSERVATIONAL,['NA']
996,NCT02902575,Morbidity,Adverse events,,2016-09-01,COMPLETED,INTERVENTIONAL,['NA']
997,NCT02215044,Occurence of dose limiting toxicity according to CTCAE,Tumor marker (CA19-9) response to treatment with BI 2536 and gemcitabine,,2007-06,TERMINATED,INTERVENTIONAL,['PHASE1']
998,NCT05428553,Adverse events,Recurrence after 6 months,Number of clips,2022-06-01,UNKNOWN,INTERVENTIONAL,['NA']
999,NCT01943864,Number of Participants With Indicated Non-progressive Disease as Assessed by Independent Radiologist Per Response Evaluation Criteria In Solid Tumor Version 1.1 (RECIST 1.1) at Week 12,Number of Participants With Independent Radiologist Assessed Duration of Response,,2013-09-19,COMPLETED,INTERVENTIONAL,['PHASE2']
1000,NCT03798769,Rates of completion,Cumulative dose of FOLFIRINOX received,Progression free survival,2019-01-31,COMPLETED,INTERVENTIONAL,['NA']
1001,NCT01026753,Fecal Occult Blood Test (FOBT) completion rate,"The most common patient questions and comments about colorectal cancer, screening, and the fecal occult blood test during the intervention(s). A patient and primary care provider survey.",,2010-08,COMPLETED,INTERVENTIONAL,['NA']
1002,NCT02047474,Progression free survival rate,Objective response rate,,2014-03-25,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1003,NCT02599103,The changs of metabolomics profile between before and after oil consumption,,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
1004,NCT02503384,Annual caseload for pediatric liver transplantation,,,2015-07,UNKNOWN,OBSERVATIONAL,['NA']
1005,NCT05420480,Overall survival(OS),Disease free survival (DFS),,2022-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1006,NCT04409990,SWE accuracy,SWE and ADC measurement,,2020-03-02,COMPLETED,INTERVENTIONAL,['NA']
1007,NCT05048017,Progression Free Survival (PFS),Mortality at 12 months,Adverse Drug Reaction (ADR),2021-10-01,RECRUITING,INTERVENTIONAL,['PHASE2']
1008,NCT04780477,Change in Ki-67+ Level,Change in CD68+ Lamina Propia Macrophages Count,,2021-06-29,RECRUITING,INTERVENTIONAL,['NA']
1009,NCT01248403,overall survival,disease control rate,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1010,NCT03705013,The number of subjects with discordant results that can be attributed to intercurrent disease,,,2018-10-30,TERMINATED,OBSERVATIONAL,['NA']
1011,NCT01251640,Tumor Response (Adjudicated Blinded Read Assessment): Phase II,Overall Survival (OS): Phase II,,2011-01-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1012,NCT00427089,"Efficacy was measured as the degree of cleansing using a 5 grades scale for each of the predefined colon areas resulting into a final grading of the overall quality of gut preparation (A or B: ""success"" versus C or D: ""failure"").","Laboratory tests (such as blood chemistry and hematology) were conducted to support the safety data as well as measurement of body weight, blood pressure and pulse rate, but also tolerance.",,2004-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1013,NCT00102011,Level of participation in screening with FOBT-directed colonoscopy vs a single colonoscopy,,,2000-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
1014,NCT06018246,Patient-generated subjective nutrition assessment,Walking time,Adverse reaction,2021-07-20,COMPLETED,INTERVENTIONAL,['NA']
1015,NCT02362048,Number of Participants With Overall Response Advanced or Metastatic Pancreatic Cancer.,,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1016,NCT00827580,the frequency of HFS; evaluation of eniluracil dose response; and assessment of any toxicity related to the topical product.,,,2009-01,TERMINATED,INTERVENTIONAL,['PHASE1']
1017,NCT01741636,"Satisfaction with the timing, content, and delivery of the intervention",,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
1018,NCT01804621,Colorectal cancer screening,,,2010-04,COMPLETED,INTERVENTIONAL,['NA']
1019,NCT01580202,The cumulative probability of HBV reactivation,Incidence of hepatic decompensation and liver-related mortality,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3']
1020,NCT02445209,Overall Survival,Safety as assessed by adverse events according to CTCAE v4.0,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE3']
1021,NCT01446666,Detection Rate of Patients With HCC,Positive Predictive Value for HCC,,2011-11,COMPLETED,OBSERVATIONAL,['NA']
1022,NCT01282658,,,,2010-11,UNKNOWN,OBSERVATIONAL,['NA']
1023,NCT05692284,Patient Identification Form,SELF CARE ABILITY SCALE,,2022-02-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1024,NCT05698459,MTD (Maximum Tolerance dose),Immunogenicity,,2023-05-05,RECRUITING,INTERVENTIONAL,['PHASE1']
1025,NCT05723965,accuracy of artificial intelligence with experienced physician,real life survival outcome of diagnosis by artificial intelligence.,,2010-10-01,COMPLETED,OBSERVATIONAL,['NA']
1026,NCT02474537,Vz/F of INC280,Unbound fraction and Vz/F based on unbound concentration in plasma,,2015-06-12,COMPLETED,INTERVENTIONAL,['PHASE1']
1027,NCT04046887,Frequency of Dose Limiting Toxicities (DLTs),European Organization for Research and Treatment of Cancer quality of life questionnaire,,2019-09-11,TERMINATED,INTERVENTIONAL,['PHASE1']
1028,NCT05759325,Progression-free survival,,,2023-03,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1029,NCT04931381,6-month disease control rate,Concordance between radiosensitivity test results and patients' treatment response (descriptive statistics).,,2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE3']
1030,NCT00804817,Health Related Quality of Life (HRQoL),Symptom experience (Common Terminology Criteria for adverse events - CTCAE v. 3.0),,2007-12,COMPLETED,INTERVENTIONAL,['NA']
1031,NCT00215644,Percentage of Participants With Objective Response Assessed by Independent Review Committee,Matuzumab Serum Concentration,,2005-08-31,COMPLETED,INTERVENTIONAL,['PHASE2']
1032,NCT01569620,"Change from baseline of colonoscopy at 3 months, 6 months, and 12 months.",,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
1033,NCT03830606,objective response rate（ORR）,safety profile: assessed by CTCAE v4.0,,2016-03-23,COMPLETED,INTERVENTIONAL,['PHASE2']
1034,NCT03039595,Correlation Between Tumour: Stroma Ratio With Local Recurrence of Cancer,Correlation Between Tumour:Stroma Ratio and Overall Survival After TEM Surgery to Remove Rectal Cancer,,2017-03-29,COMPLETED,OBSERVATIONAL,['NA']
1035,NCT05131815,Feasibility of BurnAlong,Measure of Experiential Aspects of Participation (MeEAP),,2022-01-10,COMPLETED,INTERVENTIONAL,['NA']
1036,NCT04062656,Rate of pathological complete responses,Patient-reported outcome (PRO),,2019-09-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1037,NCT03398122,PFS,QOL,,2017-11-14,UNKNOWN,INTERVENTIONAL,['NA']
1038,NCT00838578,Number of Participants With Serious and Other (Non-Serious) Adverse Events According to the CTCAE v.3.0,,,2009-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1039,NCT01801904,number of patients alive and without disease progression,worst grade toxicity per patient,gene expression on tumor tissue,2012-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1040,NCT05429203,Number of participants with procedure-related adverse events,Ability to perform interventions,,2022-10-25,RECRUITING,INTERVENTIONAL,['NA']
1041,NCT01443260,"Determine safety of administering GL-ONC1 intraperitoneally by the evaluation of the number of patients experiencing Adverse Events (type, frequency, and severity)",Detection of Anti-tumor Activity,,2012-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1042,NCT02529007,Number of polyps detected per patient,Patient comfort score,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
1043,NCT02898649,Safety (frequency of procedure-related complication and death),Change in CA 19-9,,2015-12,UNKNOWN,INTERVENTIONAL,['NA']
1044,NCT02806661,Recurrence rate,Inflammatory factors,,2016-07,UNKNOWN,INTERVENTIONAL,['NA']
1045,NCT01912131,assess the acceptability of this piloted P-COCC intervention,qualitative analyses,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
1046,NCT04450758,Number of patients with 90 day mortality,colorectal surgeon performing resectional surgery,,2020-09-01,RECRUITING,OBSERVATIONAL,['NA']
1047,NCT04271657,The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of the radiopathomics artificial intelligence model,The sensitivity of the radiopathomics artificial intelligence model,,2020-01-10,COMPLETED,OBSERVATIONAL,['NA']
1048,NCT00743964,Failure-free survival,progression-free survival,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1049,NCT02324114,Hsp90α Concentration(ng/ml) of plasma,,,2012-09,UNKNOWN,INTERVENTIONAL,['NA']
1050,NCT01350726,,,,2008-01,UNKNOWN,OBSERVATIONAL,['NA']
1051,NCT02446379,The location of PET imaging agent as measured by the LightPathTM Imaging System,Number of participants with adverse events,,na,WITHDRAWN,OBSERVATIONAL,['NA']
1052,NCT03313596,"Progression-free survival, PFS",Median overall survival time,,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
1053,NCT05329766,Objective Response Rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,Percentage of participants with anti-drug antibodies to zimberelimab,,2022-06-10,RECRUITING,INTERVENTIONAL,['PHASE2']
1054,NCT05501379,Comparison of physical activity assessments within 1 week after initiation of cancer therapy,Relation of cancer therapy modality to changes in physical activity between assessements within 1 week and 12 weeks after initiation of cancer therapy,,2022-09-21,RECRUITING,OBSERVATIONAL,['NA']
1055,NCT01761461,The primary endpoint of the study is disease-free survival (DFS).,,,2013-02-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
1056,NCT04091295,,,,na,AVAILABLE,EXPANDED_ACCESS,['NA']
1057,NCT06094868,Progression-free survival (PFS),Security,,2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1058,NCT01057953,genetic variation assessment,,,2010-01,COMPLETED,INTERVENTIONAL,['NA']
1059,NCT06261047,Progression free survival,Duration of control,,2024-01-01,RECRUITING,OBSERVATIONAL,['NA']
1060,NCT05191667,Number of participants with Dose Limiting Toxicities (DLTs),Overall survival (OS),,2022-01-18,RECRUITING,INTERVENTIONAL,['PHASE1']
1061,NCT05012527,Completeness rate of the procedures,,,2021-06-11,COMPLETED,OBSERVATIONAL,['NA']
1062,NCT02483884,Sensitivity and specificity of [68Ga]RM2 PET to identify lesions in comparison to whole-mount histopathology (number of histologically verified cancer lesions identified),Evaluation of SUV threshold,Number of patients with adverse events,2015-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1063,NCT00387387,"Plasma AUC(0-24) of pazopanib on Day 1, 14 and 21 Plasma AUC(0-46) of 5-FU and AUC(0-8) of platinum on Day 1 Plasma AUC(0-24) of capecitabine, 5-FU, and platinum on Day 1","Pharmacokinetic endpoints (AUC, C24, Cmax, tmax, and half-life)collected predose and 1, 2, 3, 4, 5, 6, 8, and 24 hours on Day 1. Assessment of disease by imaging",,2006-10-20,COMPLETED,INTERVENTIONAL,['PHASE1']
1064,NCT02745197,Muscle fatty acid content,Plasma C-reactive protein,,2017-05,WITHDRAWN,INTERVENTIONAL,['PHASE2']
1065,NCT02656524,Number of participants with treatment emergent adverse events as a measure of safety and tolerability,Resource utilization per patient,Time frame between the baseline computed tomography and the first drug delivery,2016-07-01,COMPLETED,OBSERVATIONAL,['NA']
1066,NCT03536208,Determine change in AXL pathway,Antitumor effect,,2019-05-15,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
1067,NCT03741088,Acute Technical Performance of the VORTX Rx® Medical Device for the Ablation of Primary and Metastatic Liver Tumors,Analgesic Requirements After the Ablation Procedure,,2018-03-21,COMPLETED,INTERVENTIONAL,['NA']
1068,NCT05124743,Results of HLA typing in combination with tumor genetic testing of subjects to identify a TCR match for treatment on the TCR001-201 study.,,,2021-09-24,SUSPENDED,OBSERVATIONAL,['NA']
1069,NCT03596411,Sleeve gastrectomy,Obesity related comorbidity,,2018-05-17,UNKNOWN,OBSERVATIONAL,['NA']
1070,NCT04629326,Standardized uptake value（SUV）,,,2021-07-20,RECRUITING,INTERVENTIONAL,['NA']
1071,NCT03160209,Risk factors for ESCC - Tobacco and alcohol consumption,The germline genetic and epigenetic alterations associated with susceptibility to ESCC.,,2017-07-26,COMPLETED,OBSERVATIONAL,['NA']
1072,NCT05141617,24-week re-bleeding,24-week adverse events,,2021-11-03,UNKNOWN,INTERVENTIONAL,['NA']
1073,NCT03959696,Shared Decision Making Process (SDMP) Scale Score,Clinician satisfaction with the visit,Clinician attitude toward shared decision making,2019-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1074,NCT00833131,The rate of patients with R0 resection,The rate of complete pathological response,,2008-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
1075,NCT00280761,Correlation of NF-kappa B pathway activation with therapeutic outcomes,Correlation of p53 pathway-mediated events with clinical outcomes,,2003-12,COMPLETED,OBSERVATIONAL,['NA']
1076,NCT04789980,Overall Survival (OS),Eastern Cooperative Oncology Group Performance Status (ECOG PS) scores,Adverse drug reactions(ADR) caused delay/discontinuation of planned chemotherapy,2021-01-29,RECRUITING,OBSERVATIONAL,['NA']
1077,NCT04358328,Mortality,Mortality,,2020-10-01,RECRUITING,INTERVENTIONAL,['NA']
1078,NCT05565066,Diagnostic yields of EUS-FNA with EUS-FNB for solid masses,Quality of histologic specimen,,2014-12-01,COMPLETED,OBSERVATIONAL,['NA']
1079,NCT00024063,,,,na,UNKNOWN,INTERVENTIONAL,['PHASE1']
1080,NCT01712958,"identifying specific, relevant miRNAs that may serve as biomarkers to stratify CRC patients according to their clinical characteristics",,,2012-11,UNKNOWN,OBSERVATIONAL,['NA']
1081,NCT01604798,Serum peptide mass fingerprinting (PMF),Expressed peptide peaks,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
1082,NCT01110941,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,"Tumor response according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria, and follow up till disease progression or withdrawal from study due to intolerable adverse events (AE)",,2009-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1083,NCT04380103,objective response rate (ORR),the surgical resection rate of patients with liver-only metastases,,2020-04-26,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1084,NCT03704077,Overall response rate (ORR),Overall survival (OS),,2019-10-31,WITHDRAWN,INTERVENTIONAL,['PHASE2']
1085,NCT01349881,"Event rate, defined as rate of high-risk adenoma or second primary colorectal cancer (CRC)",Cancer type (colorectal vs rectal),,2013-08-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
1086,NCT06059885,Tumor recurrence rate (DRR),,,2021-12-22,RECRUITING,INTERVENTIONAL,['PHASE2']
1087,NCT04939103,the accuracy of predicting pCR after nCRT,,,2021-07-01,COMPLETED,OBSERVATIONAL,['NA']
1088,NCT01744639,Nutritional Status,Minimal hepatic encephalopathy,,2012-12,WITHDRAWN,INTERVENTIONAL,['NA']
1089,NCT06255041,"Sensitivity of detection of any cancer (breast, lung, prostate or colorectal cancer) by the breath test.",Intra-observer variability among the detection dogs,The duration for which a breath sample collected on an alternative mask substrate remains effective for detection by a detection dog,2021-02-10,RECRUITING,OBSERVATIONAL,['NA']
1090,NCT05034783,Metabolic parameters,Diagnostic value,GLP-1R expression and SUV,2021-10-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
1091,NCT03524300,3-year disease free survival rate,operation time,,2018-06-01,RECRUITING,INTERVENTIONAL,['NA']
1092,NCT04652180,Respiratory postoperative complications.,Postoperative quality of life.,,2020-11-06,RECRUITING,INTERVENTIONAL,['NA']
1093,NCT05939063,Lymph node positive rate,Overall survival (OS),,2023-10-01,RECRUITING,INTERVENTIONAL,['NA']
1094,NCT05737615,SUV mean measurement,,,2023-02-10,RECRUITING,INTERVENTIONAL,['PHASE1']
1095,NCT03333967,Progress free survival,Disease-free survival,adverse events,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA']
1096,NCT02494973,3-year RFS rate,,,2015-05-26,SUSPENDED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1097,NCT02682589,disease-free survival,postoperative quality of life as assessed by EORTC QLQ-C30 questionnaire,,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE3']
1098,NCT01700283,"Developing Objective Fatigue Indicators: Exploring the Relationships Among Fatigue, Muscle Power and Metabolomics Through Fatigue Management and Individualized Exercise Education Program in Colorectal Cancer Survivors",,,2012-10,UNKNOWN,INTERVENTIONAL,['NA']
1099,NCT02359058,Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,Number of Participants With Treatment Emergent Anti-Ramucirumab Antibodies (TE-ADA),,2015-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1100,NCT04637893,Colorectal Cancer prevention,,,2020-12-16,COMPLETED,OBSERVATIONAL,['NA']
1101,NCT00851305,To compare the rate of EGCs/GCs using CLE versus conventional gastroscopy.,To evaluate the efficacy of in vivo CLE on different pathological characteristics of EGCs.,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
1102,NCT05478083,Liver growth,Symptoms of depression,,2022-06-01,RECRUITING,INTERVENTIONAL,['PHASE2']
1103,NCT06196775,Progression-Free-Survival,Incidence of Adverse Events,,2024-01-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1104,NCT04797884,Quality of Life Survey,Frequency of Adverse Events - PRO-CTCAE,,2023-07,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1105,NCT03397745,Change in Bispectral index score,The changes of BIS,,2018-01-15,COMPLETED,INTERVENTIONAL,['NA']
1106,NCT00145769,Local recurrence,Quality of life,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3']
1107,NCT03316872,Overall response rate,Overall survival rate,,2018-02-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1108,NCT05246943,Compare the D-dimer results of DVT positive subjects to DVT negative subjects to identify a specific result range seen in the DVT positive subjects.,,,2022-05-25,WITHDRAWN,OBSERVATIONAL,['NA']
1109,NCT03604614,PFS,Median survival,,2017-06-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
1110,NCT04714086,,,,na,AVAILABLE,EXPANDED_ACCESS,['NA']
1111,NCT05444491,To investigate the prediction and monitoring effect of plasma ctDNA methylation on postoperative recurrence of primary colorectal cancer patients after radical surgery,,,2022-06-20,RECRUITING,OBSERVATIONAL,['NA']
1112,NCT05803928,"Recurrence-free Survival, RFS",Biomarkers in tumors and peripheral blood,,2023-04-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
1113,NCT04324567,"Peak value of surgically induced C-reactive protein (CRP), expected to occur 1-3 days after surgery",Dehiscence of the perineal wound at 3 months follow-up,Monitoring intermediate metabolites in the remnant muscular tissue of the pelvis floor in up to 10 patients with microdialysis catheters after neoadjuvant CRT and subsequent APR for LARC.,2019-10-09,COMPLETED,OBSERVATIONAL,['NA']
1114,NCT03609359,"Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version. 1.1, and immune-related (ir) RECIST",Disease control rate (DCR),Tests of various biomarkers,2018-10-15,COMPLETED,INTERVENTIONAL,['PHASE2']
1115,NCT03245736,Number of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE),Number of Participants With Increased Prostate Specific Antigen (PSA),,2017-08-23,COMPLETED,INTERVENTIONAL,['PHASE2']
1116,NCT02399137,Progression Free Survival,Rate of adverse events reported with the combination of MM-141 with nab-paclitaxel and gemcitabine versus the comparator arm,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1117,NCT01387880,Clinical benefit (SD+PR+CR),,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
1118,NCT05041153,Overall response rate,,,2022-02-14,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
1119,NCT00005036,Overall survival,Quality of life,,1999-11,COMPLETED,INTERVENTIONAL,['PHASE3']
1120,NCT00087256,To determine whether celecoxib 400 mg bid for 3 years will decrease the incidence of adenomatous polyps of the colon and rectum in participants with Stage I adenocarcinoma of the colon.,To monitor the toxicity and safety of celecoxib in this population.,,2004-07,TERMINATED,INTERVENTIONAL,['PHASE3']
1121,NCT06012318,Prevalence and severity of adverse symptoms,Trajectory of adverse symptoms,,2023-09-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1122,NCT00248053,polyp number and size,side effects and medication compliance,,2005-11,WITHDRAWN,INTERVENTIONAL,['PHASE2']
1123,NCT02024009,Progression free survival,Quality of life,,2016-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1124,NCT05572528,The recurrence rate after LDLT in high risk patients,,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
1125,NCT03006302,6 Month Survival,Number of participants experiencing drug-related adverse events (AEs) requiring treatment discontinuation,,2018-01-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1126,NCT02599909,"To collect blood/urine/tumor samples, stool, and rectal swabs from HCC patients undergoing resection of primary liver tumors at the Mount Sinai Medical Center and to perform an analysis of the interaction of tumors, immune responses and the gut ...",Correlation between microbiome and patients' clinical outcome,,2015-11-06,WITHDRAWN,OBSERVATIONAL,['NA']
1127,NCT03278015,median overall survival time (mOS),Disease control rate(DCR),,2017-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
1128,NCT05371873,MRD monitor,,,2021-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1129,NCT04640480,"Number of clinically significant Chest radiograph findings(chest x-ray, CXR)",Time to progression(TTP),,2024-06-21,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
1130,NCT01632722,2 years recurrence-free survival (2Y-RFS),,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1131,NCT03785496,To evaluate efficacy of PDR001 by Objective Response rate by RECIST(Response Evaluation Criteria In Solid Tumors),To evaluate antitumor efficacy of PDR001,,2020-02-18,UNKNOWN,INTERVENTIONAL,['PHASE2']
1132,NCT00003530,,,,1977-03-21,TERMINATED,INTERVENTIONAL,['PHASE2']
1133,NCT01411579,Apparent Diffusion Coefficient (ADC) value changes of the lesion during chemotherapy.,,,2011-02,COMPLETED,OBSERVATIONAL,['NA']
1134,NCT03682276,Incidence of treatment-emergent adverse events [Safety and Tolerability],Pathologic response rate,,2019-03-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1135,NCT00020774,,,,1998-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
1136,NCT04207918,Local control rate,ctDNA in predicting tumor response rate and prognosis,,2019-11-14,UNKNOWN,INTERVENTIONAL,['PHASE2']
1137,NCT01460745,Percentage of patients who undergo liver resection following downsizing chemotherapy with or without Erbitux,"Percentage of liver resection outcomes R0, R1 and R2",,2011-11,COMPLETED,OBSERVATIONAL,['NA']
1138,NCT03278925,"Change in gamma-hydroxy-1,N(2)-propanodeoxyguanosine (gamma-OHPdG) expression in cirrhotic liver",Polyphenon E pharmacokinetic data in blood and urine in patients with cirrhosis,Incidence of hepatocellular carcinoma,2018-08-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
1139,NCT03488667,Number of Adverse Events related to toxicity.,Programmed cell death ligand 1 (PD-L1) expression in tumor cells,,2018-06-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1140,NCT00978549,Overall survival,Health economic evaluation as assessed by EQ-5D,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE3']
1141,NCT01688336,Median Overall Survival (OS) of FOLFIRINOX in Patients With Unresectable Locally Advanced (ULA) Pancreatic Cancer,Rate of Resectability (RR),"Correlation of Tumor Markers (Ca19-9, CEA) With Outcomes (RR, DCR, PFS, and OS).",2012-01,TERMINATED,INTERVENTIONAL,['PHASE2']
1142,NCT04022746,Change in percent non-viable/necrotic tumor,Change in tumor size and enhancement,,2019-06-11,RECRUITING,INTERVENTIONAL,['NA']
1143,NCT04670718,Visualisation of gastrointestinal tract,Ability to asses depth of invasion of resected GI early tumor,,2020-12-10,COMPLETED,INTERVENTIONAL,['NA']
1144,NCT00730353,Progression Free Survival Rate at 24 Weeks,Toxicity Profile,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2']
1145,NCT05278351,Progression free survival time (PFS),Overall survival (OS),,2022-07-13,RECRUITING,INTERVENTIONAL,['PHASE2']
1146,NCT02491372,Change in psychological flexibility assessed using the Acceptance and Action Questionnaire II,Change in Quality of life using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Oesophageal and Gastric Cancer,,2015-09,WITHDRAWN,INTERVENTIONAL,['NA']
1147,NCT03522649,Overall Survival (OS),Disease Control Rate in biomarker positive patients,,2018-04-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
1148,NCT04072198,ORR,Quality of life with QLQ-C30 questionnaire,,2019-09-26,UNKNOWN,INTERVENTIONAL,['PHASE2']
1149,NCT00583271,,,,2002-06,COMPLETED,OBSERVATIONAL,['NA']
1150,NCT05433402,Disease-free survival,Time occurrence of new primary colon cancer and new polyps,Biological Markers,2022-07-20,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1151,NCT04213222,estimated ORR,estimated OS,,2020-10,UNKNOWN,OBSERVATIONAL,['NA']
1152,NCT02585687,Global survival,,,2012-07,TERMINATED,INTERVENTIONAL,['NA']
1153,NCT01843829,Efficacy,Efficacy,,2013-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
1154,NCT04310839,30-day readmission rate,Ileus,,2020-11-03,COMPLETED,OBSERVATIONAL,['NA']
1155,NCT03874871,R0 resection rate,overall survival,,2019-03-20,RECRUITING,OBSERVATIONAL,['NA']
1156,NCT06168357,Correlation between tumor enhancement in arterial phase expressed as Hounsfield unit number and ADC value.,,,2024-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1157,NCT03766607,"Progression free survival, PFS",Adverse event,,2019-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE2']
1158,NCT00842686,Pathological complete remission rate (pCR),Quality of life,,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
1159,NCT05070156,Evaluate incidence of treatment-emergent adverse events [Safety and Tolerability] after B010-A injection.,Disease control Time (DDC),,2021-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
1160,NCT03462992,AUC of the MonoMark test,,,2012-12-11,UNKNOWN,OBSERVATIONAL,['NA']
1161,NCT04278144,"Objective response rate (ORR) of confirmed complete or partial responses (CR, PR)",Incidence of potential-immune related toxicities,,2020-02-24,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1162,NCT02349412,Change in Quality of Life (QOL) From Baseline to Week 12 Per the Functional Assessment of Cancer Therapy-General (FACT-G),Concordance Between Patient and Family Caregiver Report of Prognosis/Curability,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE3']
1163,NCT04121286,Find Recommended Phase 2 Dose (RP2D) of JAB-3312,Duration of response ( DOR ),,2020-06-10,RECRUITING,INTERVENTIONAL,['PHASE1']
1164,NCT05785975,To assess if positive subjects are complying with follow-up screening,,,2023-06-15,RECRUITING,INTERVENTIONAL,['NA']
1165,NCT00073138,Objective Response Rate in subjects with Recurrent Colorectal Cancer,Toxicities associated with treatment administration,,2003-08,COMPLETED,INTERVENTIONAL,['PHASE2']
1166,NCT02724202,Determine the safety using curcumin in patients with metastatic colon cancer; where toxicities will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.,Duration of Quality of Life,,2016-03,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
1167,NCT03278327,Suggest that there are significantly more than 60 % of patients with a relative decrease of at least 50 % between the total percentages of esophageal time crossed in pH4 (Ph metric dosage) before and after endoscopic treatment.,Use of Inhibitor of the pump with proton (PPI),,2017-06-27,UNKNOWN,INTERVENTIONAL,['NA']
1168,NCT02968810,Change in serum AFP-L3%,Change in Model for End-Stage Liver Disease score,Change in serum immune markers,2017-06-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1169,NCT00492193,Time to upper and lower GI recovery and post-operative hospital length of stay.,Postoperative ileus related mobidity.,,2007-06,COMPLETED,OBSERVATIONAL,['NA']
1170,NCT02484404,Ph I Determine the recommended phase II dose (RP2D) and the safety of doublet therapies of Durvalumab/olaparib (Durvalumab-O) and Durvalumab/cediranib (Durvalumab-C) in patients with advanced solid tumors,Ph I doublet tx: determine the pharmacokinetics of the doublets and correlate with safety.,,2015-06-29,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1171,NCT03898895,"Progression-free survival, PFS","Disease control rate, DCR",,2019-12-10,RECRUITING,INTERVENTIONAL,['PHASE2']
1172,NCT05830019,local progression-free survival,adverse events,,2021-06-01,RECRUITING,INTERVENTIONAL,['NA']
1173,NCT03169842,Cyst fluid glucose level,,,2017-05-25,COMPLETED,INTERVENTIONAL,['NA']
1174,NCT00988741,Evaluate time to progression among all patients treated with ARQ 197 compared to placebo,Further evaluate pharmacokinetics of ARQ 197.,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2']
1175,NCT03951337,Relationship between early tumor uptake of 64Cu-ATSM PET/CT images and prediction of histological response to neo-adjuvant chemo-radiotherapy treatment,64Cu-ATSM toxicity,,2019-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1176,NCT01897636,pancreatic tumor response rates,survival rates,,2013-12,UNKNOWN,INTERVENTIONAL,['NA']
1177,NCT00088933,Number of patients experiencing each of the toxicities by grade for each treatment arm,Average quantity of circulating CEA cells determined by quantitative real time RT-PCR,,2004-06,TERMINATED,INTERVENTIONAL,['PHASE1']
1178,NCT01821482,progression-free survival(PFS),quality of life (QOL),Laboratory findings,2013-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
1179,NCT05440708,Phase 2: Overall Response Rate (ORR) to TTI-101,Cohort A and Cohort B: Pharmacodynamics of TTI-101 as Measured By Change from Baseline in Percentage of Phosphorylated Signal Transducer and Activator of Transcription 5 (pY-STAT5) Positive Cells in Tumor Biopsy Samples,,2023-03-23,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1180,NCT04779554,Drug Half-Life (T1/2) - Pharmacokinetics,,,2021-06-04,RECRUITING,INTERVENTIONAL,['PHASE2']
1181,NCT01946854,Tumor Growth Rate,,,2013-07-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1182,NCT04302363,Diagnostic efficacy of colorectal cancer model in Chinese people,Effect of diet on intestinal flora and DNA methylation in Chinese people,Effects of intestinal microflora and DNA methylation under different stool characteristics,2018-02-01,UNKNOWN,OBSERVATIONAL,['NA']
1183,NCT05533892,Objective response rate (ORR) at 6 months,Duration of response (DOR),,2022-09-01,RECRUITING,INTERVENTIONAL,['PHASE1']
1184,NCT02106871,Skeletal Muscle Fatigue,,,2014-04,WITHDRAWN,INTERVENTIONAL,['PHASE1']
1185,NCT01227239,Phase II: pathological complete response rate,safety,,2010-09,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1186,NCT05818267,duration of disease control(DDC),The incidence of adverse events,,2023-06-26,RECRUITING,INTERVENTIONAL,['NA']
1187,NCT03757754,The number of dose-limiting toxicity,Area under the concentration-time curve from zero extrapolated to infinity (AUC0-∞),,2015-06-03,UNKNOWN,INTERVENTIONAL,['PHASE1']
1188,NCT06189898,Progression free survival,loco-regional recurrence free survival,,2023-12-15,RECRUITING,OBSERVATIONAL,['NA']
1189,NCT00003431,,,,1998-06,COMPLETED,INTERVENTIONAL,['PHASE1']
1190,NCT00795184,"Comparative Histopathology-confirmed Measures of Per Lesion Sensitivity and Per Lesion Specificity, by Using pCLE Associated With WLE, or WLE Alone, for the Detection of High Grade Dysplasia and Early Carcinoma in Barrett's Esophagus.",,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
1191,NCT03404076,Progression free survival after a three year follow-up,,,2014-12-01,COMPLETED,OBSERVATIONAL,['NA']
1192,NCT03042416,Immediate safety evaluation,Perceived clinical benefit,,2017-06-29,COMPLETED,INTERVENTIONAL,['PHASE3']
1193,NCT01246986,Time to Progression (TTP),Time to Worsening (TTW) of Symptoms (FACT-Hep),,2011-03-30,COMPLETED,INTERVENTIONAL,['PHASE2']
1194,NCT02325648,pulmonary vascular permeability index,,,2014-12,COMPLETED,OBSERVATIONAL,['NA']
1195,NCT01574027,Reduction in ACF biomarkers,,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1196,NCT05303714,Secondary Resectability Rate (percent),Complication rate,,2022-03-31,RECRUITING,INTERVENTIONAL,['PHASE3']
1197,NCT00974948,"Absolute and relative changes in 7-point Likert-score for abdominal pain at 1 and 3 months post-randomization. Secondary endpoints were change in morphine equivalent consumption (MEQ), quality of life (DDQ-15), and overall survival.",2. Quality of life 3. Survival,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE3']
1198,NCT02621658,Adenoma Detection Rate,Patient satisfaction,,2016-01,UNKNOWN,INTERVENTIONAL,['NA']
1199,NCT04695847,Part 2: Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigators,Part 2: Number of Participants with Corrected QT Interval (QTc),,2021-01-13,COMPLETED,INTERVENTIONAL,['PHASE1']
1200,NCT06252974,Accurate diagnose the invasion depth of early esophageal squamous cell carcinoma by endoscopy NBI images through deep neural network analysis,,,2024-02-02,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1201,NCT05612477,Feasibility -Accrual,Safety- HCC recurrence,,2023-01-21,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
1202,NCT05983406,DEP accuracy,,,2023-08-01,RECRUITING,INTERVENTIONAL,['NA']
1203,NCT04430985,Disease-free Survival at 3 years,Safety and tolerability of the treatment,"Explorative analysis of biomarkers predictive of response to the combination of nivolumab, ipilimumab in combination with FOLFOX",2020-09-30,WITHDRAWN,INTERVENTIONAL,['PHASE2']
1204,NCT05797870,The objective response rate,,,2024-02-14,RECRUITING,INTERVENTIONAL,['PHASE2']
1205,NCT02869503,Survival of patients with colorectal cancer,Collection of patients characteristics,,2001-01,RECRUITING,OBSERVATIONAL,['NA']
1206,NCT05030493,Progression-Free Survival (PFS),"Evaluation of Correlation between Change in Gene Expression Region in Tumor Tissue at Baseline and Discontinuation of Protocol Treatment of Main Study, and Efficacy Endpoints (OS and PFS)",,2021-08-31,RECRUITING,OBSERVATIONAL,['NA']
1207,NCT02916199,Incidence rate of post-endoscopic retrograde cholangiopancreatography,Success rate of stone removal,,2016-10-04,COMPLETED,INTERVENTIONAL,['NA']
1208,NCT02119065,Absolute difference in post-therapy Yttrium-90 microsphere and pre-therapy Technetium-99m macroaggregated albumin hepatopulmonary shunt fraction values,In vitro Technetium-99m macroaggregated albumin particle size and microsphere size for each patient,,2014-01-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1209,NCT05512182,objective response rate (ORR),Number of participants with treatment-related adverse events as assessed by CTCAE v 5.0,,2022-09-15,WITHDRAWN,INTERVENTIONAL,['PHASE2']
1210,NCT04217083,Test Sensitivity and specificity for colorectal cancer,Test Sensitivity and specificity for colorectal polyps,,2019-01-02,UNKNOWN,OBSERVATIONAL,['NA']
1211,NCT00159445,"To assess time to progression in patients with metastatic colorectal cancer treated with a combination of gemcitabine and capecitabine after progressing on two or more therapies for advanced disease, and having failed both CPT-11 and Oxaliplatin bas",To test the hypothesis that increased gene expression levels predict chemoresistance to capecitabine.,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2']
1212,NCT01276379,Progression Free Survival,Tumoral Response,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2']
1213,NCT02066233,Median Tolerability Score on 10-point Visual Analog Scale (VAS),"Preference for Either of the Two Procedures, EG II Scan Versus Standard Endoscopy",,2014-03,COMPLETED,INTERVENTIONAL,['NA']
1214,NCT02638766,Disease Control Rate,Quality of life by EQ-ED-5L questionnaire,,2015-11,COMPLETED,INTERVENTIONAL,['PHASE2']
1215,NCT00416793,Overall Survival Rate at 6 Months,Overall Response Rate,,2006-12,TERMINATED,INTERVENTIONAL,['PHASE2']
1216,NCT00004234,,,,1999-08-02,COMPLETED,INTERVENTIONAL,['PHASE3']
1217,NCT03227926,Overall response rate (ORR) to panitumumab according to RECIST v1.1.,Toxicity according to CTCAE version 4.03.,,2017-10-11,COMPLETED,INTERVENTIONAL,['PHASE2']
1218,NCT05174325,Pathologic complete remission (PCR),Radiographic response,,2020-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
1219,NCT05179824,Create robust data set of health information,Evaluate longitudinal paired tissue and cell free molecular testing,Review medical information for standard of care decisions and health outcomes,2020-10-19,RECRUITING,OBSERVATIONAL,['NA']
1220,NCT02192983,Response rate,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
1221,NCT05829291,Safety - Adverse events,To evaluate the radiological response of liver metastases using the RECIST criteria .,,2023-10-01,RECRUITING,INTERVENTIONAL,['NA']
1222,NCT02192541,Maximum Tolerated Dose (MTD) of the Combination of Ganetespib and Ziv-aflibercept,Number of Cycles on Treatment,Number of Participants Who Had a Dose Limiting Toxicity (DLT),2014-12-02,TERMINATED,INTERVENTIONAL,['PHASE1']
1223,NCT06147037,Maximum tolerated dose of [225Ac]-FPI-2068 and FPI-2053,"To assess the immunogenicity of [111In]-FPI-2107, [225Ac]-FPI-2068, and FPI-2053",,2024-02-27,RECRUITING,INTERVENTIONAL,['PHASE1']
1224,NCT00303745,Stable disease rate,Progression-free and overall survival,,2006-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
1225,NCT05892354,The incidence of severe oral mucositis,Number of participants with adverse events,,2023-06-10,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1226,NCT05648955,Change in cross-sectional skeletal muscle mass area on the third vertebral level (L3) [cm2],Change in health-related quality of life as measured with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30 global health score),Change in physical function,2023-03-31,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
1227,NCT01349517,Health related quality of life,Morbidity Mortality Survival rate,,2011-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
1228,NCT04751955,Progression free survival,Quality of life by FACT-C v4.0,,2022-01-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1229,NCT05194072,Number of participants with dose limiting toxicities (DLTs),Incidence of antidrug antibodies (ADAs),,2022-01-12,RECRUITING,INTERVENTIONAL,['PHASE1']
1230,NCT06167421,Severe complication rate,Postoperative quality of life assessment,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1231,NCT03391934,Progression Free Survival (PFS),immunogenicity,,2018-01-20,RECRUITING,INTERVENTIONAL,['PHASE3']
1232,NCT01541709,progression-free survival (PFS),percentage of successful dose escalation,,2012-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1233,NCT06233708,Multivariate Cox regression analysis of HCC recurrence at 5-year follow-up,Multivariate Cox regression analysis of overall survival at 5-year follow-up,,2008-01-01,COMPLETED,OBSERVATIONAL,['NA']
1234,NCT01369420,Safety,Efficacy,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1235,NCT03623984,Comparison of intraoperative findings to preoperative PET scan findings,Determine threshold levels of gallium dotatate uptake in order to determine tumor involvement,,2019-06-07,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
1236,NCT01339650,Pharmacokinetic profile,Safety (number of subjects with adverse events and/or dose limiting toxicities),,2011-05-06,COMPLETED,INTERVENTIONAL,['PHASE1']
1237,NCT05613478,Recurrence-free survival (RFS),Safety and toleraty,,2022-11,RECRUITING,INTERVENTIONAL,['PHASE3']
1238,NCT04282980,Progression-Free Survival(PFS) based on independent imaging review,Disease Control Rate(DCR),,2020-04-23,COMPLETED,INTERVENTIONAL,['PHASE2']
1239,NCT01198145,Maximum Severity of Diarrhea Toxicity as Measured by the CTCAE v4.0 During and After Radiotherapy (RT),Percentage of Patients in Each Arm That Experience Clinically Significant Deficits in Overall Quality of Life and Fatigue,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE3']
1240,NCT03258541,Clinical performance,Comparative dosimetric studies,,2017-01-15,TERMINATED,INTERVENTIONAL,['NA']
1241,NCT05674123,Incidence of adverse events,,,2020-01-15,COMPLETED,INTERVENTIONAL,['NA']
1242,NCT04947020,Overall survival,Disease-free survival,Lymph node ratio,2021-08-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1243,NCT04162535,Evaluation of patients serum on cell culture,Survival Comparison,,2018-11-26,UNKNOWN,INTERVENTIONAL,['PHASE1']
1244,NCT00376987,Reversal of cadmium-induced inhibition of mismatch repair,,,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2']
1245,NCT02715141,life time health effects of stool-based surveillance strategies using the ASCCA (Adenoma and Serrated pathway to Colorectal CAncer) model,presence of previously identified progression biomarker on resected tissue samples of polyps,,2015-10,COMPLETED,OBSERVATIONAL,['NA']
1246,NCT02273141,Number of Patients With 'Excellent Plus Good' (Highly Effective) Bowel Cleansing (Colon Ascendens),Polyp Detection Rate (Overall Colon),,2014-11,COMPLETED,INTERVENTIONAL,['PHASE3']
1247,NCT00522665,To evaluate the objective response (CR or PR) rates of patients treated with irinotecan and cetuximab with or without RAD001 in patients with metastatic colorectal cancer,"To evaluate the time to progression, duration of objective response (CR or PR) and overall survival of patients treated with irinotecan and cetuximab with or without RAD001",,2007-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1248,NCT00786006,Progression-free survival,Safety,,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2']
1249,NCT02336087,"Toxicity of the combination of gemcitabine hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation, metformin hydrochloride, and a dietary supplement (National Cancer Institute Common Terminology for Adverse Events criteria version 4)",Time to treatment failure,"Quality of life, assessed using the FACT-G questionnaire",2016-01-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
1250,NCT01243372,Progression-free survival as measured by RECIST,tumor response as measured by RECIST,,2009-11,COMPLETED,OBSERVATIONAL,['NA']
1251,NCT04451603,"Use of prediction software or tools to estimate volume and health of the future liver remnant (FLR), monitor changes in liver volume and health post treatment",,,2018-10-19,COMPLETED,OBSERVATIONAL,['NA']
1252,NCT00898378,Creation of an OMIC profile to predict the risk of colorectal cancer (CRC),Identification of interactive molecular pathways that underlie the development and progression of CRC,,2009-01,COMPLETED,OBSERVATIONAL,['NA']
1253,NCT01646697,Local recurrence at the site of resection,,,2011-11-07,COMPLETED,INTERVENTIONAL,['NA']
1254,NCT04548947,Incomplete resection rate (IRR),Incomplete resection of colorectal polyps,,2021-01-12,COMPLETED,INTERVENTIONAL,['NA']
1255,NCT01466569,"Safety will be assessed by analysis of adverse event, clinical laboratory tests and physical examination",Tumor response rate by Response Evaluation Criteria in Solid Tumors (RECIST),,2011-11,COMPLETED,INTERVENTIONAL,['PHASE1']
1256,NCT04916054,to determine whether the time between each anti-tumor therapy has a prognostic impact on recurrence-free survival,To evaluate the impact on overall survival,,2021-06-04,COMPLETED,OBSERVATIONAL,['NA']
1257,NCT04145141,"To establish a biospecimen repository for genomic, genetic and epigenetic analysis to study the biology of PLC development and progression",To estimate 3 years progression-free survival following immunotherapy for PLC,,2021-07-28,RECRUITING,OBSERVATIONAL,['NA']
1258,NCT03525067,Postoperative infectious complications at postoperative day 90,Mortality post operative day 90,,2017-02-01,COMPLETED,OBSERVATIONAL,['NA']
1259,NCT04473625,Stool-based test for colorectal cancer,,,2020-07-21,COMPLETED,OBSERVATIONAL,['NA']
1260,NCT02407977,Dosimetric accuracy of the device with reference to a commercially available dosimeter,Feasibility of clinical application of the nanaoFOD for dosimetric monitoring of external beam radiotherapy.,,2015-11-13,COMPLETED,OBSERVATIONAL,['NA']
1261,NCT00053222,Objective response,,,2003-02,COMPLETED,INTERVENTIONAL,['PHASE2']
1262,NCT05221398,Recurrence-free survivial,Overall survival,,2019-03-03,COMPLETED,OBSERVATIONAL,['NA']
1263,NCT05955196,Establishment of patient derived organoids (minimum n=30) resembling the primary tissue sample,"To assess the effect of immunotherapy on the antitumor activity of autologous T cells from peripheral blood samples using tumor viability measurements (cell titer glo, FACS)",,2023-01-09,RECRUITING,OBSERVATIONAL,['NA']
1264,NCT01419483,Frequency of Adverse Events (Safety),Progression Free Survival (months),,2011-07,TERMINATED,INTERVENTIONAL,['NA']
1265,NCT03698253,Progression-free survival,Rate of treatment-associated adverse events.,,2013-10-01,COMPLETED,INTERVENTIONAL,['NA']
1266,NCT04833036,PFS,ORR,,2019-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
1267,NCT00003157,Maximum tolerated dose,Survival,,1998-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1268,NCT04984096,Progression-Free Survival (PFS),Overall Survival (OS),,2021-08-01,UNKNOWN,OBSERVATIONAL,['NA']
1269,NCT04049461,Bone alkaline phosphatase,Incidence of distant metastasis and local recurrence,Overall survival,2019-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1270,NCT00378716,Compare the relative efficacy of UFT + LV with that of 5-FU + LV in prolonging disease-free survival and survival,Compare quality of life in patients with stage II and III carcinoma of the colon treated with either 5-FU + LV or UFT + LV regimen,,1997-02,COMPLETED,INTERVENTIONAL,['PHASE3']
1271,NCT01209325,Incidence of Penile/Scrotal Condyloma in HPV 18 Naive and Prior Exposed Participants,"Geometric Mean Titers for HPV 18 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level",,2011-06-28,COMPLETED,INTERVENTIONAL,['PHASE2']
1272,NCT03337841,One-year recurrence-free survival rate,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],,2017-11-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
1273,NCT03560817,Health utilities for SF-6Dv2 after the start of the chemotherapy,Health related quality of life (HRQoL) scores from the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaires after chemotherapy,,2017-01-04,COMPLETED,OBSERVATIONAL,['NA']
1274,NCT00003591,To determine the one-year and median survival rates after PXRT,To correlate p53 status with treatment response to PXRT,,1998-11,COMPLETED,INTERVENTIONAL,['PHASE2']
1275,NCT01191814,Complications related to stent dysfunction,Procedural complications,,2010-07,COMPLETED,INTERVENTIONAL,['NA']
1276,NCT05289726,incidence of grade 3 hand-foot skin reaction,tumor control rate,,2022-04-18,UNKNOWN,INTERVENTIONAL,['PHASE2']
1277,NCT05170360,1. association between some risk factors and colorectal cancer,1. Estimation of KRAS and BRAF genes mutations associated with CRC. 3. Association between these risk factors and gene mutations on different types of CRC.,,2021-12,UNKNOWN,OBSERVATIONAL,['NA']
1278,NCT00427973,Progression-free Survival,Overall Survival,,2009-05,TERMINATED,INTERVENTIONAL,['PHASE2']
1279,NCT05253651,Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Blinded Independent Central Review (BICR),Time to meaningful change in EORTC QLQ30 score,,2022-10-24,RECRUITING,INTERVENTIONAL,['PHASE3']
1280,NCT06162143,Low Anterior Resection Syndrome (LARS) score,Diarrhea,,2023-11-15,RECRUITING,OBSERVATIONAL,['NA']
1281,NCT02446574,Maximum tolerated dose of weekly paclitaxel and cisplatin with concurrent radiation(Phase I endpoint),Disease-free survival of weekly paclitaxel and cisplatin with concurrent radiation(Phase II endpoint),,2007-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1282,NCT03910140,The response to treatment,Lifetime (months),,2017-11-01,UNKNOWN,INTERVENTIONAL,['NA']
1283,NCT02592902,Occurrence of EER (percentage),Presence of pepsin,,2014-04,COMPLETED,INTERVENTIONAL,['NA']
1284,NCT06229197,Incidence of reflux gastritis assessed according to RGB classification,Long-term complications,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1285,NCT04443049,Progressive disease requiring change of therapy in both groups,Decompensation of underlying cirrhosis in both groups,,2020-07-10,UNKNOWN,INTERVENTIONAL,['NA']
1286,NCT01056809,Overall survival,Complications and side effects,,2010-01,TERMINATED,INTERVENTIONAL,['NA']
1287,NCT05047146,Clinicopathological factors of Hepatocellular Carcinoma,,,2021-01-01,COMPLETED,OBSERVATIONAL,['NA']
1288,NCT02270606,Dose limiting toxicity for continuous infusional 5-Fluorouracil given concurrently with short course pelvic radiation,Postoperative mortality rates,,2014-12-04,COMPLETED,INTERVENTIONAL,['PHASE1']
1289,NCT02619942,Disease-free survival,Metastasis rate of central lymph node (3rd station),,2016-01-09,UNKNOWN,INTERVENTIONAL,['NA']
1290,NCT04064034,Quiescin Sulfhydryl Oxidase 1 (QSOX1) in the blood,,,2019-08-01,COMPLETED,INTERVENTIONAL,['NA']
1291,NCT01815853,Disease-free Survival,Adverse effects,,2013-06,RECRUITING,INTERVENTIONAL,['PHASE3']
1292,NCT06107413,Progression Free Survival (PFS),Percentage of Participants Achieving Best Overall Response (BOR),,2023-11-12,RECRUITING,INTERVENTIONAL,['PHASE2']
1293,NCT03957096,Number of patients with dose-limiting toxicities (DLTs),Incidence of antidrug antibodies (ADA),,2019-07-17,TERMINATED,INTERVENTIONAL,['PHASE1']
1294,NCT03781934,Incidence of clinically significant changes in ECGs,Plasma levels of α fetoprotein (AFP),,2018-09-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1295,NCT00061815,"Compare overall survival in subjects with previously-treated metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with oxaliplatin, 5-FU, and LV (FOLFOX4) and cetuximab with FOLFOX4 alone.",Conduct an economic assessment comparing healthcare resource utilization between the two treatment arms.,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE3']
1296,NCT03803930,The diagnostic yields,the tissue integrity,,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA']
1297,NCT05999019,ClassIntra grade,3-year disease-free survival,,2016-08-01,COMPLETED,OBSERVATIONAL,['NA']
1298,NCT02707796,"Evaluation of the correlation between partial oxygen pressure in arterial blood sample and oxygen reserve index calculated by pulse co-oximetry, and sensitivity and specificity of oxygen reserve index in patients undergoing hemicolectomy",Sensitivity and specificity of oxygen reserve index,,2016-05,UNKNOWN,INTERVENTIONAL,['NA']
1299,NCT00950417,Safety and toxicity of this new treatment. Both acute and chronic toxicity will be evaluated.,To determine the complete response rate、partial rate、disease responserate、disease control rate in the patients subject to treatment,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE1']
1300,NCT02775695,Determine the Efficacy of Doxycycline in Inducing Metakaryotic Cell Death in Primary Pancreatic Tumors as Measured by Pathologic Response,,,2017-04-03,COMPLETED,INTERVENTIONAL,['PHASE2']
1301,NCT05872334,Incisional hernia,Wound dehiscence,,2021-06-01,COMPLETED,INTERVENTIONAL,['NA']
1302,NCT03775707,overall survival (OS),Adverse Events,,2018-12-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
1303,NCT04478110,CRC screening rates,,,2010-12,COMPLETED,INTERVENTIONAL,['NA']
1304,NCT01781520,Treatment toxicity,Phenotypic analysis of peripheral blood immune cells,,2013-06-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1305,NCT02289547,Progression free survival,Toxicity profile of each patients measured by NCI-CTCAE ver 4.0,,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
1306,NCT03357757,Proportion of subjects who complete 4 doses of Avelumab in combination with VPA,Hsp90 concentration in serum,,2018-02-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1307,NCT00327119,,,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1308,NCT01262482,Progression free survival,Toxicity,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
1309,NCT05646511,Organ-preservation adapted DFS,Proportion of radical resection in salvage surgery cases in the NOM subgroup,Artificial Intelligence (AI) (deep learning) analysis,2022-11-21,RECRUITING,INTERVENTIONAL,['PHASE3']
1310,NCT00085410,Objective Response Rate,Correlation of Treatment With Changes in Phenotypic Expression of Molecular Markers,,2004-01,TERMINATED,INTERVENTIONAL,['PHASE2']
1311,NCT02319356,maximal oxygen uptake (VO2Max),,,2015-03,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
1312,NCT02796820,Disease-free survival (DFS),Metastasis-free survival (MFS),The adverse events of Huaier Granule,2016-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
1313,NCT03419247,Number of participants with gene testing data available at 8 weeks from baseline tumor biopsy.,"Potential predictive biomarkers of response to treatment such as BRCA, PALB2 and ATM mutations.",,2020-01-01,WITHDRAWN,INTERVENTIONAL,['NA']
1314,NCT02736500,toxicity rate,Progression free survival in association with the receptor and metabolic status at OctreoScan and FDG PET,,2015-09-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1315,NCT00114946,"To compare the efficacy, as measured by progression-free survival (PFS), of FOLFOX/Avastin followed by FOLFIRI/Avastin versus FOLFOX/Avastin followed by 5-FU/LV/Avastin as first-line therapy for previously untreated metastatic colorectal cancer.",To evaluate the tolerability of sequential treatment in subjects and to evaluate the safety of an irinotecan/Avastin-based regimen versus a 5-FU/Avastin regimen for previously untreated metastatic colorectal cancer.,,2005-05,TERMINATED,INTERVENTIONAL,['PHASE4']
1316,NCT05395910,Safety Profile of PIPAC/ePIPAC with Paclitaxel by monitoring adverse events,Area under the curve (AUC) of Paclitaxel administered via PIPAC/ePIPAC using blood drawn from patient.,,2022-10,RECRUITING,INTERVENTIONAL,['PHASE1']
1317,NCT00837135,"To evaluate the feasibility of incorporating GI-4000 vaccine and activated T-cell infusion into a regimen of chemotherapy, radiation, and surgical resection to treat locally advanced pancreatic cancer.",,,2008-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
1318,NCT01570166,overall survival,disease-free survival,,2011-11-01,UNKNOWN,INTERVENTIONAL,['NA']
1319,NCT03020342,vh-chimera DNA,recurrence-free survival time ----measurement in weeks,current HCC marker (AFP ng/ml),2016-05,UNKNOWN,OBSERVATIONAL,['NA']
1320,NCT04390945,Progression-free survival，PFS,"Objective Response Rate, ORR",,2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE2']
1321,NCT01511146,"tumor response according to RECIST 1.1. Number of patients with CR, PR, SD and PR will be recorded.","Progression free survival, adverse events",,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
1322,NCT00217568,Overall survival,,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1323,NCT04076631,Pathological stage of liver cirrhosis,The effect of cirrhotic severity and extent of hepatectomy on the incidence of post-hepatectomy liver failure (PHLF),,2019-08-01,UNKNOWN,OBSERVATIONAL,['NA']
1324,NCT02862587,Progress-free survival,Quality of life,,2016-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1325,NCT02657850,Change in rate of dysphagia symptoms,change in rate of secondary treatment side effect,,2016-06-09,WITHDRAWN,OBSERVATIONAL,['NA']
1326,NCT03204019,Objective Response Rate(ORR),Progression free survival(PFS),,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
1327,NCT05673343,disease free-survival,overall survival (OS,,2023-01-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1328,NCT03567850,Healthcare Utilization of Patients,,,2018-10-19,COMPLETED,INTERVENTIONAL,['NA']
1329,NCT04673955,Overall Survival,Duration of treatment interruptions,,2020-09-03,RECRUITING,OBSERVATIONAL,['NA']
1330,NCT01461057,Number of Participants With Adverse Events (AEs),,,2011-12-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1331,NCT03079427,2-year disease-free survival,Overall survival,,2017-05-15,COMPLETED,INTERVENTIONAL,['PHASE2']
1332,NCT04192734,Incidence of adverse events,Adverse events of special interest,,2019-12-18,COMPLETED,OBSERVATIONAL,['NA']
1333,NCT03484000,Fatigue,,,2018-06-01,RECRUITING,INTERVENTIONAL,['NA']
1334,NCT00858858,Protection Against DNA Damage by UDCA,,,2009-03,COMPLETED,INTERVENTIONAL,['NA']
1335,NCT00826982,To determine the if molecular biomarkers increase the sensitivity by at least 5% for detection of malignant lymph nodes in patients with pancreatic ductal adenocarcinoma as compared to EUS-FNA cytology of lymph nodes alone.,To determine the degree of RNA overexpression of pancreas cancer specific biomarkers in the pre-operative fine needle aspirate of lymph nodes and tumors of patients with pancreatic cancer using a set of pancreas cancer specific biomarkers,,2008-01,COMPLETED,OBSERVATIONAL,['NA']
1336,NCT05768178,Durable Clinical Benefit (DCB),EQ-5D Standardised Area Under Index Value Curve (EQ5DSAUC),,2023-03-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1337,NCT00325078,Efficacy of Treatment With Study Drug,,Gut Immune Cell Types and Their Cytokine Profile,2006-05,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1338,NCT04631731,"Expression of TIM-3, LAG3, VISTA and other inhibitory checkpoint molecules on tumour-infiltrating T cells.","Association of pre-treatment BMI, neutrophil-to-lymphocyte ratio and other clinical parameters with irAEs.",,2020-12-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1339,NCT02819869,relapse-free survival of hepatocellular carcinoma patients,,,2016-08-01,TERMINATED,INTERVENTIONAL,['PHASE2']
1340,NCT02912052,Disease free survival，DFS,Overall survival,number of lymph nodes retrieved,2016-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
1341,NCT01683864,Disease Free Survival,,Kinetics of Mitomycin and Cisplatin,2012-09,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1342,NCT03428074,Overall survivals in patients with esophageal cancer who received surgeries,Death rates within 30 days after surgeries,Extents of lymph metastases,2017-12-01,COMPLETED,OBSERVATIONAL,['NA']
1343,NCT00290719,Pathological response (complete and partial) post-operatively,Compare the effects of gefitinib on biomarkers that effect EGF signaling and genomic composition of tumor samples before and after treatment,,2005-11,TERMINATED,INTERVENTIONAL,['PHASE1']
1344,NCT02813096,early recurrence,overall survival,,2016-10,UNKNOWN,INTERVENTIONAL,['NA']
1345,NCT03511963,PFSR9m,SAE,Ctrough,2018-04-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
1346,NCT01438645,Sedation Score,Ancillary maneuvers to facilitate procedure,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
1347,NCT04752930,Peritoneal Metastasis Free Survival (PMFS),The Overall Survival (OS) at 3 years after radical resection of colorectal cancer,,2020-08-24,RECRUITING,INTERVENTIONAL,['NA']
1348,NCT04923932,Objective response rate (ORR) evaluated by the Independent Review Committee (IRC) (RECIST 1.1 criteria),incidence of various adverse events (AE),,2021-07-27,RECRUITING,INTERVENTIONAL,['PHASE2']
1349,NCT05020132,Change in the Bristol stool chart between baseline and 12 months,Multivariate analysis of risk factors for LARS,,2015-11-01,COMPLETED,OBSERVATIONAL,['NA']
1350,NCT04976439,Description of survival,,,2021-05-01,COMPLETED,OBSERVATIONAL,['NA']
1351,NCT03007225,Number of Participants With Complete Response,,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE4']
1352,NCT03572400,Disease-free survival rate,Disease control rate,,2018-11-29,UNKNOWN,INTERVENTIONAL,['PHASE2']
1353,NCT02979470,progression free survival,,,2016-09,UNKNOWN,OBSERVATIONAL,['NA']
1354,NCT02156557,Validation of binding of peptide,,,2014-06,COMPLETED,INTERVENTIONAL,['PHASE1']
1355,NCT05722288,Percentage of patients completing 4 weeks of time-restricted eating during RT,Oxidative DNA damage,,2023-01-20,RECRUITING,INTERVENTIONAL,['PHASE2']
1356,NCT06115629,All-cause mortality,Fear of cancer recurrence as determined by the cancer worry scale score,,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
1357,NCT05270889,Overall Response,,,2022-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1358,NCT01202409,Response Rate (RR),Overall Progression-free Survival (PFS) for CAPOX and Panitumumab,,2010-11-02,COMPLETED,INTERVENTIONAL,['PHASE2']
1359,NCT02845258,Repeated drainage frequency,Long time complication rate,,2006-01,RECRUITING,OBSERVATIONAL,['NA']
1360,NCT01930435,Mean Change in Quality of Life as Measured by the Subscale MDASI-HN Score.,Rate of Hospitalization in Patients Who Use Personalized Sterile Humidification,,2013-07,COMPLETED,INTERVENTIONAL,['NA']
1361,NCT00227747,Rate of complete surgical resection,Acute and late toxicity,,2005-11-08,COMPLETED,INTERVENTIONAL,['PHASE3']
1362,NCT00087191,Toxicity as assessed by NCI Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE) version 3.0,,,2004-05,TERMINATED,INTERVENTIONAL,['NA']
1363,NCT05773248,Perioperative morbidity,Readmission rate,,2023-03-13,COMPLETED,OBSERVATIONAL,['NA']
1364,NCT04769414,Overall response rate (ORR),Overall survival (OS),,2021-02-20,COMPLETED,INTERVENTIONAL,['PHASE2']
1365,NCT03331562,Progression- Free Survival at 6 Months From Initiation of Trial Treatment,Cellular VDR Targets in the Immune Microenvironment With PD1 Blockade,Exploratory: Monitor and Compare the Gut Microbial Communities in Both Arms of the Trial,2017-12-27,COMPLETED,INTERVENTIONAL,['PHASE2']
1366,NCT00813605,Progression Free Survival,Incidence of antibody formation,,2009-03,COMPLETED,INTERVENTIONAL,['PHASE2']
1367,NCT02217020,The ratio of tumor downstaging to stage 0 and stage I,Reported Adverse events,,2014-08-15,COMPLETED,INTERVENTIONAL,['PHASE2']
1368,NCT00942461,Inflammatory reaction of the patients organism in laparoscopic vs open colorectal surgery for cancer,,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE4']
1369,NCT01639443,Percentage of GI Clinic Capacity Filled,Cost Comparisons,,2013-07-08,COMPLETED,INTERVENTIONAL,['NA']
1370,NCT05238922,Number of Participants Discontinue study due to TEAE,Duration of Response (DOR),,2022-07-05,RECRUITING,INTERVENTIONAL,['PHASE1']
1371,NCT04237883,Aggregate Focus Quality Measure order rates at the first visit,Number of Open Tests,,2019-11-01,COMPLETED,INTERVENTIONAL,['NA']
1372,NCT00620295,Maximum tolerated dose of bortezomib and gemcitabine,"Characterization of gemcitabine and metabolite pharmacokinetics (as part of co-enrollment in Population Pharmacokinetics and Pharmacogenetics of Gemcitabine in Adult Patients with Solid Tumors"")",,2007-03,COMPLETED,INTERVENTIONAL,['PHASE1']
1373,NCT01543620,,,,2012-02,UNKNOWN,OBSERVATIONAL,['NA']
1374,NCT04235114,The observation of differences in 89Zr-DFO-nimotuzumab uptake between the tumors and normal tissues using PET/CT.,Lesion detection rate of FDG PET/CT compared with 89Zr-DFO-nimotuzumab in patients with EGFR-positive (by IHC) lung and colorectal cancers using PET/CT.,,2020-02-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1375,NCT00532740,,,,2004-12,COMPLETED,OBSERVATIONAL,['NA']
1376,NCT00728585,Incidence of WHO grade 3 or 4 oral mucositis,Incidence of febrile neutropenia and invasive bacterial infections,,2008-03-13,WITHDRAWN,INTERVENTIONAL,['PHASE2']
1377,NCT00112099,Overall survival,perioperative blood loss,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE3']
1378,NCT05262491,Phase Ib: Recommended Phase II Dose (RP2D),Progression-free Survival (PFS),,2022-02-14,RECRUITING,INTERVENTIONAL,['PHASE1']
1379,NCT02191878,Maximum tolerated dose (MTD),Clinical Benefit Rate at maximum tolerated dose (MTD) in Expansion Cohort,Assessment of Pharmacodynamic Effect,2014-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1380,NCT02508532,"Part 2: Objective Response Rate (ORR) Determined by Central Radiology Assessment Per mRECIST, Version 1.1","KIT, PDGFRA, and Other Cancer-relevant Mutations Present in Tumor Tissue at Baseline and EOT",,2015-08,COMPLETED,INTERVENTIONAL,['PHASE1']
1381,NCT04454762,Blood pressure [Safety and Tolerability],Health-related quality of life (HRQOL),,2020-07-22,UNKNOWN,INTERVENTIONAL,['PHASE2']
1382,NCT00075868,"Prevention of the incidence of moderate, severe, or life-threatening diarrhea","Prevention of the incidence of severe or life-threatening (i.e., grade 3-5) diarrhea",,2003-12,COMPLETED,INTERVENTIONAL,['PHASE3']
1383,NCT01677468,Survival rate of the subjects,Complication rate of TACE,,2012-08,UNKNOWN,INTERVENTIONAL,['NA']
1384,NCT00151476,Time From Start of Study Follow-up to Time of First Excisional Polypectomy of a Rectal Polyp Post IPAA,Rectal or Pouch Adenoma Burden Based on Polyp Counts,,2004-11,TERMINATED,OBSERVATIONAL,['NA']
1385,NCT05628545,Overall Survival,PFS（Progression-Free Survival ),,2021-11-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1386,NCT03342937,Months of Progression-free Survival (PFS),Months of Overall Survival,,2018-01-11,COMPLETED,INTERVENTIONAL,['PHASE2']
1387,NCT03467308,Measure TRIM59 in the study groups.,Targeting new prognostic and therapeutic markers for colorectal cancer.,,2018-03-01,COMPLETED,OBSERVATIONAL,['NA']
1388,NCT03707080,Time to HCC recurrence - Prospective Cohort,Number of events of early HCC recurrence - Prospective Cohort relative to Historical Cohort,,2018-03-09,COMPLETED,OBSERVATIONAL,['NA']
1389,NCT02439385,Progression-free survival,"Fatigue (FACIT-Fatigue scale (version 4, Korean version)",,2015-08-24,COMPLETED,INTERVENTIONAL,['PHASE2']
1390,NCT04214418,Phase 1: Estimated maximum tolerated dose (MTD),Phase 1: Incidence of Treatment-Emergent Adverse Events with drug combination (Safety and Tolerability),,2020-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1391,NCT00003835,Survival,,,1999-05,COMPLETED,INTERVENTIONAL,['PHASE3']
1392,NCT00902733,"Quality of life, psychological distress, symptom relief, geriatric assessment outcome, and resource use at 3 months",Long-term impact at 6 months,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
1393,NCT01263002,Proportion of patients with HBV DNA levels < 60 IU/mL,,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE4']
1394,NCT04269941,number of patients operated for gastric GIST,,,2000-01-01,COMPLETED,OBSERVATIONAL,['NA']
1395,NCT05099211,Acceptability of the program in terms of the number of sessions attended,,,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1396,NCT05562297,2-year overall survival after the application of sintilimab and gemcitabine plus nab-paclitaxel,"Correlation among ctDNA, serum tumor markers, and CT evaluations before and after neoadjuvant therapy, before and after curative resection, during and after adjuvant therapy, and during and after the maintenance treatment of immunotherapy.",,2023-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1397,NCT05801965,Cancer-specific Quality of Life,User engagement,,2023-04-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1398,NCT00699374,Overall Survival (OS),European Quality of Life (EQ-5D)- Health State Profile Utility Score,,2008-07,TERMINATED,INTERVENTIONAL,['PHASE3']
1399,NCT00245362,Overall survival,,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1400,NCT03150615,Incident rate of delayed gastric emptying,Maximum Plasma Concentration fasting plasma GLP-1 level,,2016-09,COMPLETED,INTERVENTIONAL,['NA']
1401,NCT02606305,"Dose Expansion (Regimens A and D) and Triplet (Regimen E): Objective Response Rate (ORR); Percentage of Participants With Confirmed Response, as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1",Immunogenicity: Number of Participants With Anti-Drug Antibody (ADA) Response to Mirvetuximab Soravtansine,,2016-03-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1402,NCT06165328,Diagnostic yield in diagnosis colorectal tumor,Procedure-related adverse events,,2024-01-01,RECRUITING,OBSERVATIONAL,['NA']
1403,NCT04566133,Median Progression Free Survival (PFS),Overall Survival,Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),2022-02-15,TERMINATED,INTERVENTIONAL,['PHASE2']
1404,NCT03852290,Assessment of C677T and A1298C MTHFR polymorphisms and response rate,Assessment of C677T and A1298 MTHFR polymorphisms and toxicity,,2019-01-16,UNKNOWN,OBSERVATIONAL,['NA']
1405,NCT04651504,Number of colonoscopy completions after positive fecal immunochemical test,Proportion of patients who complete a complete diagnostic evaluation within 60 days of positive fecal immunochemical test,,2020-12-02,RECRUITING,INTERVENTIONAL,['NA']
1406,NCT02542670,Number of cancer patients with abnormal genetic mutations .,,,2015-07,UNKNOWN,OBSERVATIONAL,['NA']
1407,NCT00518557,"Safety and tolerability, Mortality","Tumor volumetry, Changes of Tumor markers such as AFP, Curriculum survival",,2007-04,UNKNOWN,INTERVENTIONAL,['NA']
1408,NCT06078657,1 year overall survival rate,adverse events,biomarker,2023-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1409,NCT05196334,Comparison between organoid's and patient's response,,,2021-07-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1410,NCT04015804,Conversion rate for robotic surgery,Operating time,,2015-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1411,NCT00766142,Median Progression-free Survival (PFS) Time,Overall Survival (OS) Time,,2007-05-01,TERMINATED,INTERVENTIONAL,['PHASE2']
1412,NCT01926236,Overall survival,Quality adjusted life years (QALYs),,2014-02,COMPLETED,INTERVENTIONAL,['PHASE3']
1413,NCT00784446,Dose limiting toxicity.,Assessment of overall response rate and progression free survival.,,2008-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1414,NCT04082364,Objective response rate (ORR) for non-microsatellite instability-high (non-MSI-H) patients (Cohort A),Number of patients who have ADA to tebotelimab,,2019-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1415,NCT02254941,Overall survival,Study other variables to identify whether there is group of patients who may benefit from monoclonal antibodies for the treatment of first-line chemotherapy,,2014-08,UNKNOWN,OBSERVATIONAL,['NA']
1416,NCT03342677,Comparison of Gd-EOB-DTPA enhanced liver MRI and CT scan images in characterizing cirrhotic nodules and HCC in liver transplant candidates,Investigation of Gd-EOB-DTPA enhanced MRI efficacy in diagnosis and staging of HCC in cirrhotic patients and its potential impact on liver transplantation eligibility in patients who are liver transplant candidates,,2017-11-07,UNKNOWN,INTERVENTIONAL,['NA']
1417,NCT02877589,hepatitis B virus (HBV) serological status,hepatitis C virus (HCV) serological status,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
1418,NCT05536362,Measurement of Post-operative Pain,,,2021-02-01,COMPLETED,INTERVENTIONAL,['PHASE1']
1419,NCT04095364,Progression-free survival (PFS),Adherence to letrozole maintenance therapy,,2019-09-20,RECRUITING,INTERVENTIONAL,['PHASE3']
1420,NCT00164944,To find the prevalence of adenomas and advanced neoplasms of the first degree relatives,,,2004-04,COMPLETED,OBSERVATIONAL,['NA']
1421,NCT00012389,,,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE3']
1422,NCT01275664,Number of Participants With Complete Control Defined as no Vomiting and no Use of Rescue Medications (for Nausea or Emesis),Percentages of Patients With NIDL Based on FLIE,,2011-06,TERMINATED,INTERVENTIONAL,['NA']
1423,NCT03447431,To develop biological tools to simplify screening in future clinical assays,,,2018-04-05,UNKNOWN,OBSERVATIONAL,['NA']
1424,NCT02591030,overall survival,quality of life (EORTC QLQ-C30 ),,2015-12-15,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1425,NCT00991952,Overall Response Rate,,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2']
1426,NCT03721653,Progression Free Survival (PFS),2nd-PFS,,2018-11-30,COMPLETED,INTERVENTIONAL,['PHASE2']
1427,NCT05128123,"The primary objective will be to assess the rates of curative treatment (either resection, ablation or liver transplantation) according to the social determinants of health",Assessment of the relationship between social health determinants and the quality of life of patients at 6 and 18 months after inclusion in the CHIEF cohort study,,2022-01-21,RECRUITING,OBSERVATIONAL,['NA']
1428,NCT03751176,Progression-free survival at 6 months,Biomarkers analysis by liquid biopsies.,,2018-11-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
1429,NCT00083122,Proportion of Confirmed Tumor Responses Defined to be Either a Complete Response (CR) or Partial Response (PR),Time to Progression,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1430,NCT01310972,"OS, PFS, DFS",,,2007-09,COMPLETED,OBSERVATIONAL,['NA']
1431,NCT04027088,Surgical fistulas,Weight loss,,2019-08-10,UNKNOWN,INTERVENTIONAL,['NA']
1432,NCT00853684,Time to progression,Overall survival,,2009-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
1433,NCT02560623,DNA Yield,Specificity of Barrett's Dysplasia Detection,,2015-10-15,COMPLETED,INTERVENTIONAL,['NA']
1434,NCT04269499,Feasibility of MR imaged administration of holmium microspheres,Tumor response after 3 months based on CT imaging (according to RECIST 1.1 criteria),,2019-11-11,COMPLETED,INTERVENTIONAL,['NA']
1435,NCT04942665,Quantitative Assessment - Bile Duct-to-liver Fluorescence Intensity Ratio,"Qualitative Assessment of Overall Intraoperative Visualization of the Extrahepatic Biliary Tree (Common Hepatic Duct, Cystic Duct, Common Bile Duct, Aberrant Ducts)",,2021-09-15,COMPLETED,INTERVENTIONAL,['PHASE2']
1436,NCT04417699,Achieve a reduction by at least 5.8 in Neoadjuvant Response (NAR) score compared to historic controls with NAR of 14.59,Safety and Tolerability,,2022-07-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1437,NCT02715089,Progression-free survival (PFS),Adverse Drug Reaction (ADR)/Adverse Event (AE),,2015-12,UNKNOWN,OBSERVATIONAL,['NA']
1438,NCT03564912,DFS,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2018-08-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1439,NCT00620607,response rate,effect of huC242-DM4 on tumor uptake of FDG,,2007-05,WITHDRAWN,INTERVENTIONAL,['PHASE2']
1440,NCT06331988,Relapse free survival,Overall survival,,2022-07-21,RECRUITING,OBSERVATIONAL,['NA']
1441,NCT03064828,Sensitivity and specificity of low-dose CTC for the polyp detection,Sensitivity and specificity of CTC for the detection of poly malignancy,,2017-01,UNKNOWN,INTERVENTIONAL,['NA']
1442,NCT02570399,Feasibility in terms of toxicity related to radiation therapy,Quality of life questionnaire of treated patients,,2015-02-26,UNKNOWN,INTERVENTIONAL,['NA']
1443,NCT02329106,Evaluate the safety of IRE for unresectable liver cancer close to diaphragmatic dome using Common terminology Criteria for Adverse Events (CTCAE).,Evaluate the efficacy of IRE for unresectable liver cancer close to diaphragmatic as measured by cell death of CRLM after IRE is demonstrated macroscopically by using vitality-staining with triphenyl-tetrazoliumchloride (TTC),,2014-12-01,COMPLETED,INTERVENTIONAL,['NA']
1444,NCT03302858,Percent of patients who have histologically cleared high-grade squamous intraepithelial lesions (HSIL) at the SCJ at 12 months as measured by HRA,Percent of patients who have histologically cleared low-grade squamous intraepithelial lesions (LSIL) at the SCJ at 12 months as measured by HRA,,2017-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
1445,NCT01465451,disease-free survival,safety profiles,,2011-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
1446,NCT00033735,Survival of Irofulven vs. 5-FU,Objective Tumor Response of Irofulven vs. 5-FU and Clinical Benefit of Irofulven vs. 5-FU,,2000-01,COMPLETED,INTERVENTIONAL,['PHASE3']
1447,NCT01977053,"emotional state (anxiety, depression, confusion, angry, fatigue, force and interpersonal relation)",relationship between psychosocial criteria and anxiety,intervention cost,2013-09,COMPLETED,INTERVENTIONAL,['NA']
1448,NCT02974556,Incidence of endoperitoneal recurrence at 36 months,EORTC QLQ-C30 Summary Score,,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
1449,NCT00091026,Objective Response Rate (Complete or Partial Response) Evaluated Using the Response Evaluation Criteria in Solid Tumors (RECIST),Overall Survival,,2004-07,COMPLETED,INTERVENTIONAL,['PHASE2']
1450,NCT00004884,,,,1999-07,COMPLETED,INTERVENTIONAL,['PHASE2']
1451,NCT02546973,HRQL in patient's with anal cancer 3 years after diagnosis,"HRQL (measured by questionnaires) differences between patient groups such as age, gender and educational level",,2015-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1452,NCT01075633,Advanced colorectal neoplasm detection rate [Time Frame: 2 years] [Designated as safety issue: No],Complications rate,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE3']
1453,NCT02482259,Time taken to complete assessments,Muscle mass and timed get up and go as predictors of outcome,Biomarker assessment of frailty and associated factors,2013-12-01,COMPLETED,OBSERVATIONAL,['NA']
1454,NCT01775449,Cold pain thresholds,QLQ-C30 (Quality of Life questionnaire C30)scores,,2013-02-02,COMPLETED,INTERVENTIONAL,['PHASE3']
1455,NCT05871099,5-years Recurrence-free survival,Toxic and side effects of the program,,2022-11-20,RECRUITING,INTERVENTIONAL,['PHASE3']
1456,NCT04599790,Progression free survival (PFS) assessed by investigators according to Modified RECIST (mRECIST),DOR assessed by investigators according to mRECIST.,,2020-10-01,COMPLETED,INTERVENTIONAL,['PHASE2']
1457,NCT03807518,Change in Physical Fitness,Change in concentration of blood markers of Inflammation- White Cell Differential,,2019-03-01,COMPLETED,INTERVENTIONAL,['NA']
1458,NCT01279291,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,"To describe any anti-tumor activity observed when KHK2866 is administered i.v. as monotherapy, or in combination with chemotherapy.",,2011-01,TERMINATED,INTERVENTIONAL,['PHASE1']
1459,NCT02394535,Maximum tolerated dose defined as the highest dose level in which 6 patients have been treated with at most 1 instance of dose limiting toxicity (DLT) according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0,Changes in MD Anderson Symptom Inventory Gastrointestinal Cancer Module (MDASI),,2015-11-12,COMPLETED,INTERVENTIONAL,['PHASE1']
1460,NCT04720716,Objective response rate (ORR),The incidence and severity of Treatment-Emergent Adverse Events,,2021-02-07,RECRUITING,INTERVENTIONAL,['PHASE3']
1461,NCT05887505,Ratio of liver failure,Complications after surgery,,2023-06-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1462,NCT04887805,Progression free survival,Incidence of adverse events,,2021-07-21,RECRUITING,INTERVENTIONAL,['PHASE2']
1463,NCT03970694,5-year overall survival rate,3-year progression-free survival rate,,2019-05-11,TERMINATED,INTERVENTIONAL,['PHASE3']
1464,NCT02842749,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,Progression free survival,,2016-03-14,COMPLETED,INTERVENTIONAL,['PHASE4']
1465,NCT01421940,Change from baseline in International Index of Erectile Function (5-item Version) at 12 and 24 week,Number of patients with adverse events during 24 weeks of the study,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE4']
1466,NCT03529760,HBV-DNA positive,,,2018-05-08,UNKNOWN,OBSERVATIONAL,['NA']
1467,NCT01488487,Time to Progression (TTP),Objective Response Rate (ORR),,2011-12,COMPLETED,INTERVENTIONAL,['PHASE2']
1468,NCT06000553,"the aim is to search for immune and metabolic abnormalities in patients with at-risk TIPMP in the blood or by echo-endoscopic sampling, then compare and combine them with the criteria used in clinical practice.",,,2023-10-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1469,NCT06225011,Immune cell composition and microenvironment,,,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
1470,NCT06179602,Safety as assessed by complications according to CTCAE v6.0.,,,2024-01-01,RECRUITING,OBSERVATIONAL,['NA']
1471,NCT00189683,,,,na,UNKNOWN,INTERVENTIONAL,['PHASE3']
1472,NCT01774266,Early detection of gastric cancer,Monitoring progression of disease,Detection of H.pylori and gastric atrophy,2012-09,UNKNOWN,OBSERVATIONAL,['NA']
1473,NCT01281683,,,,2011-01,UNKNOWN,OBSERVATIONAL,['NA']
1474,NCT02325323,Incidence of gastric cancer or high grade dysplasia of the gastric mucosa,Percentage of development of gastric cancer or high grade dysplasia,,2014-05,UNKNOWN,OBSERVATIONAL,['NA']
1475,NCT00209625,objective tumor response,"Response duration, time to progression, median survival time, and safety",,2000-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1476,NCT04435977,PFS,safety and tolerability,,2020-01-30,UNKNOWN,INTERVENTIONAL,['PHASE2']
1477,NCT04677673,Overall Survival,Disease-free survival (DFS),,2021-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1478,NCT00106054,To determine the rate of R0 resection or pathologically confirmed CR in patients with hepatic only metastases,"oTo determine the resectable rate, defined as the number of subjects with R0 resection, pathologically staged CR, or undergoing non-surgical ablative procedures with curative intent divided by the total number of evaluable subjects following treatment",,2006-01,TERMINATED,INTERVENTIONAL,['PHASE2']
1479,NCT00844675,Frequency of bleeding after EMR is performed,Measurement of a change in the size of ulcer,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE4']
1480,NCT04411589,detection rate of GIN and EGC,diagnostic accuracy in a per-biopsy analysis,,2020-05-01,UNKNOWN,INTERVENTIONAL,['NA']
1481,NCT01125865,Stent patency,Technical success,,2010-05,UNKNOWN,INTERVENTIONAL,['PHASE4']
1482,NCT05173610,Treatment efficacy (Disease free survival),Number of participants with treatment-related adverse events (acute and late toxicity) as assessed by CTCAE v4.0,,2021-09-28,RECRUITING,INTERVENTIONAL,['PHASE2']
1483,NCT01132755,Number of Study Participants With Adequate Percutaneous Lavage Specimen Collection,Safety of Peritoneal Lavage in Place of Laparoscopic Lavage.,,2010-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1484,NCT00296322,Relapse-free Survival,Overall Survival,,2001-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1485,NCT03006263,overall postoperative morbidity rates,The variation of C-reactive protein,,2016-11-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
1486,NCT03038984,cancer,"Disease course, Copenhagen IBD Disease course Type",,2016-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1487,NCT02321579,Oxidative stress marker (MDA concentation),Glutathione related enzyme activities,,2014-12,UNKNOWN,INTERVENTIONAL,['NA']
1488,NCT03833661,Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC),Durable Response Rate (DRR) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by an Independent Review Committee (IRC) According to According to Microsatellite Instability (MSI) Status,,2019-03-26,COMPLETED,INTERVENTIONAL,['PHASE2']
1489,NCT04342676,"LNR and K ras were evaluated with correlated with different clinicopathological parameters (Gender, CEA, tumor size, tumor grade and response to treatment).",LNR and K ras were evaluated and ASSOCIATION with PFS and OS.,,2017-03-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1490,NCT05757492,Assessment of the number of participants with treatment-emergent adverse events (TEAEs) receiving CHS-006 administered in combination with toripalimab,Overall survival (OS) using RECIST v1.1 assessed by the investigator,,2023-04-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1491,NCT02043184,Medication Adherence using pill count and self report,Healthcare Utilization is the use of Emergency room and Hospital admissions,,2013-03,COMPLETED,INTERVENTIONAL,['NA']
1492,NCT04800991,Score of each domain of the 'feasibility assessment of the investigational device (website)' questionnaire for investigators,The investigational device(application) usage compliance by underlying disease,Frequency of Adverse Events,2021-03-17,COMPLETED,INTERVENTIONAL,['NA']
1493,NCT06328283,glutamine synthetase,,,2024-04-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1494,NCT02047513,Time to Disease free survival (DFS),Tumor recurrence,,2015-07,COMPLETED,INTERVENTIONAL,['PHASE2']
1495,NCT01703910,gene expression profiles,,,2012-11,COMPLETED,INTERVENTIONAL,['PHASE2']
1496,NCT04927260,Survival,Quality of life in real-life according to FACT-G questionnaire,,2021-03-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1497,NCT01386697,,,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
1498,NCT00349024,"Symptoms, other than pain, considered important to the pediatric population",,,2005-07,UNKNOWN,INTERVENTIONAL,['NA']
1499,NCT00474812,Median Overall Survival,Gait Speed,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1500,NCT00536614,Overall survival,"response to treatment, and toxicity",,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1501,NCT01725321,Detection rate of proximal serrated polyp,Missed rate for proximal serrated polyps,Adenoma detection rate,2012-10,COMPLETED,OBSERVATIONAL,['NA']
1502,NCT03448874,Incidence of overall subject pre-specified* procedure related Adverse Events,"Incidence of ""deployment failure""",,2018-04,WITHDRAWN,INTERVENTIONAL,['NA']
1503,NCT02563002,Overall Survival (OS),Number of Participants Who Discontinued Study Treatment Due to an AE,,2015-11-30,COMPLETED,INTERVENTIONAL,['PHASE3']
1504,NCT03711890,Measure accuracy of using OCT to diagnose pancreatic cancer and compare with histology.,,,2019-03-26,RECRUITING,INTERVENTIONAL,['NA']
1505,NCT00448838,Progression-free survival,Time to progression,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
1506,NCT02145559,Pharmacodynamic Biomarker p70S6K,Fasting Serum Glucose and Triglycerides,,2014-04,COMPLETED,INTERVENTIONAL,['PHASE1']
1507,NCT03443921,Overall mortality at one year after randomization;,Performance status at 3 years after randomization,,2018-03,UNKNOWN,INTERVENTIONAL,['NA']
1508,NCT05593328,Overall Response Rate,Safety: Exposure Response Evaluation of Onvansertib,,2023-03-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1509,NCT04344158,Overall survival (OS),Duration of Response (DOR),,2020-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
1510,NCT03449914,Evaluate the prognostic value of baseline G8 screening tool for survival.,,,2017-10-26,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1511,NCT05787587,Part 2 (Dose Expansion): To evaluate preliminary anti-tumor activity of IDE161 monotherapy in participants by measuring Duration of Response using RECIST criteria v1.1,Area Under the Plasma Concentration Versus Time Curve (AUC) of IDE161,,2023-04-05,RECRUITING,INTERVENTIONAL,['PHASE1']
1512,NCT04401124,assorted surgical parameters,hospitals' protection measures and extent of implementation,,2020-05-25,UNKNOWN,OBSERVATIONAL,['NA']
1513,NCT04633122,PFS assessed by independent central review,"To compare the safety profile of DCC-2618 (ripretinib, ZL-2307) to the safety profile of sunitinib by using AE/SAE/AESI collection during study.",,2020-11-25,COMPLETED,INTERVENTIONAL,['PHASE2']
1514,NCT04009811,Voice Handicap Index (VHI) overall score,Head and Neck quality of life EORTC QLQ-H&N35 questionnaire score,,2020-07-17,COMPLETED,INTERVENTIONAL,['NA']
1515,NCT03043508,Time to Pancreatic Neuroendocrine Tumors (PNET),Overall Survival in Participants Who Have Confirmed MEN1 with or without PNET,,2015-04-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1516,NCT05381753,"Dose adjustment of avapritinib in cohort 1, 2, and 3",,,2022-08-29,RECRUITING,OBSERVATIONAL,['NA']
1517,NCT03867370,Pathological response rate,Incidence of adverse events,,2019-04-26,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1518,NCT02919644,immunological efficacy,evaluation of the predictive role of immune cells in tumor microenvironment,,2016-12-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
1519,NCT00049699,,,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE1']
1520,NCT02122185,Progression free survival (PFS) evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 and Gynecological Cancer Intergroup (GCIG) criteria,"Incidence of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",,2015-02-25,SUSPENDED,INTERVENTIONAL,['PHASE2']
1521,NCT01508520,diagnosis accuracy of ME-NBI,,,2009-12,COMPLETED,OBSERVATIONAL,['NA']
1522,NCT00063947,Maximum-tolerated dose (MTD) of erlotinib hydrochloride based on the incidence of dose-limiting toxicity (DLT) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0,Overall survival,,2003-05,COMPLETED,INTERVENTIONAL,['PHASE1']
1523,NCT00558155,"During the postoperative period, all patients were observed for both surgical and non-surgical complications","The secondary objective of the study was to evaluate the effect of nutritional intervention on overall morbidity and mortality rates, and hospital stay.",,2001-06,COMPLETED,INTERVENTIONAL,['PHASE4']
1524,NCT04127396,Time to progression,adverse events(AEs),,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
1525,NCT02833298,HCC screening rates,Incidence of liver transplant,,2016-11,COMPLETED,INTERVENTIONAL,['NA']
1526,NCT01243047,To evaluate two different schedules of erlotinib in combination with a modified XELOX regimen in terms of response rate,To determine the effect of intermittent versus continuous erlotinib administration on pharmacodynamic endpoints using tumor biopsies,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
1527,NCT01234272,,,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE4']
1528,NCT06116019,Number of Successfully Completed Adaptive Radiotherapy Sessions in Patients with Various Tumor Entities,Local Control,,2023-10-11,RECRUITING,OBSERVATIONAL,['NA']
1529,NCT04522752,Correlation between size and pathological type of benign epithelial gastric polyp and polyp development.,Correlation between helicobacter pylori infection and pathological type of benign epithelial gastric polyp.,,2020-09-30,UNKNOWN,OBSERVATIONAL,['NA']
1530,NCT02118064,Number of Patients with Serious and Non-Serious Adverse Events,,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2']
1531,NCT00768001,,,,2008-06,TERMINATED,OBSERVATIONAL,['NA']
1532,NCT05200221,Incidence of adverse events and serious adverse events.,overall survival(OS),,2022-01-19,UNKNOWN,OBSERVATIONAL,['NA']
1533,NCT01899118,Pathology complete remission rate,Incidence of Adverse Events,,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
1534,NCT04124406,Enrollment of Subjects,National Rates Comparison,,2019-10-18,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1535,NCT03287843,Pathological Complete Response Rate,Overall Survival,,2006-01-01,COMPLETED,INTERVENTIONAL,['NA']
1536,NCT00535041,safety,,,2007-09,COMPLETED,INTERVENTIONAL,['NA']
1537,NCT00512681,Maximal overall response rate,"Progression-free survival,Overall survival,Toxicity assessment,&genetic polymorphism and association with chemical outcomes",,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
1538,NCT04844112,Rate of complete ablation of the tumor after 1 month clinical follow up,Safety of the approach route before and after the fusion process,,2015-08-01,COMPLETED,INTERVENTIONAL,['NA']
1539,NCT03314961,Lymph node metastases in rectal cancer,,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
1540,NCT05376943,The occurrence of HCC after direct acting antiviral HCV treatment.,The difference in liver function tests among the population of patients treated with DAAs and those who were not receiving the therapy.,,2022-05-10,UNKNOWN,OBSERVATIONAL,['NA']
1541,NCT01461148,immune response against FSP peptides,safety,,2011-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1542,NCT02478892,"identifying pancreatic neoplastic lesions lesions in patients with BRCA1/2 mutations and other less common, but related mutations (ATM, PALB2) as well as mutations identified in the future.",,,2015-05,RECRUITING,OBSERVATIONAL,['NA']
1543,NCT06008925,Phase IIa:ORR,Phase Ib :Pharmacokinetic parameters: Blood concentrations of VG161 at different time points after single and multiple doses,,2022-11-17,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1544,NCT04107623,perfusion assessment,Anastomotic leakage,,2020-06-16,COMPLETED,INTERVENTIONAL,['NA']
1545,NCT05406024,Acceptability rate,European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaires (EORTC-QLQ-C30),,2022-09,UNKNOWN,OBSERVATIONAL,['NA']
1546,NCT01946711,Change of Inflammation of the Nasal Mucosa and Paranasal Sinus,Safety Assessment,Nasal Obstruction,2013-08-28,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1547,NCT04107766,Target lesion recurrence (local recurrence) rate,Numeric Pain Rating Scale,,2020-01-15,RECRUITING,OBSERVATIONAL,['NA']
1548,NCT05907824,Disease-free survival (DFS),Life quality satisfaction evaluated according to a scale.,,2023-05-01,RECRUITING,OBSERVATIONAL,['NA']
1549,NCT04259398,five year survival,3 year survival,,2020-02-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1550,NCT01850667,Treatment related toxicity-free survival,Local control rate,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2']
1551,NCT03189030,Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability),,,2017-05-02,TERMINATED,INTERVENTIONAL,['PHASE1']
1552,NCT01366144,"MTD of veliparib in combination with carboplatin and paclitaxel, determined according to incidence of DLT as graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v) 4.0",Time to progression,Change in gamma-H2AX levels,2011-06-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
1553,NCT03314649,prognostic molecular markers,DFS,,2017-12-21,COMPLETED,OBSERVATIONAL,['NA']
1554,NCT04196075,Symptomatic relief and quality of life after AP,AP side effects,,2018-03-01,COMPLETED,INTERVENTIONAL,['PHASE3']
1555,NCT02435433,Overall Survival (OS),Time to Deterioration in Eastern Cooperative Oncology Group Performance Status (ECOG PS),,2015-07-20,COMPLETED,INTERVENTIONAL,['PHASE3']
1556,NCT05738980,RFS,OS,,2023-02-01,RECRUITING,INTERVENTIONAL,['NA']
1557,NCT05913895,"Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0,Change From Baseline in Pain Scores on the Brief Pain Inventory-Taiwan Scale at 2 Weeks",,,2023-12-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1558,NCT03680508,Objective Response Rate,Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.0,,2019-12-19,RECRUITING,INTERVENTIONAL,['PHASE2']
1559,NCT05438459,Progression Free Survival (PFS) rate at 6 months (Phase II),Biomarker of GAIA-102(Phase II),,2022-06-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1560,NCT00006062,,,,2000-07,COMPLETED,INTERVENTIONAL,['PHASE1']
1561,NCT06245785,overall survival,,,2023-01-01,COMPLETED,OBSERVATIONAL,['NA']
1562,NCT01097304,Reversal of Oxidative DNA Damage as Assessed by Changes in 8-hydroxy-2' -Deoxyguanosine (8OHdG) Immunostaining,"Changes in Cell Proliferation in BE Epithelium From Baseline to Post-intervention as Assessed by Proliferation-related Ki-67 Antigen (Ki67) Immunostaining, Percentage of Positively Stained Nuclei, in BE Tissue Sections",,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1563,NCT03303495,Overall survival,Incidence of Adverse Events (Adverse Reactions),,2011-11-14,UNKNOWN,INTERVENTIONAL,['PHASE3']
1564,NCT03356002,Sensitivity and specificity of C-Scan Capsule System in detecting per segment polypoid lesions 10 mm and up as compared with Colonoscopy,Quantify the variance of the Interpretation of the data from the C-Scan System between the reviewers,,2018-01-28,COMPLETED,INTERVENTIONAL,['NA']
1565,NCT05009953,Objective Response Rate (ORR),UGT1A1,,2021-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1566,NCT02672865,Post Operative Complications,,,2016-02-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1567,NCT03482102,Best Overall Response rate,Time to Disease Progression,,2018-05-14,RECRUITING,INTERVENTIONAL,['PHASE2']
1568,NCT00599833,Progression-free survival rate at 6 months,Clinical benefit response,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1569,NCT02757859,Overall Survival,Site of first recurrence,Presence of cells in cytologic washing,2016-04-27,RECRUITING,INTERVENTIONAL,['NA']
1570,NCT04217954,Overall response rate,Progression-free survival,,2020-07-28,COMPLETED,INTERVENTIONAL,['PHASE2']
1571,NCT00059982,,,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2']
1572,NCT01312857,to determine if panitumumab with Hepatic Arterial Infusion (HAI) in combination with systemic chemotherapy can increase the recurrence free survival (RFS) for colorectal cancer patients with resected liver metastases,to analyze tumor tissue for predictive biomarkers,,2011-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1573,NCT01080248,Response Rate by RECIST Criteria.,Overall Survival,,2010-08,TERMINATED,INTERVENTIONAL,['PHASE2']
1574,NCT02071862,Safety and tolerability of CB-839: Incidence of adverse events,Clinical activity: Change in tumor volume from baseline,,2014-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1575,NCT05894837,Objective Response Rate,Overal survival,,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1576,NCT00058201,Overall survival,Survival rate at 2 and 5 years,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3']
1577,NCT05367284,Treatment acceptability questionnaire,,,2022-01-15,UNKNOWN,OBSERVATIONAL,['NA']
1578,NCT03078361,Rate of Feedback from Community Advisory Board,Rate of Receipt of Assessments from Participants,,2014-04-28,COMPLETED,INTERVENTIONAL,['NA']
1579,NCT04329000,Number of tablets consumed,,,2010-02-02,COMPLETED,INTERVENTIONAL,['NA']
1580,NCT05681949,The reproducibility of the therapy recommendations made by ADBoard (yes/no),Time between primary presentation and start of diagnostics/therapy as recommended,,2023-11,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1581,NCT02300922,To determine the maximum tolerated dose for 90Y-IMP288.,,,2015-01-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1582,NCT01344330,Cruciferous vegetable intake correlated with SFN and I3C urinary metabolites,Cruciferous vegetable intake correlated with HDAC activity (in PBMCs),,2012-01,COMPLETED,OBSERVATIONAL,['NA']
1583,NCT03642067,Cohort C: Objective response rate (ORR),Number of participants experiencing study drug-related toxicities,,2019-02-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1584,NCT01621295,Frequency/duration/content of routine cancer consultations surrounding key topics in the clinical dialogue.,,,2012-05,COMPLETED,OBSERVATIONAL,['NA']
1585,NCT04103567,"The ratio between the proportions of poor response to neoadjuvant treatment in populations so-called ""exposed"" (patients colonized by bacteria producing toxins (cyclomodulin) and unexposed (patients not colonized by bacteria producing toxins)",Types of other bacteria forming the overall bacterial composition before neoadjuvant treatment,,2020-01-14,RECRUITING,INTERVENTIONAL,['NA']
1586,NCT04229004,Overall Survival,Duration of Clinical Benefit,,2020-01-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
1587,NCT06109467,Objective Response Rate (ORR),Overall Survival (OS),,2024-01-12,RECRUITING,INTERVENTIONAL,['PHASE2']
1588,NCT03436563,Clearance of circulating tumor DNA (cohort D),Disease-Free Survival (DFS) - cohort D only,,2018-03-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1589,NCT00780169,"Toxicity spectrum of Sorafenib (MTD, DLT) and the recommended dose (RD) for phase II studies of Sorafenib when combined with FOLFIRI in first line patients with metastatic colorectal cancer (mCRC)",Time to Progression and Overall Survival,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE1']
1590,NCT02522520,Maximum oxygen uptake - ( VO2 peak),Pedometer Step Count,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
1591,NCT02987296,"NK cell killing as measured on peripheral blood mononuclear cells (PBMC) between the control (placebo) and experimental cohorts, using a standard NK cell killing assay.",Compliance with perioperative arginine supplementation,,2017-03-01,COMPLETED,INTERVENTIONAL,['NA']
1592,NCT02433938,bowel function recovery (Time to first bowel movement or flatus),Use of NG Tubes (Nasogastric tube (re)insertions),,2015-07,COMPLETED,INTERVENTIONAL,['NA']
1593,NCT05138094,Time to functional recovery,Three and five-year overall survival,,2021-08-06,RECRUITING,INTERVENTIONAL,['NA']
1594,NCT04337879,Progression-free survival (PFS),Duration of response (DOR),,2020-07-20,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1595,NCT05257135,Number of biological risk factors for colorectal cancer,,,2021-12-23,RECRUITING,INTERVENTIONAL,['NA']
1596,NCT00390416,1-year Survival,Patients With Measurable Disease the Confirmed Response Rate,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2']
1597,NCT06115174,Difference in overall survival 'OS' between the two groups.,,,2023-11-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
1598,NCT05901519,Mitigation of liver inflammation as reflected by sTNFR1 levels,Assess tumor response,,2024-02-16,RECRUITING,INTERVENTIONAL,['PHASE2']
1599,NCT05168163,Progression-free survival (PFS),Incidence of adverse events (AEs),,2022-05-27,RECRUITING,INTERVENTIONAL,['PHASE2']
1600,NCT05497726,Safety of SLN(s) or lymph node metastases with intravenous bevacizumab-800CW,Number of SLN identified,,2023-01-27,COMPLETED,INTERVENTIONAL,['NA']
1601,NCT02012023,mortality,operation data,hospital costs,2014-01,COMPLETED,INTERVENTIONAL,['NA']
1602,NCT00553332,Objective Response Rate (CR and PR),Protein Levels of RAS/RAF/MEK/ERK Signaling Pathway Activation,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2']
1603,NCT02198092,Septin9 Plasma Levels,Septin9 Levels Versus Circulating Colonic Epithelial Cell Numbers,Circulating Colonic Epithelial Cells at Blood Draws,2014-07,COMPLETED,OBSERVATIONAL,['NA']
1604,NCT03526952,Change in mutual identity from four different time points,Patients' change in adjustment to bladder cancer from four different time points,Therapeutic Alliance,2018-05-04,UNKNOWN,INTERVENTIONAL,['NA']
1605,NCT05006326,Sensitivity and specificity of 68Ga-PSMA PET/MR for diagnosis and staging in hepatocellular carcinoma.,Correlation of 68Ga-PSMA uptake in HCC patients with PSMA expression levels in tissues.,,2021-08-16,UNKNOWN,INTERVENTIONAL,['NA']
1606,NCT05121571,Progression free survival,tumor response,,2016-04-21,COMPLETED,INTERVENTIONAL,['NA']
1607,NCT03936179,overall survival rate,acute and late toxicities,,2018-08-01,UNKNOWN,INTERVENTIONAL,['NA']
1608,NCT00647153,Tumor targeting properties of iodine I 123 anti-CEA recombinant diabody T84.66,Safety of iodine I 123 anti-CEA recombinant diabody T84.66,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE1']
1609,NCT00149578,chemotherapy and concurrent chemoradiotherapy in locally advanced pancreatic cancer. .,"The secondary end points are to evaluate the distant metastasis rate and time to tumor progression, overall survival time and quality of life after induction",,2004-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
1610,NCT02832882,12 month local tumor progression (LTP) rate,Technical success rate,Technical efficacy 2,2016-10-21,COMPLETED,INTERVENTIONAL,['NA']
1611,NCT02164136,Sexual function,5-year recurrence pattern,,2014-06,UNKNOWN,INTERVENTIONAL,['NA']
1612,NCT03564834,Postoperative complication rate,Postoperative pain,,2018-08-23,UNKNOWN,INTERVENTIONAL,['PHASE2']
1613,NCT00268463,Progression-free Interval (PFI),"Quality of Life as Measured by the Functional Assessment of Cancer Therapy Trial Outcome Index at Baseline, at 4-6 Weeks Following Surgery (Before Initiation of Chemotherapy), and Periodically During Study",,2006-01,TERMINATED,INTERVENTIONAL,['PHASE3']
1614,NCT04956640,To assess the antitumor activity of LY3537982 monotherapy in participants with advanced pancreatic cancer with KRAS G12C mutation,To characterize the PK properties of LY3537982: Maximum drug concentration (Cmax),,2021-07-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1615,NCT04948034,Objective Response Rate,Acute Toxicity,,2021-08-23,UNKNOWN,INTERVENTIONAL,['PHASE2']
1616,NCT06189547,overall survival (OS),cancer-specific survival (CSS),,2023-02-02,COMPLETED,OBSERVATIONAL,['NA']
1617,NCT01704703,Objective response rate (TRO),Adverse events,,2012-10,COMPLETED,INTERVENTIONAL,['PHASE2']
1618,NCT00568308,Disease-free Survival,Compliance,,2007-12,TERMINATED,INTERVENTIONAL,['PHASE3']
1619,NCT02337673,Change of regional ventilation partition (ROI analysis in 8 pulmonary ROIs) from preoperative to postoperative state.,Ventilator-obligatory-free days,,2014-05,COMPLETED,OBSERVATIONAL,['NA']
1620,NCT03766776,PFS,,,2018-12-31,UNKNOWN,INTERVENTIONAL,['NA']
1621,NCT01471470,R0 resection rate,Angiogenetic biomarkers,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2']
1622,NCT05044676,Measurement of the phenotype of expression of CD226 3 weeks after the start of treatment,Correlation between pathology features (tumoral and non-tumoral liver) and the frequency and phenotype of expression of CD226,,2023-09-08,RECRUITING,OBSERVATIONAL,['NA']
1623,NCT01203163,Proportion of patients experiencing Adverse Reactions of Special Interest,Overall safety in patients with renal insufficiency (disease),,na,WITHDRAWN,OBSERVATIONAL,['NA']
1624,NCT04609813,Diagnostic performance of the sponge cytology-based machine learning model for the main target lesions,Diagnostic performance of abnormal cell count,,2021-01-01,COMPLETED,OBSERVATIONAL,['NA']
1625,NCT00004909,,,,1999-11,COMPLETED,OBSERVATIONAL,['NA']
1626,NCT01191632,Purpose of the study is the determination of an active local external beam radiotherapy dose leading to a maximal number of tumor infiltrating T-cells. The total T-cell activity serves as primary surrogate parameters for anti- tumor activity,"To determine the number of patients with adverse events as a measure of safety and tolerability according to CTCAE, Version 4.0 criteria",,2010-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1627,NCT00730860,disease free survival,overall survival,,2009-12,UNKNOWN,INTERVENTIONAL,['NA']
1628,NCT01313078,"Evaluation of Safety in Patients With Ovarian, Fallopian Tube, and/or Primary Peritoneal Cancer.",,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
1629,NCT00040183,,,,2001-11-29,COMPLETED,INTERVENTIONAL,['PHASE3']
1630,NCT04798898,Overall survival,Recurrence rate,Complications,2022-11-14,RECRUITING,INTERVENTIONAL,['NA']
1631,NCT00227617,Best Objective Response,Biochemical Marker Response,,2005-06-08,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1632,NCT04952753,Expansion: Progression-free survival (PFS) by investigator assessment per RECIST 1.1,ADA incidence on treatment,,2021-11-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1633,NCT05448222,progression free survival,Hospital cost,,2022-07-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
1634,NCT04107077,The PD-L1 expression can be upregulated after administration of HIPEC with greater frequency,Perioperative mortality at 30 days,,2019-11-11,RECRUITING,INTERVENTIONAL,['PHASE2']
1635,NCT06196671,Overall survival，OS,disease control rate (DCR),,2024-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1636,NCT01528059,Glycemic control,Nutritional status assessment,,2012-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1637,NCT01844375,Meters Walked During 2-Minute Walk Test,Nitrogen Balance,,2013-05,COMPLETED,INTERVENTIONAL,['NA']
1638,NCT02005419,Recurrence-free survival at one year after curative resection,Number of grade 3 and 4 toxicities according to NCI CTCAE version 4.0,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2']
1639,NCT06130644,MSI status,Tumor Mutation Burden (TMB),,2003-01-01,COMPLETED,OBSERVATIONAL,['NA']
1640,NCT02809287,Blood loss,,,2015-01,COMPLETED,OBSERVATIONAL,['NA']
1641,NCT01723969,Tumour markers assessment,,,2013-09,COMPLETED,OBSERVATIONAL,['NA']
1642,NCT02556281,Number of patient with a first relapse,Number of free tumoral DNA in blood of patient with colorectal cancer,,2012-10-15,UNKNOWN,INTERVENTIONAL,['NA']
1643,NCT04755907,Response of 3D tumor models/organoids to the same chemotherapy drugs as the corresponding patients.,Response of the colorectal cancer patients to neoadjuvant chemotherapy.,Response of the colorectal cancer patients to adjuvant chemotherapy.,2021-03-01,RECRUITING,OBSERVATIONAL,['NA']
1644,NCT04111692,Change in Polycystic Liver Disease Quality of Life,,,2017-11-06,RECRUITING,OBSERVATIONAL,['NA']
1645,NCT01183780,Overall Survival (OS),Observed Maximum Concentration (Cmax) and Observed Minimum Concentration (Cmin) of Ramucirumab,,2010-12-02,COMPLETED,INTERVENTIONAL,['PHASE3']
1646,NCT05216653,The primary objective of the study is to evaluate the pathologic complete response (pCR) rate following short-course radiation then Envafolimab Plus CAPEOX,Quality of life of the patients in a neoadjuvant setting of short-course radiation then Envafolimab Plus CAPEOX as assessed by FACT-C questionnaire,,2022-04-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1647,NCT04448652,Postoperative opioid-consumption,mortality,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA']
1648,NCT00486954,Overall Survival (OS) in the Randomized Part of the Study,Number of Participants With Mutations That May Correlate With Response and Toxicity to Lapatinib,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE3']
1649,NCT04484636,"Distribution of mutations in patients with HCC, intra- and extrahepatic CCA, GBCA, PDAC and gastric cancer",Number of patients receiving therapies in accordance to their genomic profiles,,2020-10-28,RECRUITING,INTERVENTIONAL,['NA']
1650,NCT05537129,3 year-DFS,morbidity and mortality rates,,2022-10-01,RECRUITING,INTERVENTIONAL,['NA']
1651,NCT02195180,Progression free survival (PFS),Quality of Life status,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2']
1652,NCT00066274,,,,2002-07-23,COMPLETED,INTERVENTIONAL,['PHASE2']
1653,NCT01008475,Randomized Part: Progression Free Survival (PFS),Time to Treatment Failure (TTF),,2009-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1654,NCT01596790,Predictive value of the CTC on the Progression Free Survival,Comparison of the results with the CellSearch system vs EPISPOT,,2012-04,COMPLETED,INTERVENTIONAL,['NA']
1655,NCT00047229,Rate of objective response (complete and partial),Safety and tolerability,,2002-10,COMPLETED,INTERVENTIONAL,['PHASE2']
1656,NCT03589131,Operative time of robotic-assisted rectal cancer surgery.,Accurate safety margin,,2015-04-29,COMPLETED,INTERVENTIONAL,['NA']
1657,NCT00654342,Accuracy & sensitivity of sentinel lymph node mapping,,,2007-10,UNKNOWN,INTERVENTIONAL,['NA']
1658,NCT02199002,acid pocket position,number of reflux episodes,acid pocket contents,2014-07,COMPLETED,INTERVENTIONAL,['NA']
1659,NCT04430738,Incidence of dose alterations (Cohort 1D),"Objective response rate (ORR) (Cohorts 1C, 1E, 1F, and 1G)",,2020-09-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1660,NCT00051987,,,,2002-12,COMPLETED,INTERVENTIONAL,['PHASE2']
1661,NCT03298451,Overall Survival (OS) - Treme 300 mg x1 Dose + Durva 1500 mg vs Sora 400 mg,Summary of Tremelimumab Concentration Over Time,,2017-10-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
1662,NCT04144738,Specificity with the mt-sDNA 2.0 test,Specificity for no colorectal neoplastic findings,,2019-11-15,COMPLETED,OBSERVATIONAL,['NA']
1663,NCT04436679,Relationship between known prognostic histological markers of pancreatic adenocarcinoma and patient survival.,Relationship between newly described histological markers for pancreatic adenocarcinoma and patient survival.,,2021-02-02,RECRUITING,OBSERVATIONAL,['NA']
1664,NCT03001726,overall survival,progression-free survival,adverse events,2017-01,UNKNOWN,OBSERVATIONAL,['NA']
1665,NCT04943419,Level of MDSC in patients with postoperative complications,Level of MDSC in patients with left and right sided tumours,,2016-04-01,COMPLETED,OBSERVATIONAL,['NA']
1666,NCT04482257,λz,,,2020-07-07,UNKNOWN,INTERVENTIONAL,['PHASE1']
1667,NCT06200363,Adverse event,Quality of life questionnaire (QLQ-C30),,2023-09-21,RECRUITING,INTERVENTIONAL,['PHASE1']
1668,NCT05212012,Disease control rate 12 weeks after randomization (ITT-population),Adverse events,,2022-02-17,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1669,NCT02290977,Adverse event assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 after scheduled TACE-RT for HCC with PVTT,Radiologic response assessed by modified Response Evaluation Criteria for Solid Tumors (mRECIST) after scheduled TACE-RT for HCC with PVTT,,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
1670,NCT00774839,Self-reported expenses associated with colon cancer treatment and living with this illness.,"Identify the medical, social and economic risk factors that are most closely associated with perceived adverse impact on financial and social well-being and unmet resource and service needs.",,2008-10,COMPLETED,OBSERVATIONAL,['NA']
1671,NCT05836246,Quantitative ultrasound information,,,2020-09-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
1672,NCT04993131,Overall survival,Survival in relation to biological markers,,2021-09-01,RECRUITING,INTERVENTIONAL,['NA']
1673,NCT01929122,Stool Microbiome Composition and Metabolome,"Navy Bean or Rice Bran metabolites in stool, urine and blood.",,2010-08,COMPLETED,INTERVENTIONAL,['NA']
1674,NCT01257035,Response to chemoradiotherapy measured by TRG,Survival,,2010-11,TERMINATED,OBSERVATIONAL,['NA']
1675,NCT00766155,Disease-free survival,"Toxicity according to CTCAE v.3.0 weekly during treatment, at 4-8 weeks after surgery, at therapy completion, and every 6 months for 5 years after therapy completion",,2008-08,COMPLETED,INTERVENTIONAL,['PHASE3']
1676,NCT05958550,Whether hypothermia occurs,,,2024-03-12,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1677,NCT05196867,Change in FIB-4 score,,,2022-02-11,RECRUITING,INTERVENTIONAL,['NA']
1678,NCT05551247,ORR,SAE,,2022-09-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1679,NCT02724436,Postoperative complication,,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
1680,NCT01032590,Impact of an Internet-based intervention on weight loss,Potential moderators of weight loss,,2009-07,WITHDRAWN,INTERVENTIONAL,['NA']
1681,NCT01888965,Biomarker Discovery,Safety,,2013-10,TERMINATED,INTERVENTIONAL,['PHASE2']
1682,NCT01618643,"Timing of disappearance of aceto-whitening for Barrett's metaplasia, HGD and cancer",To differentiate mucosal neoplasia from invasive cancer,,2010-11,UNKNOWN,OBSERVATIONAL,['NA']
1683,NCT00139633,local control at 4 years,,,2000-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
1684,NCT01776346,Progression to esophageal adenocarcinoma,"Evaluate the natural history of BE with and without treatment based on clinical, functional and economic outcomes of the cases",,2011-01,UNKNOWN,OBSERVATIONAL,['NA']
1685,NCT01498289,Overall Survival (OS),Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs,,2012-02,COMPLETED,INTERVENTIONAL,['PHASE2']
1686,NCT03093688,Objective Response Rate (ORR),Tumor Marker,Progression-Free Survival (PFS),2017-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1687,NCT04117945,Overall survival (OS),Incidence of adverse events,,2020-03-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1688,NCT01639352,Disease Control Rate (DCR),Toxicity Profile of Protocol Therapy,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
1689,NCT04810585,Progression free survival,Prognostic or Predictive Biomarker for Aflibercept (plasma biomarker),,2020-04-20,RECRUITING,INTERVENTIONAL,['PHASE4']
1690,NCT01684904,To assess overall survival of patients treated with proton-chemotherapy (PCT) followed by surgery in patients with resectable primary esophageal or esophagogastric cancer,Number of participants with adverse events as a measure of safety and tolerability,,2013-02-20,RECRUITING,INTERVENTIONAL,['NA']
1691,NCT00052364,Time to progression,Progression-free survival,,2002-09,COMPLETED,INTERVENTIONAL,['PHASE2']
1692,NCT00469443,Time To Progression,Symptoms improvement,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3']
1693,NCT04355156,Overall survival,Monitoring dose reductions and the reasons behind them,,2012-09-17,COMPLETED,INTERVENTIONAL,['PHASE2']
1694,NCT00386399,6-month overall survival,To explore pharmacogenetic factors that may influence the toxicity and efficacy of MMC in this patient population.,,2006-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
1695,NCT06110598,Relapse-free survival (RFS),Overall survival (OS),,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1696,NCT03721952,Hospital Anxiety and Depression Scale (HADS) - family,QUAL-E (Fam),Key Implementation Outcomes,2019-04-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1697,NCT00335491,Patient perception and pattern of change,Structural and function changes,,2006-03,COMPLETED,INTERVENTIONAL,['NA']
1698,NCT05476796,Progression free-survival,Quality of life questionnaire - Core 30 (QLQ-C30),,2023-06-23,RECRUITING,INTERVENTIONAL,['PHASE2']
1699,NCT05540925,Overall survival (OS),Local recurrence,,2022-01-01,COMPLETED,OBSERVATIONAL,['NA']
1700,NCT02173990,Progression-Free Rate will be assessed according to RECIST 1.1 with central radiological review.,Safety and tolerance,,2014-07,TERMINATED,INTERVENTIONAL,['PHASE2']
1701,NCT02023541,Overall survival,Toxicity,,2014-01,TERMINATED,INTERVENTIONAL,['PHASE1']
1702,NCT05529940,2-year survival rate,Response rate in neoadjuvant setting,,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
1703,NCT02439580,Nutritional Status,Cytotoxicity,,2013-10,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
1704,NCT05635279,Death,Censored,,2022-11-01,RECRUITING,OBSERVATIONAL,['NA']
1705,NCT02013986,Change from baseline in salivary cortisol at the first day after surgery,Days of stay in intensive care unit (ICU) after surgery,,2013-09,UNKNOWN,INTERVENTIONAL,['PHASE4']
1706,NCT03411707,"Sensitivity and Specificity of Multiple Screening Methods With Comparison to Colonoscopy, Both With Respect to Cancer.",,,2018-03-19,RECRUITING,OBSERVATIONAL,['NA']
1707,NCT03704727,Intestinal permeability,Gastrointestinal adverse events,,2018-07-01,COMPLETED,INTERVENTIONAL,['NA']
1708,NCT01186705,Overall Objective Response Rate (ORR),,,2010-08,TERMINATED,INTERVENTIONAL,['PHASE2']
1709,NCT01721954,Overall Survival (OS),Progression-free Survival,,2013-05-01,COMPLETED,INTERVENTIONAL,['PHASE3']
1710,NCT03096951,Change in cardiorespiratory fitness,Adherence,,2017-04-04,COMPLETED,INTERVENTIONAL,['NA']
1711,NCT02523911,Overall bowel cleansing,Number of patients completing the bowel preparation,Degree of haziness,2016-03,WITHDRAWN,INTERVENTIONAL,['NA']
1712,NCT01702116,measurement of circumferential resection margin,estimated blood loss,,2011-07,UNKNOWN,INTERVENTIONAL,['NA']
1713,NCT05232357,"Expression levels of PGP9.5, GFAP, VIP, nNOS, TH, ChAT and SOM of different gastrointestinal lesions",,,2022-03-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
1714,NCT00297791,locoregional recurrence rate,out-of-hospital postoperative costs,,2004-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
1715,NCT03474861,The adverse events associated with infusion of the anticancer medication or the immune cells will be assessed.,Tumor Response of the treatment in patients with advanced gastrointestinal cancer.,,2018-04,UNKNOWN,INTERVENTIONAL,['PHASE1']
1716,NCT01836120,Progression-free survival (PFS),Overall Survival (OS),,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
1717,NCT02443948,Correlation of change in cf-DNA levels with disease status in GIST patients harboring specific DNA mutations,Correlation of the level of cf-DNA related to disease status in GIST patients harboring specific DNA mutations,,2014-06,UNKNOWN,OBSERVATIONAL,['NA']
1718,NCT05368805,PK parameter for dabigatran and rosuvastatin: Cmax:,PK parameters of fruquintinib and metabolite M11: Cmax:,,2022-03-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1719,NCT05296681,Tumor Response by RECIST v1.1 Criteria,,,2022-05-03,RECRUITING,INTERVENTIONAL,['PHASE2']
1720,NCT01291420,Immunogenicity of intradermal DC vaccination,,,2010-05-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1721,NCT01031056,None: Biospecimen will be collected for future research.,,,2010-01,WITHDRAWN,OBSERVATIONAL,['NA']
1722,NCT00518349,Patient Assessment of Pain Experienced During Colonoscopy,,,2003-08,COMPLETED,INTERVENTIONAL,['NA']
1723,NCT04866290,Overall Survival,Time to Progression,,2016-09-22,COMPLETED,OBSERVATIONAL,['NA']
1724,NCT05063565,Objective Response Rate (ORR),Whole liver and remnant liver volumes at baseline and follow-up imaging assessments measured using Simplicit90Y software.,,2023-11-03,RECRUITING,INTERVENTIONAL,['PHASE2']
1725,NCT06202417,DCR,,,2021-01-01,COMPLETED,OBSERVATIONAL,['NA']
1726,NCT03254498,Adenoma miss rate,Comfort score,comparison of surveillance intervals,2016-04,COMPLETED,INTERVENTIONAL,['NA']
1727,NCT02149914,gastroesophageal reflux disease questionnaire,Upper gastrointestinal endoscopy,,2014-05,UNKNOWN,INTERVENTIONAL,['NA']
1728,NCT00423345,findings compared across investigation modes,Delayed diagnosis of CRC,,2006-10,TERMINATED,OBSERVATIONAL,['NA']
1729,NCT00165048,Symptom-free susrvival and the quality of life score within the two years of study period.,Overall survival in long-term.,,2004-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
1730,NCT01579721,morbidity,oncology,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE4']
1731,NCT00357682,Conversion of Barrett's esophagus to adenocarcinoma of the esophagus or high-grade dysplasia,All causes of mortality,,2005-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
1732,NCT02873455,Change of APAIS ((Amsterdam preoperative anxiety and information scale) from baseline APAIS to watching video.,Postoperative hospital stay,,2016-08,UNKNOWN,INTERVENTIONAL,['NA']
1733,NCT04370574,Predictive value of each protein contained in Cytolyt® for the positive diagnosis of pancreatic ductal adenocarcinoma,Identification of prognostically significant biomarkers,,2021-01-14,RECRUITING,OBSERVATIONAL,['NA']
1734,NCT01308645,Evaluating Tumor Response Rate,Determine duration of response rate by measuring time to progression,,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
1735,NCT01154335,To Determine the Maximum Tolerated Dose (MTD) of the Combination of OSI-906 and Everolimus for the Treatment of Patients With Refractory Metastatic Colorectal Cancer.,Response Rate,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1']
1736,NCT05657210,5-year Overall survival (OS) of KRAS wildtype and each codon-specific KRAS mutation,Recurrence-related factor,,2009-01-01,COMPLETED,OBSERVATIONAL,['NA']
1737,NCT01537107,MTD (Cohort I) ) and toxicity profile of combination of vismodegib plus sirolimus every 28 days.,Antitumor effect of molecularly targeted agents non-invasively by F18-FDG PET or PET/CT (Cohort II),,2012-03-05,COMPLETED,INTERVENTIONAL,['PHASE1']
1738,NCT03946033,Modification rate of adjuvant therapeutic strategy,,,2019-05,WITHDRAWN,INTERVENTIONAL,['NA']
1739,NCT06048926,PFS evaluated by IRC,Progression-free survival evaluated by Researchers,,2022-07-30,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
1740,NCT06316882,number of gastric adenocarcinoma,Socio-demographic characteristics of population in screening program,,2023-02-03,RECRUITING,INTERVENTIONAL,['NA']
1741,NCT04418843,Complete resection of the lesion,Sub-analysis by center participating in the study,,2020-06-08,COMPLETED,INTERVENTIONAL,['NA']
1742,NCT04291755,Checkpoint inhibitor response,,,2019-06-28,RECRUITING,OBSERVATIONAL,['NA']
1743,NCT05468177,Objective response rate (ORR),R0 resection rate,,2022-08-01,RECRUITING,INTERVENTIONAL,['PHASE2']
1744,NCT00336648,Number of Patients with Resection,,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1745,NCT02289378,Progression-free survival,Response rate,,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
1746,NCT00002793,,,,1991-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
1747,NCT00069095,PFS as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone,Duration of Complete Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE3']
1748,NCT05195970,Correlation of colonic lesion gene expression with urolithin production,Correlation of dietary behavior with urolithin production,,2022-01-24,RECRUITING,INTERVENTIONAL,['NA']
1749,NCT05056896,Change of ISC marker gene expression,Change in Microbiome,,2022-06-03,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
1750,NCT03813641,Progression-free Survival (PFS) Time,Percentage of Participants Achieving a Stable Disease (SD) or a confirmed CR or PR (Disease Control Rate),,2019-01-28,UNKNOWN,INTERVENTIONAL,['PHASE2']
1751,NCT02234986,Overall Response Rate,Progression Free Survival (PFS6) rate,Frequency and severity of adverse events,2015-10,COMPLETED,INTERVENTIONAL,['PHASE2']
1752,NCT04244552,"Incidence of DLTs (dose escalation cohorts only), treatment emergent adverse events (TEAEs), and changes in safety parameters",For the PLD Combination Therapy Cohort: ATRC-101 immunoreactivity in tumor biopsies at baseline and during treatment,,2020-02-11,TERMINATED,INTERVENTIONAL,['PHASE1']
1753,NCT05908643,"Safety of pTTL administration, as determined by assessment of incidence and severity of adverse events (AE). Immunological AEs and AEs known to be associated with T cell therapies will be classified as AEs of special interest (AESI).",Disease-specific survival,Evaluation of the importance of neoantigen selection to clinical outcome.,2023-03-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1754,NCT01229839,overall survival,Time to progression,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE3']
1755,NCT00986518,"Tumor size of hepatic and/or lung metastases, as measured with tomodensitometry (RECIST 1.1 criteria)","Laboratory test: hepatic function, immune function, haematology",,2012-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1756,NCT04560751,Objective response rate（ORR）,Adverse events(AEs),,2020-09-30,UNKNOWN,OBSERVATIONAL,['NA']
1757,NCT01433861,Rate of reflux esophagitis,,,2012-07,TERMINATED,INTERVENTIONAL,['PHASE3']
1758,NCT04371198,Number of Participants With Biopsies That Form Spherical Organoids,,,2020-09-18,COMPLETED,INTERVENTIONAL,['NA']
1759,NCT02078804,Mortality from colorectal cancer in the Swedish population.,To study the flora of fecal bacteria among participants and outcome of FIT and colonoscopy.,,2014-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
1760,NCT04352023,Comparison of analgesic efficacy after major surgery in pancreatobiliary cancers: Intravenous patient-controlled analgesia versus patient-controlled epidural analgesia,"Investigation and comparison of pain and clinical progress during rest after surgery, side effects of drugs administered to IV-PCA and PCEA, and complications related to PCEA procedure",,2018-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
1761,NCT02364024,Time to Recurrence (TTR),Disease-Free Survival (DFS),,2005-11,COMPLETED,OBSERVATIONAL,['NA']
1762,NCT01664169,Number and percentage of responder,,,2012-08,COMPLETED,OBSERVATIONAL,['NA']
1763,NCT02718729,Incidence of anastomotic leakage,30 days postoperative morbidity and mortality,,2015-06-01,COMPLETED,INTERVENTIONAL,['NA']
1764,NCT05238584,3y Disease Free Surveillance,Postoperative immunological changes (Interleukin monitoring),Duration of the hospital stay,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
1765,NCT03952442,Quality of Life (QOL),Knowledge-Attitude-Practice,,2019-02-21,UNKNOWN,INTERVENTIONAL,['NA']
1766,NCT00150670,Overall survival,"Overall response rate, lesion-directed response rate, time to treatment failure (TTF), hospitalization-free survival period within the periods of TTF, and safety profile",,2002-03,COMPLETED,INTERVENTIONAL,['PHASE3']
1767,NCT02017678,Radiographic response of ovarian peritoneal carcinomatosis to JX-594 treatment,Time to progressive disease,,2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
1768,NCT03492671,Curative Intent Resection (R0) rate,Overall Survival Rate,,2019-07-17,RECRUITING,INTERVENTIONAL,['PHASE2']
1769,NCT00464919,To determine the progression- free survival of sorafenib plus tegafur/uracil (UFUR®) for the treatment of advanced or metastatic HCC.,To evaluate the changes of circulating biomarkers indicating the angiogenesis activity and their correlation with objective tumor response.,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1770,NCT06237582,Evaluate the incidence of IELN invasion by ovarian cancer,"In cases of IELN positivity, review thoroughly preoperative scans and MRIs in order to detect radiological features, usually overlooked, that could help identify the positivity of these LNs prior to pathological analysis.",,2022-06-16,COMPLETED,INTERVENTIONAL,['NA']
1771,NCT01343212,,,,2011-03,UNKNOWN,OBSERVATIONAL,['NA']
1772,NCT01938716,To Quantifiably Assess Intratumoral Gemcitabine Levels in Human Pancreatic Cancer Tissue After a Single Intraoperative Infusion in Patients.,To Correlate Intratumoral Gemcitabine Levels and Its Tumoricidal Activity With Ki67 Index and Intratumoral Apoptosis.,,2012-03,TERMINATED,INTERVENTIONAL,['NA']
1773,NCT05142709,OS from start of 1st line treatment in metastatic ESCC,the role of radiotherapy for patients treated with 1st immunotherapy.,,2021-10-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1774,NCT00659022,Difference in response of liver metastases between control group and experimental groups determined by FDG-PET,Complications of surgery,,2008-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
1775,NCT04999007,The morbidity of anastomotic leakage.,,,2021-09-02,RECRUITING,INTERVENTIONAL,['NA']
1776,NCT04555135,Average Number of Adenomas Per Extraction,Procedure Time,,2020-09-28,TERMINATED,INTERVENTIONAL,['NA']
1777,NCT00460837,Patient experience and compliance with reduced laxative tagging versus standard preparation,Comparison of per polyp specificity between the two preparation regimens,,2007-11,WITHDRAWN,INTERVENTIONAL,['PHASE4']
1778,NCT01897610,To assess progression-free survival (PFS),Number of participants with adverse events,,2013-12,COMPLETED,INTERVENTIONAL,['PHASE2']
1779,NCT06031779,serum bile acid profile before treatment,concentration of serum tumor markers before treatment,,2023-05-01,RECRUITING,OBSERVATIONAL,['NA']
1780,NCT00943449,Progression Free Survival Rate (PFSR) of repeated oral doses of 4SC-201 and of the treatment combination of Sorafenib plus 4SC-201,To investigate biomarkers,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2']
1781,NCT04616534,Overall survival (expansion cohort),Increase in deoxyribonucleic acid (DNA) damage level (expansion cohort),"Pharmacodynamic (biological endpoints, toxicity and efficacy) parameters",2021-06-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
1782,NCT03610490,Objective response rate (ORR),Incidence of adverse events,Health-related quality of life,2018-08-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1783,NCT00385515,Duration of Ulcerative Oral Mucositis,Number of Participants With Ulcerative Oral Mucositis,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1784,NCT05397171,All Substudies: Incidence of AEs leading to discontinuation of AZD8853,Substudy 1 - Part B: Change in CD8 tumor infiltration in paired biopsies,,2022-06-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1785,NCT03724435,Survival,,Impact on Quality of Life and Cost,2019-12-06,TERMINATED,OBSERVATIONAL,['NA']
1786,NCT00422773,"To assess a maximal tolerable dose and the safety of a chemotherapy-combination of cetuximab, irinotecan, oxaliplatin and 5-FU/folinic acid as first-line treatment for metastatic colorectal cancer","To assess the treatment regarding the following: feasibility, toxicity, response rate, resection rate, progression free and overall survival",,2007-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1787,NCT01659346,First Variceal Bleeding,Reappearance of Esophageal varices in presence of Portal Vein Thrombosis,,2016-02,WITHDRAWN,INTERVENTIONAL,['NA']
1788,NCT05648084,Artificial intelligence's sensitivity and accuracy to predict the stage of the cancer,"to evaluate the post-treatment mortality, morbidity rates and complication rates of the patients",,2022-12-15,RECRUITING,OBSERVATIONAL,['NA']
1789,NCT02308345,Length of visit (minutes),Participant-rated usefulness of video summary,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
1790,NCT02638051,Objective Response Rate (ORR),Quality of Life (QoL),,2014-01,COMPLETED,INTERVENTIONAL,['PHASE2']
1791,NCT06134011,The differences of the metabolism information,,,2023-09-10,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
1792,NCT03771456,Anastomotic Leakage rate,Length of postoperative hospital stay,,2019-01-07,UNKNOWN,OBSERVATIONAL,['NA']
1793,NCT00031616,,,,2001-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1794,NCT05625932,Incidence of any VTE,Incidence of bleeding events according to genetic risk,,2023-03-02,RECRUITING,INTERVENTIONAL,['PHASE3']
1795,NCT05529667,PFS,Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment,,2019-05-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1796,NCT00128596,Safety and tolerability,,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1797,NCT02124317,Objective response rate,Safety and tolerability,,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
1798,NCT01180088,OVERALL BLOOD LOSS,BLOOD TRANSFUSION RATE,,2010-08,UNKNOWN,INTERVENTIONAL,['NA']
1799,NCT01232829,Survival Rate,Time to Disease Progression,,2010-10,COMPLETED,INTERVENTIONAL,['PHASE2']
1800,NCT03853733,Genitourinary toxicity after the end of radiotherapy,palliative colostomy after the end of palliative radiotherapy,,2016-10-01,COMPLETED,OBSERVATIONAL,['NA']
1801,NCT00949949,"MTD of the combination of everolimus, gemcitabine hydrochloride, and cisplatin",Timed endpoints,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE1']
1802,NCT05229874,Total Number of Retrieved Lymph Nodes,Postoperative lymph node anatomy duration,,2022-01-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1803,NCT03874026,Activity,Toxic effects,Type of cells infiltrating the tumor microenvironment.,2019-09-05,RECRUITING,INTERVENTIONAL,['PHASE2']
1804,NCT00137852,"Response rate of combination of chemotherapy, radiation therapy and surgery in resectable esophageal carcinoma",Determine the side effects of chemotherapy and radiation therapy in patients with resectable esophageal carcinoma,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2']
1805,NCT05961423,The time to recurrence of cancer after curative resection,Assessment of disability,,2020-06-19,RECRUITING,INTERVENTIONAL,['NA']
1806,NCT02365441,Objective tumour response (complete or partial response) as determined by RECIST v1.1,Overall survival,Macroscopically complete removal of all residual disease by surgery,2015-06-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1807,NCT01180153,objective response rate,overall survival,,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
1808,NCT02978612,Functional decline in instrumental activities of daily living (IADL) and/or activities of daily living (ADL),Overall survival,,2016-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1809,NCT05338307,Determine whether oral BHB supplementation is safe and tolerable,Investigate whether oral BHB supplementation leads to transcription and protein expression changes in the colonic mucosa,,2022-05-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1810,NCT01632020,Mucosal Apoptotic Status of CRC Tumor and Adjacent Normal Tissue Following Metformin Therapy,,,2012-08,TERMINATED,INTERVENTIONAL,['PHASE2']
1811,NCT02830594,Changes in Myeloid-derived Suppressor Cells (MDSC) in Non-irradiated Sites Assessed by Flow Cytometry,Overall Survival (OS),,2016-10-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1812,NCT05937438,1-year disease-free survival,3-year overall survival,,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1813,NCT01233505,Dose-limiting toxicities of veliparib in combination with oxaliplatin and capecitabine as assessed by NCI CTCAE version 4.0,Anti-tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST),,2010-10,TERMINATED,INTERVENTIONAL,['PHASE1']
1814,NCT02921139,freedom form local progression,Grade of toxicity,,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
1815,NCT02100189,Specificity of Sponge Cytology Using FISH,Tolerability of FISH Spongy Cytology,,2014-02,COMPLETED,INTERVENTIONAL,['NA']
1816,NCT04782557,"Variant allelic fraction (expressed in %) of serum ctDNA from HVB, PVB and peripheral blood",Adverse events of EUS-PVA and HVA,,2021-01-01,RECRUITING,INTERVENTIONAL,['NA']
1817,NCT01658943,Overall Survival,Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug,Objective Response Rate,2012-08,COMPLETED,INTERVENTIONAL,['PHASE2']
1818,NCT04767984,Reduction in mutant p53 staining in biopsy samples obtained during colonoscopies done before and after intervention,Banking of colorectal specimens,,2021-09-24,RECRUITING,INTERVENTIONAL,['PHASE2']
1819,NCT04741490,1-year disease-free survival rate (1-year DFS),Overall survival (OS),,2021-02,UNKNOWN,INTERVENTIONAL,['NA']
1820,NCT04172194,overall survival,tolerance,,2009-01-01,COMPLETED,OBSERVATIONAL,['NA']
1821,NCT00474734,,,,2007-05,UNKNOWN,OBSERVATIONAL,['NA']
1822,NCT05368688,"The molecular features of Fusobacterium (Fn) correlated with colorectal cancer (onset, recurrence, metastasis and survival)",,,2022-06-30,TERMINATED,OBSERVATIONAL,['NA']
1823,NCT03830801,The number of subjects from which we will be able to collect biopsy samples using IVLCM technique,,,2017-12-06,RECRUITING,INTERVENTIONAL,['NA']
1824,NCT05646030,Feasibility of CEA assessments at home using (automated) capillary sampling,Clinical laboratory sample processing time:,,2022-03-25,RECRUITING,INTERVENTIONAL,['NA']
1825,NCT02529774,Liver Relapse-Free Survival Rate,Disease free survival,,2015-09,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1826,NCT05805956,progression-free survival,,,2022-02-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1827,NCT05131243,ctDNA dynamic detection,Tumor Marker examination,,2021-12-01,UNKNOWN,INTERVENTIONAL,['NA']
1828,NCT01372735,Local recurrence rate,Overall Survival,,2011-08,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1829,NCT01716546,Objective response rate,Maximum Tolerated Dose of the combination,,2011-07,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1830,NCT00578838,To determine whether magnetic resonance techniques can detect changes in normal liver morphology and metabolism caused by chemotherapy in patients with colorectal cancer.,,,2006-08,COMPLETED,OBSERVATIONAL,['NA']
1831,NCT03585062,R0 resection rate,The quality of life,,2017-11-20,TERMINATED,INTERVENTIONAL,['PHASE2']
1832,NCT04966819,Short Form-Survivor Unmet Needs Survey (Unmet needs) at 12 months,Short Form-Survivor Unmet Needs Survey (Unmet needs),,2022-03-01,RECRUITING,INTERVENTIONAL,['NA']
1833,NCT02860234,Organ preservation rate,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Colorectal Cancer Module 29 (EORTC QLQ-CR29),,2016-08,COMPLETED,OBSERVATIONAL,['NA']
1834,NCT02148562,genetic variants of Hepatitis B,genetic variation in host-specific immune markers,,2014-04,UNKNOWN,OBSERVATIONAL,['NA']
1835,NCT03156036,Pathologic complete response rate(Pathologic staging and tumor regression grade.),,,2017-11-30,COMPLETED,INTERVENTIONAL,['PHASE2']
1836,NCT01332669,tumor response,Number of treatment required to achieve objective response,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE4']
1837,NCT06307327,Evaluation consistency,,,2024-03,RECRUITING,OBSERVATIONAL,['NA']
1838,NCT00936572,"Primary Efficacy Parameters: morphological and microbiological evaluation of the colonic microflora, gastrointestinal function","Secondary Efficacy Parameters: immune and inflammatory response, bacterial translocation",,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2']
1839,NCT03847532,Patients with germIine mutations in MutYH,,,2018-10-10,UNKNOWN,INTERVENTIONAL,['NA']
1840,NCT00004941,,,,1996-07,COMPLETED,INTERVENTIONAL,['PHASE3']
1841,NCT05361668,Incidence of treatment-emergent adverse events (TEAEs),Pharmacokinetics (PK) of paltusotine,,2022-06-17,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1842,NCT04152343,Rate of Local Occurrence,,,2019-12-07,COMPLETED,INTERVENTIONAL,['NA']
1843,NCT02928081,5-year overall survival rate,5-year disease-free survival rate,,2016-01,UNKNOWN,INTERVENTIONAL,['NA']
1844,NCT03244683,Postoperative complications,Length of stay and readmission,,2017-08-28,TERMINATED,INTERVENTIONAL,['NA']
1845,NCT05709899,postoperative analgesia,,,2023-08-30,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1846,NCT02028949,tolerance: toxicity will be evaluated according to the NCI CTC AE version 4.03 scale to determine the limiting dose,Evaluate the rate of objective response,,2012-11-22,COMPLETED,INTERVENTIONAL,['PHASE1']
1847,NCT05471401,"Percentage of participants who undergo successful inflation of the gastric balloon with oral contrast agent, with verification by MR or CT imaging",Translation movement of stomach between CBCT scans with and without balloon insufflation,,2023-04-25,RECRUITING,INTERVENTIONAL,['NA']
1848,NCT05159440,Recommended Phase 2 Dose (RP2D),Accumulation ratio (Rac) of TORL-2-307-MAB,,2022-01-20,RECRUITING,INTERVENTIONAL,['PHASE1']
1849,NCT04392609,pTRG,,,2020-01-15,UNKNOWN,OBSERVATIONAL,['NA']
1850,NCT01870791,Survival,Safety profile,,2012-05,TERMINATED,INTERVENTIONAL,['PHASE2']
1851,NCT02823860,Presence of biological and tumoral factors related to resistance to oncological treatments,"behavioral characteristics of patients by HADS Scale, according to their therapeutic car modalities",,2016-02-12,COMPLETED,INTERVENTIONAL,['NA']
1852,NCT06010862,Obtain the maximum tolerated dose of CEA CAR-T cells[Safety and Tolerability],Pharmacodynamics of CEA CAR-T cells[Cell dynamics],Duration of Response (DOR) of CEA CAR-T treatment in patients with CEA-positive advanced malignancies[Effectiveness],2023-09-30,RECRUITING,INTERVENTIONAL,['PHASE1']
1853,NCT00698204,Clinical Oral Mucosal Injury Score at Cumulative Radiation Dose of 5000 cGy,Evaluation of Pain Severity at 5000 cGy Radiation,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2']
1854,NCT05281276,Pharmacokinetics profiles-(DF),Objective response,,2022-09-20,RECRUITING,INTERVENTIONAL,['PHASE1']
1855,NCT01214512,Colonoscopy and CD24 assay correlation,,,2011-01,COMPLETED,OBSERVATIONAL,['NA']
1856,NCT00019084,,,,1996-02,COMPLETED,INTERVENTIONAL,['PHASE2']
1857,NCT03731910,Treatment response mRECIST,Time to Progression,,2018-12-11,UNKNOWN,INTERVENTIONAL,['NA']
1858,NCT01307878,Progression-free survival,Toxicity of chemotherapy,,2012-06,COMPLETED,INTERVENTIONAL,['PHASE3']
1859,NCT00883454,The primary outcome was to investigate the value of preoperative cholinesterases in predict postoperative adverse outcome after hepatic resection for hepatocellular carcinoma in cirrhosis.,,,na,COMPLETED,OBSERVATIONAL,['NA']
1860,NCT01163396,Progression-free survival (PFS),Evaluation of potential surrogate markers predictive of bevacizumab activity,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
1861,NCT05587972,Create data set,,,2022-10-06,RECRUITING,INTERVENTIONAL,['NA']
1862,NCT04114006,Diagnostic yield of the WATS approach versus standard gastric biopsy mapping,,,2019-10-01,COMPLETED,OBSERVATIONAL,['NA']
1863,NCT02491593,Number of patients with high fecal blood output in relation to colorectal cancer,Number of patients with low fecal blood output in relation to colorectal polyps,,2014-04,COMPLETED,OBSERVATIONAL,['NA']
1864,NCT00132067,Toxicity as assessed by CTCAE v 3.0,Duration of survival,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2']
1865,NCT01910909,To evaluate the SBRT effect on adverse events,To measure the progression free survival,RT response prediction probability evaluation by diffusion-weighted (DW) MRI and positron emission tomography,2013-08,COMPLETED,INTERVENTIONAL,['NA']
1866,NCT04519151,PFS of patients treated with pembrolizumab in combination with lenvatinib.,Impact of the treatment protocol on health-related quality of life using the QOL questionnaire (EORTC) QLQ-OV28.,,2021-04-12,RECRUITING,INTERVENTIONAL,['PHASE2']
1867,NCT01137162,,,,2008-08,TERMINATED,OBSERVATIONAL,['NA']
1868,NCT02640924,Local control rate (treatment in-field control rate),Patient report outcome - quality of life as assessed by the EQ-5D-3L,,2016-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
1869,NCT00205322,"Does the combination of oxaliplatin, 5-FU, leucovorin and capecitabine improve the activity of the FOLFOX regimens in metastatic colorectal cancer patients",Is the oral drug an advantage in this patient population,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2']
1870,NCT05576506,AUC (95% CI),To record and evaluate any unknown risks and adverse events of hyperspectral imaging in specimen image acquisition,,2022-10-08,RECRUITING,OBSERVATIONAL,['NA']
1871,NCT02641873,AUC0-24h (Area under the plasma concentration versus time curve),Progression Free Survival (PFS),,2015-12,COMPLETED,INTERVENTIONAL,['PHASE1']
1872,NCT01202136,Prevalence and incidence of malignant pancreatic cysts,Model for prediction of malignant pancreatic cysts,,2012-10,COMPLETED,OBSERVATIONAL,['NA']
1873,NCT05241574,Rate of patients with clinical complete response.,"Acute and late toxicity assessed by Common Terminology Criteria for Adverse Events (CTCAE), version 5.",,2021-08-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
1874,NCT03274349,"Muscle mass maintenance or increase, as assessed by Bioelectrical Impedance Analysis",Maintenance or increase in Body Mass Index (BMI) in kg/m^2-analysis (combination of weight in kilograms and height and in meters,,2017-03-17,UNKNOWN,INTERVENTIONAL,['NA']
1875,NCT01814631,image quality,,,2013-03,WITHDRAWN,OBSERVATIONAL,['NA']
1876,NCT06314022,Compliance with the laxative intake with the use of the mobile application,Evaluate colonoscopy quality indicators,,2024-05-02,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1877,NCT05331911,The presence of disease progression,Length of hospital stays,blood loss and blood transfusion,2022-04-26,RECRUITING,INTERVENTIONAL,['PHASE4']
1878,NCT04709510,The incidence of thromboembolic events by radiological assessment,Rate of predisposing factors of the patients,,2019-01-01,COMPLETED,INTERVENTIONAL,['NA']
1879,NCT03940131,Overall response rate (ORR),Overall survival (OS),,2020-06-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
1880,NCT01209962,Diffusion MRI,Apparent Diffusion Coefficient (ADC),,2008-05,COMPLETED,OBSERVATIONAL,['NA']
1881,NCT04653818,HCC recurrence,changes in Child-Pugh scores over time,,2020-10-05,COMPLETED,INTERVENTIONAL,['PHASE4']
1882,NCT02610764,"Change of numbers of CTCs in patients with resectable EAC at diagnosis, after neoadjuvant treatment and after surgery.","Number of patients with detectable CTCs at diagnosis, after neoadjuvant treatment and after surgery.",Progression free survival,2015-11,COMPLETED,INTERVENTIONAL,['NA']
1883,NCT02966054,Physical activity,Colorectal cancer-specific quality-of-life (FACT-C),,2014-08,COMPLETED,INTERVENTIONAL,['NA']
1884,NCT04050085,Incidence of adverse events,Overall survival,,2019-08-15,COMPLETED,INTERVENTIONAL,['PHASE1']
1885,NCT06171321,Accuracy of postoperative ctDNA in monitoring recurrence and metastasis,ctDNA clearance rate,,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1886,NCT01931644,Biospecimen & Clinical Data Collection,,,2013-07,COMPLETED,OBSERVATIONAL,['NA']
1887,NCT00561522,The primary end point was to determine the effect on disease-free survival and overall survival by oral capecitabine.,The secondary end point was to analyze the relationship between preventive effectiveness of capecitabine with thymidine phosphorylase expression level of tumor tissue.,,2007-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1888,NCT05864105,Objective Response Rate,,,2022-04-22,RECRUITING,INTERVENTIONAL,['PHASE2']
1889,NCT01955629,Part 2: Number of Participants With Progression Free Survival (PFS) at 6 Months After the Start of Maintenance Therapy,Part 2: Aflibercept Biomarkers Evaluation,,2013-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1890,NCT02799420,The percentage of cancer cells in biopsy samples,The expression ratio of tumor marker in biopsy samples,,2016-06-20,COMPLETED,INTERVENTIONAL,['NA']
1891,NCT00501605,"primary objective is to evaluate the safety and tolerability of ascending single&multiple oral doses of AZD2171 by assessment of AEs,BP,HR,RR,ECG,clinical chemistry,haematology,urinalysis incl 24hr collection for protein&creatinine and physical exam.","PK,assess the effects of AZD2171 on surrogate markets of activity and to make a preliminary assessment of anti-tumor activity by measurement of tumor response and time to progression",,2003-02,COMPLETED,INTERVENTIONAL,['PHASE1']
1892,NCT01335555,What is the effect of chemotherapy on the fitness of patients prior to cancer surgery?,Survival outcome at 1 year,,2007-08,COMPLETED,OBSERVATIONAL,['NA']
1893,NCT04699188,Dose expansion: ORR per RECIST 1.1 of JDQ443 single agent in patients with non-small cell lung cancer (JDQ443 dose randomization group only),Dose expansion: Duration of intracranial response (DOIR) per mRANO-BM,,2021-02-24,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1894,NCT01823471,"The primary endpoint of the study was the difference in adenoma detection between HD-WLE and i-scan, expressed as the miss rate for polyps for each technique.",The difference in overall adenoma detection between HD-WLE and i-scan,The difference in advanced adenomas between HD-WLE and i-scan and between the first and second inspection round.,2010-11,COMPLETED,INTERVENTIONAL,['NA']
1895,NCT04810299,Nausea-vomiting,,,2021-04-16,COMPLETED,INTERVENTIONAL,['NA']
1896,NCT02454140,Maximum Tolerated Dose,Overall Survival,,2014-06-20,COMPLETED,INTERVENTIONAL,['NA']
1897,NCT04730102,Existence of intraluminal malignant cells in fluid samples from rectal washout,Fluid volume needed to perform rectal washout during transanal total mesorectal excision to eliminate intraluminal malignant cells,,2020-02-13,COMPLETED,OBSERVATIONAL,['NA']
1898,NCT05064410,"Change in Knowledge Related to Colorectal Cancer Risk, Prevention, and Screening",,,2017-05-11,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
1899,NCT05320328,Prospectively evaluate the safety and efficacy of combining intraductal Radio frequency ablation with biliary metal/ plastic stent placement for patients with malignant biliary obstruction.,Stent patency at 1 year,,2021-06-10,UNKNOWN,OBSERVATIONAL,['NA']
1900,NCT00525200,Tumor response (clinical and pathological) to neoadjuvant treatment in relation to p53 genotype,Disease free and overall survival and relation to p53 genotype,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3']
1901,NCT03559335,Postoperative inflammatory complications,,,2018-01-15,COMPLETED,OBSERVATIONAL,['NA']
1902,NCT03032224,Changes in Body composition after surgery for esophageal cancer with curative intent.,Mortality,,2015-03-23,COMPLETED,OBSERVATIONAL,['NA']
1903,NCT01142713,Dose and irradiated volume of small bowel and urinary bladder,,,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
1904,NCT06149741,Low anterior resection syndrome (LARS),Bowel ischaemia,,2023-11-20,RECRUITING,INTERVENTIONAL,['NA']
1905,NCT05269381,Incidence of adverse events,Immunogenicity responders,Pre-existing Immunity,2022-03-31,RECRUITING,INTERVENTIONAL,['PHASE1']
1906,NCT04910386,Progression-free survival (PFS),Disease control rate (DCR),,2024-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1907,NCT02308722,Maximum tolerated dose (MTD),Overall survival and progression free survival at 12 and 24 months post D1 SBRT,,2015-04,COMPLETED,INTERVENTIONAL,['PHASE1']
1908,NCT00270647,Major cardiovascular events,Colorectal cancer,,1997-07,COMPLETED,INTERVENTIONAL,['NA']
1909,NCT04031872,Phase II: Response rate (RR) of galunisertib in combination with capecitabine in patients with chemotherapy resistant activated TGF-β signature-like CRC.,Progression free survival (phase II only),,2020-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1910,NCT01344902,Determine the carcinoma- and adenoma lesion true detection rate,,,2009-02,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1911,NCT04192539,serum taurine levels,,,2017-01-18,COMPLETED,INTERVENTIONAL,['NA']
1912,NCT02016534,Objective Response Rate (RECIST v1.1) in subjects with MET Amplified measurable G/GEJ/E adenocarcinoma (Cohort 1),Objective Response Rate (per RECIST v1.1) in subjects with other MET amplified solid tumors (subjects with measurable disease in cohort 2).,"Response to AMG 337 and MET amplification, expression or presence of mutation in tumor specimens",2014-02,TERMINATED,INTERVENTIONAL,['PHASE2']
1913,NCT00319007,"Pouch mucosal apoptosis index at 0, 1 and 2 months","Faecal cytotoxicity at 0, 1 and 2 months",,2006-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
1914,NCT02964468,Gastrointestinal toxicity,Quality of Life during the treatment,,2016-09,UNKNOWN,INTERVENTIONAL,['NA']
1915,NCT02291211,PFS: Progression Free Survival,Safety as measured by recording the subjects' Adverse Events from randomization to termination,,2014-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
1916,NCT00735566,"Relationship between antiangiogenic factor and tumor, node, metastasis","Overall survival, treatment failure",,2006-04,COMPLETED,OBSERVATIONAL,['NA']
1917,NCT00045175,,,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE1']
1918,NCT04759794,The usefulness of new staining method,,,2021-02-04,RECRUITING,INTERVENTIONAL,['NA']
1919,NCT00003873,Overall survival,,,1999-04,COMPLETED,INTERVENTIONAL,['PHASE3']
1920,NCT03698643,Patient effective radiation dose per TACE,Tumor response,,2018-04-01,COMPLETED,OBSERVATIONAL,['NA']
1921,NCT02570529,Gastrointestinal ulcer incidence,Adverse event of gastrointestinal hemorrhage,,2015-10,WITHDRAWN,INTERVENTIONAL,['PHASE4']
1922,NCT01288833,Rate of Accurate High Confidence Polyp Histology Predictions by the Endoscopist in the Two Groups.,Learning Curve,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
1923,NCT00487552,Success Rate Associated With the Creation of a Gastro-jejunal Anastomosis Using the Cook Magnetic Anastomosis Device With Trans-anastomotic Deployment of a Gastro-jejunal or Duodenal Stent,,,2008-01,TERMINATED,INTERVENTIONAL,['NA']
1924,NCT02882269,disease-free survival,number of lymph nodes retrieved,,2016-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
1925,NCT02866383,Clinical benefit rate (CBR),QoL,,2016-11,COMPLETED,INTERVENTIONAL,['PHASE2']
1926,NCT02405585,Progression Free Survival,Resection Rate,,2015-04,TERMINATED,INTERVENTIONAL,['PHASE2']
1927,NCT03981497,Time to Local Progression,Organ specific Progression Free Survival (PFS),,2018-02-28,RECRUITING,OBSERVATIONAL,['NA']
1928,NCT03331055,visal analogue scale (VAS) score,times of breakthrough pain (BTP),complications,2017-10-27,COMPLETED,INTERVENTIONAL,['NA']
1929,NCT02872831,Diagnostic Accuracy of the 22G SharkCore™ and the 22G BNX EUS-FNA needle,Specificity of the 22G SharkCore™ needle and the 22G BNX EUS-FNA Needle for the diagnosis malignancy in solid lesions of the pancreas and gastrointestinal tract.,,2016-07,TERMINATED,INTERVENTIONAL,['NA']
1930,NCT01276002,Recurrence of pancreatic pseudocyst,,,2011-01,WITHDRAWN,INTERVENTIONAL,['NA']
1931,NCT05836064,Re-scheduled colonoscopy,GastroBot functionality,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
1932,NCT01116804,"To evaluate the efficacy of PET-imaging versus classic response assessment (MRI, CT-scam) in patients with inoperable liver cancer",,,2010-06-16,COMPLETED,INTERVENTIONAL,['PHASE1']
1933,NCT03154190,Hospitalization Visits (Chart Review),Palliative Care Consult (Chart Review),,2017-08-08,UNKNOWN,INTERVENTIONAL,['NA']
1934,NCT01598194,Comparison of Diagnostic Adequacy Scores With SST vs. CST for Histologic Diagnosis Using a 22G Core Needle.,Comparison of Diagnostic Adequacy of Single Pass With 22G Core Needle and Standard 25G Needle for Cytologic Diagnosis,,2012-01-30,COMPLETED,INTERVENTIONAL,['NA']
1935,NCT06332079,Progression-free survival (PFS) Rate,Quality of Life (QoL) assessed using the EuroQol EQ-5D questionnaire,,2024-03-13,RECRUITING,INTERVENTIONAL,['PHASE2']
1936,NCT04708951,Comparison between adenoma detection rate of G-EYE® colonoscopy and EndoCuff Vision®,,,2021-01-01,COMPLETED,INTERVENTIONAL,['NA']
1937,NCT02082691,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
1938,NCT03916510,MRI tumour regression grade,Neoadjuvant Rectal (NAR) score,Analyse the immune microenvironment as evidenced by immune cell infiltrates,2019-07-01,COMPLETED,INTERVENTIONAL,['PHASE1']
1939,NCT02184910,the change of pepsinogen level before and after H. pylori eradication,,,2013-12,UNKNOWN,OBSERVATIONAL,['NA']
1940,NCT00428220,Number of Participants With Treatment-emergent AEs (Treatment-Related),,Summary of Duration of Clinical Benefit,2007-07,COMPLETED,INTERVENTIONAL,['NA']
1941,NCT04776837,Treatment Response at 1st Scan,Skeletal Muscle Analyses,,2019-05-15,COMPLETED,OBSERVATIONAL,['NA']
1942,NCT01750918,Part 3: Progression Free Survival (PFS),Part 3: Number of Participants With Treatment Emergent Adverse Events,,2012-12-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
1943,NCT04359498,Surgical complications,,,2020-04-01,COMPLETED,OBSERVATIONAL,['NA']
1944,NCT05547828,Objective Response Rate (ORR),Drug-Related Safety Indicators,,2022-12-20,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1945,NCT01830621,Overall Survival,Change of Global Quality of Life at 8 Weeks From Baseline,,2013-05-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1946,NCT05171517,Microflora analysis accomplished,,,2022-01-01,COMPLETED,OBSERVATIONAL,['NA']
1947,NCT05986383,Postoperative liver failure rate (50-50 criteria),Clavien-Dindo grade of postoperative complications,,2023-08,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
1948,NCT01946282,FIT Completion Among Patients Offered Any Incentive vs. Outreach Alone Each Year,"FIT Completion for Groups Offered $5 vs. Outreach Alone, $10 vs. Outreach Alone, and $5 vs. $10 Incentive",,2013-11,COMPLETED,INTERVENTIONAL,['NA']
1949,NCT00176774,Toxicity,To determine the success rate of TM leading to target levels of copper depletion in patients treated concurrently with chemotherapy,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE2']
1950,NCT00172640,,,,2005-01,UNKNOWN,OBSERVATIONAL,['NA']
1951,NCT04547881,Total time for lesion removal,,,2016-12-12,COMPLETED,OBSERVATIONAL,['NA']
1952,NCT04358341,Disease control rate (DCR),EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores,,2020-06-17,UNKNOWN,INTERVENTIONAL,['PHASE2']
1953,NCT05738421,To provide objective data on the bolus transit during swallowing in tracheostomized patients with tracheal tube and without tracheal tube,To evaluate the features of swallowing,,2021-12-06,RECRUITING,OBSERVATIONAL,['NA']
1954,NCT00002773,,,,1996-05,COMPLETED,INTERVENTIONAL,['PHASE2']
1955,NCT01628211,overall survival,list of therapies and clinical outcomes of patients who had radiologic evidence of disease within 6 months after initial surgery,,2012-04,RECRUITING,INTERVENTIONAL,['PHASE2']
1956,NCT04694183,R0 resection rate,Serious adverse events(≥grade 3）,,2020-08-17,COMPLETED,INTERVENTIONAL,['PHASE2']
1957,NCT04775056,Immunogenicity index-seroconversion rates of neutralizing antibody,Immunogenicity index-seropositive rates of neutralizing antibody,,2022-08,WITHDRAWN,OBSERVATIONAL,['NA']
1958,NCT00633295,To evaluate the efficacy of nilotinib in GIST patients resistant or intolerant to imatinib and or 2nd line TK inhibitor as measured by tumor up take of FDG PET quantitated by maximum,To assess the safety and tolerability of nilotinib as measured by rate and severity of adverse events,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1959,NCT00972465,Safety and toxicity of this new treatment. Both acute and chronic toxicity will be evaluated.,"To determine the complete response rate, partial rate, disease response rate, disease control rate in the patients subject to treatment",,2009-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
1960,NCT05768503,Progression-Free Survival (PFS),Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CR29 (EORTC QLQ-CR29),,2023-03-01,RECRUITING,INTERVENTIONAL,['PHASE3']
1961,NCT00220168,Time to disease progression (TTP),"Toxicity (incidence of febrile neutropenia, in-patient admissions, severity of diarrhea, mucositis, aesthesia, transfusion requirements).",,2003-01,COMPLETED,INTERVENTIONAL,['PHASE4']
1962,NCT03949907,Combined endpoint - overall survival and weight maintenance,Abnormal values in safety laboratory variables,Serum levels of immunologic profiles,2020-04-14,RECRUITING,INTERVENTIONAL,['NA']
1963,NCT05673772,5-year disease-free survival,Distant metastasis,,2020-10-23,RECRUITING,INTERVENTIONAL,['PHASE2']
1964,NCT01751919,Area under the plasma concentration-time curve from zero time until the last measurable concentration (AUClast) of Imatinib mesylate,Terminal Elimination Half-life (t1/2) of Imatinib mesylate,,2012-05,COMPLETED,INTERVENTIONAL,['PHASE1']
1965,NCT02142322,response rate,resection rate,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2']
1966,NCT00019786,Overall survival,,,1999-08,COMPLETED,INTERVENTIONAL,['PHASE2']
1967,NCT01140347,Overall Survival (OS),Number of Participants With Treatment Emergent Positive Anti-Ramucirumab Response [Serum Anti-Ramucirumab Antibody Assessment (Immunogenicity)],,2010-10,COMPLETED,INTERVENTIONAL,['PHASE3']
1968,NCT01366833,To investigate the change in dysphagia score (0-4 Likert scale) measured at baseline and at 10 weeks,,,2011-06,TERMINATED,INTERVENTIONAL,['NA']
1969,NCT03274882,Progression free survival (PFS) rate,Abnormalities in 12-leads ECG parameters [safety and tolerability],,2017-03-03,COMPLETED,INTERVENTIONAL,['PHASE2']
1970,NCT03432676,Best objective response rate,,,2019-07-31,WITHDRAWN,INTERVENTIONAL,['PHASE2']
1971,NCT03321630,Progression-Free Survival (PFS),,,2017-10-24,COMPLETED,INTERVENTIONAL,['PHASE2']
1972,NCT02269631,Change in Weight,Satiety,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
1973,NCT06157996,Progression-free Survival (PFS),Duration of response (DoR),,2024-01,RECRUITING,INTERVENTIONAL,['PHASE2']
1974,NCT02436564,Number of tumour-derived organoids successfully cultured in vitro for a minimum of 3 months.,Proportion of tumour-derived organoids that are genetically identical to the source tumour.,,2015-07,UNKNOWN,OBSERVATIONAL,['NA']
1975,NCT05498506,the number of linear stapler cartridges,,,2022-12-01,COMPLETED,OBSERVATIONAL,['NA']
1976,NCT06203613,To assess the sensitivity and specificity of using [18F]F-H3RESCA-3A12 and [68Ga]Ga-NOTA-3A12 for the diagnosis of metastatic gastric and pancreatic cancer,,,2023-12-01,RECRUITING,INTERVENTIONAL,['NA']
1977,NCT04516174,The prognosis of aged patients,,,2020-09-01,UNKNOWN,INTERVENTIONAL,['NA']
1978,NCT00757640,Reduced biliary complications,Improved quality of life,,2008-09,COMPLETED,INTERVENTIONAL,['NA']
1979,NCT02782949,Absolute Change in IL-1beta Cytokine Levels in the Gastric Mucosa,Gastric Mucosal Deoxyribonucleic Acid (DNA) Damage,"Proinflammatory Cytokine Genotype Status (IL-1beta, IL-8, and TNFalpha Single Nucleotide Polymorphisms)",2017-04-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
1980,NCT00002650,,,,1995-06-12,COMPLETED,INTERVENTIONAL,['PHASE2']
1981,NCT05497869,pectoralis minor length through Rigid standard plastic transparent right angle,,,2022-08-10,COMPLETED,INTERVENTIONAL,['NA']
1982,NCT02587247,Evaluate the sensitivity of the immuno-PET PET / CT pretargeted with the bispecific anti-CEA x anti-HSG TF2 antibody and IMP-288 peptide labeled with Gallium-68,"To evaluate the clinical impact (new lecture of imaging, new examens)",,2016-03,COMPLETED,INTERVENTIONAL,['PHASE2']
1983,NCT03912857,Objective Response Rates (ORR),Disease Control Rate (DCR),,2018-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
1984,NCT05794750,Pathologic complete response rate (pCR),Incidence and severity of adverse events (AEs) and clinically meaningful abnormal laboratory test results,"Relationship between the expression of immune markers in tumor tissues and blood,the distribution of immune cells, and the efficacy and prognosis of patients",2023-04-24,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1985,NCT05634590,Progression-Free Survival (PFS),Overall survival (OS),,2022-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
1986,NCT05362344,Sensitivity of multi-target stool DNA test and quantitative fecal immunochemical (FIT) test,Specificity of multi-target stool DNA test and quantitative fecal immunochemical (FIT) test,Ease of stool testing,2022-09-01,RECRUITING,OBSERVATIONAL,['NA']
1987,NCT01707758,,,,2012-10,WITHDRAWN,OBSERVATIONAL,['NA']
1988,NCT02156700,Tumor stiffness,tumor to parenchyma stiffness ratio,,2013-09,COMPLETED,OBSERVATIONAL,['NA']
1989,NCT00958386,Objective response rate,Evaluation of molecular predictive markers,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2']
1990,NCT03142516,Progression-free survival at one year,Combined analysis of prognostic factors in metastatic disease,RAS/BRAF mutations' detection proportion,2017-10-31,COMPLETED,INTERVENTIONAL,['PHASE2']
1991,NCT00003867,,,,1999-03,COMPLETED,INTERVENTIONAL,['PHASE1']
1992,NCT05234450,Establishment of the number of tumor subgroups by integrating data from all multi-omics analyses,,,2021-12-01,UNKNOWN,OBSERVATIONAL,['NA']
1993,NCT00588263,determine the prevalence of recurring BRCA1 and BRCA2 mutations,,,2000-07,WITHDRAWN,OBSERVATIONAL,['NA']
1994,NCT01787500,Maximum tolerated dose of vemurafenib defined as the highest dose studied in which the incidence of dose limiting toxicity was less than 33% as graded by the National Cancer Institute Common Toxicity Criteria version 4.0,,,2013-02-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
1995,NCT00950820,Progression-free survival rate at 6 months for subjects with KRAS wild-type tumours,safety-endpoints,,2009-09,TERMINATED,INTERVENTIONAL,['PHASE2']
1996,NCT00148226,,,,2003-11,COMPLETED,INTERVENTIONAL,['PHASE2']
1997,NCT01703026,,,,2009-08,COMPLETED,OBSERVATIONAL,['NA']
1998,NCT04842968,At least 12 lymph nodes harvested,Overall survival,,2021-04-15,UNKNOWN,INTERVENTIONAL,['NA']
1999,NCT06018714,2-year recurrence and metastasis rate,2-year disease-free survival rate,completion rate of maintenance therapy,2023-05-01,RECRUITING,INTERVENTIONAL,['PHASE2']
2000,NCT04487002,recurrence rate,post-operative complications,,2016-01,COMPLETED,INTERVENTIONAL,['NA']
2001,NCT01303393,,Information needs - patients' and next of kins',,2007-01,COMPLETED,OBSERVATIONAL,['NA']
2002,NCT01824004,Disease free survival,Number of participants with adverse events as a measure of safety and tolerability,Health -related quality of life,2009-04,COMPLETED,INTERVENTIONAL,['PHASE2']
2003,NCT00677144,overall response rate,"Safety, time to progression, and overall survival",,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
2004,NCT00628186,the length of hospital stay after pancreaticoduodenectomy,early and late complications after pancreaticoduodenectomy,,2005-04,COMPLETED,INTERVENTIONAL,['NA']
2005,NCT05830097,Incidence and severity of Adverse Events (AEs),MTD/RP2D of CBP-1019.,,2023-03-14,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2006,NCT05178095,ADR,Procedural time,,2020-09-30,COMPLETED,INTERVENTIONAL,['NA']
2007,NCT03398512,radical resection rate,complication rate,,2018-02-01,TERMINATED,INTERVENTIONAL,['NA']
2008,NCT02530593,QoL in colon cancer patients,Analyse health economy aspects of QoL and morbidity in the patient population,,2015-06,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2009,NCT03307941,Phase II: pCR rate,Phase II: Number of the tumour-infiltrating lymphocytes (TILs),,2017-07-20,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2010,NCT01941992,"Proportion of subjects with Grade III or IV of mucositis assessed by the WHO mucositis scale, developing at any time during the whole study period.",Incidence of adverse events assessed by NCI-Common Terminology Criteria for Adverse Effects (CTCAE version 4.0),Quality of life assessed by European Organization for Research and Treatment of Cancer quality of life core questionnaire (EORTC QLQ-C30) and specific head and neck module (QLQ-H&N35),2012-12,COMPLETED,INTERVENTIONAL,['PHASE2']
2011,NCT04952272,Assessing safety and treatment efficacy on intratumor injection of CpG-ODN and in situ tumor antigen release for advanced tumors,,,2021-03-01,RECRUITING,INTERVENTIONAL,['PHASE1']
2012,NCT05076591,Number of patients with Adverse Events（AEs）,,,2022-06-20,RECRUITING,INTERVENTIONAL,['PHASE1']
2013,NCT02024412,The incidence of neurotoxicity including acute neurotoxicity and accumulating neurotoxicity,quality of life,,2013-11,UNKNOWN,INTERVENTIONAL,['PHASE3']
2014,NCT03698461,Serial changes in Cluster of Differentiation(CD) 8+ T cell densities,Microbiome profile,,2019-05-15,COMPLETED,INTERVENTIONAL,['PHASE2']
2015,NCT05221320,"The incidence and frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, severity (as defined by the NCI CTCAE, version 5.0), seriousness, duration, and relationship to study treatment.",Progression-free survival (PFS) as defined as the time from study drug initiation to the time of documented disease progression (as assessed by RECIST 1.1) or death from any cause.,,2022-05-26,RECRUITING,INTERVENTIONAL,['PHASE2']
2016,NCT04854668,Progression Free Survival (PFS) assessed by IRC,Duration of Response (DOR),,2020-07-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
2017,NCT01157039,To evaluate potential pharmacokinetic interactions between oxaliplatin and glutamine at 30g and 40g in patients with metastatic colorectal cancer.,To compare the toxicity profile of glutamine and FOLFOX to historical data.,,2011-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
2018,NCT05040438,Objective Response Rate (ORR) of administering VAX-NK/HCC combined with HAIC,The serum cytokine levels,,2019-10-15,RECRUITING,INTERVENTIONAL,['PHASE2']
2019,NCT01818973,The pathologic tumor regression grade (TRG),5-y local relapse free survival,,2013-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
2020,NCT02241499,Improvement of dysphagia.,Endoscopic response of the primary tumor.,Metabolic response,2014-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2021,NCT06044311,Metabolic Response,Ability to take vactosertib before and after standard of care chemoradiation,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2022,NCT01224990,The aim of the study is to asses whole body diffusion weighted imaging (WB-DWI) in patients with proven gastro-intestinal tumors and to evaluate this non-invasive method for staging and therapy monitoring.,,,2010-11,UNKNOWN,INTERVENTIONAL,['NA']
2023,NCT05694559,genetic risk screening tool (GRST) questionnaire,,,2022-11-23,RECRUITING,INTERVENTIONAL,['NA']
2024,NCT04161092,Five-year overall survival,Health economic evaluation,,2020-12-01,RECRUITING,INTERVENTIONAL,['NA']
2025,NCT05702385,CPV-measured differences in cost of care between control and intervention arms,,,2023-09-01,WITHDRAWN,INTERVENTIONAL,['NA']
2026,NCT05155475,Evaluation of the common bile duct size,,,2019-06-04,COMPLETED,OBSERVATIONAL,['NA']
2027,NCT04705363,Credibility score,,,2021-06-29,RECRUITING,INTERVENTIONAL,['NA']
2028,NCT01722162,Progression Free Survival (Arm B),Incidence and Severity of Adverse Events as Measured by Number of Participants Who Experience Grade 3 and Higher Adverse Events,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE2']
2029,NCT03713229,Incidence of anal cancer,,,2010-09-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
2030,NCT04348838,Variation of overall survival time (OS) after pharmaceutical treatment,Variation of serious adverse event rate of HCC treatments in clinical practice,,2019-08-26,RECRUITING,OBSERVATIONAL,['NA']
2031,NCT00004190,overall response rate,objective tumor response,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2032,NCT06301672,Body Mass Index,Feeding amount,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2033,NCT04018872,Percentage of pathological complete response with itraconazole,Levels of itraconazole and metabolites in esophageal tissue,,2019-06-24,RECRUITING,INTERVENTIONAL,['PHASE2']
2034,NCT03037385,(Phase 2) Number of Participants with AEs and SAEs,(Phase 2) Assess Intracranial Response Rate and Time to Intracranial Progression in Participants With NSCLC,,2017-03-17,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2035,NCT05957016,Pathologic complete response (pCR),overall survival (OS),,2023-08-30,RECRUITING,INTERVENTIONAL,['PHASE2']
2036,NCT06129604,EP2 and EP4 receptor subtypes tumor biomarker expression within the PGE2 signaling pathway.,Incidences of TPST-1495 drug therapy based potential adverse events,,2024-04-30,RECRUITING,INTERVENTIONAL,['PHASE2']
2037,NCT04604158,Absolute change in patient-reported anxiety scores at Day 30 compared with baseline.,Participant's experience with Elly app at Day 180-360.,,2020-12-02,UNKNOWN,INTERVENTIONAL,['NA']
2038,NCT05816902,lung metastasis,,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
2039,NCT03775850,Evidence of anti-tumor activity of EDP1503 based on ORR,Overall Survival,,2018-12-19,COMPLETED,INTERVENTIONAL,['PHASE1']
2040,NCT03980288,Dose limited toxicity and Maximum Tolerated Dose,Antitumor efficacy-Disease control rate (DCR),,2019-07-23,COMPLETED,INTERVENTIONAL,['PHASE1']
2041,NCT00612586,Progression Free Survival (PFS),PFS From Start of First Line Therapy,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
2042,NCT00665197,Dysphagia relief,Treatment Toxicity,,2007-02,COMPLETED,INTERVENTIONAL,['PHASE3']
2043,NCT02305459,Description of the clinical context in which SIR-Spheres are applied,Hepatic PFS,,2014-11,COMPLETED,OBSERVATIONAL,['NA']
2044,NCT03776435,Age and sex-standardized incidence rate ratio (IRR) for malignancies of hematologic system,Age and sex-standardized incidence rate ratio (IRR) for all cancers,Subgroup analysis,2018-01-15,UNKNOWN,OBSERVATIONAL,['NA']
2045,NCT04006041,Pathologic complete response rate,Perioperative mortality,,2019-06-25,UNKNOWN,INTERVENTIONAL,['PHASE2']
2046,NCT05166577,Phase 2: Overall response rate (ORR),Pharmacokinetic parameter - area under the plasma concentration-time curve [AUC],,2021-10-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2047,NCT00508690,Incidence and classification of surgical site infection (SSI),"Incidence of colitis, other infectious diseases and other postoperative complications.",,2007-09,COMPLETED,INTERVENTIONAL,['PHASE3']
2048,NCT03590275,Overall survival,Toxicity rate,,2017-10-02,COMPLETED,OBSERVATIONAL,['NA']
2049,NCT02194829,Progression-free Survival,Disease Control Rate,,2014-08-19,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2050,NCT02725125,Disease control rates,Duration of remission,,2015-11,UNKNOWN,INTERVENTIONAL,['NA']
2051,NCT02999893,Establish the safety profile of combined APR-246 plus cisplatin and 5FU as measured by the satisfactorily low rate of adverse events described according to NCI CTCAE v 4.03.,Evidence of clinical efficacy of a combined APR-246 and cisplatin/5FU chemotherapy regimen as confirmed by CT/PET/MRI scan.,Number of patients who will benefit from APR-246 therapy as assessed by quantitation of ctDNA levels in patient serum and plasma samples.,2017-04-11,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2052,NCT05934331,PFS,OS,,2023-07-27,RECRUITING,INTERVENTIONAL,['PHASE2']
2053,NCT00006981,,,,2000-12,COMPLETED,INTERVENTIONAL,['PHASE1']
2054,NCT05129787,Local tumor progression,Inflammatory response,,2021-12-16,RECRUITING,INTERVENTIONAL,['NA']
2055,NCT00952003,To determine efficacy in terms of response rate according to RECIST criteria,To determine overall survival time following treatment with a chemoimmune therapy,,2009-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2056,NCT03892681,Specificity,Inter-reader agreement between two radiologists,,2019-04,UNKNOWN,INTERVENTIONAL,['NA']
2057,NCT06208436,Recurrence-free survival,Overall survival,,2023-10-07,RECRUITING,OBSERVATIONAL,['NA']
2058,NCT03161925,Overall survival,,,2016-11-28,UNKNOWN,OBSERVATIONAL,['NA']
2059,NCT01074333,Safety and toxicity of Erbitux treatment,Clinical efficacy of Erbitux treatment,,2008-09,TERMINATED,OBSERVATIONAL,['NA']
2060,NCT01816256,Incidence of asymptomatic portal vein thrombosis (PVT) and/or portal hypertension (PHTN) in patients with Philadelphia negative myeloproliferative neoplasms (MPNs),Comparison of survival and number of patients with leukemic transformation in patients with or without asymptomatic PVT/PHTN,Identify any genetic markers or biomarkers associated with asymptomatic PVT and PHTN,2013-05,COMPLETED,INTERVENTIONAL,['NA']
2061,NCT05498779,Recurrence after ablation,Overall survival related to HCV virus,,2022-06-01,COMPLETED,OBSERVATIONAL,['NA']
2062,NCT06313190,Progression-free survival (PFS) rate,Treatment-related adverse events,Correlation between ctDNA and overall survival,2024-04-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2063,NCT03495674,Retention,,,2018-04-04,COMPLETED,INTERVENTIONAL,['NA']
2064,NCT00088816,Overall survival,Adverse events,,2003-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
2065,NCT01486251,Echography measure,,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
2066,NCT00640081,Failure-free survival at 10 months,Toxicity of each treatment regimen by NCI CTCAE v3.0,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2067,NCT04274868,Establish a national bank of rare biological material,,,2015-09-10,RECRUITING,OBSERVATIONAL,['NA']
2068,NCT04520737,Physical Fitness- 6MWT,Nutritional status- UMA,,2020-09,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2069,NCT05576480,Pathological complete remission rate (pCR),Number and severity of adverse events,,2022-10,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2070,NCT04032119,Overall procedural time,Lymphovascular invasion,,2020-01-10,COMPLETED,INTERVENTIONAL,['PHASE3']
2071,NCT02679495,gastric caner occurrence,gastric tissue DNA methylation change of selected genes,,2015-03-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2072,NCT02311907,"Paclitaxel/Carboplatin (PC) Induced Peripheral Neuropathy as Assessed by EORTC QLQ-CIPN20 (European Organization for Research and Treatment of Cancer (EORTC), Quality of Life (QLQ), Chemotherapy Induced Peripheral Neuropathy 20 (CIPN20)).",Times to Onset of CTCAE Grade 3+ PN,,2009-12,COMPLETED,INTERVENTIONAL,['PHASE3']
2073,NCT05181605,Overall Survival,Adverse events,,2022-04-15,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2074,NCT00663741,Safety and pharmacokinetics,Duration of response,,2008-05,COMPLETED,INTERVENTIONAL,['PHASE1']
2075,NCT00534053,Our primary outcome is FOBT card return rate,Predictors of Non-compliance to fecal occult blood testing,,2007-06,COMPLETED,INTERVENTIONAL,['NA']
2076,NCT01198743,local recidivism or metastasis reappearance,specificity and global safety,,2005-11,COMPLETED,OBSERVATIONAL,['NA']
2077,NCT00920023,To Determine the Specificity of High Resolution Magnetic Resonance Imaging With Lymphotrophic Superparamagnetic Nanoparticles to Identify Small and Otherwise Undetectable Lymph Node Metastases.,,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE4']
2078,NCT01945879,Incidence of NCI CTC Toxicity III°/IV° and severe bleedings,overall survival,,2003-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2079,NCT00482586,"Development of a data repository for health-related quality of life outcome measures by administering the Medical Outcomes Study Short Form questionnaire at baseline, during routine follow-up after image-guided therapy, and then annually thereafter",,,2003-10,COMPLETED,OBSERVATIONAL,['NA']
2080,NCT02815150,preoperative gastric residual volume of gastric fluid,Reoperation rate within 30 days post operation,,2016-04-01,COMPLETED,INTERVENTIONAL,['NA']
2081,NCT06218810,1-year Progression Free Survival rate,irORR,,2024-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
2082,NCT03498885,Anastomotic leakage,5-years disease free survival rate,,2018-01-01,RECRUITING,INTERVENTIONAL,['NA']
2083,NCT05250843,Recurrence-free Survival,Adverse effects,,2022-05-30,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2084,NCT02502474,Number of patient with Staphylococcus aureus colonic carriage,Number of patient with Staphylococcus aureus carriage in the groin,,2015-02-02,COMPLETED,INTERVENTIONAL,['NA']
2085,NCT01477229,"To describe QoL, symptoms and functional impairments in an unselected population of rectal cancer patients",QoL in an unselected population of rectal cancer patients,,2012-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2086,NCT04699994,"Histological response rate (Grade 2 or 3 in Japanese Classification of Esophageal Cancer, 11th Edition)",Incidence rate of all adverse event,,2020-06-25,RECRUITING,INTERVENTIONAL,['PHASE2']
2087,NCT00003939,,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
2088,NCT05775159,Progression free survival (PFS),Objective response rate (ORR),,2023-04-24,RECRUITING,INTERVENTIONAL,['PHASE2']
2089,NCT01252498,Salivary levels of PGE2 and PGI2 during and after radiotherapy,Patient reports of oral pain during and after radiation therapy,,2010-12,COMPLETED,OBSERVATIONAL,['NA']
2090,NCT01082757,Mutational status of KRAS: study of codons 12 and 13 in exon 1 of KRAS gene,Subject and tumour characteristics and their association with KRAS mutational status,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
2091,NCT01034683,objective response rate(ORR) time to progression (TTP) toxicities,1-year survival rate KPS score,,2009-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
2092,NCT04810156,Time to response or downgrading of liver injury in days,Overall survival rates at 6 months,Description of changes in the fecal microbiome,2021-04-07,RECRUITING,INTERVENTIONAL,['PHASE2']
2093,NCT01867697,Response rate (RR),Frequency of secondary micro-radical surgical resection (R0 resection),,2012-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2094,NCT00257322,Participants Exhibiting Immune Response,Response Rates and Overall Survival.,,2003-04,COMPLETED,INTERVENTIONAL,['PHASE2']
2095,NCT05978193,PFS,Incidence of Grade III and higher treatment-related adverse events,,2023-01-01,RECRUITING,INTERVENTIONAL,['PHASE2']
2096,NCT04582981,progression free survival (PFS),disease control rate (DCR),quality of life score (QOL),2020-09-28,UNKNOWN,INTERVENTIONAL,['PHASE2']
2097,NCT04276909,Assess the initial safety and efficacy of the LUM Imaging System for detection of primary pancreatic cancer and peritoneal invasion from primary pancreatic cancer during surgery,Correlate resected tissue with LUM Imaging System to identify imaging threshold,,2026-01,WITHDRAWN,INTERVENTIONAL,['NA']
2098,NCT05018182,Pathological response,Number of patients with 30-day post-operative mortality,,2021-08-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
2099,NCT03452774,Proportion of patients Eligible for CTE versus Actual CTE,Time from Intervention to Actual CTE (months),,2018-01-01,RECRUITING,OBSERVATIONAL,['NA']
2100,NCT01622569,Change in Total Polyp Grade,Nasal Polyp Surgery Eligilbilty,,2013-11-19,COMPLETED,INTERVENTIONAL,['PHASE3']
2101,NCT03925428,Maximum tolerated dose,Duration of response,Effect of GSK525762C and entinostat combination therapy on gene expression patterns,2020-09-18,WITHDRAWN,INTERVENTIONAL,['PHASE1']
2102,NCT00976768,Progression-free survival,Response rate,,2004-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2103,NCT01171755,Response rate,,,2008-02,TERMINATED,INTERVENTIONAL,['PHASE2']
2104,NCT01766765,The time to the first adjuvant chemotherapy,Rehospitalization rate,,2013-04,UNKNOWN,INTERVENTIONAL,['PHASE4']
2105,NCT04656392,Specificity of the eNose for detecting confirmed BE,Safety of eNose based on reported Adverse Events.,,2021-04-20,COMPLETED,INTERVENTIONAL,['NA']
2106,NCT03499808,Overall confirmed hematologic response rate,Progression free survival,,2018-06-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2107,NCT05101382,Number of retrospectively recruited CRC cases,,Biomarkers correlation with OS,2020-10-28,RECRUITING,OBSERVATIONAL,['NA']
2108,NCT04751448,Microbiome-Based Prediction of Chemotherapy-induced Diarrhea in Colon Cancer,Dietary-Based Prediction of Chemotherapy-induced Diarrhea in Colon Cancer,,2021-02-01,RECRUITING,OBSERVATIONAL,['NA']
2109,NCT05832372,Prevalence or occurrence of upper gastrointestinal diseases,,,2023-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2110,NCT00224601,Number of pre-cancer lesions or early cancer detected.,"Anatomopathologic criteria (size of lesions, …).",,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2111,NCT04406974,Patient experiences after local recurrence,,,2018-01-01,RECRUITING,OBSERVATIONAL,['NA']
2112,NCT02650271,overall survival,Recurrence rate,Perioperative reactivation of hepatitis B virus replication,2021-02-02,COMPLETED,INTERVENTIONAL,['PHASE3']
2113,NCT05699746,Recurrence-free survival,Clearance of circulating tumor DNA (ctDNA),,2023-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
2114,NCT02766842,Diagnostic accuracy of needle as assessed by diagnostic yield of needle and final diagnosis method,Procedure time,,2016-04,WITHDRAWN,INTERVENTIONAL,['PHASE2']
2115,NCT02656134,Genetic profile in FAP patients,,,2015-03,UNKNOWN,OBSERVATIONAL,['NA']
2116,NCT03043950,Overall Survival (OS) of pre-defined risk groups low vs. high,Antineoplastic treatment in later lines,Adverse Drug Reactions,2017-01-25,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2117,NCT01763450,To assess the objective response rate(ORR),To assess the R0 resection rate of liver metastases,To assess the incidence of adverse events of level 3-4 （Bleeding、Gastrointestinal Perforation、Anastomotic Fistula、Hypertension、Wound Healing Delay）,2012-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
2118,NCT05547568,Major postoperative complications (Dindo-Clavien ≥ 3 grade),,,2012-09,COMPLETED,OBSERVATIONAL,['NA']
2119,NCT00210184,2-month Response Rate,Progression-free Survival,,2004-07-21,COMPLETED,INTERVENTIONAL,['PHASE2']
2120,NCT05004350,Randomized Phase 2: Progression-free Survival (PFS) by Blinded (to treatment received) Independent Central Review (BICR),Randomized Phase 2: Population pharmacokinetic (PK) analysis using the ARRAY 818 302 study PK data,Randomized Phase 2: Microsatellite Instability (MSI) status in Formalin-fixed and Paraffin Embedded (FFPE) samples using established Polymerase Chain Reaction (PCR) assays in tumor sample versus germline control at screening,2021-09-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2121,NCT05183425,The consistency of drug sensitivity,The establishment of PDO,,2022-01-01,RECRUITING,OBSERVATIONAL,['NA']
2122,NCT00352833,safety and efficacy data,,,2006-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2123,NCT04179773,"Frequency of patients with ENT, upper digestive-tract or colorectal cancer with a diagnosis of cirrhosis",Frequency of chemotherapy side effects according to CTCAE version 5.0 classification in cirrhotic patients who have received chemotherapy,,2019-01-24,RECRUITING,OBSERVATIONAL,['NA']
2124,NCT03843905,Overall survival (OS),Microbiota composition,,2018-11-15,UNKNOWN,OBSERVATIONAL,['NA']
2125,NCT02054598,Colorectal cancer screening completion,Colorectal cancer screening related intent,,2014-01,COMPLETED,INTERVENTIONAL,['NA']
2126,NCT05665322,Efficacy of conventional CT versus porto-scanner for thermoablation of colorectal cancer liver metastases between groups,Reason for for failure of technique requiring switch to different guidance technique,,2023-01-31,RECRUITING,INTERVENTIONAL,['NA']
2127,NCT03093116,Overall Response Rate (ORR) Phase 2,Intracranial objective response rate (Phase 2),,2017-03-07,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2128,NCT05495048,disease-free survival rate,,,2023-07-01,RECRUITING,INTERVENTIONAL,['NA']
2129,NCT06178211,pCR rate,Potential biomarkers such as ctDNA or PD-L1 expression,,2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2130,NCT05643989,Bowel preparation (absence of feaces) according to Boston Bowel Preparation Scale,Late complications rate during resectional surgery,,2019-11-01,RECRUITING,INTERVENTIONAL,['NA']
2131,NCT05519202,Pathological complete response(pCR),tumor regression grade(TRG),,2022-08-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2132,NCT02473094,Pathological Complete Response,Quality of Life,,2015-07,TERMINATED,INTERVENTIONAL,['PHASE2']
2133,NCT06228599,Adverse Events,,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2134,NCT01399684,Progression-Free Survival Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 as Determined by the Investigator,Change From Baseline in ATAs Levels of MEGF0444A,,2011-11,COMPLETED,INTERVENTIONAL,['PHASE2']
2135,NCT02002195,progression-free survival,time to treatment failure,,2013-11,UNKNOWN,OBSERVATIONAL,['NA']
2136,NCT06141031,Phase 2: To assess pathologic response rate (R0 resection) for those who revert to resectable status,Phase 2: Assess quality of life associated with treatment protocol using EORTC QLQ-C30,,2024-01-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2137,NCT01538680,,,,na,NO_LONGER_AVAILABLE,EXPANDED_ACCESS,['NA']
2138,NCT02674100,Adverse Events,Overall Survival,,2016-01,RECRUITING,OBSERVATIONAL,['NA']
2139,NCT03334708,Change in biomarkers to determine sensitivity and specificity of the assay to diagnose early stage pancreatic cancer,,,2017-10-30,RECRUITING,OBSERVATIONAL,['NA']
2140,NCT04917289,Overall Survival,Adverse event,,2021-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
2141,NCT01895504,Cecal intubation rate,Pain,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
2142,NCT01473940,Number of Dose Limiting Toxicities (DLTs) Seen in Patients With Pancreas Adenocarcinoma Treated With Ipilimumab and Gemcitabine Combination in Order to Define the Maximum Tolerated Dose (MTD),Recovery of Tumor Immune Surveillance: T-cell Response to Defined Pancreatic Cancer Tumor Antigens,,2012-06-11,COMPLETED,INTERVENTIONAL,['PHASE1']
2143,NCT01845337,The primary endpoint of the study will be a difference in the duration of ST deviation pre-treatment and during treatment.,,,2014-02-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2144,NCT00154778,To evaluate the response rate,To determine time to progression and safety,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2145,NCT06218914,Adverse events and Serious adverse events,"Preliminary anti-tumor activity of NT-112 in subjects with unresectable, advanced, and/or metastatic solid tumors",,2024-02-05,RECRUITING,INTERVENTIONAL,['PHASE1']
2146,NCT05582109,Objective response rate,Adverse Events,,2022-10-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2147,NCT03417570,Number of Participants Who Had a Diagnostic Yield Obtained,Safety as Measured by Number of Participants With Procedure-related Adverse Events,,2017-12-22,TERMINATED,INTERVENTIONAL,['NA']
2148,NCT03471403,Number of serious and non-serious adverse events,Change in Spigelman stage,,2017-10-10,RECRUITING,OBSERVATIONAL,['NA']
2149,NCT02589483,"Evidence of clinical anastomotic leak( elevated C reactive protein and white blood corpuscles, fever, nausea). Suspicion of a leak will be investigated with a Ct scan.",,,2016-02,UNKNOWN,INTERVENTIONAL,['NA']
2150,NCT03231722,Overall response rate,R0 Resection Rate,,2017-09-13,COMPLETED,INTERVENTIONAL,['PHASE3']
2151,NCT05691491,Dose limiting toxicity and the maximum tolerated dose,Rate of >= grade 3 adverse events (AE),,2023-09-28,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2152,NCT00533078,efficacy of an omega-3 PUFA containing lipid emulsion in reducing the incidence of °3-4 colitis (CTC AE v3.0),,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2']
2153,NCT00777478,Maximum Tolerated Dose,determine the safety and toxicity profile using the CTCAE criteria.,,2008-12,UNKNOWN,INTERVENTIONAL,['PHASE1']
2154,NCT05706558,. Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery),"Survival outcomes stratified by use of adjuvant therapy (i.e., adjuvant therapy or no adjuvant therapy).",,2016-12-13,RECRUITING,OBSERVATIONAL,['NA']
2155,NCT00004136,Efficacy of Radiofrequency Ablation in Patients with Primary or Metastatic Liver Cancer,,,1998-03-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2156,NCT02192671,Hospital mortality,Recurrence rate,,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
2157,NCT01341197,Important Lower and Upper GI tract Lesions,,,2011-03,COMPLETED,OBSERVATIONAL,['NA']
2158,NCT03974984,Changes in neutrophil to lymphocyte ratio from preoperatively to day 1 postoperatively,Changes in quality of recovery-15 score from preoperatively to day 1 postoperatively.,,2020-06-04,WITHDRAWN,OBSERVATIONAL,['NA']
2159,NCT00006094,Latent toxicities graded using the Common Toxicity Criteria (CTC) version 2.0,,,2000-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2160,NCT01428141,Determination of the maximum tolerated dose (MTD),,,2011-09,COMPLETED,INTERVENTIONAL,['PHASE1']
2161,NCT03083613,Objective Response Rate,Progression-free survival,,2015-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2162,NCT05074966,median PFS,Overall Survival OS,,2021-09-06,RECRUITING,INTERVENTIONAL,['PHASE3']
2163,NCT01291823,Tumor response rate,The safety (The safety was evaluated according to the National Cancer Institute Common Toxicity Criteria version 3.0.),,2010-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
2164,NCT04770207,Assessing safety and treatment efficacy on intra-tumor injection of DEB for advanced tumors,,,2020-11-01,RECRUITING,INTERVENTIONAL,['PHASE2']
2165,NCT06271629,Impairment in the quality of sleep and quality of life in patients with Low Anterior Resection Syndrome (LARS).,European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-CR29),,2022-02-26,COMPLETED,OBSERVATIONAL,['NA']
2166,NCT01681368,Objective Response (Complete Response (CR) or Partial Response (PR) Defined by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Criteria) or Disease Stabilization for Greater Than 6 Months,Total Clearance of Birinapant After Administration,,2012-08-15,TERMINATED,INTERVENTIONAL,['PHASE2']
2167,NCT00069953,Overall Survival (1-year Rate Reported),Frequency of Patients With Persistent or Recurrent Disease Eligible for Surgical Salvage Resection,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2168,NCT06016725,Physical function,Anthropometry measuring waist circumference in centimeters,,2023-08-28,RECRUITING,INTERVENTIONAL,['NA']
2169,NCT01996306,Overall survival,Correlation between UGT1A1 genotype and safety,,2013-12-02,COMPLETED,INTERVENTIONAL,['PHASE3']
2170,NCT04461275,Rate of the successful and safe application of the 23-hour accelerated ERAS 2.0 protocol for patients undergoing elective colorectal surgery.,• Patient satisfaction evaluation by means of a questionnaire to evaluate the patients subjective experience during the duration of this study.,• Groningen Frailty Index (GFI),2020-06-19,COMPLETED,INTERVENTIONAL,['NA']
2171,NCT00828672,"Pathologic Response at Surgery. Overview of Complete Pathologic Responses, Good and Little Tumour Regression Rates at Surgery.",Death Rates and Overall Survival,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2172,NCT03195699,Pharmacokinetics - AUC(0-t),Best Overall Response,Assess the bioavailability between different formulations of TTI-101,2017-11-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
2173,NCT06109779,Recurrence free survival (RFS) for Arm A vs. Arm B,Overall Survival (OS) for Arm A vs. Arm B,Progression Free Survival (PFS) following recurrence Arm A vs. Arm B.,2023-12-04,RECRUITING,INTERVENTIONAL,['PHASE3']
2174,NCT02721550,pathologic Complete Response,Disease-Free Survival,,2016-08-01,TERMINATED,INTERVENTIONAL,['PHASE4']
2175,NCT00440817,Occurrence of lymphoma,Evaluation of association of Epstein-Barr Virus (EBV) with the lymphoma,,2006-02,COMPLETED,OBSERVATIONAL,['NA']
2176,NCT04144751,Blood-based biomarkers associated with genetic and epigenetic alterations.,,,2019-11-15,COMPLETED,OBSERVATIONAL,['NA']
2177,NCT04373928,OS,DFS,,2017-11-10,RECRUITING,INTERVENTIONAL,['NA']
2178,NCT04313114,CRC Screening,,,2021-09-20,RECRUITING,INTERVENTIONAL,['NA']
2179,NCT04683783,Percentage of patients who complete the entire cycle,Morbidity rate,,2019-06-01,COMPLETED,OBSERVATIONAL,['NA']
2180,NCT02905578,Overall survival,Adverse event frequency and categorization,,2018-11-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2181,NCT00039078,Adverse experiences,,,2000-08,WITHDRAWN,INTERVENTIONAL,['PHASE2']
2182,NCT03727126,Lymph node yield,Conversion rate,,2018-11-01,UNKNOWN,INTERVENTIONAL,['NA']
2183,NCT04090164,Prevalence of HCV Seropositivity in Breast Cancer Patients.,Disease-related Events,,2019-09-01,COMPLETED,OBSERVATIONAL,['NA']
2184,NCT05493930,diagnosis of lymph node metastasis,,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
2185,NCT05760391,OS from start of 1st line treatment in metastatic ESCC,Disease control rate,,2023-02-28,RECRUITING,INTERVENTIONAL,['NA']
2186,NCT04420013,Plasma CD154 level dosage,Clinical evolution parameters,,2020-09,UNKNOWN,OBSERVATIONAL,['NA']
2187,NCT05629845,90-day death adjusted cumulative incidence of variceal rebleeding after secondary prevention by EUS-guided therapy or conventional endoscopic therapy,procedure related adverse events within 30 days of secondary prevention,,2022-11-22,RECRUITING,INTERVENTIONAL,['NA']
2188,NCT01175733,Phase II: safety and tolerability,Time-to-progression (TTP) and overall survival,,2010-07-08,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2189,NCT00233935,Toxicity defined according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (Version 3.0),Dose-related biologic effects and pharmacodynamic properties of Poly E,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE1']
2190,NCT01186263,Percentage of liver volume for which the accumulation of SIR spheres was correctly predicted by the preceding Tc-99m MAA scintigraphy,Adverse events as elicited upon indirect questioning.,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2191,NCT01665937,Phase 2 dose of STA 9090 given once weekly in patients with advanced hepatocellular carcinoma,Overall Survival,,2010-08,COMPLETED,INTERVENTIONAL,['PHASE1']
2192,NCT04654247,Gastric precancerous detection rate,Adcanced ADR,,2019-04-20,COMPLETED,INTERVENTIONAL,['NA']
2193,NCT02633436,optical density (ODs) of each slice by immunohistochemistry assay,SLC1A5 expression detected by WesternBlot,,2015-12,UNKNOWN,OBSERVATIONAL,['NA']
2194,NCT03143270,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,,2017-04-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
2195,NCT00979680,Sphincter preservation rate,Overall Survival,,2001-04,COMPLETED,INTERVENTIONAL,['PHASE3']
2196,NCT00385970,3-Year recurrence-free survival rate,"5-Year survival rate, incidence of adverse events, treatment compliance, QOL, type of metastasis/recurrence, and 3-year and 5-year recurrence-free survival rates and survival rates based on each parameter including colon/rectum, stage, and IAP.",,2006-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
2197,NCT01454180,Overall survival,,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2198,NCT05143619,Teaching rates of the hepatocellular carcinoma diagnosis guidelines,,,2019-05-10,RECRUITING,OBSERVATIONAL,['NA']
2199,NCT02894775,Number of participants included in a clinical trial,,,2013-01,COMPLETED,OBSERVATIONAL,['NA']
2200,NCT01557101,Participation to colorectal cancer screening in first-degree relatives of patients with colorectal cancer,,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE4']
2201,NCT05425472,Objective response rate,ECOG Score for performance status,,2022-07-27,RECRUITING,INTERVENTIONAL,['PHASE2']
2202,NCT06207981,Disease-related event free survival (DREFS) at 2 years,,,2024-02-26,RECRUITING,INTERVENTIONAL,['PHASE3']
2203,NCT00468455,Evaluate the quality of life in patients with abdominal wall hernias using a user-friendly survey that is designed specifically for this population of patients,,,2005-10,COMPLETED,OBSERVATIONAL,['NA']
2204,NCT01234051,Response rate,Overall survival,,2010-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
2205,NCT03884400,Distribution of Biospecimens From Biorepositories/Biobanks for Research Use,,,2021-01-01,WITHDRAWN,OBSERVATIONAL,['NA']
2206,NCT04057365,Overall Response Rate,Treatment Emergent Adverse Events,,2019-10-07,TERMINATED,INTERVENTIONAL,['PHASE2']
2207,NCT06205862,CRA recurrence rate,Changes in intestinal mucosal microbiota Pre- and Post-FMT,,2024-04-09,RECRUITING,INTERVENTIONAL,['PHASE2']
2208,NCT02648880,Change in 400-meter Walk Time,Determination of Hospital Readmission,,2016-05-10,COMPLETED,INTERVENTIONAL,['NA']
2209,NCT02713386,Progression-free survival (PFS) (Phase II),Overall survival (OS) (Phase II),Change in serum C-reactive protein (CRP),2016-11-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2210,NCT02226380,The 3-year overall survival rate in patients who will receive mFOLFOX6 regimen as neoadjuvant chemotherapy regimen,The 3-year disease-free survival rate in the patients who will receive mFOLFOX6 regimen neoadjuvant chemotherapy regimen,The R0 resection rate in the patients who will receive mFOLFOX6 regimen as neoadjuvant chemotherapy regimen,2013-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
2211,NCT04792515,pathologic complete response (PCR),Percentage of Progression-free survival (1-PFSR),,2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
2212,NCT00479752,"The primary endpoint of the trial is: • Objective response (CR/PR), as assessed by RECIST criteria",• Progression Free Survival (PFS) • Overall survival • Safety/Adverse events Safety,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2213,NCT04478929,gastroscopy image data set,,,2020-08,UNKNOWN,OBSERVATIONAL,['NA']
2214,NCT05787535,"Incidence of treatment related AEs, AEs of special interest and serious adverse events (SAEs).",Duration of TCR T cells in-vivo persistence,,2023-03-21,RECRUITING,INTERVENTIONAL,['PHASE1']
2215,NCT03129139,Anti-tumor activity,,,2017-10-10,RECRUITING,INTERVENTIONAL,['PHASE1']
2216,NCT05146297,Change in Clinical Trial Accrual,Physician Post -intervention survey,,2022-12-24,RECRUITING,INTERVENTIONAL,['NA']
2217,NCT03428529,Clinical downstaging,Pathological downstaging,,2011-01-12,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2218,NCT01561014,Toxicity rate of combination chemotherapy followed by surgery and erlotinib hydrochloride,Test the predictive value of FDG-PET-CT imaging in identifying patients who will have a complete response,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE1']
2219,NCT04770623,Overall response rate (ORR),Overall survival (OS),,2021-03-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2220,NCT00536770,Overall survival rate at 6 months,Duration of overall survival,,2007-09,SUSPENDED,INTERVENTIONAL,['PHASE2']
2221,NCT01051596,Percent of Patients With Disease Control,Percent of Patients With an Objective Response,,2009-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2222,NCT06334926,overall survival,,,2017-12-01,COMPLETED,OBSERVATIONAL,['NA']
2223,NCT01023984,Incidence of recurrence at 12 months,Number of days not spent in hospital from initial treatment until 2 years afterwards,,2012-01,WITHDRAWN,INTERVENTIONAL,['PHASE4']
2224,NCT03732508,Duration of Progression-Free Survival (PFS),Adverse Events(AE),,2018-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
2225,NCT05379907,Impact of SIGNATERA™ on treatment decisions,Patient satisfaction of SIGNATERA™ ctDNA on treatment recommendations,,2022-08-23,WITHDRAWN,OBSERVATIONAL,['NA']
2226,NCT02688023,3-year disease-free survival,Number of participants with surgery complications,,2014-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
2227,NCT04095468,Percentages of pCR in the patients after total mesorectal excision performed because of tumour persistence.,Anorectal function assessed by low anterior resection syndrome (LARS) score,,2017-09-18,RECRUITING,OBSERVATIONAL,['NA']
2228,NCT02092298,Overall Survival (OS) From the First Laparoscopic HIPEC,,,2014-05-08,COMPLETED,INTERVENTIONAL,['PHASE2']
2229,NCT05889806,Enrollment and collection totals for a diverse population of subjects/conditions involved in diseases and in healthy/control populations.,,,2023-05-10,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
2230,NCT05336643,Lymph node detection with technetium 99m colloid and SENSEI gamma probe,Concordance of nodes seen on PET MRI/CT and SPECTCT,,2023-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2231,NCT03605706,Overall Survival,Overall Survival (OS) rate at 9 months and 12 months,,2019-05-31,UNKNOWN,INTERVENTIONAL,['PHASE3']
2232,NCT05589675,Participation rates to the screening program,Participation rates to the screening program,,2023-04-01,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
2233,NCT00328887,"Since this is a dose escalation, phase I design to evaluate toxicity, the analysis for this section will be purely descriptive. Adverse events will be considered on an individual basis.",,,2004-11,WITHDRAWN,INTERVENTIONAL,['PHASE1']
2234,NCT00849264,overall survival,disease-free survival,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
2235,NCT02604784,Overall Response Rate (ORR) according to RECIST criteria (version 1.1) after 2 and 3 cycles of PIPAC.,The Peritoneal Carcinomatosis Index (PCI) before and after therapy,,2015-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2236,NCT01469611,Determine the maximum-feasible dose,,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE1']
2237,NCT05835947,The incidence of anal HSIL and cancer in women with genital HSIL and/cancer in England,The amount of time in years and months between the diagnosis of genital HSIL/SCC and anal HSIL/SCC,,2022-09-01,RECRUITING,OBSERVATIONAL,['NA']
2238,NCT05172713,Retrospective study of the patient outcomes who had an incomplete colonoscopy after a positive immunological fecal test,,,2021-01-16,UNKNOWN,OBSERVATIONAL,['NA']
2239,NCT00259402,"Efficacy endpoints include tumor response, progression free and overall survival.","Safety endpoints include summary of adverse events assessed by history, physical exams and laboratory evaluations.",,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2']
2240,NCT00990860,"Safety and tolerability (such as adverse events and laboratory changes (haematology, clinical chemistry))",No. of TACE cycles,,2009-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
2241,NCT03705442,Incidence of grade III/IV diarrhoea between the two groups of patients,Difference in quality of life using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core 30 (EORTC QLQ-C30) between the two groups of patients,,2018-02-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
2242,NCT06060847,Comprehensive Complication Index,Control of obesity-induced comorbidities,,2024-03-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2243,NCT01268943,Dose Related Toxicity,,,2010-11,COMPLETED,INTERVENTIONAL,['PHASE1']
2244,NCT02355262,Total number of months uninsured (total gap months),,,2014-07-01,COMPLETED,OBSERVATIONAL,['NA']
2245,NCT03304210,Maximally Tolerated Dose (MTD) of Abraxane,Decreased Platelets - Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0,,2017-09-16,COMPLETED,INTERVENTIONAL,['PHASE1']
2246,NCT02468362,Disease Free survival,5 year survival,,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
2247,NCT04177407,postoperative complications,Overall complication rate within 30 days after surgery.,,2017-03-23,UNKNOWN,INTERVENTIONAL,['NA']
2248,NCT02043821,DDC:Duration of Disease Control,DCR:Disease Control Rate,Safety,na,UNKNOWN,INTERVENTIONAL,['NA']
2249,NCT01748851,Progression free survival,performance status (quality of life),,2012-12,TERMINATED,INTERVENTIONAL,['PHASE3']
2250,NCT02577588,Safety,evaluation of p53 specific T cell Responses by analysing data from EliSpot assay,,2016-05-01,TERMINATED,INTERVENTIONAL,['PHASE1']
2251,NCT01368094,Surgical Site Infection at D30,,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
2252,NCT03267524,Geriatric assessment,,,2017-11-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2253,NCT05951127,2-year OS,3 years PFS,,2022-11-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2254,NCT02437071,response rate,Toxicity,,2015-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2255,NCT05130073,Overall survival (OS),,,2019-07-31,COMPLETED,OBSERVATIONAL,['NA']
2256,NCT04935853,Rate of patients with advanced bile duct cancer (BDC) experiencing overall survival (OS) less than 6 months,The complications and postoperative mortality rates in patients who underwent surgery,,2022-05-23,RECRUITING,OBSERVATIONAL,['NA']
2257,NCT05185739,"Major pathological response rate, defined as the proportion of patients with less than 10% viable tumour at resection.",Determine the toxicity of pre-operative therapy according to Common Terminology Criteria for Adverse Events (CTCAE) V5.,,2022-08-25,RECRUITING,INTERVENTIONAL,['PHASE2']
2258,NCT02050659,tumorload in the greater omentum,,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
2259,NCT06101836,Patient comfort during colonoscopy - Sedation,,,2020-10-01,COMPLETED,INTERVENTIONAL,['NA']
2260,NCT03908255,Overall Survival,Quality of life using FACT-Hep,International normalized ratio (INR),2021-06-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
2261,NCT01318200,Freedom from local progression,Freedom from local progression,,2011-02,WITHDRAWN,INTERVENTIONAL,['PHASE3']
2262,NCT04896879,Needs and experiences of healthcare professionals caring for patients with LARS through focus groups,,,2016-11-22,COMPLETED,OBSERVATIONAL,['NA']
2263,NCT04655807,Change from Baseline in the Crohn's Disease Activity Index (CDAI) Score at Week 12,Change in PD Biomarker Levels of Fecal Lactoferrin from Baseline Compared with Placebo,,2021-03-03,WITHDRAWN,INTERVENTIONAL,['PHASE2']
2264,NCT02931981,Overall Survival,Relapse-free Survival,,2016-10,UNKNOWN,OBSERVATIONAL,['NA']
2265,NCT01328223,Response rate,Overall survival,,2010-09,UNKNOWN,OBSERVATIONAL,['NA']
2266,NCT00019474,,,,1998-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2267,NCT00222664,,,,1983-09,COMPLETED,INTERVENTIONAL,['PHASE4']
2268,NCT02066363,Changes in body composition,Time to to exacerbate Quality of Life,Survival in study,2014-03-01,TERMINATED,INTERVENTIONAL,['NA']
2269,NCT01111292,The Effect of Myo-inositol (Inositol) on P-β-catenin Staining in Areas of Low Grade Dysplasia in Subjects With Known Colitis-induced Low Grade Dysplasia.,,,2010-10,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2270,NCT06133439,Implementation outcomes,,Maintenance,2023-01-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
2271,NCT05394129,Diagnostic accuracy,Cytomorphologic feature,,2019-04-09,RECRUITING,OBSERVATIONAL,['NA']
2272,NCT02718235,The HCC immune score (HCCIS) is a survival prognosticator of patients after liver resection for HCC,The HCC immune score (HCCIS) to prognosticate disease free survival of patients after liver resection for HCC,,2016-06,UNKNOWN,OBSERVATIONAL,['NA']
2273,NCT02073435,Complications,,,2010-10,COMPLETED,OBSERVATIONAL,['NA']
2274,NCT04871321,collected blood samples,Biomarkers on the efficacy of Gemcitabine/Cisplatin/Nab-paclitaxel for advanced biliary tract cancer,,2021-04-14,RECRUITING,OBSERVATIONAL,['NA']
2275,NCT04972994,early recurrence of the cancer,,,2021-06-01,UNKNOWN,INTERVENTIONAL,['NA']
2276,NCT03053544,Pathological Complete Response (pCR) rate,Tumor Hypoxia,,2016-12-08,COMPLETED,INTERVENTIONAL,['PHASE2']
2277,NCT05159050,Determine the maximum tolerated dose (MTD) of intraperitoneal Paclitaxel-loaded Tumor Penetrating Microparticles (TPM),Assess whether intra-abdominal pressure is location-dependent,,2022-04-26,RECRUITING,INTERVENTIONAL,['PHASE1']
2278,NCT03257033,Overall Survival,"Safety, defined as adverse event rate, and tolerability, defined as occurrence of treatment discontinuation",,2018-03-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
2279,NCT05654896,Liver abscess and intervention,,,2022-11-26,RECRUITING,INTERVENTIONAL,['PHASE3']
2280,NCT00213486,clinical complete response defined as no tumor detectable on esophagus endoscopy and no appearance of distant metastasis on CT scan,overall survival rate at one and two years,,2002-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2281,NCT03640572,Overall survival (OS),Systemic recurrence,,2007-06-01,COMPLETED,OBSERVATIONAL,['NA']
2282,NCT03723304,Tumour-specific liver transplant failure rate,,,2018-03-01,COMPLETED,OBSERVATIONAL,['NA']
2283,NCT05248048,Maximal Tolerable Dose#MTD#,Antitumor efficacy-Overall survival (OS),,2021-09-13,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
2284,NCT02866019,Proportion of participants without stenosis until 8 weeks after endoscopic submucosal dissection (ESD),QOL assessed by the EORTC QLQ-OG 25,,2016-04,COMPLETED,INTERVENTIONAL,['PHASE3']
2285,NCT03716089,3-year disease free survival rate,The variation of C-reactive protein,,2018-10-11,RECRUITING,OBSERVATIONAL,['NA']
2286,NCT04224402,Regression Free Survival,Overall Survival,EORTC Quality of Life Questionnaire(QLQ)-C30,2020-01-31,COMPLETED,INTERVENTIONAL,['PHASE2']
2287,NCT00485316,Overall survival and disease-free survival,Direct cost,,1993-09,COMPLETED,INTERVENTIONAL,['PHASE3']
2288,NCT01046864,"Safety-Toxicity, evaluated according to NCI Common Terminology Criteria for Adverse Events v3.0. Assessments based on medical review of adverse events, results of vital signs, ECGs, echocardiography, physical examinations, and clinical laboratory tests","Exploratory Measures (Biomarkers for Predictive Analysis): Potential predictive markers, including activity of FGF, VEGF and related pathways as well as K-RAS mutation status, will be evaluated based on blood or tumor samples",,2010-02,COMPLETED,INTERVENTIONAL,['PHASE1']
2289,NCT00081549,,,,na,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2290,NCT05916846,Assess the efficacy of EUS-RFA post-procedure after one year,Assess the long-term response to EUS-RFA for efficacy of significant and durable ablation response,,2023-04-24,RECRUITING,INTERVENTIONAL,['NA']
2291,NCT06126419,Liver regeneration improvement after high-dose insulin therapy after LVD measured CT volumetry,,,2023-11-08,RECRUITING,INTERVENTIONAL,['NA']
2292,NCT03009747,Risk factors of bowel dysfunction after sphincter-preserving surgery,Incidence of bowel dysfunction after sphincter-preserving surgery,,2017-01,UNKNOWN,OBSERVATIONAL,['NA']
2293,NCT00287976,Best overall response (complete response and partial response),Surgical resection (complete or incomplete),,2003-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
2294,NCT03242187,Number of lymph nodes retrieved,Functional outcome,,2017-05-25,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2295,NCT05160740,3-year disease free survival rate,Mortality rates,,2021-09-23,RECRUITING,INTERVENTIONAL,['NA']
2296,NCT04725994,Dose Limiting Toxicities (DLTs),,,2021-06-28,RECRUITING,INTERVENTIONAL,['PHASE1']
2297,NCT01065688,the postoperative quality of life (QOL),"the incidence of postoperative complications, nutritional status, and the incidence of the remnant gastritis and the reflux esophagitis",,2009-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2298,NCT01904656,Rates of colorectal cancer screening-within-guidelines (status obtained by medical record review).,Effect Modification,,2009-09,COMPLETED,INTERVENTIONAL,['NA']
2299,NCT04959448,Baseline Disease Characteristics,Physician Assessment: Global Impression for Disease Severity (Global Physician Assessment),,2021-08-12,RECRUITING,OBSERVATIONAL,['NA']
2300,NCT00335816,Effect of different chemoradiation-to-surgery intervals on postoperative complications,,,2008-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2301,NCT05407272,"the knowledge, attitudes, service intentions and service start-up effects of the eight major non-cancer disease end-stage caregivers on well-being and palliative care",,,2021-09-14,COMPLETED,INTERVENTIONAL,['NA']
2302,NCT00901732,The primary objective is to estimate ht incidence of OM in H&N cancer patients undergoing radiation therapy with or without chemotherapy and/or sensitizer who receive Caphosol.,"The secondary objective of this study is to correlate components of OM data with clinical outcomes (pain, narcotic use, oral intake)",,2009-05,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2303,NCT02903498,Progression Free Survival (PFS),Number of Participants with Adverse Events,,2009-08,COMPLETED,INTERVENTIONAL,['PHASE2']
2304,NCT05497778,"National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0",,,2022-10-21,RECRUITING,INTERVENTIONAL,['PHASE1']
2305,NCT02413476,Five-year disease free survival rate,"Intraoperative situation (The number of lymph node dissection,the number of positive lymph nodes,extra-cavity anastomosis time,intraoperative blood loss,the rate of conversion)",,2015-05,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2306,NCT04216251,Change in the Marine Omega-3 Polyunsaturated Fatty Acid (MO3PUFA) Composition in Colorectal Tissues as a Result of the AMR101 Treatment.,Change in Stool Metabolite Profile,,2020-12-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2307,NCT04491929,Feasibility and translational analysis,Overall Survival,,2020-11-01,RECRUITING,OBSERVATIONAL,['NA']
2308,NCT00851045,Progression free survival based on tumor assessments (CT/MRI),"Safety in the CT-322 plus irinotecan, 5-FU and leucovorin arm as measured by incidence of serious and non-serious adverse events, significant laboratory evaluations and significant physical examination findings in subjects",,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2309,NCT00606619,Days of hospital stay after operation,Postoperative morbidity rate in hospital days: Clinically definite morbidity confirmed by physicians according to offered protocol,,2008-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2310,NCT06328868,Concentration of Serum prealbumin,Feeding amount,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2311,NCT03621644,Gastrointestinal toxicity assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5,Patient-reported quality of life (QOL),,2019-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2312,NCT05287672,Weight gain by BMI by kg/m2,,,2022-06,UNKNOWN,OBSERVATIONAL,['NA']
2313,NCT00318604,,,,na,UNKNOWN,OBSERVATIONAL,['NA']
2314,NCT06031480,"Objective response rate (ORR, RECIST v1.1)",,,2023-10-31,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2315,NCT05898854,Patient management,Prognostic value,,2024-02-15,RECRUITING,INTERVENTIONAL,['PHASE2']
2316,NCT05056714,Develop a severity score for PNS using latent variable modeling: Polyps Severity Index (PSI),,,2022-01-27,RECRUITING,OBSERVATIONAL,['NA']
2317,NCT05982301,"Progression-Free survival 2, PFS2",After Effects,,2023-02-09,RECRUITING,INTERVENTIONAL,['PHASE2']
2318,NCT03257332,Global health status/quality of life: EORTC QLQ-C30,Low anterior resection syndrome,Physical performance,2019-11-12,WITHDRAWN,OBSERVATIONAL,['NA']
2319,NCT00288119,Assay of DNA and RNA markers,Score of tolerability and acceptability,,2005-10-01,RECRUITING,OBSERVATIONAL,['NA']
2320,NCT01837446,Mucositis severity,Patient's satisfaction,,2011-07,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2321,NCT00381173,"Determine the feasibility, safety and tolerability of administering ZYC300 intramuscularly every other wk for 6 doses (400 micrograms DNA/total dose) to the study pop. pre-dosed with 600 mg/m^2 cyclophosphamide intravenously 3 days prior to study drug.","Assess the effect of cyclophosphamide on T reg number and function. Assess the generation of CYP1B1-specific immun. as a result of vac. regimen. Assess the effect of vac. regimen on tumor response, if any, in pat. pop.",,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
2322,NCT04524676,1-year rebleeding rate,Complications of portal hypertension,,2020-08-31,UNKNOWN,INTERVENTIONAL,['NA']
2323,NCT03559543,Nutritional status,,,2018-10-25,COMPLETED,INTERVENTIONAL,['PHASE2']
2324,NCT05731726,Pathological complete response rates,single cell sequence,,2023-02-22,RECRUITING,INTERVENTIONAL,['PHASE2']
2325,NCT02585362,Change in physical performance,Overall survival,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
2326,NCT03383159,Differences In Microbiota,Predictive model validation,,2016-05-01,UNKNOWN,OBSERVATIONAL,['NA']
2327,NCT02555358,The pathological complete response rate,Adverse events,,2014-11,COMPLETED,INTERVENTIONAL,['PHASE2']
2328,NCT03061370,Survival,,,2010-01-01,COMPLETED,OBSERVATIONAL,['NA']
2329,NCT00963092,"Creation of repository of blood, saliva, and tumor samples",,,2002-08,UNKNOWN,OBSERVATIONAL,['NA']
2330,NCT02969122,Overall survival,morbidity and mortality of HIPEC and EIPL,,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
2331,NCT01853618,Number of Participants With Serious and Non-Serious Adverse Events Regardless of Attribution,Overall Survival,,2013-05-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2332,NCT00001276,Treatment Outcomes,,,1991-05-21,RECRUITING,OBSERVATIONAL,['NA']
2333,NCT00419978,,,,2004-06,TERMINATED,INTERVENTIONAL,['NA']
2334,NCT06241066,DFS,,,2014-01-01,COMPLETED,OBSERVATIONAL,['NA']
2335,NCT01856322,Difference in Circulating S100A4 Transcript in Patients Receiving Sulindac 150 mg BD (Twice Daily) by Mouth Following Resection of Colorectal Cancer Metastases Compared to Those Who do Not.,,,2013-04,TERMINATED,INTERVENTIONAL,['PHASE2']
2336,NCT02967094,"""Visibility score"" evaluated by blinded performing endoscopist",Duration of endoscopy,,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
2337,NCT02646241,diagnostic accuracy,accuracy of malignant potential on contrast enhanced EUS,,2016-01-02,COMPLETED,INTERVENTIONAL,['NA']
2338,NCT05981235,"Changes from baseline in vital signs, laboratory parameters, physical examination, and 12-lead ECG.",PFS,,2023-12-14,RECRUITING,INTERVENTIONAL,['PHASE1']
2339,NCT01218854,The difference between MD-NASS and standard method,,,2012-03-20,COMPLETED,INTERVENTIONAL,['PHASE1']
2340,NCT03780439,diagnostic accuracy of procalcitonin to detect post-operative infection,diagnostic accuracy of procalcitonin to detect overall post-operative complications,,2018-06-01,COMPLETED,OBSERVATIONAL,['NA']
2341,NCT03620461,Assess adverse events (per CTCAE v4.0 criteria),,,2013-12-01,COMPLETED,OBSERVATIONAL,['NA']
2342,NCT04515082,"Sensitivity, specificity, positive predictive value and negative predictive value of bi-target stool DNA testing (the methylation status of SDC2 and SFRP2) with comparison to colonoscopy, both with respect to cancer and advanced precancerous neoplasm.","To compare the performance of the bi-target stool DNA testing to a commercially available FIT assay, both with respect to cancer and advanced precancerous neoplasm.",,2020-08,UNKNOWN,OBSERVATIONAL,['NA']
2343,NCT01596582,Concordance Between Patient Preference and Test Ordered,Provider Satisfaction,Concordance Between Patient Preferences for a Screening Tests Other Than Colonoscopy and Test Ordered for High Versus Low Risk Patients,2012-04,COMPLETED,INTERVENTIONAL,['NA']
2344,NCT05053971,Objective response rate (ORR) (Phase II),Progression free survival,Non-sequencing biomarker analysis,2022-11-16,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2345,NCT02021604,Accuracy of PET imaging compared to intraoperative pancreatic biopsy in patients with congenital hyperinsulinism,Ratio of Standard Uptake Value max to sub max,,2013-10-09,RECRUITING,INTERVENTIONAL,['PHASE1']
2346,NCT00282100,To study the changes of selected genetic or protein markers through the treatment and find out whether some of them can be potential biomarkers for disease relapse.,To evaluate the effect of gefitinib as an adjuvant therapy on recurrence free survival in patients with resectable hepatocellular carcinoma; to evaluate the treatment toxities of genifitib.,,2005-12,UNKNOWN,INTERVENTIONAL,['PHASE2']
2347,NCT00812942,Participation to colorectal cancer screening,,,2003-11,COMPLETED,INTERVENTIONAL,['NA']
2348,NCT00149396,Clinical Laboratory Safety - Coagulation,Pharmacodynamic Effects of NV1020: Serum Cytokines (TNF-alpha),,2004-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2349,NCT00101036,Response Rate,Disease Control Rate.,,2004-11,COMPLETED,INTERVENTIONAL,['PHASE2']
2350,NCT06096896,5-years overall survival (OS) after MWA for early HCC,Rate of completed ablation after MWA,,2023-08-30,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2351,NCT06205732,Progression-Free-Survival,,,2024-01-01,RECRUITING,OBSERVATIONAL,['NA']
2352,NCT02135419,Anal Cancer Incidence,Change in Physical Symptom Score From Baseline (2-7 Days Post Randomization) Until 4 Weeks Post Randomization,Quality of Life Assessment Measured by the A-HRSI (Validated Tool),2014-09-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
2353,NCT05355155,"Objective Response Rate (ORR) ,Based on RECIST 1.1",Safety as measured by number and grade of adverse events,,2022-05-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2354,NCT03007407,Overall Objective Response Rate (ORR) of Dual Immune Checkpoint Blockade by RECIST 1.1,"Frequency of Adverse Events Assessed by CTCAE 4.0, From Beginning of Treatment to 90 Days After Last Dose",,2017-07-31,COMPLETED,INTERVENTIONAL,['PHASE2']
2355,NCT04457193,Percentage of participants with normal esophageal acid exposure time,Change in Gastroesophageal Reflux Disease (GERD) symptoms assessed by the Reflux Symptom Index (RSI),,2018-06-07,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
2356,NCT01149434,Tumor Response in the Ovarian Cancer Cohort,Tumor Response,,2010-09,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2357,NCT03188991,Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability),Cyst Volume Response,,2017-09-29,COMPLETED,INTERVENTIONAL,['PHASE2']
2358,NCT04896931,Establishment of BTC population,establishment of sample collection (tumorblocks and blood),,2022-07-12,RECRUITING,OBSERVATIONAL,['NA']
2359,NCT05057845,Objective Response Rate (ORR),Adverse Events,,2021-09-26,RECRUITING,INTERVENTIONAL,['PHASE2']
2360,NCT00646139,Maximum tolerated dose,Biological effects,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE1']
2361,NCT03853473,6 Minute Walk Test Distance (Pre Surgery),Intraoperative Blood Pressure Variability,Length of Hospital Stay,2019-02-22,COMPLETED,INTERVENTIONAL,['NA']
2362,NCT00900419,Genetic mutations or altered growth factor expression,Establishment of a tissue repository of normal and dysplastic respiratory epithelium,,2001-05-03,RECRUITING,OBSERVATIONAL,['NA']
2363,NCT03065257,Number of participants with reduction in clinical symptoms,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,Number of participants with successful completion of treatment,2017-03-15,UNKNOWN,OBSERVATIONAL,['NA']
2364,NCT02700555,Incidence of newly developed diabetes mellitus,3-year recurrence-free survival & 5-year recurrence-free survival,,2016-02,TERMINATED,OBSERVATIONAL,['NA']
2365,NCT05040360,Recurrence-free survival (RFS),Incidence of adverse events,,2022-05-05,RECRUITING,INTERVENTIONAL,['PHASE2']
2366,NCT00585312,Time to Disease Progression,Colorectal Polyp Burden,,2006-09,TERMINATED,INTERVENTIONAL,['PHASE3']
2367,NCT05943041,Incidence of Adverse Events from baseline to 8 weeks,,Changes of LARS(Low Anterior Resection Syndrome) score from baseline to 8 weeks,2023-04-28,RECRUITING,INTERVENTIONAL,['PHASE1']
2368,NCT00262171,,,,2002-05,UNKNOWN,OBSERVATIONAL,['NA']
2369,NCT02887313,Pathological complete response rate,Disease free survival,,2016-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
2370,NCT05846035,the prevalence of Paraneoplastic Syndrome in cirrhotic Patients with HCC.,,,2023-04-15,RECRUITING,OBSERVATIONAL,['NA']
2371,NCT00882973,The recommended phase II dose of the combination therapy with Genexol-PM and gemcitabine,Safety profiles,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE1']
2372,NCT02137356,Number of patients with adverse events,Number of patients whose tumors demonstrate pathological complete response at resection,,2014-12,UNKNOWN,INTERVENTIONAL,['PHASE1']
2373,NCT03259009,Progression-free survival (PFS),Overall survival (OS),,2017-10-01,UNKNOWN,OBSERVATIONAL,['NA']
2374,NCT00748215,Number of Participants With Grade 3/4 Diarrhea,,,2009-02-04,COMPLETED,INTERVENTIONAL,['PHASE2']
2375,NCT06109805,Plasma metabolite content,,,2023-10-20,RECRUITING,OBSERVATIONAL,['NA']
2376,NCT06121622,Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours,,,2024-01-16,RECRUITING,OBSERVATIONAL,['NA']
2377,NCT01523353,Anaerobic threshold prior to liver resection,Recovery of fitness,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE1']
2378,NCT04345770,overall survival,complication rate,,2020-04-01,RECRUITING,INTERVENTIONAL,['PHASE2']
2379,NCT00147147,Overall survival,the site of recurrence,,1993-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2380,NCT04207463,Overall response rate (ORR),Overall survival (OS),,2020-06-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
2381,NCT01697462,Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs),Number of Participants With Hand-Foot Syndrome (HFS),,2009-07,COMPLETED,OBSERVATIONAL,['NA']
2382,NCT05720559,Overall Survival (OS),,,2023-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2383,NCT02572687,Number of Participants with Dose Limiting Toxicities (DLTs),Number of Participants with Treatment Emergent Anti MEDI4736 Antibodies,,2016-02-19,COMPLETED,INTERVENTIONAL,['PHASE1']
2384,NCT05571644,Pathological complete response (pCR) rates,Local recurrence rate,,2023-07-10,RECRUITING,INTERVENTIONAL,['PHASE2']
2385,NCT04807972,Phase 2: Overall Survival,Phase 2: Percentage of Participants Experiencing Adverse Events,,2021-05-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2386,NCT05837065,the Harrell concordance index (C-index),the time-dependent area under the receiver operating characteristic curve(tdAUROC),,2022-09-15,RECRUITING,OBSERVATIONAL,['NA']
2387,NCT01807390,Change in pain perceptions,Change in general health related quality of life,,2012-07,UNKNOWN,OBSERVATIONAL,['NA']
2388,NCT05163483,Objective Response Rate（ORR）,Overall survival(OS),,2022-07-01,RECRUITING,INTERVENTIONAL,['PHASE2']
2389,NCT05609695,Overall Survival,Progress Free Survival,,2023-03-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2390,NCT06287671,Correlation between biomarker in plasma and tissue,,,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2391,NCT05027425,Cellular rejection rates,Recurrence-free survival and overall survival outcomes based on survival follow up reporting,,2021-12-07,RECRUITING,INTERVENTIONAL,['PHASE2']
2392,NCT05444088,Objective Response Rate,Progression-Free-Survival assessed by investigator,,2022-08-01,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2393,NCT05412082,Incidence of Toxicity Among Participants After Start Receiving MRI-g Pelvic ART,Health-related Quality of Life (HRQOL) Scores: Pittsburgh Sleep Quality Index (PSQI),,2022-10-05,RECRUITING,INTERVENTIONAL,['PHASE1']
2394,NCT00003446,,,,1997-12,COMPLETED,INTERVENTIONAL,['PHASE2']
2395,NCT02824835,percentage of cells in G2/M arrest after dose-dependent exposure,,,2016-07,UNKNOWN,OBSERVATIONAL,['NA']
2396,NCT01666756,"Recommended phase II dose, determined according to incidence of dose-limiting toxicity (DLT) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4",Sorafenib tosylate concentration after co-administration with Chinese herbal formulation PHY906,Change in levels of soluble biomarkers,2014-06-11,COMPLETED,INTERVENTIONAL,['PHASE1']
2397,NCT00642603,Progression-free Survival (PFS) in U.S. Patients Only,,,2008-05,TERMINATED,INTERVENTIONAL,['PHASE2']
2398,NCT02094105,incidence and mortality of ESCC,"Cumulative incidence and mortality of total cancer, and gastric cardia cancer",,1999-11,COMPLETED,INTERVENTIONAL,['NA']
2399,NCT03300544,Incidence of dose limiting toxicities of TVEC,Overall survival,,2017-09-20,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
2400,NCT03421288,Comparison of Event free survival (EFS) between arms,Overall survival (OS) and EFS in the subgroup of patients with PD-L1 CPS score ≥ 5 and ≥ 10 and patients with MSI,ctDNA clearance on treatment,2018-09-14,RECRUITING,INTERVENTIONAL,['PHASE2']
2401,NCT03803267,Postoperative pain score,Serum C-reactive protein (CRP),,2019-05-01,COMPLETED,INTERVENTIONAL,['NA']
2402,NCT02106858,Percentage of patients with adverse drug reactions (ADRs),Overall survival (OS),,2014-06-25,COMPLETED,OBSERVATIONAL,['NA']
2403,NCT03536793,"Measurement of the accuracy of protein markers (e.g., TF, AM) in detecting early stage pancreatic cancer by comparison of laboratory results from ELISA assays and platform technologies to patient clinical data.",,,2018-10-24,RECRUITING,OBSERVATIONAL,['NA']
2404,NCT01247506,,,,2010-02,UNKNOWN,OBSERVATIONAL,['NA']
2405,NCT03755921,M. D. Anderson Dysphagia Inventory (MDADI),Deglutition evaluation,,2018-12-01,UNKNOWN,INTERVENTIONAL,['NA']
2406,NCT04082455,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,progression-free survivals,,2018-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2407,NCT03209765,Compliance rate,Compliance rate of second round,,2017-06-16,COMPLETED,INTERVENTIONAL,['NA']
2408,NCT03499795,Percentage of Participants With no Histologic Evidence of Anal or Anal/Peri-Anal HSIL and no Evidence of HPV-16/18 at Week 36,Percentage of Participants With no Histologic Evidence of Anal or Anal/Peri-Anal HSIL or no Evidence of HPV-16/18 at Week 36,"Percent Change From Baseline in the Size of Peri-Anal Lesions as Determined by the Investigator at Weeks 36, 64, and 88",2018-05-15,COMPLETED,INTERVENTIONAL,['PHASE2']
2409,NCT02547610,The imaging biomarkers determined by MR-PET,,,2014-05,UNKNOWN,OBSERVATIONAL,['NA']
2410,NCT00603460,"Disease status will be assessed with CT (or MRI) of chest/abdomen/pelvis at enrollment, after vaccine 2 and at the conclusion of the study . Rates of disease progression will be recorded at the time of study conclusion.",,,2012-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2411,NCT00443573,"Safety measured by major hemorrhage (NCI CTCAE v3.0 grade 3 or greater), during and up to 30 days after completion of study drug administration or, if treatment is ongoing, by 8 months after study enrollment (Stage I) or randomization (Stage II)","Tumor response rate, as assessed by RECIST criteria",,2006-12,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2412,NCT04904042,Pathological evaluation,Global mortality.,,2021-06-01,COMPLETED,INTERVENTIONAL,['NA']
2413,NCT01622543,Progression Free Survival,Overall Survival,,2012-10-26,COMPLETED,INTERVENTIONAL,['PHASE2']
2414,NCT00307736,"Maximum Tolerated Dose (MTD) of Erlotinib When Administered in Combination With 5-fluorouracil (5-FU), Bevacizumab, and External Beam Radiation Therapy","Post-operative Complications After Resection of Rectal Cancers Following Preoperative 5-FU, Bevacizumab, Erlotinib, and External Beam Radiation Therapy.",Pathologic Complete Response,2006-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2415,NCT04975516,Progression free survival,Incidence of adverse events,,2023-07-18,RECRUITING,INTERVENTIONAL,['PHASE2']
2416,NCT00171912,To assess the efficacy and the safety of imatinib mesylate therapy,To evaluate the effects of imatinib on quality of life and healthcare resource use,,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2417,NCT04906343,Advanced neoplasia and colorectal cancer incidence at 3 years,,,2021-06-05,UNKNOWN,INTERVENTIONAL,['NA']
2418,NCT02697058,Progression Free Survival (PFS) in Part 2 of Study,"Volume of Distribution at Steady-State (Vss)-Total Irinotecan, SN-38, and SN-38-Glucuronide (SN-38G)",,2016-03-30,COMPLETED,INTERVENTIONAL,['PHASE2']
2419,NCT01273090,Toxicities of imetelstat sodium,,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE1']
2420,NCT02402842,Progression-free survival rate,HPV-specific T cell responses measured by ELISPOT assay before and after DCF treatment,,2014-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2421,NCT01052376,"Evaluate and validate CEM in terms of its ability to diagnose neoplastic lesions and to distinguish between normal and neoplastic mucosa in vivo, based on comparison between ""optical biopsies"" and standard histology.",,,2008-12,TERMINATED,INTERVENTIONAL,['NA']
2422,NCT00769483,Progression Free Survival,Treatment Toxicity,Correlation Between Plasma IGF-I Expression in Patients Treated With MK-0646 and OS,2008-11-13,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2423,NCT05802407,Disease-free survival,Overall survival,The prognostic role of targeted therapy selected based on MRD,2023-02-01,RECRUITING,INTERVENTIONAL,['NA']
2424,NCT04582500,Patient Satisfaction,Assessing Workflow of incomplete colonoscopies,,2021-02-15,RECRUITING,OBSERVATIONAL,['NA']
2425,NCT01484925,,,,2011-11,COMPLETED,OBSERVATIONAL,['NA']
2426,NCT06124131,Difference in proportion of participants completing colorectal cancer screening between study arms,"Difference in proportion of participants completing all three services between study arms: colorectal cancer screening, COVID-19 shot, flu shot",Number of patients who receive intended treatment,2023-11-11,COMPLETED,INTERVENTIONAL,['NA']
2427,NCT05823584,Sensitivity (vh-DNA vs AFP) (the vh-DNA which could be detected in the pre-operative plasma of participants.),Sensitivity (TERT C228T vs AFP/AFP-L3/PIVKA-II),,2019-12-22,COMPLETED,OBSERVATIONAL,['NA']
2428,NCT00482222,Progression-free survival,Safety,,2007-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
2429,NCT01323400,Progression-free survival,"Overall survival in patients not randomly assigned to pazopanib, but receiving pazopanib on a compassionate basis after progression",,2011-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2430,NCT00383266,Overall Response Rate (ORR),Overall Survival (OS),,2006-10,TERMINATED,INTERVENTIONAL,['PHASE2']
2431,NCT01360411,Malignant or benign lesion,Value of a Visual Analog Scale for strain image categorisation,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
2432,NCT03868215,Sensitivity,,,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA']
2433,NCT03819088,Quality of life scores,Serum albumin level,,2019-04-17,COMPLETED,INTERVENTIONAL,['NA']
2434,NCT02204150,Feasibility of OFDI Imaging in Subjects Swallowing the OFDI Capsule,,,2012-02,COMPLETED,INTERVENTIONAL,['NA']
2435,NCT02726997,"Pharmacodynamic Changes Induced by Treatment with Durvalumab in Combination with Paclitaxel and Carboplatin in Women with Advanced Stage, Metastatic Ovarian Cancer Using a 2-Sample T-Test","Feasibility of Treatment with Durvalumab in Combination with Paclitaxel and Carboplatin in Women with Advanced Stage, Metastatic Ovarian Cancer Determined by Methods of Thall et all",,2016-07-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2436,NCT03556384,Overall Response Rate,Adverse events related to TMZ,,2018-09-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2437,NCT04223401,Postoperative morbidity rate by Clavien-Dindo,Psychological status by Hospital Anxiety and Depression Scale (HADS).,,2020-02-06,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2438,NCT00354679,Evaluation of Safety and Toxicity,,,2006-04,COMPLETED,INTERVENTIONAL,['PHASE2']
2439,NCT00177853,"Determine efficacy of combination of irinotecan, celecoxib and concurrent radiotherapy on pancreatic cancer; determine highest/safest doses of these drugs",Tumor diminishment for safe excision,,2006-12,TERMINATED,INTERVENTIONAL,['PHASE1']
2440,NCT06022861,Objective Response Rate(ORR) as assessed by IRC,Incidence of Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (Nab),,2023-10-12,RECRUITING,INTERVENTIONAL,['PHASE3']
2441,NCT04927897,Maximum distance of microscopic tumor spread per patient in all directions from the macroscopic tumor remnant in the pathology specimen,Evaluation of risk factors for the presence and/or the extent of microscopic tumor spread identified by the meta-analysis we performed,Analysis of (re)biopsy material,2022-08-16,RECRUITING,OBSERVATIONAL,['NA']
2442,NCT02762448,HCV clearance and complete regression of NHL by ASV+ DCV,,,2016-07,WITHDRAWN,OBSERVATIONAL,['NA']
2443,NCT05616533,The coincidence rate of tumor response obtained from 50 PDX models with clinical real tumor response acquired from corresponding patients received neoadjuvant therapy.,,,2023-09-12,RECRUITING,OBSERVATIONAL,['NA']
2444,NCT00798746,Reflux Symptoms: Open Esophagectomy versus Minimally Invasive,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
2445,NCT03814005,"Part A, Cmax: Maximum Observed Plasma Concentration for Pevonedistat Following a Single Dose","Part B, Percentage of Solid Tumors Participants with CR or PR",,2019-07-10,COMPLETED,INTERVENTIONAL,['PHASE1']
2446,NCT05124704,Predicted effect-site concentration of propofol (Ceprop) at certain time points,Postoperative exhaust time,,2021-07-01,COMPLETED,INTERVENTIONAL,['NA']
2447,NCT04633512,"Support personnel satisfaction with ActivSightTM, as quantified by Likert scale.",Ability of ActivSightTM to display biliary tree.,,2020-11-17,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
2448,NCT04635488,metastasis rate of lateral lymph node,,,2020-01-01,UNKNOWN,OBSERVATIONAL,['NA']
2449,NCT04843189,Number of lymph nodes harvested,5-year overall survival,,2021-05-01,UNKNOWN,OBSERVATIONAL,['NA']
2450,NCT03120195,Feasibility of EndoRotor® for the ablation of Barrett's mucosa,Ease of performing the EndoRotor® procedure,,2017-01-27,COMPLETED,INTERVENTIONAL,['NA']
2451,NCT01735799,,,,2012-11,UNKNOWN,OBSERVATIONAL,['NA']
2452,NCT02781935,Negative Predictive Value (NPV) of the diagnostic imaging (DW-MRI),Long term outcomes of patients who underwent surgery in terms of: - recurrence rates for 2 years after surgery - progression free survival for 2 years after surgery - overall survival for 2 years after surgery,,2016-11,COMPLETED,OBSERVATIONAL,['NA']
2453,NCT04312633,Primary Outcome Measure:,Secondary Outcome Measure:,,2020-04-01,RECRUITING,OBSERVATIONAL,['NA']
2454,NCT05055648,Pulmonary complications,Overall survival (OS),Concordance of observed cardiac complications with predicted,2022-05-01,RECRUITING,INTERVENTIONAL,['NA']
2455,NCT03162510,MTD of Oxaliplatin,Overall survival,,2018-06-26,COMPLETED,INTERVENTIONAL,['PHASE1']
2456,NCT03368859,Progression Free Survival (PFS),Overall Survival (OS),,2018-03-20,TERMINATED,INTERVENTIONAL,['PHASE2']
2457,NCT04740346,3-year overall survival,Incidence of vitamin B12 deficiency,,2021-07-05,RECRUITING,INTERVENTIONAL,['NA']
2458,NCT01186731,Response rate of tumor size reduction at 110 mg/m2 LE-DT dose level,SPARC tumor expression following the treatment of LE-DT at 110 mg/m2 dose level,,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2']
2459,NCT04375930,means of quality of life change,,,2019-01-18,COMPLETED,INTERVENTIONAL,['NA']
2460,NCT02024607,The Objective Response Rate of Napabucasin Administered in Combination in FOLFIRI in Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer,Overall Survival of Patients With FOLFIRI/XELIRI-refractory Metastatic Colorectal Cancer,,2014-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2461,NCT01133132,Change in level of physical activity,,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
2462,NCT00114179,Overall survival rate,Response rate,,2005-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2463,NCT05425940,Overall Survival,Overall Survival,Duration of Response (DOR) as assessed by the Investigator per RECIST 1.1,2022-09-07,RECRUITING,INTERVENTIONAL,['PHASE3']
2464,NCT05732662,ORR,Treatment Related Severe Adverse Effects,,2023-04,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2465,NCT06104241,Dose-limiting toxicity (DLT）,PFS,,2023-10-22,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
2466,NCT04293497,The comparison of sensitivity between conventional staining method and new staining method,The evaluation of correlation index of staining at three type slides,,2020-02-17,COMPLETED,INTERVENTIONAL,['NA']
2467,NCT04186117,Isolation of circulating tumoral cells,,,2016-09-09,RECRUITING,INTERVENTIONAL,['NA']
2468,NCT04161287,Local control rates,Adverse reaction,,2019-10-11,RECRUITING,OBSERVATIONAL,['NA']
2469,NCT02586701,Six Minute Walk Test (6MWT),,,2013-09,COMPLETED,INTERVENTIONAL,['NA']
2470,NCT00297648,Mean Change From Baseline in CDEIS (Crohn's Disease Endoscopic Index of Severity) Score at Week 10 Using Central Blinded Assessments,Change From Baseline in Crohn's Disease Activity Index (CDAI) Score at Week 54,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE3']
2471,NCT04866381,Objective Response Rate,Subject safety,,2021-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
2472,NCT02352337,Rate of patients alive and without radiological and/or clinical progression,Progression survival,,2014-12-23,COMPLETED,INTERVENTIONAL,['PHASE2']
2473,NCT02965209,Diagnostic yield of NMSE in patients with suspected small bowel diseases,Adverse events,,2015-11,COMPLETED,INTERVENTIONAL,['NA']
2474,NCT02600143,Genetic predisposition for immunotherapy-induced colitis,Analysis of the gut microbiome in stool samples,,2013-08,COMPLETED,OBSERVATIONAL,['NA']
2475,NCT01605305,TPP,OS,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2476,NCT05856305,Acute Toxicity,Tumor Volume reduction kinetics,,2023-07-05,RECRUITING,INTERVENTIONAL,['PHASE2']
2477,NCT04469556,Progression free survival(PFS) in mFFX and GA arms pancreatic ductal adenocarcinoma (PDAC) in a randomized phase II trial.,Cluster Tendency analysis using artificial neural networks and radiomic methods combined,,2020-10-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2478,NCT01269216,pathologic complete response rate,,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2479,NCT05605600,Development of LARS Severity tool,Commence initial psychometric evaluation of the New LARS score,,2022-10-03,COMPLETED,OBSERVATIONAL,['NA']
2480,NCT02665026,Postoperative complication,Disease-free survival,,2016-01-04,COMPLETED,INTERVENTIONAL,['NA']
2481,NCT05480306,Progression Free Survival (PFS),Incidence of ≥Grade 3 related treatment-related adverse events (TRAEs).,Exposure-response relationships for DKN-01 as data permit.,2022-08-30,RECRUITING,INTERVENTIONAL,['PHASE2']
2482,NCT04361162,Overall response rate (ORR),Overall survival (OS) in patients,,2020-05-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2483,NCT06210724,Colorectal Cancer,Microscopic colitis,Blood tests,2023-10-09,RECRUITING,OBSERVATIONAL,['NA']
2484,NCT04793958,Progression-free Survival (PFS),Quality of Life Assessment,,2021-03-15,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
2485,NCT05181306,Recurrence,Cost,,2010-10-01,COMPLETED,OBSERVATIONAL,['NA']
2486,NCT01214681,Faecal calprotectin concentration,Plasma short chain fatty acid concentration,,2010-05,UNKNOWN,INTERVENTIONAL,['NA']
2487,NCT05013697,Progression free survival (PFS， RECIST assessment),Incidence of Treatment-related adverse Events,,2021-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
2488,NCT02789891,3-year disease overall survival rate,EORTC QLQ-C30 and QLQ - STO22,,2016-06,UNKNOWN,INTERVENTIONAL,['NA']
2489,NCT01284504,"Blood Samples Taken Before Initiation of Study, Day of Surgery, Days 1 and 3 Post-op, and 30 Days Post-op. Analyzed for 50 Serum Cytokines, Cell-specific Gene Expression, and TCR Repertoire.","Surveys to Evaluate Patient Pain, Fatigue, and Quality of Recovery, Recorded From Day of Surgery to 30 Days Post-op.",,2011-01,TERMINATED,INTERVENTIONAL,['NA']
2490,NCT05091346,Phase 2 Part: Objective Response Rate (ORR),Phase 2 Part: Apparent Clearance for Lenvatinib When Co-administered With E7386 and Pembrolizumab,,2021-10-27,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2491,NCT05382364,Percentage of participants discontinuing from study therapy due to AE,Duration of Response (DOR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1),,2022-06-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
2492,NCT05440552,Detection rate,,,2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2493,NCT00353015,Participant Response Rate of Irinotecan and Cisplatin,,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2494,NCT04833959,Incidence of treatment emergent adverse events assessed by CTCAE v5,,,2021-03-26,SUSPENDED,INTERVENTIONAL,['PHASE1']
2495,NCT06207656,Efficacy of cetuximab in combination with encorafenib plus binimetinib as induction therapy for the treatment of BRAF-V600E mutated MSS aCRC to perform radical treatment of the primary and/or metastases,Incidence and severity of AEs CTCAE v5 criteria,To determine the presence/expression level/levels of serum and tumour tissue biomarkers associated with cell and tumour growth and/or involved in the mechanisms of action of EBC,2024-01-19,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2496,NCT02231723,Determination of the Recommended Phase 2 Dose by assessing dose-limiting toxicities (DLTs),Assess pharmacodynamic activity of BBI608 when administered in combination with standard chemotherapies,,2014-08,COMPLETED,INTERVENTIONAL,['PHASE1']
2497,NCT00408122,,,,2007-01,COMPLETED,OBSERVATIONAL,['NA']
2498,NCT01691664,Disease free survival,quality of life,Immunological assessment,2012-09,UNKNOWN,INTERVENTIONAL,['NA']
2499,NCT04186156,Proportion of patients alive and progression free at 4 months,To determine the pharmacodynamic response to KA2507,,2020-03-05,WITHDRAWN,INTERVENTIONAL,['PHASE2']
2500,NCT03963206,survival of the patient after start of treatment,Number of patients with each dose of Cabozantinib,,2019-09-09,COMPLETED,INTERVENTIONAL,['PHASE4']
2501,NCT03490461,A new lesion with radiographic features compatible with HCC was defined as recurrence of HCC.,,,2017-11-22,COMPLETED,OBSERVATIONAL,['NA']
2502,NCT06275997,Miss rate reduction,patient satisfaction,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2503,NCT05116085,Major pathological response (MPR) rate,Number of Participants with Treatment-emergent Adverse Events (TEAEs),,2022-01-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2504,NCT06091930,Part IV: Objective response based on the response evaluation criteria in solid tumors (RECIST v1.1),Part IV: Area under the concentration-time curve of BI 765049 over a uniform dosing interval τ (AUCτ) after multiple administrations,,2024-01-31,RECRUITING,INTERVENTIONAL,['PHASE1']
2505,NCT01608022,Overall Response Rate,,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2506,NCT04692454,The number of CD8+ T,,,2020-08-31,COMPLETED,INTERVENTIONAL,['NA']
2507,NCT05579353,expressional quantity,,,2023-01-01,RECRUITING,OBSERVATIONAL,['NA']
2508,NCT03131102,Acute Fatigue Score (AFS),Hospital length of stay,Quality of life,2017-08-29,COMPLETED,OBSERVATIONAL,['NA']
2509,NCT02243267,Response to Treatment,,,2014-09,COMPLETED,OBSERVATIONAL,['NA']
2510,NCT02399735,GVHD,Acute rejection,,2014-10,UNKNOWN,INTERVENTIONAL,['PHASE1']
2511,NCT03797443,Disease control rate (CR+PR+SD x18 weeks),Changes in patient's self-reported pain levels,,2019-01-01,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2512,NCT00134758,SPIGELMAN severity score of duodenal lesion after 2 years of follow-up,Compliance to the treatment,,2004-10,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2513,NCT00047333,Progression-free survival,Overall survival,,2002-08,TERMINATED,INTERVENTIONAL,['PHASE2']
2514,NCT06194734,Overall survival (OS),Quality of Life (QOL) scores,,2024-02-05,RECRUITING,INTERVENTIONAL,['PHASE3']
2515,NCT03928678,length of hospital stay in days,,,2019-05-01,COMPLETED,INTERVENTIONAL,['NA']
2516,NCT00465023,"To determine the maximum tolerated dose (MTD) of proton beam irradiation in patients with unresectable or locally recurrent hepatocellular cancer, cholangiocarcinoma, or hepatic metastases.","to evaluate tumor response, local control and survival in this patient population.",,2003-06,COMPLETED,INTERVENTIONAL,['NA']
2517,NCT03488953,Overall survival three years after 2nd-stage of hepatectomy,Morbidity of the donor,,2018-04-10,UNKNOWN,INTERVENTIONAL,['NA']
2518,NCT05026905,Best objective response rate (ORR),Incidence of Treatment-related Adverse Events [Safety and Tolerability],,2021-12-28,RECRUITING,INTERVENTIONAL,['PHASE2']
2519,NCT01388101,The performance of e- Ab sensor,,,2010-09,UNKNOWN,INTERVENTIONAL,['NA']
2520,NCT02592304,"DECT as imaging tool for diagnosing response to chemo radiotherapy of malignant lymph nodes, and tumors.",,,2014-09,UNKNOWN,INTERVENTIONAL,['NA']
2521,NCT03003065,Safety (will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0),"Quality of life (in every visit, European Organization for Research and Treatment of Cancer core questionnaire [EORTC QLQ-C30] will be filled and specific symptom enquiry is made; itchiness, fever and general well-being over a Likert 0-4 scale.",,2014-03-28,COMPLETED,INTERVENTIONAL,['PHASE2']
2522,NCT00845819,Incidence of oral mucositis of grade 2 or higher (NCI CTCAE 3.0),OMDQ (oral mucositis daily questionnaire) score during treatment,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE2']
2523,NCT00230399,"To determine the objective response rate to the combination of celecoxib, capecitabine, and irinotecan in patients with metastatic colorectal cancer.","To evaluate the time to progression of metastatic colorectal cancer after treatment with celecoxib, capecitabine, and irinotecan.",,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2524,NCT02620865,Median Overall Survival (OS),TTP,,2015-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2525,NCT06101277,Number of participants with controlled disease,Time to treatment failure,,2023-10-05,RECRUITING,INTERVENTIONAL,['NA']
2526,NCT01748773,Change from Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status Score,Overall Survival,,2013-01-29,COMPLETED,INTERVENTIONAL,['PHASE2']
2527,NCT04265417,Disease-free survival,Postoperative C-reactive protein,,2015-01-06,COMPLETED,OBSERVATIONAL,['NA']
2528,NCT03413254,Proportion of peritoneal metastases detected after a negative second look DLS,Quality of life assessed with the EQ-5D-5L questionnaire,,2018-03-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
2529,NCT02330913,Anastomosis related complication rate,,,2014-12,COMPLETED,INTERVENTIONAL,['NA']
2530,NCT05110573,Major complication rate,Oncological outcomes,,2000-01-01,COMPLETED,OBSERVATIONAL,['NA']
2531,NCT03548948,Change in colonic inflammation,Change in serum hepcidin,,2015-07-15,COMPLETED,INTERVENTIONAL,['NA']
2532,NCT06231017,Objective response rate (ORR),Adverse events (Safety）,,2024-01-19,RECRUITING,INTERVENTIONAL,['PHASE2']
2533,NCT04638010,Number of participants who complete needed cancer screening and prevention services,,,2011-02-16,COMPLETED,INTERVENTIONAL,['NA']
2534,NCT02169388,Frequency and severity of Adverse effects during Chemotherapy,The observed changes in nutritional status after chemotherapy,,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE1']
2535,NCT02659241,Change in level of protein expression in p53-related pathways,,,2016-02-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
2536,NCT01182922,Percentage of invitees attending screening colonoscopy in each invitation letter group,"Percentage of forms with consent for examination, sent back after invitation letter but before reminding letter. Differences in attendance between men and women depending on type of the invitation.",,2010-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
2537,NCT01822613,Phase II primary outcome measure: Progression free survival (PFS),Progression free survival (PFS) per RECIST 1.1 (Ph 1b ),,2013-07-26,COMPLETED,INTERVENTIONAL,['PHASE1']
2538,NCT05775146,Progression free survival (PFS),Toxicity Assessment,Exploratory endpoints/outcomes. To identify blood biomarkers that can correlate with disease events,2024-09-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2539,NCT02106650,Grade 2 Oral Mucositis Prevention,Objective Response Rate,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2540,NCT05095636,PFS,AEs,,2021-03-17,UNKNOWN,INTERVENTIONAL,['PHASE2']
2541,NCT01067053,Time to progression,Safety of treatment according to the number of adverse events reported,,2009-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
2542,NCT05280444,Objective Response Rate(ORR),Adverse Events(AEs),,2022-05-28,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2543,NCT05202314,Pathological complete remission,Overall Survival,,2021-12-12,RECRUITING,INTERVENTIONAL,['NA']
2544,NCT00327132,Hp eradication rate and complete histological rate,overall survival (OS)Relapse-free survival (RFS),,2006-07,COMPLETED,INTERVENTIONAL,['NA']
2545,NCT05325528,Objective Response Rate (ORR),progression-free survival,,2022-04-10,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2546,NCT01655693,Overall Survival (OS),Objective Response Rate (ORR),Number of Participants Experiencing Clinically Significant Changes in Left Ventricular Ejection Fraction (LVEF) and the Severity of the Event,2012-06,COMPLETED,INTERVENTIONAL,['PHASE3']
2547,NCT01896531,Progression-Free Survival (PFS) in All Randomized Participants and Participants With PTEN Loss Tumors at Primary Analysis,Serum Concentration of Ipatasertib,,2013-08-14,COMPLETED,INTERVENTIONAL,['PHASE2']
2548,NCT05130710,presence of peritoneal seeding,presence of peri-gastric lymph node involvement,,2020-02-25,COMPLETED,OBSERVATIONAL,['NA']
2549,NCT01688700,Pathology complete remission rate,Quality of life,,2012-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
2550,NCT00230646,Minutes of moderate-intensity physical activity (PA) at 3 months among 134 sedentary patients who have completed treatment for colorectal cancer (CRC).,"Examine the maintenance of outcomes (minutes of moderate intensity activity, physical functioning, vigor, fatigue and body esteem) at 6 and 12 months.",,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2551,NCT05193604,Overall response rate (ORR),Overall survival (OS),,2022-03-24,TERMINATED,INTERVENTIONAL,['PHASE1']
2552,NCT03412773,Safety Run-In Substudy[Japan only]: Percentage of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Findings,Percentage of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Findings,,2017-12-28,COMPLETED,INTERVENTIONAL,['PHASE3']
2553,NCT04230603,Inflammatory classification with HSI,Tissue perfusion,,2019-06-06,UNKNOWN,INTERVENTIONAL,['NA']
2554,NCT04573881,Primary Safety: Procedure-Related Major Complications,Secondary Safety: All Adverse Events,,2021-06-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2555,NCT01728480,"The percentage of patients with mucositis, measured using the World Health Organization (WHO) mucositis global severity score and the oral mucositis daily questionnaire (OMDQ)",,,2014-01,WITHDRAWN,INTERVENTIONAL,['PHASE1']
2556,NCT05970302,Objective Response Rate (ORR),Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],,2023-07-07,RECRUITING,INTERVENTIONAL,['PHASE2']
2557,NCT05227014,Transfusion rate,Postoperative hemoglobin values,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA']
2558,NCT02730533,The total bleeding rate according to grading of intraoperative bleeding during ESD procedure,The mean percentage of mucosal defect reduction at follow-up endoscopy on 28 days after ESD procedure.,,2016-03,COMPLETED,INTERVENTIONAL,['NA']
2559,NCT01898741,Safety,,,2013-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
2560,NCT00627042,Progression Free Survival (PFS) in Participants With Unresectable Hepatocellular Cancer Treated With the Monoclonal Antibody Ramucirumab,Number of Participants With Drug-Related Treatment-Emergent Adverse Events,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
2561,NCT05663788,Pooled sensitivity of endoscopic optical diagnosis for predicting deep submucosal invasion in routine colonoscopies,Pooled LR- of endoscopic optical diagnosis for predicting deep submucosal invasion in a 20-image test before and after the learning module in the intervention group,,2022-07-01,RECRUITING,INTERVENTIONAL,['NA']
2562,NCT04831632,diagnostic performance,qualitative iFOBT positivity rate,,2021-05-01,UNKNOWN,OBSERVATIONAL,['NA']
2563,NCT00225641,Overall and cancer-specific mortality,Quality of life. Cost-effectiveness of follow-up,,2006-03,UNKNOWN,INTERVENTIONAL,['NA']
2564,NCT00502502,Patient Symptom Assessment (Questionnaire),,,2002-11,COMPLETED,OBSERVATIONAL,['NA']
2565,NCT03315195,Postoperative complications,,,2017-11-25,UNKNOWN,INTERVENTIONAL,['NA']
2566,NCT03182179,Change in LARS score,Irritable Bowel Syndrome-Quality of Life,,2016-11-01,COMPLETED,INTERVENTIONAL,['NA']
2567,NCT02215447,Response rate,Rates of adverse events as defined by NCI- Common Terminology Criteria for Adverse Events (CTCAE) V4.0,,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
2568,NCT00136669,To determine the duration of acupuncture effects,,,2003-09,COMPLETED,INTERVENTIONAL,['PHASE3']
2569,NCT05088889,"Objective tumor response rate 2 (ORR2) after first progression, assessed by RECIST v1.1","Incidence of Treatment-Emergent Adverse Events, as assessed by CTCAE version 5.0",Assessment of disease biomarkers as a surrogates or predictors to response following administration of SBRT and immunotherapy: Exploratory,2022-01-25,RECRUITING,INTERVENTIONAL,['PHASE1']
2570,NCT02764801,Percentage of Patients Correctly Identified as Requiring Tumor Re-treatment One Month After Initial Chemoembolization,,,2016-04,COMPLETED,INTERVENTIONAL,['PHASE3']
2571,NCT04130971,Tumour response to treatment,Normal tissue response to treatment,,2019-02-01,RECRUITING,OBSERVATIONAL,['NA']
2572,NCT04592211,dose limiting toxicity,overall response rate,,2021-10-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2573,NCT00619541,"N° of non progressive disease (complete and partial responses, stable disease)","Toxicity of the combination,ORR,Duration of responses, TTP and OS.PK, PD,Baseline pERK concentration, phospho VEGF-R2 concentration, plasma proteomics and gene expression profiling on blood cells and tumor biopsy",,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2574,NCT04523389,Association between the number and size of exosomes and their content on cancer stage and progression,,,2020-07-01,UNKNOWN,OBSERVATIONAL,['NA']
2575,NCT00590434,"proportion of patients with complications including perforation, bleeding, MI or CVA within 24 hours of colonoscopy in >80 vs. <80 agr group",Five year disease free survival and five year mortality rates after the diagnosis of colon cancer in older (>80 yrs) vs. younger group (<80 yrs),,2006-08,COMPLETED,OBSERVATIONAL,['NA']
2576,NCT05515185,Maximum tolerable dose,,,2022-09-09,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
2577,NCT05004441,objective response rate (ORR),adverse events (AE),,2021-07-22,RECRUITING,INTERVENTIONAL,['PHASE2']
2578,NCT02831842,Overall Survival (OS) in Participants With mCRC and a Documented KRAS Mutation who Received Bevacizumab-Containing Treatment or Chemotherapy Alone in Routine Clinical Practice,OS in Participants With mCRC and a Documented KRAS Wild Type Status who Received Bevacizumab-Containing Treatment or Anti-EGFR Treatment in Routine Clinical Practice,,2016-06-09,COMPLETED,OBSERVATIONAL,['NA']
2579,NCT05274945,pathological assessment of response to treatment,adverse events of chemotherapy,,2020-01-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2580,NCT05307926,Disease-free survival,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],,2019-02-01,COMPLETED,OBSERVATIONAL,['NA']
2581,NCT01822444,Identification of biomarkers,Validation of identified biomarkers,,2012-11,COMPLETED,OBSERVATIONAL,['NA']
2582,NCT00152230,Relapse-free survival and overall survival,Adverse events,,1996-10,COMPLETED,INTERVENTIONAL,['PHASE3']
2583,NCT01822210,Change of tumor volume in the stomach.,performance status,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2584,NCT03801915,Number of Grade 3-5 Adverse Events Related and/or Not Related to Drug,Define Disease Free Survival (DFS) for Participants Treated With Preoperative MVT-5873,Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0),2019-11-13,COMPLETED,INTERVENTIONAL,['PHASE2']
2585,NCT00033462,Proportion of patients who are progression-free at 24 weeks,Overall response rate in EGFR positive patients,,2002-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2586,NCT02558504,complete histological eradication of the high grade glandular epithelial neoplasia,"Percentage of patients with severe adverse reaction and minor adverse reactions linked to the procedure used, described by anatomical site",,2013-01-07,COMPLETED,INTERVENTIONAL,['PHASE4']
2587,NCT01419769,Safety - Freedom From Major Complications: SAE's,Clinical Success,,2011-08,COMPLETED,INTERVENTIONAL,['NA']
2588,NCT05815082,5-year progression-free survival,Complications,,2023-02-20,RECRUITING,INTERVENTIONAL,['PHASE3']
2589,NCT01666444,Overall Survival,Frequency and Severity of Adverse Events (AEs),,2012-10-31,COMPLETED,INTERVENTIONAL,['PHASE2']
2590,NCT04272034,Number of treatment-emergent adverse events,Vz/F of INCB099318,,2021-03-26,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
2591,NCT01908478,Maximum-tolerated dose (MTD) of veliparib based on the incidence of dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I),Change in PAR [Poly(ADP-ribosyl)ation] levels in peripheral blood mononuclear cells,,2013-10-02,COMPLETED,INTERVENTIONAL,['PHASE1']
2592,NCT02809898,Pathological diagnosis of gallbladder polyps （Cholesterol / Adenoma / Others）,Tumor status （worse/ maintain/ better）,,2016-07,UNKNOWN,OBSERVATIONAL,['NA']
2593,NCT01130337,Percentage of Participants With Disease-free Survival (DFS) at Month 18,Percentage of Participants With Objective Response,,2010-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2594,NCT04568330,Scale,Scale,Scale,2014-03-21,COMPLETED,INTERVENTIONAL,['NA']
2595,NCT01719926,Number of dose limiting toxicities at each dosage cohort,Efficacy,,2012-09,COMPLETED,INTERVENTIONAL,['PHASE1']
2596,NCT03565029,Distant Relapse-Free Survival (DRFS),Patient reported outcomes,,2018-06-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2597,NCT03174574,"Genomic and risk factor differences among family members who share identical predisposing CDKN2A gene mutations, with different phenotypes; will discover patterns of tumorigenesis, tissue specificity, gene-gene, and gene-environment interactions.",,,2016-08-17,COMPLETED,OBSERVATIONAL,['NA']
2598,NCT02250209,3-year disease-free survival (DFS),Prognostic value of biomarkers,,2014-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
2599,NCT05849571,Children's International Mucositis Evaluation Scale (ChIMES),,,2023-03-01,COMPLETED,INTERVENTIONAL,['NA']
2600,NCT02510378,percentage of patients undergo R0 surgery during the follow-up,The rate of early toxicity of radiotherapy according to the NCI Common Toxicity Criteria for Adverse Effects (version 3.0),,2014-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
2601,NCT06228963,6-months CR rate,Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,Exploratory biomarkers,2024-03,RECRUITING,INTERVENTIONAL,['PHASE2']
2602,NCT02871245,Number of participants and classification with operation-related adverse events as assessed by CTCAE v4.03.,Immune cell number ratio in blood.,,2016-09-21,UNKNOWN,INTERVENTIONAL,['NA']
2603,NCT00003677,Number of Patients with Toxicity,,,1999-02-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2604,NCT00741676,2 year survival,efficacy and clinical out come,,2008-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
2605,NCT02889328,Disease control rate,Toxicity profile by the NCI-CTCAE v4.03,,2016-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2606,NCT02437916,AMG 228 half-life (t1/2),Changes in numbers of cytotoxic T lymphocytes (CTL),,2015-04-21,TERMINATED,INTERVENTIONAL,['PHASE1']
2607,NCT04692987,Number of participants with colorectal cancer screening completion,Barriers towards the colorectal cancer screening uptake,,2021-03,UNKNOWN,INTERVENTIONAL,['NA']
2608,NCT01266187,Disease free survival,Secondary objectives,,2011-07,TERMINATED,INTERVENTIONAL,['NA']
2609,NCT00310115,Number of Patients with Smoking Abstinence,Number of Cigarettes Smoked Daily,,2002-04,COMPLETED,OBSERVATIONAL,['NA']
2610,NCT04117100,Assess the number of patients with intraprocedural bleeding,,,2018-06-01,RECRUITING,OBSERVATIONAL,['NA']
2611,NCT04228614,prediction accuracy of recurrent rate,Mutation Consistency of tissue and blood sample,,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA']
2612,NCT02455648,Post-operative stenosis,,,2012-01,COMPLETED,INTERVENTIONAL,['NA']
2613,NCT02386397,Limiting toxicity,,,2014-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2614,NCT06034860,Proportion of participants with objective response,Evaluate the immunogenicity of MT-8421 in patients with selected advanced solid tumors.,,2023-11-01,RECRUITING,INTERVENTIONAL,['PHASE1']
2615,NCT01145404,Objective response rate (ORR),Biomarker analysis,,2010-06,TERMINATED,INTERVENTIONAL,['PHASE2']
2616,NCT01953419,ORR,,,2010-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2617,NCT01326065,Long term outcome,Quality of the surgical specimen,,2011-02,TERMINATED,OBSERVATIONAL,['NA']
2618,NCT00022139,Proportion of successes,Quality of life,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2619,NCT01650428,Pathological Complete Response (PCR),Tumour Cell Density,,2013-04,COMPLETED,INTERVENTIONAL,['PHASE2']
2620,NCT03476057,cfDNA,Tumor mutation burden,,2018-07-01,UNKNOWN,OBSERVATIONAL,['NA']
2621,NCT00856375,Kaplan-Meier Estimate of PFS by Central Radiological Review: ITT Population,PK Parameters of NKTR-102 or Irinotecan and Respective Metabolites,,2008-12,COMPLETED,INTERVENTIONAL,['PHASE2']
2622,NCT03181334,Increase in colorectal cancer screening rate of the 5 tested invitation approaches.,,,2017-09-05,COMPLETED,INTERVENTIONAL,['NA']
2623,NCT05278195,Overall Survival(OS),Accuracy,,2022-04-01,UNKNOWN,OBSERVATIONAL,['NA']
2624,NCT03470883,Complete long-term remission (> 12 months),Endoscopic description and anatomopathological results,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA']
2625,NCT03392103,The ratio of patients occured Grade 3 or higher adverse events,3-year overall survival probability,,2017-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
2626,NCT06038578,Progression free Survival (PFS),Change from Baseline in Patient Reported Quality of Life assessed by Questionnaire - EuroQOL Five Dimensions questionnaire 3L (EQ-5D-3L) scores,,2023-10-04,RECRUITING,INTERVENTIONAL,['PHASE2']
2627,NCT01838109,Body weight decrease rate 8weeks after discharge compared with preoperative body weight,serum albumin,ONS related gastrointestinal adverse event,2013-04,COMPLETED,INTERVENTIONAL,['NA']
2628,NCT06014944,cCR rate,,,2023-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2629,NCT05526846,Effect of the intervention on participant's Healthy Plant-Based Diet Index,Secondary health gains associated with adopting a plant-based diet,,2024-12,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2630,NCT00504322,Expression of CD40L and cytokines,,,2011-07,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2631,NCT00079066,Overall survival,Safety profile,,2003-12-30,COMPLETED,INTERVENTIONAL,['PHASE3']
2632,NCT00575523,Occurrence of dysrhythmias,Clinical complications,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE4']
2633,NCT02066272,The frequency of adverse events on induction of remission and maintenance treatment using anti-TNFs (including biosimilars) in a cohort of IBD patients,,,2014-01,UNKNOWN,OBSERVATIONAL,['NA']
2634,NCT01596283,Postoperative Complications,Postoperative Length of Stay,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE3']
2635,NCT00541125,Toxicities by NCI-CTC v. 2.0,Time to treatment failure,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2']
2636,NCT01789229,Establishment of blood/tissue bank consisting of oncological samples from cancer patients and benign and healthy controls.,,,2003-09,RECRUITING,OBSERVATIONAL,['NA']
2637,NCT05642338,HGD/EAC,The rate of progression to HGD/EAC after a WATS-positive-biopsy-negative diagnosis for HGD/EAC,,2022-11-01,RECRUITING,OBSERVATIONAL,['NA']
2638,NCT04178642,The survival rate without hepatic recurrence at 1 year,Overall survival,,2020-09-22,WITHDRAWN,INTERVENTIONAL,['PHASE2']
2639,NCT02937519,Number of Participants with Adverse Events as a Measure of Safety,Overall survival,,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
2640,NCT04722055,Kappa coefficient,,,2021-01-26,COMPLETED,OBSERVATIONAL,['NA']
2641,NCT04245683,patient preferences for operative vs. non-operative management of rectal cancer,Patient adherence to surveillance protocols,,2020-02-01,RECRUITING,OBSERVATIONAL,['NA']
2642,NCT05856500,Appendicular skeletal muscle mass index(kg/㎡),Survival rate(%),,2023-06-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2643,NCT00574353,"the feasibility of a non-invasive method of detecting hypoxia, using F-FMISO-PET imaging in colorectal cancer patients.","determine volume of hypoxic tumor ROIs as a proportion of the entire tumor volume by this non-invasive imaging technique. ROIs are defined as those voxels, within the tumor volume defined on FDG PET/CT, for which the 18F-F-FMISO radioactivity concent",,2007-12,WITHDRAWN,INTERVENTIONAL,['NA']
2644,NCT04149613,microRNA expression Level,Dietary pattern,,2018-05-25,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
2645,NCT00885885,Objective response rate,Evaluation of molecular predictive markers for response.,,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2646,NCT03172377,Cumulative incidence of persistent disease flares.,The decremental cost effectiveness ratio of this interval lengthening strategy,,2017-05-03,UNKNOWN,INTERVENTIONAL,['PHASE4']
2647,NCT01457976,"Survey respondents are presented with scenarios that seek to elicit views and attitudes on the concepts of personal responsibility, and the acceptability of financial incentives. The analysis will present these views and attitudes in aggregate form.",,,2011-09,WITHDRAWN,OBSERVATIONAL,['NA']
2648,NCT05088733,Survival rate,quality of life (QOL) questionnaire,,2020-07-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
2649,NCT04845490,overall survival,The positive rate of cancer cells of participants by exfoliative cytology examination,,2022-09-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2650,NCT04123574,To characterize the quantitative and qualitative effects of BXCL701 on relevant immune effector cytokines and various immunological effector cells that are consistent with its known mechanism of action.,Genomic analysis before and after treatment.,,2019-10-15,WITHDRAWN,INTERVENTIONAL,['EARLY_PHASE1']
2651,NCT05025371,Overall survival,,,2021-04-01,COMPLETED,OBSERVATIONAL,['NA']
2652,NCT04912258,liver relapse-free survival,response rate,,2021-08-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
2653,NCT05493332,Conversion therapy success rate,Patient reported outcome（PRO）,,2022-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2654,NCT00792350,"Efficacy: status of tumor, patients performance status",Reports of adverse events,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
2655,NCT02124148,Part E: Maximum Tolerated Dose of Prexasertib in Combination with LY3023414,"B2, E2, E3 Dose Expansion: Duration of Response",,2014-06-18,COMPLETED,INTERVENTIONAL,['PHASE1']
2656,NCT04104633,Feasibility of molecular karyotype performed from liquid biopsy: copies number variations (CNV),Identification of patient's tumor genomic profile with blood sample,,2018-06-14,UNKNOWN,INTERVENTIONAL,['NA']
2657,NCT01505166,Percent of Patients Who Survived After Treatment (Part 2),,Number of Alive Subjects (Part 1),2012-03,TERMINATED,INTERVENTIONAL,['PHASE2']
2658,NCT02383797,Number and severity of adverse events to vaccination,,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE4']
2659,NCT01324882,Intubation of Cecum,,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
2660,NCT01825603,"Recommended dose of ADH-1, defined as the highest dose tested which results in dose-limiting toxicities in no more than 1 of 6 evaluable patients based on the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",Survival,,2013-04-09,COMPLETED,INTERVENTIONAL,['PHASE1']
2661,NCT05178628,The number of VTE events during the trial,Change from baseline in QoL,,2022-02-10,RECRUITING,INTERVENTIONAL,['PHASE3']
2662,NCT03292991,"Safety as per CTCAE 4.03, incidence of AEs and baseline change in liver function paired t-test or Wilcoxon signed rank test.",Liver transplantation rate,,2015-06-09,UNKNOWN,OBSERVATIONAL,['NA']
2663,NCT01260194,Median Progression Free Survival (PFS),Number of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Gastric Cancer,,2011-06,TERMINATED,INTERVENTIONAL,['PHASE4']
2664,NCT02418988,overall survival,progression-free survival,,2014-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
2665,NCT00130689,Overall Response Rate,,,2005-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2666,NCT00019344,,,,1997-08,COMPLETED,INTERVENTIONAL,['PHASE1']
2667,NCT01482442,Median overall survival time,Health care costs,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE3']
2668,NCT05722275,The aera under the receiver operating characteristic curve (AUC) of intelligent analysis system,The accuray of intelligent analysis system in predicting peritoneal metastasis,Overall survival,2023-01-01,RECRUITING,OBSERVATIONAL,['NA']
2669,NCT05545046,Visual Analogue Scale (VAS),,,2019-09-01,COMPLETED,OBSERVATIONAL,['NA']
2670,NCT01348503,Number of Participants with Dose Limiting Toxicities as a Measure of Safety of the combination of lenalidomide and sorafenib.,,,2011-05,TERMINATED,INTERVENTIONAL,['PHASE1']
2671,NCT05505370,Intubation of terminal ileum and cecum,User feedback for operating characteristics of the device,,2022-04-21,COMPLETED,INTERVENTIONAL,['NA']
2672,NCT04763824,Percent change in evidence based cancer screening,,Participation rates in the Telementoring and Practice Facilitation Sessions,2020-11-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2673,NCT02217891,qualitive data,,,2014-08,COMPLETED,OBSERVATIONAL,['NA']
2674,NCT05948449,Pathological complete response rate (pCR),Safety and Tolerability,,2023-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2675,NCT03095209,Serum inflammation markers,Quality of life and pain,,2017-02-24,COMPLETED,OBSERVATIONAL,['NA']
2676,NCT02930278,3-year disease overall survival rate,Visual Analog Score for pain,,2016-09-01,UNKNOWN,OBSERVATIONAL,['NA']
2677,NCT00952497,The primary objective is to assess progression free survival (PFS). PFS will be measured from the date of first study drug administration to the date of first scan that first documents disease progression.,"Other efficacy variables are overall survival, overall response rate, safety and tolerability. Exploratory analyses may be performed to investigate the correlation of biomarker status with treatment effect and response.",,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2678,NCT03533920,Objective Response Rate by independent evaluator,,,2017-10-25,COMPLETED,INTERVENTIONAL,['NA']
2679,NCT01134276,Incidence of Infectious Complications After Biliary Drainage,Total Hospital Cost During Admission After Biliary Drainage,,2010-08,COMPLETED,INTERVENTIONAL,['NA']
2680,NCT00334984,,,,2007-01,WITHDRAWN,INTERVENTIONAL,['NA']
2681,NCT00333099,Frequency and grade of mucositis,Cost,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE4']
2682,NCT00004910,,,,2000-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2683,NCT01437618,Progression-Free Survival,,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
2684,NCT04361682,Predictive value of PIBs and drains amylase values for Pancreatic Fistula (PF),,,2005-01-01,COMPLETED,OBSERVATIONAL,['NA']
2685,NCT00504153,Progression-free Survival Rate,Change in Plasma Vascular Endothelial Growth Factor (VEGF) Levels Over 15 Days,,2007-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2686,NCT04965454,Lack of Objective Response,Disease Control,,2022-03-28,RECRUITING,INTERVENTIONAL,['PHASE2']
2687,NCT03528876,Progression free survival,Decline in quality of life,,2018-09-01,TERMINATED,INTERVENTIONAL,['PHASE2']
2688,NCT03277716,Overall survival (OS),Distant metastasis-free survival,,2017-12-01,UNKNOWN,INTERVENTIONAL,['NA']
2689,NCT04622423,Definition of the antigenic landscape and TCR repertoire of CRC and PDAC liver MTS,Biobanking of biospecimens collected from CRC and PDAC patients and from healthy donors,,2019-11-06,RECRUITING,OBSERVATIONAL,['NA']
2690,NCT02198274,Anti-tumour response,Mean residence time (MRT),,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2']
2691,NCT05969171,PFS,DCR,,2023-08,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2692,NCT01659619,degree of food stasis,,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE2']
2693,NCT00939666,Local recurrence,Percentage of patients that chooses the minimal invasive strategies over standard surgery,,2009-07-01,COMPLETED,INTERVENTIONAL,['NA']
2694,NCT06060899,Intraoperative blood loss,Length of hospital stay,,2023-01-01,RECRUITING,INTERVENTIONAL,['NA']
2695,NCT01269229,complete resection (R0) rate for rectal and liver lesions.,Toxicity profile,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2696,NCT01319890,Return to normal activity/work,Cancer free survival,,2011-07,UNKNOWN,OBSERVATIONAL,['NA']
2697,NCT02295930,10 months-progression free rate (10m-PFR),Overall toxicity rate,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2698,NCT00083226,Objective Response Rate Measured by Response Evaluation Criteria In Solid Tumors (RECIST),Progression Free Survival,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2699,NCT04943679,Incidence of adverse events,12-month survival rate,,2021-06-15,RECRUITING,OBSERVATIONAL,['NA']
2700,NCT00605722,Percentage of Participants With Progression-free Survival (PFS),Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),,2008-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2701,NCT03654950,Patient reported experiences in themes,Patient reported experiences divided into themes,,2018-06-01,COMPLETED,OBSERVATIONAL,['NA']
2702,NCT02441998,"ASGE PIVI Thresholds: >90% NPV in rectosigmoid, > 90% agreement in surveillance intervals","Ex vivo overall and individual performance assessed by accuracy, sensitivity, specificity, positive predictive value, negative predictive value",,2013-10,COMPLETED,OBSERVATIONAL,['NA']
2703,NCT00576563,"The metabolic tumour response by PET scan will be determined according to the EORTC criteria (appendix 1)61. The pathological tumour response will be determined according to Dworak and Wheeler.62,63","Clinical examination(weight, performance status including the CTCv3.0 scale for acute and late reactions)",,2007-03,COMPLETED,INTERVENTIONAL,['NA']
2704,NCT05978349,Follow-up and record DFS of patients,Follow-up and record OS of patients,,2022-02-14,RECRUITING,INTERVENTIONAL,['NA']
2705,NCT00541112,Complete remission at ≥ 6 months by abdomino-pelvic-thoracic scan and a pelvic MRI,Predictive biomarkers of response to cetuximab,,2007-10-29,TERMINATED,INTERVENTIONAL,['PHASE2']
2706,NCT03172559,Difference between the two treatment arms in the proportion of participants that get to be transplanted (do not drop-out from the waiting list due to tumor progression).,Difference between the two arms in disease-free survival,,2020-09,WITHDRAWN,INTERVENTIONAL,['NA']
2707,NCT06241352,Decrease rate of CA19-9,Disease control rate,,2024-01-20,RECRUITING,INTERVENTIONAL,['PHASE2']
2708,NCT01189903,,,,2011-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2709,NCT03336216,Progression free survival (PFS) by Blinded Independent Central Review (BICR),Number of clinically significant changes in lab assessment: Urine,,2017-12-19,COMPLETED,INTERVENTIONAL,['PHASE2']
2710,NCT00844688,RECIST criteria for response evaluation by CT sacan abdomen in Target lesion of HCC,Toxicity evaluation in accordance with CTCAE v3.0,,2008-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
2711,NCT04142203,Analgesic consumption postoperatively,Analgesic use after 23 h surgery,Adverse events after 23 h surgery,2017-05-16,COMPLETED,OBSERVATIONAL,['NA']
2712,NCT00573911,The specific aim of this proposal will be: To assess the association between acid reflux and subepithelial fibroblasts in Barrett's esophagus.,,,2007-08,COMPLETED,INTERVENTIONAL,['PHASE1']
2713,NCT04237740,3 years recurrence-free survival rate,5 years overall survival rate,,2020-05-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
2714,NCT05714553,Number of patients achieving a reduction in tumour volume (Objective response rate; ORR),,,2023-03-08,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2715,NCT00428597,Progression Free Survival (PFS),EORTC QLQ-C30 - Pain Subscale,,2007-06,TERMINATED,INTERVENTIONAL,['PHASE3']
2716,NCT02148731,Occurrence of Adverse Events,Performance of the brief screening tool,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
2717,NCT02371304,Recurrence free at 3 year follow-up,Treatment related morbidity,,2015-10,UNKNOWN,INTERVENTIONAL,['PHASE3']
2718,NCT04618692,Biliary complications after living donor liver transplantation,Time to biliary complications,,2020-12-02,COMPLETED,INTERVENTIONAL,['NA']
2719,NCT00083616,Duration of Response,Overall Survival,,2004-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2720,NCT03801083,Objective Response Rate (ORR),EuroQol 5 dimensions 5 levels (EQ-5D-5L),,2019-02-19,RECRUITING,INTERVENTIONAL,['PHASE2']
2721,NCT01188980,determine if early increase blood supply (EIBS)can predict presence of Dysplasia,determine if EIBS can predict presence of BE in patients undergoing upper endoscopy,,2010-06,COMPLETED,OBSERVATIONAL,['NA']
2722,NCT05616494,Overall response rate (ORR) by Independent Review Committee (IRC),Disease control rate (DCR) by IRC and investigator,Plasma concentration of docetaxel (free and total),2022-12-06,RECRUITING,INTERVENTIONAL,['PHASE2']
2723,NCT03650348,Incidence of DLTs and recommended Phase 2 dose (RP2D) of PRS-343 administered in combination with atezolizumab,Presence and/or concentration of anti-PRS-343 and anti-atezolizumab antibodies (anti-drug antibodies [ADAs]),,2018-08-21,UNKNOWN,INTERVENTIONAL,['PHASE1']
2724,NCT01924741,Morbidity and mortality (peripoerative),Liver Growth as assessed by imaging-based volumetry,Inclusion criteria by registry participants,2013-08,UNKNOWN,OBSERVATIONAL,['NA']
2725,NCT05545436,"Pathological complete response rate (pCR, Becker criteria, TRG 1A)","R0 resection rate and objective response rate (ORR, RECIST 1.1)",,2022-09-20,RECRUITING,INTERVENTIONAL,['PHASE2']
2726,NCT02942706,Progression Free Survival 1 (PFS1),Quality of life (QoL),,2021-11,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2727,NCT06202001,Objective Response Rate (ORR),"Safety and tolerability by incidence, severity and outcome of adverse events",,2022-10-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2728,NCT01946061,3-year disease-free survival,,,2015-05,TERMINATED,INTERVENTIONAL,['PHASE2']
2729,NCT01924533,Overall Survival,Duration of Response,,2013-09-03,COMPLETED,INTERVENTIONAL,['PHASE3']
2730,NCT04258956,"Participants Achieving 3-Month Progression-Free Survival (PFSR) Rate of participants who are progression-free at 3 months after the start of protocol therapy, using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria",,,2019-04-30,UNKNOWN,INTERVENTIONAL,['PHASE2']
2731,NCT02552017,Adenoma detection rate,Adenoma detection rate of individual endoscopist before and after trial commencement,,2014-11,UNKNOWN,INTERVENTIONAL,['NA']
2732,NCT05430841,Diagnostic accuracy,Number of lesions,,2022-06-01,RECRUITING,INTERVENTIONAL,['NA']
2733,NCT01148056,Bowel Quality of Life,Accuracy,,2010-03,TERMINATED,INTERVENTIONAL,['PHASE2']
2734,NCT06193733,Disease-free survival,Overall survival,,2024-02-19,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2735,NCT06200259,"Test the hypothesis that ""Spot Delete"" technique in proton therapy reduces late toxicity in low- and intermediate-risk prostate cancer patients",,,2024-01-08,RECRUITING,INTERVENTIONAL,['NA']
2736,NCT03478449,Migration of pN stage in gastric cancer patients,,,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA']
2737,NCT03779035,Disease free survival (DFS) rate,The rate of patients with hepatic or locoregional recurrence,,2018-12-15,UNKNOWN,INTERVENTIONAL,['PHASE3']
2738,NCT00531115,Confirmed objective response rate,Treatment safety,,2007-11,TERMINATED,INTERVENTIONAL,['PHASE2']
2739,NCT03646110,Overall survival rate,Postoperative pulmonary complication,,2018-08-17,UNKNOWN,INTERVENTIONAL,['NA']
2740,NCT05916040,Response to therapy,Anxiety and depression state via HADS,,2023-10-03,RECRUITING,OBSERVATIONAL,['NA']
2741,NCT02847429,Progression-free survival (PFS) will be measured from the date of randomization to the date of the first objective radiological disease progression according to centralized committee assessment using modified RECIST version 1.1 or death.,Overall survival (OS) will be measured from the date of randomization to the date of death from any cause. OS will be estimated using the Kaplan-Meier method.,,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE3']
2742,NCT06235164,pathological complete response,major pathological response,,2019-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2743,NCT04891016,pathological complete response rate,disease-free survival,,2021-06-25,RECRUITING,INTERVENTIONAL,['PHASE2']
2744,NCT03009227,Overall survival,Quality of life in patients after D2 and D3 lymph node dissection using questionnaire,,2017-02-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2745,NCT04447092,Objective Response Rate,Immune-related response,,2020-07-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2746,NCT05877599,Adverse events and serious adverse events,"Preliminary anti-tumor activity of NT-175 in subjects with unresectable, advanced, and/or metastatic solid tumors",,2023-07-27,RECRUITING,INTERVENTIONAL,['PHASE1']
2747,NCT06210360,2-year Overall Survival Rate,Incidence of adverse events,,2024-02-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2748,NCT02647177,Detection of early progression to Tumor,,,2015-05,RECRUITING,OBSERVATIONAL,['NA']
2749,NCT02790333,Pancreatic fibrosis accessed by histopathology and pancreatic stellate cell,Readmission rate,,2016-05,COMPLETED,INTERVENTIONAL,['NA']
2750,NCT01101906,Time to progression (TTP),"Safety assessed via physical examination, vital signs, clinical laboratory tests, electrocardiograms (ECGs) and recording adverse events",,2011-01-10,TERMINATED,INTERVENTIONAL,['PHASE2']
2751,NCT04969029,3-year relapse-free survival,,,2021-06-01,RECRUITING,INTERVENTIONAL,['PHASE2']
2752,NCT00469963,Tumor response,Survival,,2003-12,TERMINATED,INTERVENTIONAL,['NA']
2753,NCT00457691,Progression-free Survival (PFS),Change From Baseline in EuroQol (EQ) Visual Analog Scale (VAS) (EQ-VAS),,2007-06,COMPLETED,INTERVENTIONAL,['PHASE3']
2754,NCT04518800,Incidence of degree 3-4 neutropenia in each cycle of chemotherapy,The proportion of patients receiving antibiotics during the entire chemotherapy period.,,2020-08-18,UNKNOWN,INTERVENTIONAL,['NA']
2755,NCT02476045,Efficacy,overall survival,,2015-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
2756,NCT05016869,progression-free survival (PFS),Adverse events (AEs),,2022-04-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2757,NCT04716010,Percentage of Red Meat Containing Products,Intention to Reduce,Ease of Store Use,2021-10-18,COMPLETED,INTERVENTIONAL,['NA']
2758,NCT00003487,"Number of Participants With Objective Response, Stable Disease, Progressive Disease or Not Evaluable",,,1996-05-30,TERMINATED,INTERVENTIONAL,['PHASE2']
2759,NCT00444782,Response rate (Partial and Complete Response) according to modified RECIST.,Immune Response,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2']
2760,NCT05544812,AE,OS,,2022-05-01,RECRUITING,OBSERVATIONAL,['NA']
2761,NCT02497157,Response rate (RR) by response evaluation criteria in solid tumors (RECIST v1.1),Incidence of adverse events,Deepness of response (DoR),2015-05-21,COMPLETED,INTERVENTIONAL,['PHASE2']
2762,NCT00937456,To decrease postoperative major 30-days morbidity from 45% in the open arm to 25% in the laparoscopically-assisted arm.,economical interest of the surgical technique apprehended through a hospital point of view,,2009-10-07,COMPLETED,INTERVENTIONAL,['NA']
2763,NCT02460432,Cumulative stent patency during 6months after stent placement,Adverse events,,2015-05,COMPLETED,INTERVENTIONAL,['NA']
2764,NCT03880877,Progression-free survival,Duration of treatment,,2019-02-26,UNKNOWN,INTERVENTIONAL,['PHASE2']
2765,NCT02238769,SUVratio of FECH PET,Patients' lifespan,Data analysis,2014-07,UNKNOWN,OBSERVATIONAL,['NA']
2766,NCT03781960,Objective Response Rate,Overall Survival,,2019-07-31,TERMINATED,INTERVENTIONAL,['PHASE2']
2767,NCT01292356,Main criteria is the variation of skin pro-inflammatory cytokines in pre and post-therapeutic punch skin biopsies,,,2010-12-20,COMPLETED,INTERVENTIONAL,['PHASE2']
2768,NCT04890171,3-year disease-free survival in the ITT population,Cost-effectiveness measured with Incremental cost effective ratio (ICER),,2021-06-11,RECRUITING,INTERVENTIONAL,['NA']
2769,NCT03253822,CRC screening participation,Ethnicity,,2017-08-15,COMPLETED,INTERVENTIONAL,['NA']
2770,NCT01520324,Intraepithelial Neoplasia (IN) Detection Rate (False Negative Findings),Bowel Cleansing Quality Evaluated by Boston Bowel Preparation Scale After Intake of Bowel Cleansing Formulation and of a Total Dose of 200 mg of Methylene Blue MMX Tablets Administered During and at the End of the Intake of the Bowel Cleansing Formulation,,2012-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2771,NCT02980146,"The phenotype of TIL will be precised by immunohistochemisry and flow cytometry using various combinations of monoclonal antibodies to identify different subset of TIL and their frequency, especially those expressing NKG2A or NKG2C chain.",,,2016-06-01,COMPLETED,OBSERVATIONAL,['NA']
2772,NCT03260842,Pancreas Cancer,,,2017-09-01,RECRUITING,OBSERVATIONAL,['NA']
2773,NCT01270360,"To determine the performances (sensitivity, specificity and likelihood ratios) of a panel of blood and/or faecal molecular DNA markers",To create biological collections for screening purposes (asymptomatic subjects),,2010-09,COMPLETED,OBSERVATIONAL,['NA']
2774,NCT05648318,Bowel preparation,withdrawal time,,2022-01-08,COMPLETED,INTERVENTIONAL,['NA']
2775,NCT02243735,Normalization of Hb-level.,Difference in Morbidity score,,2014-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
2776,NCT01453894,Completion of a Fecal Occult Blood Test (FOBT),,,2012-03,COMPLETED,INTERVENTIONAL,['NA']
2777,NCT01099111,Colonic-Mucosa Associated Microbial Species Per Compiled Participants in 5 Different Arms,,,2010-07,COMPLETED,OBSERVATIONAL,['NA']
2778,NCT01555450,Reduction of social inequalities,Evaluation of psychological mechanisms,,2011-03,COMPLETED,INTERVENTIONAL,['NA']
2779,NCT03790475,Completion of the assigned screening strategy within 18 weeks of enrollment,Diagnostic yield for CRC and advanced adenomas,,2018-08-25,UNKNOWN,INTERVENTIONAL,['NA']
2780,NCT02606292,Sensitivity and specificity of PA endoscopic imaging for identification of Barrett's epithelium compared to esophageal biopsy,,,2014-08,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
2781,NCT04948697,Objective Response Rate (ORR) as assessed by the investigator,Immunogenic Response to BAT1706,,2021-08-20,COMPLETED,INTERVENTIONAL,['PHASE2']
2782,NCT01025570,To estimate the median disease-free survival rate of patients with completely resected pancreatic cancer treated with this combination,To estimate both disease-free and overall survival at one and two years of patients with completely resected pancreatic cancer treated with this combination,,2010-05,TERMINATED,INTERVENTIONAL,['PHASE1']
2783,NCT00776399,Primary Outcome Measures:3-year survival,"Secondary Outcome measures:safety, change in respiratory function, cancer-specific survival, and local tumor progression, Radiological studies",,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2784,NCT01258192,response to induction therapy,safety and tolerability,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2785,NCT05332496,Overall Survival(OS),Adverse event(AE) per Common Terminology Criteria for Adverse Events(CTCAE) 5.0,,2022-12-28,RECRUITING,OBSERVATIONAL,['NA']
2786,NCT06238167,1-year Disease-free survival rate,"Safety will be analyzed through the incidence of adverse events, serious adverse events",,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2787,NCT01232296,Overall Survival - Overall Survival,Pharmacokinetic (PK) Parameter of AUCtau Following a Single Dose of TKI258,,2011-07,COMPLETED,INTERVENTIONAL,['PHASE2']
2788,NCT05682768,Post operative Pancreatic Fistula,,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
2789,NCT00320515,Objective Best Tumor Response,Overall Survival,,2004-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2790,NCT01687673,Median Time to Progression (TTP),Number of Participants Whom Discontinued Treatment Due to Intolerable Toxicity,,2012-10-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2791,NCT04835324,overall survival,Incidence of Adverse Events (AEs),,2020-10-01,UNKNOWN,OBSERVATIONAL,['NA']
2792,NCT03218345,Severe adverse events,Survival,,2016-08,RECRUITING,INTERVENTIONAL,['NA']
2793,NCT00552149,Evaluation of treatment efficacy by assessing the crude progression-free survival (PFS) rate at 4 months,Evaluation of PFS and over,,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2794,NCT00004108,,,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2795,NCT04230499,Efficacy of eRapa in delaying polyp progression in patients with FAP as measured by change in polyp burden over time.,Clinical effect of eRapa on duodenal polyp number and burden.,Explore correlation between immune markers influenced by mTOR inhibition and clinical outcomes,2021-01-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2796,NCT00003485,,,,1996-04-10,TERMINATED,INTERVENTIONAL,['PHASE2']
2797,NCT01512589,Total Toxicity Burden (TTB),,,2012-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2798,NCT01489332,Pathological complete remission rate (pCR),Quality of life,,2011-10,UNKNOWN,INTERVENTIONAL,['PHASE2']
2799,NCT05795296,Objective response rate (ORR),Adverse Events,,2022-12-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2800,NCT00155883,tumor response rate,"clinical benefit response, toxicities, quality of life, time to disease progression, overall survival",,2004-06,TERMINATED,INTERVENTIONAL,['PHASE2']
2801,NCT01155258,To assess the response rate based on the Response Evaluation Criteria in Solid Tumors (RECIST),Progression-free and overall survival,,2010-06,COMPLETED,INTERVENTIONAL,['PHASE1']
2802,NCT00392366,Accuracy of predicted lesion geometry to histologically measured dimensions,,,2006-07,COMPLETED,INTERVENTIONAL,['NA']
2803,NCT00709826,Progression Free Survival,Overall Survival,,2008-08,COMPLETED,INTERVENTIONAL,['PHASE2']
2804,NCT04592861,Overall survival duration,"Quality-of-life, measured using the EORTC (European Organisation for Research and Treatment of Cancer) QLQ-C30 questionnaire",,2020-11-01,TERMINATED,INTERVENTIONAL,['PHASE3']
2805,NCT00335543,Median survival,"Quality of life before, during, and after therapy",,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2806,NCT01533740,Impact of Tregs frequency on overall survival,Impact of Tregs frequency radiologic response rate,,2012-03,COMPLETED,OBSERVATIONAL,['NA']
2807,NCT03836352,Safety as measured by the rate of adverse events,Overall survival,Changes in immune cell infiltration,2018-12-21,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2808,NCT00035035,,,,na,COMPLETED,INTERVENTIONAL,['PHASE3']
2809,NCT00003610,severity of mouth pain,,,1998-10,COMPLETED,INTERVENTIONAL,['PHASE3']
2810,NCT04929223,Objective Response Rate,Plasma Concentrations of Divarasib,,2021-10-22,RECRUITING,INTERVENTIONAL,['PHASE1']
2811,NCT00075712,Quality of life by Quality of Life Questionnaire Core 30 Items (QLQ-C30) and QLQ-ovarian cancer (QLQ-OV28),,,2003-09,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2812,NCT03072095,FIT completion within 3 months,Response to text-based CRC screening outreach,,2017-04-17,COMPLETED,INTERVENTIONAL,['NA']
2813,NCT05228431,Rate of pCR,OS,,2022-12-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2814,NCT04188002,Metabolic Equivalent Task Hours (METs) for Physical Activity,Number of Times Visiting the Site,,2017-03-25,COMPLETED,INTERVENTIONAL,['NA']
2815,NCT04495088,disease-free survival,Patient reported outcome: Functional outcome according to Wexner score,,2020-09-30,RECRUITING,INTERVENTIONAL,['PHASE3']
2816,NCT00654160,Maximum tolerated dose of genotype-based dosing of FOLFIRI with or without monoclonal antibody therapy,Response rate of genotype-based dosing in the subset of patients that has colorectal cancer,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1']
2817,NCT05382741,Disease Free Survival,Incidence of adverse events,,2022-03-02,RECRUITING,INTERVENTIONAL,['PHASE2']
2818,NCT05601505,"Disease-related treatment failure, DrTF","overall survival, 2yOS",,2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE2']
2819,NCT05714111,Local progression free survival,Overall Survival,,2022-03-04,RECRUITING,OBSERVATIONAL,['NA']
2820,NCT02288728,postoperative mortality and morbidity,reflux esophagitis,,2014-12,TERMINATED,INTERVENTIONAL,['NA']
2821,NCT04232735,SOURCE observational scale,Health care providers' (numerical) precision of treatment outcome information measured with SOURCE observational scale simulated patient consultations (effect intervention),SOURCE evaluation questionnaire (tailor made evaluation questionnaire),2020-10-13,RECRUITING,INTERVENTIONAL,['NA']
2822,NCT02186574,Rate of reverse seroconversion,All-cause mortality,,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
2823,NCT03818165,Assess preliminary efficacy by overall survival,Assess preliminary efficacy by in-liver progression free survival (PFS),Assess if circulating tumor cells (CTC) correlate with response,2019-07-29,TERMINATED,INTERVENTIONAL,['PHASE1']
2824,NCT01139242,"Higher incidence of CRC screening, if needed, among experimental participants.",,,2008-02,COMPLETED,INTERVENTIONAL,['NA']
2825,NCT02401802,Inadequate bowel preparation.,"Acceptability of the preparation (interference with work, leisure activities or sleep",,2015-01,COMPLETED,INTERVENTIONAL,['NA']
2826,NCT04293419,Pathological complete response (pCR) rate,Calculation of the neoadjuvant rectal (NAR) score,,2019-12-18,RECRUITING,INTERVENTIONAL,['PHASE2']
2827,NCT00111904,Safety,,,2005-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2828,NCT02948309,Overall survival (OS),Incidence of treatment-emergent adverse events (AE),,2016-06,COMPLETED,INTERVENTIONAL,['PHASE3']
2829,NCT01239082,The primary outcome is colorectal cancer mortality.,FIT Positive - If Colonoscopy is Warranted,,2012-04-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2830,NCT04836741,Disease free survival,,,2015-07-01,COMPLETED,INTERVENTIONAL,['NA']
2831,NCT04667351,overall survival,Adverse Events,,2019-03-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
2832,NCT02864381,Objective Response Rate (ORR),Percentage of Participants Who Experienced Treatment-emergent Laboratory Abnormalities,,2016-09-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2833,NCT00486356,Toxicities of combined chemotherapy regimen,Antitumor activity,,2004-10-01,COMPLETED,INTERVENTIONAL,['PHASE1']
2834,NCT03122548,Objective Response Rate (ORR),Overall Survival (OS),,2017-08-14,TERMINATED,INTERVENTIONAL,['PHASE2']
2835,NCT04652271,Mortality,Morbidity,,2021-09,UNKNOWN,OBSERVATIONAL,['NA']
2836,NCT00509561,Overall survival,Health economics,,2008-02,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2837,NCT04287335,Sensitivity and specificity of the ColoClear screening test with comparison to colonoscopy,"Sensitivity of the ColoClear screening test with comparison to FIT, with respect to advanced adenoma (AA) and CRC",,2018-09-18,COMPLETED,OBSERVATIONAL,['NA']
2838,NCT03990974,30-day postoperative infection rate,Distant infection rate,,2020-09,SUSPENDED,INTERVENTIONAL,['PHASE3']
2839,NCT05022511,Participation,Rate of compliance to follow-up with colonoscopy after a positive FIT,Survey evaluation,2021-09-01,COMPLETED,INTERVENTIONAL,['NA']
2840,NCT01768988,Pain intensity (Visual Analogue Scale; VAS Score),Neuropathic Pain,,2012-08,TERMINATED,INTERVENTIONAL,['PHASE4']
2841,NCT00906997,Colorectal cancer-related mortality,Advanced colorectal neoplasm detection rate,,2008-11,COMPLETED,INTERVENTIONAL,['NA']
2842,NCT05215535,Cost effectiveness,Survival,,2022-04-12,RECRUITING,INTERVENTIONAL,['NA']
2843,NCT02304978,TNM primary colorectal tumor stage,Interaction plate / tumor cell,,2009-06-22,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
2844,NCT04404647,90-day complication rate and severity,Longitudinal changes in nutritional status assessment,,2020-06-01,WITHDRAWN,INTERVENTIONAL,['NA']
2845,NCT04988191,"Pathological complete response rate based on blinded, independent, central review",Incidence of Treatment-Related Adverse Events,,2020-12-24,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2846,NCT06266091,"Puncture-free survival, PuFS",Peak serum concentration (Cmax),,2021-11-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2847,NCT06251726,Lymph node invasion rate,Molecular profile of the tumor,,2024-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2848,NCT02602067,Dose Limiting Toxicity evaluated using NCI Common Toxicity Criteria (CTCAE 4.03),Adverse Events,Tumor response,2015-11,TERMINATED,INTERVENTIONAL,['PHASE1']
2849,NCT03552744,"Number of PCPs who have at least one patient ever tested with FOBT, or who prescribe at least one FOBT to eligible patients (patients not already tested within recommended intervals, with no contra-indication for screening).",Change in PCPs' future intentions to prescribe colonoscopy vs. FOBT over the next 6 months,,2018-04-26,COMPLETED,INTERVENTIONAL,['NA']
2850,NCT01700062,biochemistry data; Various inflammation-related cytokines ;,clinical outcome(hospital stay..),,2007-04,COMPLETED,INTERVENTIONAL,['PHASE4']
2851,NCT02752698,complication,change of blood and biochemiacl,,2015-01-01,UNKNOWN,INTERVENTIONAL,['NA']
2852,NCT00209677,Determine the clinical response rate with Recommended dose in Phase II setting.,Determine the MST(Median Survival Time) and DFS(Disease Free Survival) in Phase II setting.,,2004-12,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2853,NCT00003543,,,,1998-06,COMPLETED,INTERVENTIONAL,['PHASE1']
2854,NCT00561275,Toxicity of multiple peptide vaccinations,"Immune responses including LY6K, VEGFR1 and VEGFR2 specific T cells",,2007-10,COMPLETED,INTERVENTIONAL,['PHASE1']
2855,NCT01584544,Number of Participants Experienced Dose Limited Toxicity,,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE1']
2856,NCT01053013,Overall Survival - Based on Most Recent Scan,Overall Survival - Based on Stage IV Disease Diagnosis,Pain Assessment of Pancreatic Cancer Participants,2010-04-15,COMPLETED,INTERVENTIONAL,['PHASE2']
2857,NCT05203978,Complete colonoscopy defined by caecum intubation (binary criterion : yes or no),Polyp removal (binary criterion : yes or no),,2022-03,UNKNOWN,OBSERVATIONAL,['NA']
2858,NCT01386242,Overall survival (OS),Disease Control Rate,,2011-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2859,NCT01416662,capability of CDA to predict the occurrence of early severe hematological toxicity upon gemcitabine,Overall Survival,,2011-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2860,NCT04851106,The negative predictive value (NPV) determined from shear wave elastography,,,2021-09-21,RECRUITING,OBSERVATIONAL,['NA']
2861,NCT06310564,Progression-free survival (PFS).,questionnaire QLQ-C30,,2024-04,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2862,NCT05496491,Disease Free Survival,Treatment Compliance,,2022-08-30,RECRUITING,INTERVENTIONAL,['NA']
2863,NCT05223673,"Overall Survival (OS) (In Double Negative, KRAS/NRAS and BRAF Wild Type Patients) (Phase III Part)",Adverse Events (Phase III Part),,2022-04-21,TERMINATED,INTERVENTIONAL,['PHASE3']
2864,NCT05439993,Progression-free survival rate (PFSR) at 4 months,,,2022-03-01,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2865,NCT03550001,lymph node yield,Local recurrence rate,,2018-06-01,UNKNOWN,INTERVENTIONAL,['NA']
2866,NCT04967183,Adverse effects,Preferences of the subjects,,2022-06-01,RECRUITING,INTERVENTIONAL,['NA']
2867,NCT04216901,Accuracy of Vision location,Consistent of vision positioning between diagnostic system and endoscopists,,2019-12-24,UNKNOWN,OBSERVATIONAL,['NA']
2868,NCT00644618,Survival,"response rate, clinical benefit response, and safety",,2003-01,COMPLETED,INTERVENTIONAL,['PHASE3']
2869,NCT03524287,overall postoperative morbidity rates,Lymph node noncompliance rate,,2018-03-01,COMPLETED,INTERVENTIONAL,['NA']
2870,NCT02563548,"Dose Expansion Phase: Objective Response Rate (ORR): Percentage of Participants With Objective Response, as Assessed by Investigator Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1",Dose-Expansion Phase: Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG),,2015-10-22,COMPLETED,INTERVENTIONAL,['PHASE1']
2871,NCT00004042,,,,1998-11,COMPLETED,INTERVENTIONAL,['PHASE1']
2872,NCT03384511,Tumor response defined by RECIST criteria,Treatment-Related Adverse Events as Assessed by CTCAE,,2016-09-30,COMPLETED,INTERVENTIONAL,['PHASE4']
2873,NCT05997147,Recurrence-free survival,Overall survival,,2023-05-01,RECRUITING,OBSERVATIONAL,['NA']
2874,NCT06070376,Reinterventions,Patency time of the prostheses.,,2023-06-26,RECRUITING,INTERVENTIONAL,['NA']
2875,NCT05648487,R0 resection,Relapse-Free Survival,,2023-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
2876,NCT01471756,Efficacy of Two Devices used in EMR,Compare the Use of Two Injectates,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE4']
2877,NCT06301464,The level of serum pepsinogens,,,2003-03-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2878,NCT04154124,"Number of patient that shown the different between diagnostic value of single PET/MR scan in RC staging and compare it to that of MRI alone, PET/CT alone, and combined MRI and PET/CT",,,2019-11-23,UNKNOWN,INTERVENTIONAL,['NA']
2879,NCT00041275,Survival measured weekly,Quality of life as measured by EORTC quality of life instrument monthly,,2002-05,COMPLETED,INTERVENTIONAL,['PHASE3']
2880,NCT02864485,disease-free survival,disease-free survival,,2016-08-03,RECRUITING,INTERVENTIONAL,['NA']
2881,NCT04535024,Objective Response Rate,Acute Toxicity,,2021-03-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
2882,NCT04856046,Multi-target hepatocellular carcinoma panel (MHP) score,,,2021-11-06,RECRUITING,OBSERVATIONAL,['NA']
2883,NCT03029988,Visualization of Lesions by FDG PET/CT Imaging and by Tc 99m Tilmanocept SPECT/CT Imaging.,,,2017-07-26,TERMINATED,INTERVENTIONAL,['PHASE1']
2884,NCT05299840,progression-free survival,Quality of life of patients,,2023-06-07,RECRUITING,INTERVENTIONAL,['NA']
2885,NCT03563586,Surgical Site Infections,Time to beginning of adjuvant treatment for colorectal cancer,,2018-04-01,UNKNOWN,INTERVENTIONAL,['NA']
2886,NCT03087864,feasibility defined as percentage completion of treatment with atezolizumab.,Overall survival,"Potential biomarker development based on assessment of tumour biopsies, blood- and faecal samples and the proposed mechanism of action of study drugs.",2017-06-28,COMPLETED,INTERVENTIONAL,['PHASE2']
2887,NCT02416609,Progression-free survival,Overall survival,,2014-01,RECRUITING,INTERVENTIONAL,['NA']
2888,NCT02880020,Overall response rate defined as the number of subjects with a best objective response of confirmed CR or PR divided by the number of subjects,Response rate by Choi criteria,,2016-12-14,COMPLETED,INTERVENTIONAL,['PHASE2']
2889,NCT05646043,Individual patient compliance,Laboratory examinations - coagulation factors (fibrinogen),,2022-12-01,RECRUITING,INTERVENTIONAL,['NA']
2890,NCT03631407,Number of Participants Who Discontinued Study Treatment Due to an AE,Trough Plasma Concentration (Ctrough) of Vicriviroc,,2018-09-24,COMPLETED,INTERVENTIONAL,['PHASE2']
2891,NCT02608203,level of changes (%) between care management before DOTANOC PET and care management after DOTANOC PET,number of patients for whom PET allowed the detection of lesions not described by standard imaging,,2016-05-26,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2892,NCT06054906,Percentage of participants with ≤10% tumor cell survival in resection specimens,Number of participants with treatment-related adverse events as assessed by NCI-CTC,Distribution of immune cells in tumor tissue,2023-09-25,RECRUITING,INTERVENTIONAL,['PHASE2']
2893,NCT02075086,Progression Free Survival,Feasibility,,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
2894,NCT02406170,Toxicity graded according to NCI Common Terminology Criteria for Adverse Events Version 4.0,Overall survival,,2015-04,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2895,NCT05006131,Proportion of screening patients found to have high-risk pancreatic lesions amenable to treatment,Proportion of screening patients who experience complications/adverse events of screen-related procedures,,2020-07-10,RECRUITING,OBSERVATIONAL,['NA']
2896,NCT04907864,Median change (kg) in handgrip strength,"Rate of toxicity with clinical significance, and possible relationship to either study intervention",,2020-01-31,UNKNOWN,INTERVENTIONAL,['PHASE2']
2897,NCT00268398,disease-free survival,Pharmacogenetics,,2002-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2898,NCT02027363,progression-free survival (PFS),Safety,,2010-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
2899,NCT04657848,Rate of reflux esophagitis after operation,Postoperative nutrition status,,2020-06-01,UNKNOWN,INTERVENTIONAL,['NA']
2900,NCT06013098,the occurrence of atelectasis,oxygenation index,,2023-09-06,RECRUITING,INTERVENTIONAL,['PHASE4']
2901,NCT06247293,Intra-abdominal recurrence-free survival (RFS),survival rate,,2024-02-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2902,NCT03278626,Phase 2: Number of Subjects Who Achieved cCR (Clinical Complete Response) or pCR (Pathological Complete Response),,,2017-06-27,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2903,NCT05606549,Fear of Progression Questionnaire-Short form (FoP-Q-SF) for Partners,Dyadic Coping Inventory(DCI),,2022-10-19,RECRUITING,INTERVENTIONAL,['NA']
2904,NCT05789797,"Difference of average ALP values in both of the groups, between the two timepoints: Visit 3 vs. baseline at Visit 1 (before starting therapy with the study medicines).","Proportion of patients with detected toxic damage to at least one system or organ (by selected parameters), according to the criteria of common toxicity grade III of the CTCAE scale, from the baseline (Visit 1) to Visit 4, measured in both groups.",,2022-05-12,RECRUITING,OBSERVATIONAL,['NA']
2905,NCT00509964,response rate,safety,,2007-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
2906,NCT00952029,Disease-control duration,Geriatric evaluation,,2010-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2907,NCT04513808,Recurrence-free survival,QoR-15,,2020-08-15,RECRUITING,INTERVENTIONAL,['PHASE3']
2908,NCT06190847,pCR,the surgical conversion rate,,2023-07-01,RECRUITING,OBSERVATIONAL,['NA']
2909,NCT00939848,Progression free survival,"• Response Rate (RECIST) • Toxicity • Survival (as part of the follow-on phase III study) • Biomarker evaluation (inc. circulating VEGF, sVEGFR-2, bFGF, LDH and CA 19-9) • Quality of Life",,2011-04,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2910,NCT04071964,Number of participants with an anastomotic leak,Number of participants with cancer reoccurence,,2019-07-09,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
2911,NCT00026403,overall survival,quality of life,,2001-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2912,NCT00317772,Maximum Tolerated Dose (MTD) of Topotecan,Response Rate,,2004-09-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2913,NCT00825474,overall survival,,,2008-08,COMPLETED,INTERVENTIONAL,['NA']
2914,NCT05308446,Progression-free survival (PFS),Incidence of adverse events,,2022-07-19,RECRUITING,INTERVENTIONAL,['PHASE2']
2915,NCT04276090,Percent Completion of 1st Cycle of Hepatic Artery Chemotherapy,Percent of Patients Who Remain on Hepatic Artery Infusion Pump Chemotherapy at 6 Months.,,2020-05-01,TERMINATED,INTERVENTIONAL,['NA']
2916,NCT03422432,Time to adjuvant systemic chemotherapy,,,2017-09-28,UNKNOWN,INTERVENTIONAL,['NA']
2917,NCT04920214,Specificity,,,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA']
2918,NCT03291106,Distribution of Lynch syndromes in endometrial cancer,Reliability of clinical criteria for screening Lynch syndromes,,2017-09-01,UNKNOWN,OBSERVATIONAL,['NA']
2919,NCT02551237,IADL (Instrumental Activities of Daily Living) Score,EORTC QLQ-C30 + EDL14,,2016-01-07,COMPLETED,INTERVENTIONAL,['PHASE3']
2920,NCT02374411,Collect questionnaire data from 150 HIPEC surgeons,HIPEC surgeon attitudes toward patient nutritional support self-assessed by questionnaire,,2014-09,COMPLETED,OBSERVATIONAL,['NA']
2921,NCT02510469,Disease free survival,,,2015-07,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2922,NCT05482516,Rate of ctDNA Progression of Disease (POD) or Clinical/radiographic Relapse,Reasons for failure of enrollment,,2023-03-29,RECRUITING,INTERVENTIONAL,['PHASE3']
2923,NCT05482477,Clock Drawing Task(CDT),The time of get out of bed for the first time after operation,,2024-01-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2924,NCT02688699,effectiveness of EndoClotTM in preventing post-procedural bleeding,,,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE4']
2925,NCT05303298,Objective gastro-oesophageal reflux (GOR),Survival,,2022-10-01,RECRUITING,INTERVENTIONAL,['NA']
2926,NCT05908747,Surgical complete resection rate (R0),Adverse events (AEs),,2023-05-31,RECRUITING,INTERVENTIONAL,['PHASE2']
2927,NCT03890198,Systemic Cytokine Concentrations,Overall Survival (OS) after administration,,2019-04-22,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
2928,NCT03857737,5-year DSS,Complication,,2019-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
2929,NCT05514561,The diagnostic performance of fecal calprotectin in diagnosis of significant ileocolonic lesions,The diagnostic performance of fecal immunochemical test in diagnosis of significant ileocolonic lesions,,2020-03-22,COMPLETED,OBSERVATIONAL,['NA']
2930,NCT05301465,PFS,,,2021-11-01,UNKNOWN,OBSERVATIONAL,['NA']
2931,NCT00247338,Infectious complications,Post-operative nutritional cost & total treatment cost,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE4']
2932,NCT04666727,Somatic mutation burden,,,2020-09-29,RECRUITING,OBSERVATIONAL,['NA']
2933,NCT03829748,Increase in diagnostic yield of pancreatic solid lesions,Number of passes to reach diagnosis,,2019-01-16,COMPLETED,INTERVENTIONAL,['NA']
2934,NCT02591784,The rate of AE(adverse event) or toxicity ( Both acute and chronic toxicity will be evaluated.),Overall survival (OS),,2008-11,COMPLETED,INTERVENTIONAL,['PHASE2']
2935,NCT05722327,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)",,,2023-12-06,RECRUITING,INTERVENTIONAL,['PHASE1']
2936,NCT01764087,Tumor Overall Response Rates (ORRs) in Phase II Portion,Pharmacokinetic (PK) Evaluation in Phase II Portion,Exploratory Biomarker Evaluation in Phase II Portion,2012-12,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2937,NCT03478943,Disease-free surviva,Disease Control Rate,,2016-01-30,UNKNOWN,OBSERVATIONAL,['NA']
2938,NCT05959564,Intentions toward HPV vaccination,Ratings of the Chatbot,,2023-07-26,COMPLETED,INTERVENTIONAL,['NA']
2939,NCT05105828,Shear wave elastography score,,,2020-07-01,COMPLETED,OBSERVATIONAL,['NA']
2940,NCT01127711,"Fractures, hip fractures",,,1997-09,COMPLETED,OBSERVATIONAL,['NA']
2941,NCT03480971,Mucositis,Mucositis,,2019-05-13,UNKNOWN,INTERVENTIONAL,['PHASE2']
2942,NCT04903340,Average dose value (Gy) of tumor liver and healthy liver obtained according to reconstruction configuration.,,,2021-04-12,COMPLETED,OBSERVATIONAL,['NA']
2943,NCT02624271,Sensitivity of GastroPanel blood test,,,2016-08-04,COMPLETED,INTERVENTIONAL,['NA']
2944,NCT01504126,Proportion of patients who successfully complete 6 cycles of chemotherapy with propranolol hydrochloride,Changes in mood state as measured by Center for Epidemiologic Studies Depression Scale (CES-D,"Changes in immune response, measured by serum levels of VEGF",2012-03-09,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
2945,NCT05994859,Success rate of conversion to resection,Adverse Events (AEs),,2023-08-10,RECRUITING,INTERVENTIONAL,['NA']
2946,NCT03676517,pathologic complete response (pCR) rate,Cost effectiveness,,2019-03,UNKNOWN,INTERVENTIONAL,['NA']
2947,NCT00557102,Tumor response rate,Tolerability,,2007-09,COMPLETED,INTERVENTIONAL,['PHASE2']
2948,NCT02584556,recurrence free survival,Time of tumor distant metastasis,,2015-10,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
2949,NCT02901301,The overall response rate using RECIST 1.1,Time to response,,2017-02-06,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2950,NCT00932724,Tumor assessment by using CT scans and/or MRIs,"Assessment of survival by ""physical exam""",,2009-07,TERMINATED,INTERVENTIONAL,['PHASE2']
2951,NCT03443661,pCR,Safety,,2016-02-06,COMPLETED,INTERVENTIONAL,['PHASE2']
2952,NCT00447746,5 year overall survival,: Postoperative morbidity and mortality rates,,2007-03,UNKNOWN,INTERVENTIONAL,['NA']
2953,NCT00422864,Tolerability rate,Distant response rate,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2954,NCT05849480,Phase II: Overall response rate (ORR),5-year overall survival,,2024-04-23,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2955,NCT03513198,Change of Wash-in Perfusion Index (WiPI) from baseline to 2 months after the first course of treatment,Tumor response to treatment,,2018-05-01,UNKNOWN,OBSERVATIONAL,['NA']
2956,NCT00906373,Progression Free Survival (PFS),The Number of Participants With Serum Anti-Cixutumumab Antibody Assessment (Immunogenicity),,2009-05,COMPLETED,INTERVENTIONAL,['PHASE2']
2957,NCT05779553,Tumor endothelial marker 1 in colorectal cancer,,,2023-05-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
2958,NCT04069975,Detection rate of precancerous lesions and cancer of upper digestive system improvement,,,2019-06-02,UNKNOWN,OBSERVATIONAL,['NA']
2959,NCT03979547,Acceptability-scientifically adequate,visceral adipose tissue (VAT),,2019-01-03,TERMINATED,INTERVENTIONAL,['NA']
2960,NCT03473925,Number of Participants Who Discontinue Study Treatment Due to an AE,Navarixin Trough Plasma Concentration (Ctrough),,2018-04-10,COMPLETED,INTERVENTIONAL,['PHASE2']
2961,NCT04859400,QoL,Success of recruitment rate in comparison to former studies,,2021-06-07,RECRUITING,INTERVENTIONAL,['NA']
2962,NCT05880667,To assess the ability of adaptive SBRT to deliver increased doses of radiation safely to patients with challenging anatomical locations of metastatic disease without causing unacceptable toxicity.,,,2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE1']
2963,NCT00232453,Assess acute toxicity and complete remission rate of combined preoperative radiation and chemotherapy,,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE2']
2964,NCT04937673,biomarkers related to pCR,Safety,,2021-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
2965,NCT04280666,"sensitivity, specificity, positive predictive value, and negative predictive value",Characteristics of the gene map and the correlations with clinical characteristics,,2019-06-20,UNKNOWN,OBSERVATIONAL,['NA']
2966,NCT00875147,Overall complications,"specific complications such as liver insufficiency, length of hospital stay",,2009-04,COMPLETED,OBSERVATIONAL,['NA']
2967,NCT06206603,Traceability of microRNA/mRNA expression of polyps and cancer in blood,Correlation of Intestinal microbiota and microRNA/mRNA expression,,2024-01,RECRUITING,OBSERVATIONAL,['NA']
2968,NCT01280825,Feasibility of incorporating pharmacogenomic testing into routine medical care,Find out whether availability of pharmacogenomic information impacts drug decision making in the health care setting,To determine whether access to pharmacogenomic information improves satisfaction with care.,2011-01-14,RECRUITING,OBSERVATIONAL,['NA']
2969,NCT00820053,Overall survival,Time to recurrence,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
2970,NCT04720430,"Incidence of ""Wait List Drop Off""",Clinical Status of the subset of patients successfully reaching liver transplant,,2019-12-03,COMPLETED,OBSERVATIONAL,['NA']
2971,NCT03278444,Overall Survival,Chinese Quality of Life Questionnaire - EORTC QLQ-C30 score,,2017-07-18,UNKNOWN,INTERVENTIONAL,['PHASE3']
2972,NCT00578201,"objective response rate (ORR) at 12 weeks with radiochemotherapy (first evaluation), and if applicable, within 2 to 4 weeks following the end of additional treatment with the combination Cetuximab-FOLFOX (second evaluation)",Progression free survival Quality of life Dysphagia score Overall survival toxicity of this regimen,,2007-11,COMPLETED,INTERVENTIONAL,['PHASE2']
2973,NCT02008383,Objective response rate (ORR) of cabozantinib monotherapy in patients with prospectively identified MET amplified metastatic colorectal cancer,To describe the safety and tolerability of cabozantinib monotherapy in patients with MET amplified colorectal cancer,,2014-01,COMPLETED,INTERVENTIONAL,['PHASE1']
2974,NCT02504411,Complete adenoma resection rate (CARE) for adenoma > 10 mm in diameter as determined by Colonoscopy,Cecal Intubation Rate (CIR),,2015-08,WITHDRAWN,INTERVENTIONAL,['NA']
2975,NCT05039333,Complication rate,,,2021-09-01,UNKNOWN,OBSERVATIONAL,['NA']
2976,NCT00005638,,,,1999-10,COMPLETED,INTERVENTIONAL,['PHASE1']
2977,NCT02429622,Disease-free survival (DFS),Overall survival (OS),Adverse events,2015-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2978,NCT04228601,Objective Response Rate,Time to maximum concentration (Tmax),,2020-01-21,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
2979,NCT03439891,Overall response rate (ORR) (Part 2),Proportion of participants with Child Pugh B Liver Function reporting immune-related adverse event (irAE),,2018-04-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
2980,NCT03781778,Feasibility: Retention,Variability in Gut Microbial Communities From Human Stool Samples -- BETA DIVERSITY,,2019-05-07,TERMINATED,INTERVENTIONAL,['PHASE2']
2981,NCT03011268,Proportion of patients in sustained clinical remission,Adverse events and serious adverse events frequency and severity,,2017-06-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
2982,NCT00584363,To diagnose Pancreatic Cancer,Preventing patient form being misdiagnosed,,2004-06,COMPLETED,OBSERVATIONAL,['NA']
2983,NCT06192030,Peritoneal-free survival,Rates of key gene mutation,,2022-08-27,RECRUITING,OBSERVATIONAL,['NA']
2984,NCT00777504,"Signs of progressive disease on CT-scan, DCE-MRI or Avastin scan",Effect on Quality of life as record by questionaires,,2008-10,UNKNOWN,INTERVENTIONAL,['PHASE4']
2985,NCT05482451,Overall response,Progression-free survival,Overall survival,2021-03-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
2986,NCT03976284,Stool weight,Sugary beverage intake,,2019-03-17,UNKNOWN,INTERVENTIONAL,['NA']
2987,NCT04632459,Objective Response Rate (ORR),Best Overall Response Rate (ORR),,2021-06-16,UNKNOWN,INTERVENTIONAL,['PHASE2']
2988,NCT00372840,Number of sections of the Facing Forward manual read with satisfaction and comprehension,Changes in psychological outcomes from baseline to 8-week follow-up,,2006-05,COMPLETED,INTERVENTIONAL,['NA']
2989,NCT05996666,Performance of liver cancer early detection model based on selected cfDNA methylation markers using qPCR,Comparison of currently used biomarkers for liver cancer detection,,2023-07-01,RECRUITING,OBSERVATIONAL,['NA']
2990,NCT03167268,Skin toxicity reduction,,,2016-08-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
2991,NCT01412294,Progression-free survival,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,,2011-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
2992,NCT00556023,Dose Limiting Toxicities: assessed through adverse event data collected weekly,Progression-Free Survival:,,2008-06,COMPLETED,INTERVENTIONAL,['PHASE1']
2993,NCT00583934,"Early detection of esophageal cancer or dysplasia in patients without symptoms, after treating their primary cancer, may improve their chances of being cured of a secondary disease.",,,2007-09,COMPLETED,OBSERVATIONAL,['NA']
2994,NCT01280643,"Feasibility, Defined as a Sufficient Proportion of Subjects Having Available Tissue and an Acceptable Composite Assay Success Rate Among Tested Subjects",Progression-free Survival,,2010-03,TERMINATED,INTERVENTIONAL,['NA']
2995,NCT03634202,"maximum tolerated radiation dose (MTD) delivered by IMRT with SIB, in combination with oral capecitabine, for initially metastatic, low and middle rectal cancer after 4 induction cycles of mFolfox6 regimen.",The prognostic value of PET,,2015-05-05,TERMINATED,INTERVENTIONAL,['NA']
2996,NCT04274972,Microbiome evaluation,Microbiome long-term evaluation,,2020-02-01,RECRUITING,OBSERVATIONAL,['NA']
2997,NCT01628328,Changes of circulating tumor cell level before and after colonic stenting for patients with obstructive colorectal cancer,,,2010-07,COMPLETED,OBSERVATIONAL,['NA']
2998,NCT05494866,occurrence of DLTs,,,2022-12-07,RECRUITING,INTERVENTIONAL,['PHASE1']
2999,NCT03602092,To establish the database for GIST,,,2018-10-16,RECRUITING,OBSERVATIONAL,['NA']
3000,NCT00003950,Reduction in occurrences of severe diarrhea due to CPT-11 administration,,,2000-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3001,NCT03798132,peritoneal carcinomatosis,surgical decision making.,,2019-01-01,UNKNOWN,OBSERVATIONAL,['NA']
3002,NCT02402972,disease-free survival,adverse events of Chemotherapy and IPC,,2015-02,UNKNOWN,INTERVENTIONAL,['PHASE3']
3003,NCT03608540,Incidence of all Adverse Device Effects,R0 resection,,2018-07-09,TERMINATED,INTERVENTIONAL,['NA']
3004,NCT01640444,progression free survival (PFS),"Correlation of molecular status of bio markers related to the cellular and tumoral reproduction and/or mode of action and clinical anti-tumour activity outcome ( PFS, OS, RR)",,2012-07,COMPLETED,INTERVENTIONAL,['PHASE2']
3005,NCT05087992,Phase 1b: Number of patients with DLTs during the MTD evaluation period assessed in the first 6 patients,Phase 1b: AUC0-t2: Area under the concentration-time curve of BI 9057 after multiple cycles,,2021-11-24,COMPLETED,INTERVENTIONAL,['PHASE1']
3006,NCT06265272,Assessment of LI-RADS with Ga-PSMA-PET/MRI,PET/MR protocol in liver cirrhosis,,2023-12-10,RECRUITING,OBSERVATIONAL,['NA']
3007,NCT02967770,4 month progression free survival rate,Change in tumor marker levels,,2016-11,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3008,NCT00369109,Level of p-Chk1 and phospho-histone 2AX (p-H2AX) and possibly downstream pathway markers in hair follicles from skin biopsies of patients treated with gemcitabine hydrochloride or irinotecan hydrochloride for advanced solid tumors,Dynamic time course of p-Chk1 and p-H2AX after administration of a DNA-damaging agent,,2006-02,COMPLETED,OBSERVATIONAL,['NA']
3009,NCT06181656,Impact of grade IV radiation-induced lymphopenia on serologic responses to pneumococcal vaccination,,,2024-02-05,RECRUITING,OBSERVATIONAL,['NA']
3010,NCT00898482,Test new hypotheses as they emerge,,,2005-05,COMPLETED,OBSERVATIONAL,['NA']
3011,NCT01441388,Dose Limiting Toxicities (DLTs).,Peak plasma concentration (Cmax) of crizotinib and each VEGF inhibitor,,2011-12,WITHDRAWN,INTERVENTIONAL,['PHASE1']
3012,NCT00841035,Epidermal Growth Factor Receptor Signaling(EGFR) in the Presence of Pancreatic Tumor Related to the Mechanism to Erlotinib.,The Secondary Objectives Include Analysis of Recurrence-free and Overall Survival and the Development of a Predictive Assay for Response to Erlotinib Based on Selected Bio-markers in Endoscopic Ultrasound-Fine-needle Aspiration Specimens.,,2009-02,TERMINATED,INTERVENTIONAL,['PHASE2']
3013,NCT01777477,Maximum tolerated dose (MTD) of orally administered Chloroquine with concomitant intravenous Gemcitabine.,,,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1']
3014,NCT02936193,Progression-free Survival,3 years overall survival,,2017-08-01,UNKNOWN,INTERVENTIONAL,['NA']
3015,NCT01424293,Evaluate the Vascular Supply of the Bowel Intra-operatively and Correlate This With Postoperative Complications Identified During Their Hospital Stay at One Week and One Month Postoperatively.,,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
3016,NCT02085005,Progression Free Survival rate at 10 months (PFS@10m),Number of participants with adverse events,,2014-03,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3017,NCT04515394,Number of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Investigators,Number of Participants With At Least 1 Postive Anti-Drug Antibodies (ADAs) for Cetuximab,,2021-01-28,TERMINATED,INTERVENTIONAL,['PHASE2']
3018,NCT00591981,"Morbidity (Cardiac, pulmonary, infectous, etc.) and Mortality in Cohort",,,2007-08,COMPLETED,OBSERVATIONAL,['NA']
3019,NCT04831944,Pharmacokinetics Parameter : AUC(0-t) of parsaclisib,Pharmacokinetics Parameter : Vz/F of parsaclisib,,2021-03-29,COMPLETED,INTERVENTIONAL,['PHASE1']
3020,NCT02271464,progression-free survival (PFS),Overall toxicity rate,,2012-03,COMPLETED,INTERVENTIONAL,['PHASE2']
3021,NCT01952951,downstaging rate,quality of life,,2014-06,UNKNOWN,INTERVENTIONAL,['PHASE2']
3022,NCT04607590,The patient 6-minute walk test (6-MWT) over the 6-month follow up (6-MFU),Patient and partner short form survey (SF-36) domains,Treatment efficacy,2019-05-31,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3023,NCT03176082,Polypectomies,,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
3024,NCT02319304,Primary Outcome Measure (Overall Survival Rate),Secondary Outcome Measure (Number of Adverse Events),,2015-03,TERMINATED,INTERVENTIONAL,['PHASE2']
3025,NCT00569387,The primary objective of this Phase II trial is to assess disease-free survival (DFS) at one (1) year following initiation of treatment as the primary endpoint of the study in subjects treated with the HyperAcute®-Pancreatic Cancer Vaccine,We will use overall survival and adverse events rates as secondary endpoints.,,2007-12,COMPLETED,INTERVENTIONAL,['PHASE2']
3026,NCT05269056,Area under curve of the model for detecting stage I/II gastric cancer,Area under curve of the early detection model at sequencing depth downsampling,,2021-09-01,RECRUITING,OBSERVATIONAL,['NA']
3027,NCT01959269,Overall survival,Incidence of treatment emergent adverse events (TEAE),,2013-10-31,COMPLETED,OBSERVATIONAL,['NA']
3028,NCT04896073,disease control rate,Overall Survival (OS),,2022-03-07,RECRUITING,INTERVENTIONAL,['PHASE2']
3029,NCT01232101,The primary aim of the present study was to compare and stent patency between covered and uncovered bileduct SEMS,"Secondary objectives were to study difference in technical success, efficacy of drainage and complication rate between covered and uncovered metal stents",,2007-03,COMPLETED,INTERVENTIONAL,['NA']
3030,NCT02285660,Whole body 4D PET-CT for improved Target Definition/Delineation (feasibility and benefit) (ability to identify the cancer and ability to show areas within the cancer that are potentially more active allowing target of higher dose to these areas),,,2011-06,UNKNOWN,INTERVENTIONAL,['NA']
3031,NCT02481635,Type and the severity of side effects,Time to Progression,,2016-07,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3032,NCT00725400,Objective tumor response rate,Quality of life,,2010-02,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3033,NCT04752384,The number of subjects who achieve at least a 30 percent decrease in pain from baseline in VAS pain score calculated from BPI questionnaire.,The number of subjects who achieve at least a 30 percent decrease in pain from baseline in average daily pain score calculated by OM pain app.,,2021-07-08,RECRUITING,INTERVENTIONAL,['PHASE2']
3034,NCT05476380,pCR,DFS,,2021-02-19,RECRUITING,INTERVENTIONAL,['PHASE2']
3035,NCT04867525,Course of treatment (treatment reality).,"Carcinoma Health-related quality of life (Patient-reported outcome, PRO).",,2021-05-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3036,NCT03586050,Number of Patients Whose Ablation Resulted in Technical Success,Number of Patients Whose Ablation Resulted in Technique Efficacy,,2017-12-11,COMPLETED,INTERVENTIONAL,['NA']
3037,NCT00893503,"Compare the diagnostic performance characteristics of the guaiac based Hemoccult II FOBT and two FIT's, the Hemoccult ICT and MagStream HemSp, using colonoscopy as the gold standard.",Estimate the probability of participants of the SCOPE pilot who have adenomas or colorectal cancer using urine metabolomics and correlate those with results from the FOBT / FIT's and screening colonoscopy.,,2008-04,COMPLETED,OBSERVATIONAL,['NA']
3038,NCT03608878,time-to-ITTVP,,,2019-04-26,TERMINATED,INTERVENTIONAL,['PHASE2']
3039,NCT00023972,,,,2001-07,COMPLETED,INTERVENTIONAL,['PHASE3']
3040,NCT04060342,"Phase 2 - Basket Cohorts 1, 2 and 3: Objective Response Rate (ORR)","Phase 2 - Basket Cohort 1, 2 and 3: PK profile of GB1275",,2019-08-13,TERMINATED,INTERVENTIONAL,['PHASE1']
3041,NCT04194801,Phase II: Objective Response Rate (ORR) Assessed by Investigator Based on RECIST Version 1.1,Pharmacokinetic Parameters of Time to Maximum Serum Concentration (Tmax) of Sugemalimab (CS1001),,2019-12-16,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3042,NCT01991522,Transfer of Skills to Clinical Colonoscopy,Retention of Clinical Skills,,2011-06,COMPLETED,INTERVENTIONAL,['NA']
3043,NCT04191655,Detection rate of dysplastic lesions in High Definition White Light Colonoscopy versus Dye Spraying Chromo-colonoscopy,Appropriateness of reported follow up recommendations per standard guideline recommendations,,2019-04-03,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
3044,NCT00224562,,,,2004-02,UNKNOWN,OBSERVATIONAL,['NA']
3045,NCT00087360,Colorectal cancer (CRC) screening rates by chart review at 4 months,CRC risk perception by questionnaires at 4 and 12 months,,2003-11,COMPLETED,INTERVENTIONAL,['NA']
3046,NCT01277653,the difference of curative treatments & survival rates,the difference of early detection rates of HCC between both groups,,2007-06,UNKNOWN,OBSERVATIONAL,['NA']
3047,NCT00576199,Progression-free Survival,Tumor Necrosis,,2008-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3048,NCT02777710,part 2 (extension part) : objective response rate (ORR),Peak Pexidartinib plasma concentration (Cmax),,2016-06,COMPLETED,INTERVENTIONAL,['PHASE1']
3049,NCT05904665,Secondary resection rate,ctDNA clearance rate,,2023-06-15,RECRUITING,INTERVENTIONAL,['NA']
3050,NCT05262335,Objective response rate (ORR),Radical Resection Rate of Liver Metastases,,2021-12-01,RECRUITING,INTERVENTIONAL,['PHASE2']
3051,NCT05554744,Imaging response,Safety of EUS-FNI,,2015-06-18,RECRUITING,INTERVENTIONAL,['NA']
3052,NCT01260701,Overall Survival (OS),Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug,,2011-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3053,NCT03253250,Recurrence-free Survival Rate (RFS）,Overall Survival Rate (OS）,,2017-09-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
3054,NCT04753996,Number of participants in study.,Number of clinical phenotypes and/or observations.,,2021-03-08,RECRUITING,OBSERVATIONAL,['NA']
3055,NCT03021135,Local recurrence.,Sydney resection ratio (characterized by the following equation - lesion size in millimeters,,2018-06-07,COMPLETED,INTERVENTIONAL,['NA']
3056,NCT02009176,Survival rate,postoperative complications,,2013-03,UNKNOWN,INTERVENTIONAL,['NA']
3057,NCT03599752,Overall survival (High risk),,,2018-07-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3058,NCT00203411,Number of Subjects Requiring Dose Modifications,Quality of Life of Patients,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE2']
3059,NCT03674294,Complete response rate during the overall phase,Effects of CINV on daily life,,2015-08-04,COMPLETED,INTERVENTIONAL,['PHASE3']
3060,NCT05495308,The main objective of the study is to update long-term oncologic follow-up of those patients treated for LARC with nCRT and surgery (either TME or subtotal TME; S-TME) who had obtained a pCR.,"To analyze clinical data in search of related factors to adverse oncologic outcomes, like distant recurrence or tumor-related deaths.",,2021-09-01,COMPLETED,OBSERVATIONAL,['NA']
3061,NCT05199649,Species and abundance of gut microbiota,Explore the changes of intestinal flora and metabolomics before and after medication,,2021-12-01,UNKNOWN,INTERVENTIONAL,['NA']
3062,NCT04363983,Overall survival (OS),Survival without progression (SWP),,2021-01-13,RECRUITING,INTERVENTIONAL,['NA']
3063,NCT00008294,,,,2000-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3064,NCT01646853,Objective Tumor Response,adverse events,,2012-08,UNKNOWN,INTERVENTIONAL,['NA']
3065,NCT00873002,Assessment of Safety and Tolerability,Adverse events and abnormal laboratory value severity as assessed by NCI CTCAE version 3.0,,2009-03,TERMINATED,INTERVENTIONAL,['PHASE1']
3066,NCT01632306,Change From Baseline to 4 Hours Post-Treatment on Day 0 in Glycogen Synthase Phosphorylation,Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)],,2013-03,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3067,NCT04157985,Progression-free Survival (PFS),Best Objective Response (BOR),,2019-11-15,RECRUITING,INTERVENTIONAL,['PHASE3']
3068,NCT00271986,anastomotic leakage,,,2006-01,COMPLETED,OBSERVATIONAL,['NA']
3069,NCT06225843,Treatment-Emergent Adverse Events,Presence of ADA,,2024-02-15,RECRUITING,INTERVENTIONAL,['PHASE2']
3070,NCT01159171,Percentage of Participants by Best Overall Response,Overall Survival,,2006-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3071,NCT05692323,PREHAB Program feasibility will be measured by tracking participant attendance at PREHAB sessions. PREHAB will be considered feasible if 50% of participants attend at least 60% of scheduled sessions.,PREHAB Program safety will be assessed through the reporting of unanticipated problems from the baseline visit through to the 3 Month visit.,,2023-04-04,RECRUITING,INTERVENTIONAL,['NA']
3072,NCT00757172,Number of Participants With Pathologic Complete Response Following Surgery,Number of Participants With Frequent (>=15% Grade 3/4 Incidence) Adverse Events Regardless of Attribution,,2009-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3073,NCT01651624,Costs of the three different screening strategies proposed,Number and type of complications in all groups,,2012-12,COMPLETED,INTERVENTIONAL,['NA']
3074,NCT00003422,"Local recurrence by biopsy, imaging, or imaging and carcinoembryonic antigen result",Economic implications,,1998-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3075,NCT02254486,Number of Patients With 'Excellent Plus Good' (Highly Effective) Bowel Cleansing (Colon Ascendens),Polyp Detection Rate (Overall Colon),,2014-09,COMPLETED,INTERVENTIONAL,['PHASE3']
3076,NCT00202969,Response rate,"Safety profile, time to treatment failure",,2005-07,COMPLETED,INTERVENTIONAL,['PHASE3']
3077,NCT01567917,The incidence of symptomatic or asymptomatic VTE,Risk factors for the development of VTE,,2011-06,UNKNOWN,OBSERVATIONAL,['NA']
3078,NCT02161822,pathologic complete response rate,lipid lowering effect of simvastatin,,2014-10-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
3079,NCT05023720,Regorafenib in combination with other drugs,Survival differences among the patients with different clinical phenotypes and genotypes,,2021-07-20,UNKNOWN,OBSERVATIONAL,['NA']
3080,NCT00159484,Once MTD is established we propose to expand the dose level of the MTD to 62 new patients to evaluate whether the addition of Celebrex to EPO906 can reduce the incidence of grade 3-4 diarrhea to 6% or less.,"To investigate whether the molecular biomarkers including protein expression changes from plasma, the expression levels of VEGF, E-cadherin, TP, COX-2, and β-tubulin in tumor tissue associated with clinical outcome for this regimen.",,2004-10,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3081,NCT05850130,2-point improvement in the global NRS,Peripheral sensory neuropathy grading scale,,2023-11-22,RECRUITING,INTERVENTIONAL,['NA']
3082,NCT02299596,Recovery measured as physical recovery measured in questionnaire,Health economic analysis,,2015-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3083,NCT06076837,Safety and Tolerability,"CA 19-9 (or CA 125, or CEA if not expressers of CA 19-9)",Baseline neutrophil lymphocyte ratio (NLR),2023-12,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
3084,NCT00621556,"MR & MRCP - Images will be evaluated for quality, main and branch duct visualization, ductal diameter and improved visualization of structural abnormalities with and without use of RG1068.",Laboratory,,2008-02,TERMINATED,INTERVENTIONAL,['PHASE1']
3085,NCT03630978,Morbidity,Readmission rate,,2018-07-01,COMPLETED,OBSERVATIONAL,['NA']
3086,NCT04674956,Progress free survival,Duration of Response,CA19-9 in serum,2021-03-04,RECRUITING,INTERVENTIONAL,['PHASE3']
3087,NCT06147180,score of Quality of life,Recurrence or metastasis,,2023-11-27,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3088,NCT05776524,Overall Survival,Disease Control Rate,,2023-06-13,RECRUITING,INTERVENTIONAL,['PHASE2']
3089,NCT05328908,OS in all randomized participants,DoR by investigator per RECIST v1.1 in all randomized participants,,2022-04-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
3090,NCT04996095,Analysis of Predictive Markers,,,2021-10-01,RECRUITING,OBSERVATIONAL,['NA']
3091,NCT01387061,Overall survival plus multivariate analysis,Disease-free survival,,2001-06,COMPLETED,INTERVENTIONAL,['NA']
3092,NCT01264705,Number of Patients With Dose Limiting Toxicity,Median Months of Disease Specific Survival Calculated From Treatment Initiation to Death From Advanced HCC (Hepatocellular Carcinoma) or Last Follow-up.,,2011-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3093,NCT01824875,Progression-free Survival,Association Between Methyl Guanine Methyltransferase (MGMT) Status by Promoter Methylation and Response,,2013-08-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3094,NCT00359476,"The Response Rate (RR: Complete Response [CR]+Partial Response [PR], as defined by Response Evaluation Criteria in Solid Tumors [RECIST]",The evaluation of the safety profile of vinflunine,,2007-03,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3095,NCT03347162,Cohort 2: Medical treatment complications,Change in physical activity level,,2017-12-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3096,NCT04587739,Drop-out rate,Actuarial overall survival and disease-free survival.,,2021-01-31,RECRUITING,INTERVENTIONAL,['PHASE1']
3097,NCT02128425,Progression-free survival after induction and maintenance chemotherapy (PFS1),Translational research,,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
3098,NCT02138383,Maximum Tolerated Dose (MTD),,,2014-05-22,COMPLETED,INTERVENTIONAL,['PHASE1']
3099,NCT04368702,Rate of Pathologic complete response-Gastric,Characterizing MRI-based tumor alterations/changes following MR-image guided radiation,,2021-05-01,SUSPENDED,INTERVENTIONAL,['NA']
3100,NCT04430842,Determination of maximum tolerated dose (MTD),Time to maximum concentration of QBS10072S in plasma (Tmax),,2020-07-20,COMPLETED,INTERVENTIONAL,['PHASE1']
3101,NCT00616941,Overview of Treatment-emergent Adverse Events (TEAEs),Tumor Measurement Results According to the Response Evaluation Criteria for Solid Tumors (RECIST) Up to 16 Weeks Post-Baseline,,2008-03,COMPLETED,INTERVENTIONAL,['PHASE1']
3102,NCT05171439,Bioinformatics analysis of single-cell sequencing in hepatocellular carcinoma,adverse events(AE),,2022-03-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
3103,NCT02052908,Incidence of toxicity,Changes in the number and type of immune and mesenchymal cells recruited to the colorectal mucosa,,2014-01-27,COMPLETED,INTERVENTIONAL,['PHASE1']
3104,NCT03007550,Early operative morbidity and mortality rate,Postoperative hospital stay,,2017-01-04,COMPLETED,INTERVENTIONAL,['NA']
3105,NCT01147965,"The primary objective of this protocol is to determine the safety of immunization with Ad5 [E1-, E2B-]-CEA(6D), in patients with advanced or metastatic CEA-expressing malignancies, including Maximum Tolerated Dose (MTD).",The secondary objectives of this protocol are to evaluate CEA-specific immune responses to the immunizations and to obtain preliminary data on clinical response rate.,,2010-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3106,NCT03161574,The rate of R0 resection,Reported Adverse events,,2017-08-11,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3107,NCT02054923,Change in screening centre adenoma detection rate before and after intervention,Rates of proximal (to the splenic flexure) serrated polyps ≥10mm in size,,2014-03,COMPLETED,INTERVENTIONAL,['NA']
3108,NCT05864755,Overall response rate ( ORR) per RECIST 1.1,Time To Progress(TTP) per RECIST 1.1,,2023-06-20,RECRUITING,INTERVENTIONAL,['PHASE2']
3109,NCT01064375,To evaluate the safety and immunogenicity of a DNA immunisation approach where tetwtCEA DNA will be administered in combination with electroporation.,To compare effects (safety and immunogenicity) of additional adjuvance with GM-CSF,,2009-12,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3110,NCT02277834,"Compare the proteomic signature of pancreatic adenocarcinoma , pancreatic cancer and control participants to the disease process",Compare the proteomic profile between pancreatic cancer and pancreatitis,,2014-08,COMPLETED,OBSERVATIONAL,['NA']
3111,NCT01276483,Radiologic-pathologic correlation,,,2011-02,COMPLETED,OBSERVATIONAL,['NA']
3112,NCT05039736,To evaluate overall response rate,,,2023-02-24,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3113,NCT05141747,Adverse Events (AEs),Immunogenicity (ADA),,2022-01-19,UNKNOWN,INTERVENTIONAL,['PHASE2']
3114,NCT05996484,Pathologic complete remission (PCR),Change From Baseline in HRQoL Score Using EORTC Quality of Life Questionnaire-Oesophageal Module (QLQ-OES18),,2023-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
3115,NCT02826837,Maximum tolerated dose,Changes in global health/QoL standardized score at post-treatment visits compared to baseline,,2022-09-01,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3116,NCT02021253,Area under the plasma concentration versus time curve (AUC) of endotoxins circulating levels,,,2013-04,COMPLETED,INTERVENTIONAL,['NA']
3117,NCT03638297,Response rate,duration of response,,2018-08-23,RECRUITING,INTERVENTIONAL,['PHASE2']
3118,NCT04566367,Detection rate of a second cancer or precancerous lesions,,,2020-09-22,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3119,NCT03287947,Disease Control Rate,"Treatment Administration of Nintedanib, as Measured by Average Daily Dose of Nintedanib.",,2017-11-10,TERMINATED,INTERVENTIONAL,['PHASE2']
3120,NCT00005832,Survival rate in patients with advanced adenocarcinoma of the pancreas treated with R115777,Assess confirmed response (complete & partial) in patients with measurable advanced adenocarcinoma of the pancreas,,2000-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3121,NCT02131493,DFS,OS,,2015-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3122,NCT01001377,Overall Survival,Number of Participants With Adverse Events (AEs),,2010-02-02,COMPLETED,INTERVENTIONAL,['PHASE3']
3123,NCT00024427,Open Label Randomized Phase 3 Multi-Center Trial of PN401 plus high dose 5-FU versus Gemcitabine in Advanced Pancreatic Cancer Patients,,,2001-02,COMPLETED,INTERVENTIONAL,['PHASE3']
3124,NCT03042091,"Incidence of post-operative surgical site infection (SSI) including superficial/incisional, deep, and organ space, anastomotic dehiscence and leak",Incidence of mortality,,2016-09,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
3125,NCT00906984,,,,na,APPROVED_FOR_MARKETING,EXPANDED_ACCESS,['NA']
3126,NCT05982899,frailty trajectories,,,2021-03-01,COMPLETED,OBSERVATIONAL,['NA']
3127,NCT01850316,One year local progression-free rate,Functional imaging with 11C-choline/18F-FDG CT-PET and perfusion CT to that characterize treatment-related effects,,2013-07,UNKNOWN,INTERVENTIONAL,['NA']
3128,NCT01525953,Identification of prognostic factors for overall survival,Disease-free survival,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
3129,NCT01420874,"Determining in a dose-escalation phase Ib trial the safety of 3 infusions of EGFR2Bi aATC, and a booster infusion after 3 months, for patients with advanced colorectal or pancreatic cancer.",Overall Survival,,2011-08-17,COMPLETED,INTERVENTIONAL,['PHASE1']
3130,NCT04397783,parastomal hernia rate by imaging,Ease / difficulty in the management of stomatherapy devices,,2019-04-15,UNKNOWN,INTERVENTIONAL,['NA']
3131,NCT03634332,Progression Free Survival,Overall Survival,Evaluate Blood Translational Biomarkers--T cell receptor (TCR) sequencing,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
3132,NCT02755311,Overall survival,Mortality,,2014-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
3133,NCT06055387,"Utilize CTCAE v5.0 to assess the grade and frequency of adverse events and treatment-related toxicity in frail and non-frail patient groups, and compare the differences between the two.",To compare overall survival between two distinct groups: frail and non-frail patients.,,2022-01-01,RECRUITING,INTERVENTIONAL,['NA']
3134,NCT05261542,Accuracy of intraoperative Flow Cytometry for cancer cell identification in colorectal cancer.,,,2017-01-26,COMPLETED,OBSERVATIONAL,['NA']
3135,NCT04734821,Evaluation of the usefulness of ICG fluorescence to guide lymphadenectomy in oncological esogastric resections,Evaluation of the impact of fluorescence guidance in intraoperative evaluation of pre-anastomotic tissue perfusion,,2021-04-01,RECRUITING,INTERVENTIONAL,['NA']
3136,NCT01786538,Progression-free survival,Number of participants with adverse events,,2013-06,WITHDRAWN,INTERVENTIONAL,['PHASE3']
3137,NCT05056337,Tumor response: Objective response rate (assessed based on mRECIST criteria),Adverse Events as assessed by CTCAE 5.0 criteria,,2021-08-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
3138,NCT00060268,,,,1997-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3139,NCT02199223,Safety of regorafenib + panitumumab,,,2014-06,TERMINATED,INTERVENTIONAL,['PHASE1']
3140,NCT01729923,"Rate of CR, Assessed According to CEA and CA 19-9 Measurements and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1",Relapse Free Survival in Patients Achieving CR,,2013-03,TERMINATED,INTERVENTIONAL,['PHASE2']
3141,NCT06224738,Adverse effects,Overall Survival (OS),,2024-03-01,NOT_YET_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
3142,NCT04310553,Overall survival,"clinical benefit rate, CBR",,2017-12-01,UNKNOWN,INTERVENTIONAL,['NA']
3143,NCT03471468,"Microparticles level will be assessed by automated and standardised measure of their procoagulant power using Kit STA©Procoag-PPL (Diagnostica Stago, Asnière, France)","Khorana score does assess the risk of thrombosis uner chemotherapy according to 3 levels :Score 0, 1, 2 or 3",,2018-07-23,TERMINATED,INTERVENTIONAL,['NA']
3144,NCT01423214,Surgical quality based on pathological examination,5-year disease-free survival rate,,2013-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
3145,NCT04431791,Time To Treatment Failure,Incidence of adverse events（AEs）,,2020-05-25,UNKNOWN,OBSERVATIONAL,['NA']
3146,NCT05915637,Fatigue Assessment,,,2021-09-01,COMPLETED,OBSERVATIONAL,['NA']
3147,NCT03068403,Area under the echo-power curve (AUC),mrTNM staging,,2018-06-18,COMPLETED,INTERVENTIONAL,['NA']
3148,NCT01964235,Time to progression using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1,Tolerability of study drug,,2016-12,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3149,NCT00407407,Primary: Safety/tolerability endpoints are the maximum tolerated dose and dose-limiting toxicities,"Safety-AEs, SAEs, Lab abnormalities, incidence of patients experiencing dose modification of those interruptions &/or premature of d/c pf study drug",,2006-11-01,TERMINATED,INTERVENTIONAL,['PHASE1']
3150,NCT03686254,"Overall survival (OS), Month","Time to progression (TTP), Month",,2018-07-16,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3151,NCT00027768,Recurrence-free survival,Overall survival,,2001-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
3152,NCT04229459,Incidence of Treatment-Emergent Adverse Events (Safety),Overall survival (OS),,2019-12-30,RECRUITING,INTERVENTIONAL,['PHASE2']
3153,NCT06276686,withdrawal rate,Physical activity levels,,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3154,NCT05357846,Overall survival,Perioperative mortality,,2022-11-01,RECRUITING,INTERVENTIONAL,['PHASE3']
3155,NCT06034197,Feasibility of VGT-309,,,2023-09-27,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
3156,NCT04139070,Incidence of Treatment-Emergent Adverse Events (CTCAE),Tumor volume,,2020-06-15,UNKNOWN,INTERVENTIONAL,['PHASE1']
3157,NCT04428905,Quality of life: survey,,Outcome Measure for facilitators,2020-07-11,RECRUITING,INTERVENTIONAL,['NA']
3158,NCT03800693,Effect of 2 versus 6-hour oxaliplatin infusion time on neuropathy as measured by patient reported outcome (PRO) scores on the European Organization for Research and Treatment of Cancer (EORTC) chemotherapy-induced peripheral neuropathy (CIPN-20) scale,Frequency of dose holds or reductions,,2019-03-14,RECRUITING,INTERVENTIONAL,['PHASE2']
3159,NCT03931044,Accuracy (%; 95% CI),Mean difference of total number of LNs retrieved during the lymphadenectomy of the D2 anatomical plane (mean±DS).,,2019-04,UNKNOWN,INTERVENTIONAL,['NA']
3160,NCT03572283,Change in cell proliferation by Ki-67 expression in tumor cells,Number of Adverse Events,,2018-04-08,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
3161,NCT03465501,Evaluation of the tolerance of interstitial brachytherapy of the anal canal,Comparison of the incidence of toxicities (CTCAE v4) between the 2 groups,,2007-08-17,COMPLETED,OBSERVATIONAL,['NA']
3162,NCT00002947,,,,1996-10,TERMINATED,INTERVENTIONAL,['PHASE1']
3163,NCT00003548,,,,1998-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3164,NCT02596256,Progression free survival,,,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
3165,NCT00405587,Percentage of Participants With BOR of CR or PR According to RECIST v1.0 - Dose Escalation: MBP Formulation,"Tumor Levels of Phosphorylated Extracellular Signal-Regulated Kinapse (ERK), Cyclin D1, and Ki-67",,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
3166,NCT01967875,Progression-Free Survival (PFS),Quality of Life(QOL),,2013-07,TERMINATED,INTERVENTIONAL,['PHASE2']
3167,NCT00646022,Study the natural history of familial carcinoid tumors,Screen for occult disease and determine whether early detection affects the natural history of the disease,,2008-08-25,RECRUITING,OBSERVATIONAL,['NA']
3168,NCT00623831,"Number of Participants With Pyrogenicity at Each Dose Level Tested in the Intrasubject Dose Escalation Performed Over a Dose Range of 250 to 547,000 EU",Number of Participants With Best Overall Tumor Response,,2007-05,COMPLETED,INTERVENTIONAL,['PHASE1']
3169,NCT05456165,Incidence and Severity of Adverse Events,T-cell response using Peripheral Blood Mononuclear Cells (PBMCs),,2022-05-19,TERMINATED,INTERVENTIONAL,['PHASE2']
3170,NCT05498168,The ratio of predicted neoantigens being immunogenic,,,2022-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3171,NCT05115916,Overall Colorectal Cancer Screening Uptake,Effect of electronic primer message on CRC uptake among participants who opened,,2019-08-28,COMPLETED,INTERVENTIONAL,['NA']
3172,NCT03238820,Complications,Body composition,,2014-01-10,COMPLETED,INTERVENTIONAL,['NA']
3173,NCT04889456,30-day morbidity with Clavien-Dindo grading,"Long term morbidity: incisional hernia, adhesion related small bowel obstruction, readmissions, reinterventions",,2021-07-01,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3174,NCT05051592,Detection rate of alterations of anti-epidermal growth factor receptor primary resistance using Circulating tumour DNA,Adverse reactions experience by patient,,2021-03-26,UNKNOWN,OBSERVATIONAL,['NA']
3175,NCT03674073,Safety of neoantigen-based DC vaccine as measured by the number of subjects experiencing each type of adverse event according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0.,Progression-free survival at 2 years,,2018-10-15,UNKNOWN,INTERVENTIONAL,['PHASE1']
3176,NCT00243633,Medical and economic interest of CEUS,Harmony inter-readers,,2005-04,COMPLETED,INTERVENTIONAL,['NA']
3177,NCT01510561,Safety (change in hematology and chemistry laboratory values from baseline),Efficacy,,2012-03,WITHDRAWN,INTERVENTIONAL,['PHASE1']
3178,NCT01041404,Overall Survival - Time to Event,Trastuzumab Maximum Serum Concentration (Cmax),,2005-09,COMPLETED,INTERVENTIONAL,['PHASE3']
3179,NCT00068068,,,,2003-10,COMPLETED,INTERVENTIONAL,['PHASE2']
3180,NCT01789723,Optimal dose and schedule of Fusilev to prevent or reduce mucositis,Relationship between Fusilev use and oral mucositis,Overall Response Rate (ORR),2013-03,WITHDRAWN,INTERVENTIONAL,['PHASE1']
3181,NCT04617067,Overall survival (OS),Tumour response rate Duration of response,Incidence of hypercalcaemia,2020-10-16,COMPLETED,INTERVENTIONAL,['PHASE2']
3182,NCT04936399,Distribution of patient quality of life through EQ-5D-3L (EQ-5D) every two weeks for 24 weeks post-treatment initiation following patient enrolment into the EAMS,,,2020-06-25,COMPLETED,OBSERVATIONAL,['NA']
3183,NCT06078787,To evaluate the ORR according to RECIST 1.1 following Olaparib administration,To evaluate the OS according to RECIST 1.1 following Olaparib,,2023-08-01,RECRUITING,INTERVENTIONAL,['PHASE2']
3184,NCT04423354,Perioperative mortality,5-year disease-free survival rate,,2019-03-25,UNKNOWN,INTERVENTIONAL,['NA']
3185,NCT03219372,Time to Recurrence,Levels of Liver Tissue Markers Related to HCC,,2018-09-27,TERMINATED,INTERVENTIONAL,['PHASE2']
3186,NCT04400383,Stage 2: The incidence and case number of DLT (Dose Limiting Toxicity) during observation period,Efficacy: overall survival (OS) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1),,2020-06-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
3187,NCT00025090,Recurrence-free survival,Cause-specific and overall survival,,2001-03,COMPLETED,INTERVENTIONAL,['PHASE3']
3188,NCT05470738,"The main study's objective is to definite the effective rate of adjuvant chemotherapy performed after surgery (at the 3-month post operatively), which is essential marker recognized as improving overall survival.","The secondary objective of the study is to know, in patients operated for pancreatic adenocarcinoma, the rate of postoperative complications, the rate of the postoperative morbidity and mortality, and the quality of the resection.",,2022-09-15,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3189,NCT04526886,Unplanned chemotherapy treatment delay,Out of pocket costs associated with chemotherapy treatment visits,,2020-10-15,COMPLETED,INTERVENTIONAL,['NA']
3190,NCT01719380,Phase 2: Progression Free Survival (PFS),Phase 2: Number of Participants With Any Variant in Gene Status at Baseline,,2012-11-23,COMPLETED,INTERVENTIONAL,['PHASE2']
3191,NCT04714983,Maximum tolerated dose (MTD) achieved during dose-escalation phase,Measure Immune response with ELISPOT,,2021-02-15,SUSPENDED,INTERVENTIONAL,['PHASE1']
3192,NCT04094688,Progression-free survival (PFS),Prognostic effect of highest achieved 25(OH)D,,2019-09-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
3193,NCT00874406,progression free survival,overall survival,,2008-01,UNKNOWN,INTERVENTIONAL,['PHASE4']
3194,NCT06028516,ctDNA positive patients are detedcted before PET-CT,,,2021-01-06,RECRUITING,OBSERVATIONAL,['NA']
3195,NCT03841201,"Safety and tolerability (AEs, SAEs according to NCI-CTCAE V 4.03)",Translational research,,2019-06-12,COMPLETED,INTERVENTIONAL,['PHASE2']
3196,NCT01486329,Safety and tolerability,Tumor perfusion,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE1']
3197,NCT03015038,Immune cells trafficking,"Safety (Number of adverse events, ECOG status)",,2017-02-05,UNKNOWN,OBSERVATIONAL,['NA']
3198,NCT02085031,Anastomosis-related early complication rate,Postoperative quality of life,,2014-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
3199,NCT04665921,Incidence of dose limiting toxicities,Incidence of antidrug antibodies (ADA),,2021-01-18,TERMINATED,INTERVENTIONAL,['PHASE1']
3200,NCT00827723,concordance rate between ICGR-15 and Portal Pressure values in patients with resectable HCC and cirrhosis Child A from alcoholic and non-alcoholic origin.,postoperative liver failure.,,2009-02,COMPLETED,OBSERVATIONAL,['NA']
3201,NCT06102772,Progression Free Survival,Overall survival,,2023-11-10,RECRUITING,OBSERVATIONAL,['NA']
3202,NCT04492215,Rate of organised colorectal cancer screening at 24 months,Identification of denial of the colorectal cancer screening,,2021-05-31,RECRUITING,INTERVENTIONAL,['NA']
3203,NCT05947201,pathologic complete response (pCR) of the patients' resected tumors,R0 resection rate,,2023-05-08,RECRUITING,INTERVENTIONAL,['PHASE2']
3204,NCT03247231,Removal of the subepithelial tumour (initial clinical success).,Long-term recurrence.,,2017-03-31,TERMINATED,OBSERVATIONAL,['NA']
3205,NCT02988921,Evaluation of tumor heterogeneity with IBEX software,Reduction in acute and late side effects based on modified RT treatment volumes with pre- and post-chemoradiotherapy based on MRI and CT simulation,,2016-10,RECRUITING,INTERVENTIONAL,['NA']
3206,NCT03250091,Risk stratification,"Gastric, faecal microbiome in cancer patients and patients with precancerous lesions",,2017-06-19,RECRUITING,OBSERVATIONAL,['NA']
3207,NCT04984174,"age, sex, types of institutions and chemotherapy regimens",,,2021-08-04,RECRUITING,OBSERVATIONAL,['NA']
3208,NCT05596435,Area under curve of the model for detecting stage I/II/III pancreatic cancer,Specificity of the early detection model,,2022-10-10,RECRUITING,OBSERVATIONAL,['NA']
3209,NCT03699657,Minimum diameter of ablative zone,2-year LTP,Maximal diameter of ablative zone,2014-12-15,COMPLETED,INTERVENTIONAL,['NA']
3210,NCT00316862,Proportion of Patients With Adenocarcinoma Achieving a Pathologic Complete Response (CR) After Surgery,Proportion of Patients Experiencing Grade 3 or Greater Hematologic and Non-hematologic Toxicity,,2006-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3211,NCT05963776,pulmonary complications of liver cirrhosior or HCC,,,2023-09-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3212,NCT05551039,Proportion of patients with reasons for discontinuation,Descriptive summary of Pre-existing comorbidities,,2022-08-15,COMPLETED,OBSERVATIONAL,['NA']
3213,NCT04617457,Overall survival after R0/R1 resection (OS-res),QoL-adjusted OS,,2021-10-10,RECRUITING,INTERVENTIONAL,['PHASE2']
3214,NCT05547529,Disease-free survival,R0 resection rate,,2022-09-14,RECRUITING,INTERVENTIONAL,['PHASE3']
3215,NCT00562666,"Onset of: thrombosis of hepatic artery, grade 4 liver toxicity, or grade 3 or more allergic, neurological, dermatological, infectious, or respiratory reaction","Onset of clinical, biological signs or images evocative of lymphocyte-induced tumor cytotoxicity and/or of a persistence of gamma-delta T cells in peripheral blood. Tumor response will be evaluated with the RECIST criteria.",,2008-02,TERMINATED,INTERVENTIONAL,['PHASE1']
3216,NCT01919242,the type of complications and the incidence of it,,,2013-01,UNKNOWN,OBSERVATIONAL,['NA']
3217,NCT03265743,Realization of human papillomavirus vaccination,Reasons for non-vaccination,,2017-09-25,COMPLETED,OBSERVATIONAL,['NA']
3218,NCT03947840,Rate of immunological response,Rate of recovery in physical activity,,2019-01-30,COMPLETED,OBSERVATIONAL,['NA']
3219,NCT02725424,major Pathological response rate,,,2015-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3220,NCT04639180,"Recurrence-Free Survival (RFS), as Determined by the blinded independent review committee (BIRC)",The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0,,2021-04-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
3221,NCT05910099,Rate of patients who remain in a rectal cancer clinical study to completion,,,2024-07,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3222,NCT05380557,Overall survival,,,2021-08-23,TERMINATED,OBSERVATIONAL,['NA']
3223,NCT03052478,Objective response rate (ORR) by RECIST 1.1,,,2017-02-10,COMPLETED,INTERVENTIONAL,['PHASE2']
3224,NCT03851133,Presence of Visceral Adiposity,Progression Free Survival,,2019-03-04,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3225,NCT03605186,"Change in ""patient-reported oral mucositis"".","Change in ""Clinical assessment of oral mucositis"".",,2019-02,UNKNOWN,INTERVENTIONAL,['NA']
3226,NCT04316013,Comparison of disease free survival (DFS) with lidocaine compared with no lidocaine,Health utility with intravenous lidocaine versus no lidocaine,MINS Substudy,2020-07-31,RECRUITING,INTERVENTIONAL,['PHASE3']
3227,NCT05865132,ORR,OS,,2023-04-06,RECRUITING,INTERVENTIONAL,['PHASE2']
3228,NCT01008657,2 years global (local+distant) recurrence rate,Primary treatment effectiveness (assessed 1 month after completion of treatment course which can include up to 3 radiofrequency ablation (RFA) procedures performed monthly),,2010-02-09,COMPLETED,INTERVENTIONAL,['NA']
3229,NCT04847167,Enteroscopy success rate,Therapeutic success rate,,2020-02-24,COMPLETED,INTERVENTIONAL,['NA']
3230,NCT03507699,Number of participants with serious dose-limiting treatment-related adverse events as assessed by CTCAE v5.0,Progression free survival,,2018-12-15,COMPLETED,INTERVENTIONAL,['PHASE1']
3231,NCT00024362,,,,2001-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
3232,NCT06055439,Objective Response Rate (ORR),Overall survival (OS),,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3233,NCT02827565,"Technical Optimization of KRAS, BRAF and NRAS mutations detection","KRAS, NRAS et BRAF mutational status",,2016-02-03,COMPLETED,INTERVENTIONAL,['NA']
3234,NCT04430725,Time to local recurrence per treated nodule,Changes in patient reported outcomes per patient,,2019-08-07,RECRUITING,OBSERVATIONAL,['NA']
3235,NCT00216424,Tumor response and resectability of tumor following treatment with radiation and capecitabine (Xeloda).,,,2005-02,TERMINATED,INTERVENTIONAL,['PHASE4']
3236,NCT05075421,5-year survival rates,,,2012-01-01,COMPLETED,OBSERVATIONAL,['NA']
3237,NCT00178243,,,,na,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3238,NCT05859750,The number of subjects experiencing adverse events (AEs),Number of subjects who develop detectable anti-drug antibodies (ADAs),,2023-05,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
3239,NCT04848311,number of harvested station 253 lymph nodes,number of total lymph nodes harvested,complications,2021-05-01,UNKNOWN,INTERVENTIONAL,['NA']
3240,NCT05007587,Objective Response Rate and Disease Control Rate of the HCC Participants,Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0,Hepatitis B infection,2021-07-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
3241,NCT05878405,Change in oral pain,Change in the amount of daily requirements of oral morphine equivalents,,2023-05-30,RECRUITING,INTERVENTIONAL,['PHASE3']
3242,NCT03908840,Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) observed during the trial,Determination of Maximum Tolerated Dose,,2019-12,UNKNOWN,INTERVENTIONAL,['PHASE1']
3243,NCT00003600,Quality of life,Response rate,,1998-12,COMPLETED,INTERVENTIONAL,['PHASE3']
3244,NCT02338752,efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1,immunology index,,2015-01,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3245,NCT03468231,Overall survival,Tumor response,,2018-03-09,UNKNOWN,INTERVENTIONAL,['PHASE3']
3246,NCT00826800,To Determine the Pathologic Complete Response (Path CR) Rate in Patients With Locally Advanced (Stage II or III) Colon Cancer to FOLFOX-bevacizumab Administered as Neoadjuvant.,,,2009-02,TERMINATED,INTERVENTIONAL,['NA']
3247,NCT05832398,1. Progression-free survival,Overall survival,,2023-05-01,RECRUITING,INTERVENTIONAL,['NA']
3248,NCT00024401,,,,2001-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
3249,NCT05394259,Accuracy is defined as the number of concordant cases between PYLARIFY PET-CT and the gold standard truth divided by the total sample size.,,,2022-10-28,RECRUITING,INTERVENTIONAL,['PHASE1']
3250,NCT00574275,Overall Survival (OS),Number of Participants With Anti-drug Antibodies,,2007-12,TERMINATED,INTERVENTIONAL,['PHASE3']
3251,NCT03435289,The maximally tolerated dose of CPI 613 combined with Gemcitabine and nab-paclitaxel,The number of participants with complete or partial response,,2017-10-19,UNKNOWN,INTERVENTIONAL,['PHASE1']
3252,NCT04695964,anastomotic leak,Length of post-operative hospital stay,,2019-02-01,UNKNOWN,INTERVENTIONAL,['NA']
3253,NCT01030263,Whether specialized columnar epithelium was detected.,,,2008-06,TERMINATED,INTERVENTIONAL,['PHASE4']
3254,NCT05524428,Primary Outcome 3: Appropriateness of Implementation Strategies,Secondary Outcome: CRC Screening Rates,,2023-03-24,RECRUITING,INTERVENTIONAL,['NA']
3255,NCT04250948,TRG0/1,Overall survival (OS),,2019-10-12,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3256,NCT01811108,Number of Participants with AE,Patients Overall Survival,,2009-07,COMPLETED,OBSERVATIONAL,['NA']
3257,NCT05312372,Objective response per central review of antitumor activity (using Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) (Phase 2),"Changes in vital signs : SBP, DBP, respiratory rate and temperature (Phase 2)",,2025-05,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3258,NCT02735941,Analysis of cannabinoid receptors in blood leukocytes and biopsies from patients with IBD and colon cancer,Assessment of malignancy of colon cancer by tumor staging,,2017-06-13,COMPLETED,OBSERVATIONAL,['NA']
3259,NCT04810910,Relapse Free Survival(RFS),Overall Survival(OS),Peripheral blood T cell receptor sequencing analysis,2021-03-30,RECRUITING,INTERVENTIONAL,['PHASE1']
3260,NCT03162198,Number of cell-free DNA (cfDNA) in cirrhotic patients with hepatocellular carcinoma (HCC),Number of cfDNA amount with the Barcelona Clinic of Liver Cancer (BCLC) stage of HepatoCellular Carcinoma.,,2017-05-15,COMPLETED,OBSERVATIONAL,['NA']
3261,NCT05816187,Changes in Health Related Quality of Life: EORTC QLQ-30,The five Times Sit to Stand Test (5x Sit-To-Stand Test),,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3262,NCT01249859,To test the hypothesis that 5-year survival rate is significantly lower in the signet ring cells (SRC) adenocarcinoma when compared to non-SRC adenocarcinoma in the upper digestive tract,"Overall 3 year survival according to tumor stage, node invasion, and tumor localization",,2010-03,COMPLETED,OBSERVATIONAL,['NA']
3263,NCT00003514,,,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3264,NCT03683004,Change from Beck Depression Inventory (BDI) from baseline to 12 and 24 weeks (Specific Aim III),Change from Optical Coherence Tomography baseline at 12 weeks and 24 weeks,,2018-01-22,COMPLETED,OBSERVATIONAL,['NA']
3265,NCT01135849,Development of cardiomyopathy,,,2008-11,COMPLETED,OBSERVATIONAL,['NA']
3266,NCT04452357,"Acute grade 3+ gastrointestinal toxicity possibly, probably or definitely related to radiation.",,,2020-01-13,SUSPENDED,INTERVENTIONAL,['NA']
3267,NCT05328765,Overall survival,,,2023-06-09,RECRUITING,OBSERVATIONAL,['NA']
3268,NCT01877135,at least one anal cancer,patient's feelings about his therapeutic care and impact on his emotional life,,2013-08,UNKNOWN,OBSERVATIONAL,['NA']
3269,NCT00609336,Median Overall Survival of Patients With Adenocarcinoma of the Pancreas,Percent of Patients Surviving at Annual Intervals,,2008-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3270,NCT02635087,DFS,OS,,2015-12,RECRUITING,OBSERVATIONAL,['NA']
3271,NCT03043729,Pathologic complete response (pCR),ECOG,,2017-03-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3272,NCT01267578,overall survival,Progression free survival,,2010-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
3273,NCT02449109,Number of participants with Adverse events,Overall survival (OS),,2015-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3274,NCT03303469,Measure Changes in Treated HCC Tumor Hypoxia Following TACE and Radiotherapy,,,2017-10-30,TERMINATED,INTERVENTIONAL,['PHASE2']
3275,NCT03765736,Companion Trial Enrollment,,,2020-04-20,TERMINATED,OBSERVATIONAL,['NA']
3276,NCT03104582,Acute cholangitis,Overall procedure related complication rate,,2011-11-01,COMPLETED,INTERVENTIONAL,['NA']
3277,NCT05438667,The duration of efficacy,Adverse events,,2022-06-07,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
3278,NCT00072098,toxicity grading,tumor response compared at four weeks to baseline,,2003-09,TERMINATED,INTERVENTIONAL,['PHASE1']
3279,NCT05901194,The proportion of patients with lenvatinib who have a Liver transplantation (LT),Incidence of Treatment-Emergent Adverse Events,,2023-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3280,NCT04443309,Objective Response Rate (ORR),Adverse Events (AE),Biomarker,2020-09-11,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3281,NCT05043532,Rate of ability to perform successful molecular profiling in core tissue obtained during EUS-guided fine needle biopsy,Type of actionable mutations detected on molecular profiling,,2021-08-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3282,NCT00826488,"It is anticipated that out of 100 subjects recalled for additional breast imaging that 10 women will be recalled for biopsy. By adding 2D & 3D imaging, it is anticipated that 30 subjects out of 100 will have needed no workup.",,,2009-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
3283,NCT05942807,Overall survival,,,2021-05-15,RECRUITING,OBSERVATIONAL,['NA']
3284,NCT00049023,"Evaluate the short term and long term safety (mild/moderate/severe/life-threatening adverse events, premature discontinuations and serious adverse events)",,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE1']
3285,NCT01436617,Validate the utility of an IgE anti-cetuximab test in the treatment strategy,,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
3286,NCT01010945,Maximum Tolerated Dose,Overall Survival,,2010-02-03,COMPLETED,INTERVENTIONAL,['PHASE1']
3287,NCT00789633,Overall Survival (OS),Progression Free Survival (PFS),,2008-11-25,COMPLETED,INTERVENTIONAL,['PHASE3']
3288,NCT03745170,Overall survival (OS),Number of participants experiencing clinical and laboratory adverse events (AEs),,2018-12-19,COMPLETED,INTERVENTIONAL,['PHASE3']
3289,NCT02063529,"the percentage of patients who had a curative liver treatment following protocol treatment, i.e., liver metastases that can be completely resected and/or ablated with no evidence of residual malignant disease.",Quality of life (QLQ C30),,2014-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3290,NCT01545804,disease stabilization,,,2011-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3291,NCT00441155,Safety and tolerability of nilotinib either as single agent or in combination with Imatinib,To assess any clinical responses in Imatinib-resistant GIST patients. Assessment of tumor response will be made based on modified RECIST criteria - to be assessed at the end of every cycle of treatment,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE1']
3292,NCT05235490,The main objective of this work is to identify biomarkers from CT scan (non-invasive imaging phenotypes from radiological images) which have a prognostic value for an early recurrence in patients with hepatocellular cancer.,Identify biomarkers from CT scan (non-invasive imaging phenotypes from radiological images) which have a prognostic value for a tardive recurrence in patients with hepatocellular cancer.,To correlate the imaging signatures predictive of recurrence with the cell population molding of tissue microenvironment (TME) and the tumor biology using tissue assessment as reference.,2021-01-28,COMPLETED,OBSERVATIONAL,['NA']
3293,NCT00123760,To demonstrate the safety of 18F-FDG synthesized from cyclotron produced radiofluoride in the Coincidence Technologies automated synthesis unit (ASU) in the Edmonton PET Centre facility,To confirm the diagnostic effectiveness of 18F-FDG in subjects with known or suspected oncologic disease and compare this to literature values,,2004-02,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3294,NCT04848051,Total number of participants who completed their colorectal cancer screening,Screening outcomes: diagnostic results,,2021-10-12,COMPLETED,INTERVENTIONAL,['NA']
3295,NCT00842348,Adverse Events,Progression Free Survival (PFS): Kaplan-Meier Estimate,,2009-02,COMPLETED,INTERVENTIONAL,['PHASE3']
3296,NCT03600623,Number of participants with adverse events as a measure of safety and tolerability,Proportion of participants undergoing surgery after preoperative chemoradiation therapy,,2017-09-25,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
3297,NCT06055543,Improvement in nutritional status,ONS Satisfaction,,2023-08-09,RECRUITING,INTERVENTIONAL,['PHASE4']
3298,NCT01501903,Diagnostic accuracy,Number of passes for diagnosis,,2011-09,COMPLETED,INTERVENTIONAL,['NA']
3299,NCT02325986,overall response rate,overall survival,,2015-03,UNKNOWN,INTERVENTIONAL,['PHASE2']
3300,NCT01675999,Histological tumor response in the primary tumor according to the simplified Tumor Regression Grade (TRG) of Ryan,•Evaluation of another histopathological grade,,2012-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
3301,NCT04072445,Progression-free Survival (PFS),Number of Participants With Adverse Events,Prediction of Clinical Benefit by Thymidine Kinase 1 (TK1),2019-10-18,COMPLETED,INTERVENTIONAL,['PHASE2']
3302,NCT00006050,,,,1999-04-04,COMPLETED,INTERVENTIONAL,['PHASE2']
3303,NCT03981614,Progression Free Survival (PFS),Number of Participants With Adverse Events,,2019-10-29,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3304,NCT01505400,Molecular profiling data to be made available in patient's electronic medical records.,Clinical trial accrual rates among patients with available molecular profiling data,,2012-02,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3305,NCT05460403,Overall survival (OS),Distant metastasis (DM),Adverse events,2022-04-23,RECRUITING,OBSERVATIONAL,['NA']
3306,NCT06251973,Overall Response Rate,,,2024-02-01,RECRUITING,INTERVENTIONAL,['PHASE2']
3307,NCT03591965,ORR,"6, 9 and 12 month of survival rate",Additional metabolites of ATG-008 in plasma and urine,2018-08-07,TERMINATED,INTERVENTIONAL,['PHASE2']
3308,NCT05613465,Cancer-related fatigue,Immunologic function,,2022-10-25,RECRUITING,INTERVENTIONAL,['NA']
3309,NCT02234180,Disease Free Survival (DFS),Overall Survival (OS),,2014-09,TERMINATED,INTERVENTIONAL,['PHASE2']
3310,NCT00390182,Overall Response,,Time of Advanced/Recurrent Disease Without Distant Metastases.,2003-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3311,NCT06314750,OS,,,2010-01-01,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3312,NCT00828607,"Malignancy of the liver mass, as determined on US, on CEUS, and on CECT or CEMRI.","Diagnosis of the liver mass, as determined on US, on CEUS, and on CECT or CEMRI.",,2009-01,COMPLETED,OBSERVATIONAL,['NA']
3313,NCT01704820,Per patient adenoma detection rate (average # adenomas detected/ patient in each arm of the study).,Evaluate endoscopist comfort with performing retroflexion in the proximal colon.,,2012-09,UNKNOWN,INTERVENTIONAL,['NA']
3314,NCT06071598,To define the functional role of MFSD2A in CRC through Polyunsaturated fatty acid (PUFA) ad genes analysis.,,,2023-03-15,RECRUITING,OBSERVATIONAL,['NA']
3315,NCT02279771,anastomotic leak,Number of overall postoperative complications,,2015-01,UNKNOWN,INTERVENTIONAL,['NA']
3316,NCT00113256,survival,,,2005-02,TERMINATED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3317,NCT03081988,Prediction model for CCRT response based on clinical and genetic molecular factors,in-vitro prediction of CCRT using primary esophageal cancer organoid,Clinical prediction factors for CCRT response (retrospective study),2015-10-19,RECRUITING,OBSERVATIONAL,['NA']
3318,NCT03662841,Time to progression,Tumor response,,2018-07-13,TERMINATED,INTERVENTIONAL,['NA']
3319,NCT00087282,,,,2004-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3320,NCT02749513,Inhibition of Hedgehog pathway signaling as measured by real-time PCR.,Inhibition of VEGFR2 pathway signaling as measured by Western blot,,2016-01,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
3321,NCT04934618,Overall Suvival time（OS）,Disease control rate（DCR）,Safety and tolerability,2020-05-19,RECRUITING,INTERVENTIONAL,['PHASE2']
3322,NCT03752398,Treatment-related adverse events as assessed by CTCAE v4.03,,,2019-05-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
3323,NCT02151864,Rate of dose limiting toxicities,,,2014-07,COMPLETED,INTERVENTIONAL,['PHASE1']
3324,NCT02079220,anti-tumor activity of ziv-aflibercept in combination with XELOX in the first-line treatment of patients with metastatic colorectal cancer (mCRC),Progression-free survival (PFS),,2014-03,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3325,NCT01882972,Retention feasibility,Self-reported Exercise-related Injury,,2013-06,WITHDRAWN,INTERVENTIONAL,['NA']
3326,NCT06013943,6-month progression-free survival rate (PFS),Objective response rate (ORR) per RECIST 1.1,Adverse events,2023-03-17,RECRUITING,INTERVENTIONAL,['PHASE2']
3327,NCT04455945,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Colorectal Cancer 29 (EORTC QLQ-CR29) Symptom scales,,,2017-01-01,COMPLETED,OBSERVATIONAL,['NA']
3328,NCT04482608,Progression-Free Survival (PFS),Overall survival,,2019-09-01,COMPLETED,OBSERVATIONAL,['NA']
3329,NCT00078468,To determine the overall objective response rate (complete and partial responses) of AG-2037 in patients with metastatic colorectal cancer who failed treatment with 5FU/LV regimen and up to one other chemotherapeutic regimen.,"To correlate the various genetic markers of MTAP, folate and purine metabolism with clinical response.",,2003-12,COMPLETED,INTERVENTIONAL,['PHASE2']
3330,NCT00697047,Long-term adherence to CRC screening,Impact of SOS interventions on outcomes and CRC-related costs,,2008-07,COMPLETED,INTERVENTIONAL,['NA']
3331,NCT01373346,Operation Related Mortality,Albumin : Good Response Group,,2010-02,COMPLETED,INTERVENTIONAL,['NA']
3332,NCT05433467,The position of the needle,Intraoperative bleeding,,2022-05-01,RECRUITING,INTERVENTIONAL,['NA']
3333,NCT04248647,"Functional capacity: Six-minute walk test (Enright, 2003)","Nutritional status: body weight loss, serum albumin, hand grip strength, body mass index, lean body mass and percentage of body fat",,2016-10-26,COMPLETED,INTERVENTIONAL,['NA']
3334,NCT06157892,Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by investigator assessment,Incidence of anti-drug antibodies (ADAs) against disitamab vedotin,,2024-04-30,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3335,NCT00402961,To determine whether a Phase III trial of acupuncture for postoperative recovery after colorectal surgery is warranted as defined by evidence of reduction of postoperative ileus when compared to sham acupuncture,Number of emetic episodes during hospital stay,,2006-10,COMPLETED,INTERVENTIONAL,['PHASE2']
3336,NCT03228095,Performance of nanoarray sensor testing to detect target lesions and diseases,Groups of gastrointestinal microbiota correlating to VOCs,,2017-07-24,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
3337,NCT01084330,Progression Free Survival,"Evaluate Safety by measuring cardiac safety, recording Adverse Events (AEs) and tracking the tolerability of AUY922",,2010-04,COMPLETED,INTERVENTIONAL,['PHASE2']
3338,NCT00365391,Number of Patients With Confirmed Tumor Response Defined to be Either a Complete Response (CR) or Partial Response (PR).,Time to Treatment Failure,,2006-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3339,NCT02716688,response rate,Overall survival,Dysphagia score,2016-01,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3340,NCT05475288,Overall survival of patients with locoregionally recurrent colon cancer;,,,2015-01-01,COMPLETED,OBSERVATIONAL,['NA']
3341,NCT01959906,overall survival,,,2013-07,UNKNOWN,OBSERVATIONAL,['NA']
3342,NCT03118882,screening-related indicators,Circulating biomarkers association with breast and colorectal cancer,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
3343,NCT03067012,"micronutrients' deficiency (iron, folate, vitamin B12)",Remission rates of co-morbidities,,2015-09-01,COMPLETED,INTERVENTIONAL,['NA']
3344,NCT05494359,"The number of 15 Nitrogen, 14 Nitrogen, 28 Nitrogen, 29 Nitrogen, 30 Nitrogen",The stage of the cancer,,2023-04-04,RECRUITING,OBSERVATIONAL,['NA']
3345,NCT04682847,Develop a platform to maintain liver functionality during treatment for liver cancer,Examine the dose-response of tumor and liver tissue in patients who received liver transplant after receiving SBRT,,2020-11-19,ACTIVE_NOT_RECRUITING,OBSERVATIONAL,['NA']
3346,NCT01656746,"Oncologic sample including size of specimen removed, number of lymph nodes (LN) removed, pathological type and staging, lymph node, vessel or perineural invasion, and status of margins","Visual analogue cosmesis scale scored on the scale from 0 to 10 where 0 is ""worst scar"", and 10 is the ""best scar""",,2010-05,COMPLETED,INTERVENTIONAL,['NA']
3347,NCT01383343,"Maximum tolerated dose of sorafenib tosylate in combination with FOLFIRI and bevacizumab, defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients)","Time until hematologic nadirs (ANC, platelets, hemoglobin)",,2011-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3348,NCT05688176,Identification of biomarkers (messenger RNAs) for therapy response prediction,Development of a quantitative Polymerase Chain Reaction (qPCR) test for clinical use,,2016-06,RECRUITING,OBSERVATIONAL,['NA']
3349,NCT01769534,To validate the Sendai criteria prospectively in patients with pancreatic cysts.,,,2012-06,TERMINATED,OBSERVATIONAL,['NA']
3350,NCT02972034,Percentage of Participants Who Experience a Dose-limiting Toxicity (DLT),Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as Assessed by the Investigator,,2017-01-13,COMPLETED,INTERVENTIONAL,['PHASE1']
3351,NCT00912327,Objective response rate (ORR),Overall survival,,2009-06,COMPLETED,OBSERVATIONAL,['NA']
3352,NCT04602117,Overall response rate (ORR),Duration of response (DOR) of patients treated with the weekly paclitaxel with tri-weekly trastuzumab duocarmazine (SYD985) combination,,2021-07-28,WITHDRAWN,INTERVENTIONAL,['PHASE1']
3353,NCT05093920,Tumor size,Serum Alpha-fetoprotein level ng/ml.,,2022-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
3354,NCT01274143,Colonoscopy,Decisional Conflict,,2008-05,COMPLETED,INTERVENTIONAL,['NA']
3355,NCT03659903,median OS,,,2004-01-01,COMPLETED,OBSERVATIONAL,['NA']
3356,NCT03852251,Anti-tumor activity of AK104 using objective response rate (ORR) based on RECIST v1.1 as assessed by the investigator (Phase II),Number of subjects who develop detectable anti-drug antibodies (ADAs),,2019-01-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3357,NCT03877601,Fluorescence signal in patients with Barrett's Esophagus,Interrogate potential new EC biomarkers,,2019-07-29,UNKNOWN,INTERVENTIONAL,['PHASE2']
3358,NCT03941080,Prediction of response to conventional systemic anti-tumor therapy conventional systemic anti-tumor therapy for metastatic or irresectable colorectal cancer,Prediction of serious side effects to conventional systemic anti-tumor therapy for metastatic or irresectable colorectal cancer,,2020-09-09,RECRUITING,OBSERVATIONAL,['NA']
3359,NCT04248634,Perineal complications,Quality of life assessement: EORTC QLQ30 score,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
3360,NCT06189846,The rate of complete and/or nearly complete response,Rate of changing attitude after using the digital rectoscope platform (intra-observer changing management).,,2024-01-04,RECRUITING,OBSERVATIONAL,['NA']
3361,NCT02528526,Safety and tolerability as measured by collection of adverse effects information,Efficacy as measured by MRI,,2014-02,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3362,NCT05311189,Progression-free survival,Safety and tolerability based on incidence of treatment-emergent adverse events as assessed by CTCAE,,2022-04-15,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
3363,NCT06300879,Postoperative TNM staging by Pathological findings .,Quality of Life at 3 Months Postoperatively will be assessed by EORTC QLQ-STO22 scale,,2024-01-01,RECRUITING,INTERVENTIONAL,['NA']
3364,NCT04514822,SUVmax 60/30 comparison between MLNs and BLNs,SUVmax 60/30 comparison from PTs between N0 and non-N0 stage,Accuracy,2019-03-01,UNKNOWN,INTERVENTIONAL,['NA']
3365,NCT02041793,Resolution of Pseudocyst,Recurrence rate of pseudocyst,,2010-05,COMPLETED,INTERVENTIONAL,['NA']
3366,NCT03713593,Overall Survival (OS),Number of Participants Who Discontinued Study Drug Due to an Adverse Event,,2018-12-31,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
3367,NCT01504477,Maximum Tolerated Dose,Duration of Disease Control,,2011-12,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3368,NCT04763642,Intra-abdominal infection,Length of hospital stay (day),progression-free survival,2020-01-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3369,NCT02190071,positive malignancy rate of cover slides set and base slides set.,"positive malignancy rate of (1) cytologic smear, (2) cell block and (3) histologic biopsy",,2014-06,COMPLETED,OBSERVATIONAL,['NA']
3370,NCT02066974,Response rate,"Overall survival, relapse-free survival",,2014-01,UNKNOWN,OBSERVATIONAL,['NA']
3371,NCT01151839,operative mortality,Treatment toxicity,,2010-06,UNKNOWN,INTERVENTIONAL,['NA']
3372,NCT03127774,Progression Free Survival,Overall Survival,,2017-09-22,RECRUITING,INTERVENTIONAL,['PHASE2']
3373,NCT04008082,Presence or absence of factors with a possible influence on OS,,,2019-05-14,COMPLETED,OBSERVATIONAL,['NA']
3374,NCT05396807,Progression Free Survival (PFS),Quality of Life (QoL),,2023-03-21,RECRUITING,INTERVENTIONAL,['NA']
3375,NCT00078975,Prolonged stable disease rate,Safety and tolerability,,2004-04,COMPLETED,INTERVENTIONAL,['PHASE2']
3376,NCT06210334,Overall Survival (OS),Adverse Events (AE),,2024-03,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
3377,NCT00258232,Response rate by RECIST criteria at every other course,Time to treatment failure,,2002-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3378,NCT03111732,Progression Free Survival (PFS),"Number of Participants With Grade 1-4 Adverse Events Unrelated, Unlikely, Possibly, and Probably Related to Capecitabine",Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0),2017-06-14,COMPLETED,INTERVENTIONAL,['PHASE2']
3379,NCT04700527,The rate and severity of patient reported and physician determined toxicities between subjects who receive therapeutic SCFA and those who receive placebo.,Subject reported acute toxicity profile as ascertained by patient-reported outcomes version of the CTCAE (PRO-CTCAE) for both subjects who receive therapeutic SCFA versus those who receive placebo.,,2023-12-15,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3380,NCT03430440,Postoperative pain (numerical rating scale: 0 ~ 10),Side effects of PCA (area and vomiting / hypotension / muscle weakness,,2017-03-01,UNKNOWN,INTERVENTIONAL,['NA']
3381,NCT05187416,Elastic modulus measured by Ultrasonic shear wave and tumor stromal component assessed by pathological analysis in pancreatic cancer,,,2022-02-01,UNKNOWN,OBSERVATIONAL,['NA']
3382,NCT00002593,"Compare effectiveness of bolus 5-FU, leucovorin, levamisole vs continuous infusion 5-FU, levamisole as adjuvant therapy for patients with colon cancer, measured in overall survival",Disease free survival,,1994-12,COMPLETED,INTERVENTIONAL,['PHASE3']
3383,NCT00618384,determination of time to progression (TTP),adverse events,,2008-01,TERMINATED,INTERVENTIONAL,['PHASE2']
3384,NCT02735317,EORTC QLQ-C30,The change of body weight from baseline.,,2016-04,UNKNOWN,INTERVENTIONAL,['PHASE2']
3385,NCT01286662,mortality,Incidence of desmoid tumors,,1978-01,COMPLETED,OBSERVATIONAL,['NA']
3386,NCT04097067,Response rate,Acute and chronic toxicities,,2019-09-01,RECRUITING,INTERVENTIONAL,['NA']
3387,NCT02521727,number of participants having advanced neoplasms.,number of participants having advanced neoplasms based on age of the proband,,2015-11-26,COMPLETED,OBSERVATIONAL,['NA']
3388,NCT01643278,Maximum tolerated dose defined as the highest dose studied for which the observed incidence of dose-limiting toxicity is less than 33% according to the National Cancer Institute Common Toxicity Criteria,"RR as measured by RECIST 1.1, Choi and immune-related response criteria",Genotype (v-Kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog [KIT] and platelet-derived growth factor receptor-alpha [PDGFR-a]) mutation status,2012-07,COMPLETED,INTERVENTIONAL,['PHASE1']
3389,NCT02907086,Number of blood samples collected,,,2017-07-07,COMPLETED,OBSERVATIONAL,['NA']
3390,NCT05177393,Median Overall Survival,,,2019-02-28,RECRUITING,OBSERVATIONAL,['NA']
3391,NCT03129685,Short term mortality rate,Tumor response rate according to mRECIST criteria.,,2017-05-20,UNKNOWN,INTERVENTIONAL,['NA']
3392,NCT02041325,Positive for Hepatitis B Surface Antigen,Phenotypic Changes,,2005-04,COMPLETED,INTERVENTIONAL,['PHASE2']
3393,NCT01835925,Tumor tissue to predict likelihood of achieving pathologic complete response post standard treatment.,Tumor tissue results with clinical outcome post standard treatment. .,,2013-07,COMPLETED,OBSERVATIONAL,['NA']
3394,NCT05817994,"Number of endoscopic, endosonographic, and radiologic interventions undergone to reach a diagnostic liver biopsy [Phase 2]",Number of diagnostic liver biopsies,,2023-04,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3395,NCT03569761,CRC screening intentions,CRC screening completion,,2017-08-01,COMPLETED,INTERVENTIONAL,['NA']
3396,NCT00793871,Progression-free Survival (PFS),Eastern Cooperative Oncology Group (ECOG) Performance Status,Time to Tumor Response (TTR),2008-11,COMPLETED,INTERVENTIONAL,['PHASE4']
3397,NCT03599895,operation time,hospitalization expenses,,2018-08-01,UNKNOWN,INTERVENTIONAL,['NA']
3398,NCT03946969,Safety and feasibility,Overall Survival (OS),Exploratory Outcomes,2019-05-09,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3399,NCT04856761,"RFS, recurrence-free survival","OS, overall survival",,2020-11-01,RECRUITING,OBSERVATIONAL,['NA']
3400,NCT01839487,Percentage of Participants in the PAG Arm Who Experienced Any Thromboembolic (TE) Event in Stage 2 of the Study,Area Under the Concentration-Time Curve From Time 0 to Last Quantifiable Concentration (AUC0-last) of PEGPH20,,2013-05-14,COMPLETED,INTERVENTIONAL,['PHASE2']
3401,NCT05919264,During dose expansion describe the Overall Response Rate using RECIST v1.1,During dose expansion describe Progression Free Survival,,2023-05-19,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3402,NCT03619538,Estimate morphine consumption,,,2011-07,COMPLETED,INTERVENTIONAL,['NA']
3403,NCT00351195,Response,Survival,,2006-02,TERMINATED,INTERVENTIONAL,['PHASE2']
3404,NCT00574860,NCI v3 to measure severity of OM,WHO criteria for measuring severity of OM,,2007-12,TERMINATED,INTERVENTIONAL,['PHASE3']
3405,NCT06033976,Rate of curative resection,Rate of R0 resection,Rate of delayed bleeding,2021-01-01,RECRUITING,OBSERVATIONAL,['NA']
3406,NCT00005599,,,,2000-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3407,NCT05568433,Role of the cyst fluid concentrations of the specific biomarkers for differentiation the pancreatic cystic lesions,The Correlation between cyst fluid concentration and serum level of the specific biomarkers,,2018-04-02,COMPLETED,OBSERVATIONAL,['NA']
3408,NCT03875144,overall survival,Quality of life evaluation,,2020-08-14,RECRUITING,INTERVENTIONAL,['PHASE2']
3409,NCT00985556,Progression-free survival,Time to progression,,2009-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
3410,NCT01291615,frequency in adverse events,,,2010-12,COMPLETED,INTERVENTIONAL,['PHASE1']
3411,NCT01803009,Preferred CRC screening test,Uptake of CRC screening,,2012-11,COMPLETED,INTERVENTIONAL,['NA']
3412,NCT00987857,Overall survival,Frequency of endoscopy,,2009-03,UNKNOWN,INTERVENTIONAL,['NA']
3413,NCT05813028,"Change of Beck Anxiety Inventory score at baseline and one week later fisrt,second,third and forth chemothraphy.",,,2022-07-15,RECRUITING,INTERVENTIONAL,['NA']
3414,NCT05323058,Severity of mucositis,Pain and burning sensation,Patient-Reported Oral Mucositis( PROMS scale),2022-07,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
3415,NCT05483075,Number of Intervention Arm Participants in Compliance with HCP Exercise Intervention,Minutes Spent in Rapid Eye Movement (REM) Sleep,,2022-11-15,RECRUITING,INTERVENTIONAL,['NA']
3416,NCT01403727,Radiation Dose,Accuracy of needle targeting,,2011-11,COMPLETED,OBSERVATIONAL,['NA']
3417,NCT06074536,"The Measurement of the achievement oh the shared decision shared decision making in CRC screening using the patient shared a self-decision-making questionnaire (SDM-Q9), validated in French",Explore understanding of the shared decision process among general practitioners and patients,,2024-03-06,RECRUITING,INTERVENTIONAL,['NA']
3418,NCT05415917,Safety as assessed by number of participants experiencing adverse events,,To measure the tumor with the Response Evaluation Criteria in Solid Tumors (RECIST),2022-07-29,RECRUITING,INTERVENTIONAL,['PHASE2']
3419,NCT04527068,Progression-free survival (PFS),Duration of Response (DOR),,2020-09-20,UNKNOWN,INTERVENTIONAL,['PHASE2']
3420,NCT00417209,overall survival (OS) defined as the time interval from the date of randomization to the date of death due to any cause,Progression free survival (PFS); Overall Response Rate (proportion of patients with confirmed RECIST-defined complete response (CR) or partial response (PR); clinical benefit based on the measurement of tumor related symptoms;,,2006-12,COMPLETED,INTERVENTIONAL,['PHASE3']
3421,NCT01328171,overall response rate,translational research (EGFR genetics and proteomics): prognostic and predictive impact on efficacy outcomes,,2011-04,COMPLETED,INTERVENTIONAL,['PHASE2']
3422,NCT05396846,Weight Loss,,Skin Carotenoids,2023-06-13,RECRUITING,INTERVENTIONAL,['NA']
3423,NCT04384757,3 year relapse-free survival by Kaplan Mayer,Resected lymph nodes,,2020-07-29,RECRUITING,INTERVENTIONAL,['NA']
3424,NCT04891146,investigate the effect of anesthesia management on the change of preoperative systemic inflammatory immune index(SII) and postoperative 2.hour and 24.hour SII value,,,2020-03-05,COMPLETED,OBSERVATIONAL,['NA']
3425,NCT05873699,"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",,,2023-08-18,RECRUITING,INTERVENTIONAL,['PHASE1']
3426,NCT05682157,Change in LARS score,,,2023-03-21,RECRUITING,INTERVENTIONAL,['NA']
3427,NCT04801719,Overall survival,Complications of endoluminal RFA of biliary tract,,2010-01-04,COMPLETED,INTERVENTIONAL,['NA']
3428,NCT05233007,Predicting treatment resistance to anti-cancer therapy,,,2022-01-25,SUSPENDED,OBSERVATIONAL,['NA']
3429,NCT06152757,"AE, SAE, AESI, CRS, ICANS, TEAE",,,2023-10-09,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
3430,NCT05420922,The treatment-related adverse events (TRAEs),The progression-free survival (PFS),,2021-11-01,RECRUITING,OBSERVATIONAL,['NA']
3431,NCT00765180,Colorectal adenoma detection rate,"Procedure time, complication",,2007-01,COMPLETED,INTERVENTIONAL,['NA']
3432,NCT02132468,"Number of Participants With Improved, Stable, or Worsened Change In Serotonin Biomarker Levels From Baseline","Number of Participants With Partial Response (PR), Progressive Disease (PD), or Stable Disease (SD) Based on RECIST 1.1",,2014-09,COMPLETED,INTERVENTIONAL,['PHASE2']
3433,NCT01057017,Number of Patients With Toxicity to Combination of Panitumumab and Bevacizumab,,,2010-01,TERMINATED,INTERVENTIONAL,['PHASE2']
3434,NCT01619423,Number of Patients With Neuropathy Grade 2 or Higher (According to the Oxaliplatin Specific Sanofi Scale (OSSS) Criteria Related Paraesthesia/Dysaesthesia),,,2012-09,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3435,NCT00482846,Maximum tolerated dose of melphalan when treated with palifermin to prevent mucositis,Reduction in incidence and duration of mucositis,,2007-06,COMPLETED,INTERVENTIONAL,['PHASE1']
3436,NCT01908426,Overall Survival (OS),Objective Response Rate (ORR),,2013-09-26,COMPLETED,INTERVENTIONAL,['PHASE3']
3437,NCT05524090,In-hospital major morbidity,Shared decision-making: patients' healthcare satisfaction,,2021-07-01,RECRUITING,OBSERVATIONAL,['NA']
3438,NCT02275403,Change in Measure Yourself Medical Outcome Profile (MYMOP2) score of the most troubling symptom of CIPN,Uptake of the offer of acupuncture at 10 weeks,,2015-04-13,COMPLETED,INTERVENTIONAL,['PHASE2']
3439,NCT00001532,evaluating the role of hereditary factor,"low dose radiation CT scan, and Zoom Scan",,1996-09-13,RECRUITING,OBSERVATIONAL,['NA']
3440,NCT00564720,Overall Survival,Symptoms improvement,,2006-12,TERMINATED,INTERVENTIONAL,['PHASE2']
3441,NCT04543019,Progression free survival (PFS) and overall survival (OS),response to systemic therapy,,2020-12,UNKNOWN,OBSERVATIONAL,['NA']
3442,NCT00135577,"Incidence of reported adverse events, including serious adverse events","Incidence of treatment-limiting toxicities, changes in pain intensity, patient satisfaction, health outcome measures",,2004-09,COMPLETED,INTERVENTIONAL,['PHASE2']
3443,NCT03098589,Adverse Events (AEs),,,2017-05-30,RECRUITING,OBSERVATIONAL,['NA']
3444,NCT05677724,single cell RNA sequencing,,,2022-07-01,RECRUITING,OBSERVATIONAL,['NA']
3445,NCT03215290,Cutting surface related complications,Interventions for cutting surface related complications,,2016-10,COMPLETED,INTERVENTIONAL,['NA']
3446,NCT01547130,Efficacy of Large Bowel Cleansing as Assessed by the Physician Performing the Colonoscopy,Total Preparation Time,,2008-05,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3447,NCT03264807,Superiority verification of disease-free survival after lymphadenectomy for D2 + 14v lymph node dissection in gastric resection in patients with T3N + and T4N + stomach cancer,,,2015-08-06,UNKNOWN,INTERVENTIONAL,['PHASE3']
3448,NCT04276415,Progression-free Survival (PFS) Following Intravenous Administration of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) (Dose Expansion),Number of Participants With Anti-drug Antibodies Against DS-6157a Following Intravenous Administration of DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumors (GIST),,2020-05-08,TERMINATED,INTERVENTIONAL,['PHASE1']
3449,NCT00745927,Degree of abdominal discomfort during and after colonoscopy,Number of neoplasm detected,,2008-06,UNKNOWN,INTERVENTIONAL,['NA']
3450,NCT05077839,ORR,OS,,2021-09-01,RECRUITING,INTERVENTIONAL,['PHASE2']
3451,NCT00003995,,,,1999-09,COMPLETED,INTERVENTIONAL,['PHASE2']
3452,NCT05248581,percentage overall survival,,,2019-08-16,RECRUITING,OBSERVATIONAL,['NA']
3453,NCT00940758,To characterize the pharmacokinetics of biweekly PEP02 in patients with metastatic colorectal cancer who failed to first-line oxaliplatin-based chemotherapy,To explore the association of the pharmacogenetics of PEP02 including UGT1A family - UGT1A1 and UGT1A9 with pharmacokinetic parameters and toxicity,,2009-06,COMPLETED,INTERVENTIONAL,['PHASE1']
3454,NCT05795920,progression free survival progression free survival,Duration of response Duration of Response,,2023-03-08,RECRUITING,INTERVENTIONAL,['PHASE2']
3455,NCT02432963,"Tolerability of combined modified vaccinia virus Ankara vaccine expressing p53 and pembrolizumab, using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.3","T cell reactivity to p53, assessed by flow cytometry",,2016-06-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
3456,NCT04513223,DLT and the recommended Phase 2 dose (RP2D),,,2021-03-30,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
3457,NCT01979029,The Blood Pressure of the Arterial Arcade,Distal Colon Length,Systemic Blood Pressure,2013-02,COMPLETED,INTERVENTIONAL,['NA']
3458,NCT03532711,Objective Response Rate (ORR),Progression Free Survival (PFS),,2012-01-01,COMPLETED,OBSERVATIONAL,['NA']
3459,NCT00639925,"Adverse effect, toxicities as assessed by NCI CTCAE version3.0",feasibility,,2007-03,UNKNOWN,INTERVENTIONAL,['PHASE1']
3460,NCT02088333,Completion of CRC Screening,Usability of the mCRC system,,2014-06,COMPLETED,INTERVENTIONAL,['NA']
3461,NCT05027347,The sensitivity and and specificity of our mutation-based assay for detecting early-stage gastric cancer patients,The concordance rate of mutation results between plasma and tissue biopsy assay,,2021-10-10,UNKNOWN,OBSERVATIONAL,['NA']
3462,NCT00243854,"To determine if giving chemotherapy, radiation, and Tarceva,(EGFR-tyrosine kinase inhibitor)will have side effects that will prevent surgery following this therapy",,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE1']
3463,NCT04837742,Drug spread level of erector spinae plane block,Postoperative recovery quality,,2021-04-14,COMPLETED,INTERVENTIONAL,['NA']
3464,NCT00569790,Safety,"Progression-free survival, Response rate, Overall survival, Treatment situation",,2007-10,COMPLETED,INTERVENTIONAL,['PHASE2']
3465,NCT04022109,Specific chemistry identification in the exhaled breath,Gut microbiota analysis in relation to breath VOCs,Confounding factor analysis,2019-11-01,RECRUITING,OBSERVATIONAL,['NA']
3466,NCT00806611,The primary endpoint is cancer related pain control.,,,2008-09,COMPLETED,INTERVENTIONAL,['PHASE3']
3467,NCT00826813,Overall survival,Dysphagia relief,,2009-01,UNKNOWN,INTERVENTIONAL,['NA']
3468,NCT03864211,Progression free survival,The general health status,,2019-06-15,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3469,NCT04553458,"PROGRESSIVE((Number of patients with progression of the disease) (measured by follow-up CT scans, increase in size, appearance of new intratumoral lesions, or appearance of new lesions",DEATH (Number of patients died from the disease),,2015-06,COMPLETED,OBSERVATIONAL,['NA']
3470,NCT01220934,Overall survival according to Response Evaluation Criteria in Solid Tumors (RECIST),Safety (incidence of adverse events),,2010-04-16,COMPLETED,OBSERVATIONAL,['NA']
3471,NCT03169777,ORR by Immune-related response criteria (irRC ),"Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03",,2018-08,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3472,NCT03939845,OS,,,2019-04-23,UNKNOWN,INTERVENTIONAL,['PHASE3']
3473,NCT01503411,Primary Effectiveness Endpoint,,,2012-01,COMPLETED,OBSERVATIONAL,['NA']
3474,NCT05875753,Adverse events after injection of 68Ga-FAPI-FS,SUVmax of tumor lesions on 68Ga-FAPI-FS,,2022-06-01,RECRUITING,INTERVENTIONAL,['EARLY_PHASE1']
3475,NCT01384695,to determine whether tissue is neoplastic or non-neoplastic,,,2009-06,TERMINATED,INTERVENTIONAL,['EARLY_PHASE1']
3476,NCT04922853,pathological Tumor Regression Grade evaluation,cumulative local recurrence rate,,2021-08-26,RECRUITING,INTERVENTIONAL,['PHASE3']
3477,NCT04429841,Operative mortality rate,5 years Overall survival rate,,2010-01,COMPLETED,OBSERVATIONAL,['NA']
3478,NCT03483922,DNA methylation of circulated tumor and PBMC DNA and its Correlation to Development and prediction of HCC,,,2018-08-20,COMPLETED,OBSERVATIONAL,['NA']
3479,NCT01413022,Optimal dose and dose-limiting toxicity of PF-04136309 in combination with FOLFIRINOX,Prevalence and function of MDSC in peripheral circulation before and after treatment with PF-04136309 plus FOLFIRINOX or with FOLFIRINOX alone,,2012-04,COMPLETED,INTERVENTIONAL,['PHASE1']
3480,NCT06200831,"Comprehensive Complication Index, CCI",Quality of Life: EORTC QLQ-30,,2024-06-01,RECRUITING,INTERVENTIONAL,['NA']
3481,NCT06026774,Number of Participants with Adverse Events (AEs) [safety and tolerability],Cytokines Level [immunogenicity],,2023-09-08,RECRUITING,INTERVENTIONAL,['PHASE1']
3482,NCT04735107,Defunction ileostomy rate,Postoperative morbidity,,2018-11-01,UNKNOWN,INTERVENTIONAL,['NA']
3483,NCT05686122,Feasibility of PainPac,Change in PROMIS - Emotional Distress (Depression) Short Form,,2023-09-28,RECRUITING,INTERVENTIONAL,['NA']
3484,NCT05172310,Diagnostic accuracy of FAPI-PET/CT in primary tumors,Safety of 68Ga-FAPI-46,,2021-06-02,RECRUITING,INTERVENTIONAL,['PHASE1']
3485,NCT00323518,the incidence of grade 3/4 oral mucositis using WHO grading system,,,2006-05,COMPLETED,INTERVENTIONAL,['PHASE2']
3486,NCT06279351,ETS,PFS,,2024-04-01,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
3487,NCT01840592,overall survival,toxicity,,2013-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3488,NCT06108310,Identification of radiogenomics signature (ATTRACT AI-model) of stage II-III colon tumors,Correlation of radiogenomics signature (ATTRACT AI-model) of colon cancer with clinical outcomes (DFS and RFS),,2021-01-02,RECRUITING,OBSERVATIONAL,['NA']
3489,NCT04456140,Incidence rate of germline pathogenic genetic mutations in cancer patients seen at St Vincent's and uptake rate of cascade testing in families,Differences in survey responses between patient groups,,2020-06-29,COMPLETED,INTERVENTIONAL,['PHASE1']
3490,NCT05079438,≥Grade 2 proctitis,,,2021-09-07,RECRUITING,INTERVENTIONAL,['PHASE3']
3491,NCT00900003,Cellular localization of BRCA1 as a predictor of response to cytotoxic agents or radiotherapy,Application of a method of extracting and identifying secreted cytokines and growth factors from biopsy tissue to the pancreatic cancer population,,2007-05,COMPLETED,OBSERVATIONAL,['NA']
3492,NCT04493125,The number of radiopaque markers transferred to the large intestine 3 days after surgery,,,2020-07-27,UNKNOWN,INTERVENTIONAL,['NA']
3493,NCT00800969,Diagnostic Accuracy of PET-CT,,,2008-10,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3494,NCT05723107,Percentage of Participants who Complete Therapy without Grade III-IV Adverse Events (AEs) as Assessed by CTCAE v. 5.0,Percentage of Participants who Report Post-Procedural Complications,,2023-03-31,RECRUITING,INTERVENTIONAL,['PHASE1']
3495,NCT05572151,lymph node number,,,2009-01-01,COMPLETED,OBSERVATIONAL,['NA']
3496,NCT05171309,Objective response rate (ORR),Number of participants with treatment-related adverse events as assessed by CTCAE v5.0,,2021-01-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
3497,NCT06171854,Progression free survival (PFS),Safety as the description of adverse events,,2019-09-01,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3498,NCT02867839,disease-free survival,Incidence of Treatment-Emergent Adverse Events [Safety],,2017-04-24,UNKNOWN,INTERVENTIONAL,['PHASE3']
3499,NCT01887509,Concordance in identification of lower pole of tumor,Assessment of predictive value of interpretation criteria,,2013-11-07,TERMINATED,INTERVENTIONAL,['NA']
3500,NCT00287768,overall survival,safety,,2006-03,COMPLETED,INTERVENTIONAL,['PHASE3']
3501,NCT00490685,,,,2007-04,COMPLETED,INTERVENTIONAL,['PHASE2']
3502,NCT03100461,CRC screening completion rate,Cost analysis of each intervention pathway,,2018-01-22,UNKNOWN,INTERVENTIONAL,['NA']
3503,NCT03413930,Circumferential resection margin (CRM),5-year overall survival rate,,2019-06,WITHDRAWN,INTERVENTIONAL,['NA']
3504,NCT03940027,the incidence of serious complications,Improvement of quality of life,,2019-02-10,UNKNOWN,INTERVENTIONAL,['NA']
3505,NCT02863367,Objective Response Rate (ORR),Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2016-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
3506,NCT02568267,Objective Response Rate,Bone Biomarkers,,2015-11-19,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3507,NCT04790448,"Overall response rate from the date of first drug administration until the date of first documented progression or date of death, whichever came first.",Number of patients with adverse events and severity according to NCI CTCAE v5.0,,2020-07-27,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3508,NCT06194708,1-year non-reversal rate of temporary stoma,,,2023-05-15,RECRUITING,OBSERVATIONAL,['NA']
3509,NCT03050268,Identification of novel cancer predisposing genes,,,2017-04-06,RECRUITING,OBSERVATIONAL,['NA']
3510,NCT06308354,DFS,,,2011-01-01,RECRUITING,OBSERVATIONAL,['NA']
3511,NCT06059924,Cancer-specific survival,Recurrence-free survival,,1991-02-01,COMPLETED,OBSERVATIONAL,['NA']
3512,NCT02559674,Overall Survival; Phase II,Correlation between the level of tumor DNA in patient plasma and response to study treatment,,2016-07,COMPLETED,INTERVENTIONAL,['PHASE1']
3513,NCT02548169,Safety and feasibility of combining the DC vaccine with chemotherapy DC vaccine dose-limiting toxicities will be measured according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03,Average of all changes in Quality of Life (QoL) Score,,2015-08,TERMINATED,INTERVENTIONAL,['PHASE1']
3514,NCT03776591,Complications,Prognostic significance of CTCs,Hospitalization,2016-09-01,RECRUITING,INTERVENTIONAL,['NA']
3515,NCT00600613,"Number of Participants Eligible for Cone Beam Tumor Localization""",,,2006-01,COMPLETED,INTERVENTIONAL,['NA']
3516,NCT04336202,Workload,Local control,,2024-08,RECRUITING,INTERVENTIONAL,['NA']
3517,NCT00864513,Progression-free Survival,Number of Participants With Adverse Events,,2007-10,TERMINATED,INTERVENTIONAL,['PHASE2']
3518,NCT02942563,Pelvic complete resection rate,The incidence of >=3 grade adverse events,,2016-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
3519,NCT05345613,Postprocedural bleeding,Intraprocedural bleeding,,2022-05-01,RECRUITING,INTERVENTIONAL,['PHASE4']
3520,NCT00813293,Coagulation Zone Volume,Number of Treatment-Related Grade 1-4 Adverse Events (AEs) One Month After Radiofrequency Ablation (RFA),,2009-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3521,NCT00070122,Overall survival in patients with colorectal cancer treated with fluorouracil/leucovorin calcium and oxaliplatin with and without becavizumab versus those treated with capecitabine and oxaliplatin with our without bevacizumab,Whether gene expression variables are predictive of survival and progression-free survival,,2004-04,TERMINATED,INTERVENTIONAL,['PHASE3']
3522,NCT03422835,Positive rate of circumferential resection margin (CRM) of the specimens,the rate of postoperative complications,Quality of life outcomes evaluation,2018-02-15,UNKNOWN,INTERVENTIONAL,['PHASE2']
3523,NCT04213118,Disease free survival,Incidence of Treatment-Emergent Adverse Events Safety and Tolerability,,2020-04-23,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3524,NCT02577263,Quality of life deterioration > 10% (dichotomic),Significant chemotherapy induced neurotoxicity > 10%,,2015-04,UNKNOWN,OBSERVATIONAL,['NA']
3525,NCT04543617,Arm B vs Arm C: OS,Percentage of Participants With ADAs to Atezolizumab,,2020-09-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
3526,NCT00337389,Progression Free Survival,Incidence and Severity of Adverse Events,,2006-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
3527,NCT00821912,Response rate,Quality of life,,2006-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3528,NCT03990025,Difference in detection rate of duodenal lesions between Linked Color Imaging and White Light Imaging,Sensitivity and Specificity of detection of duodenal lesions,,2019-03-27,COMPLETED,INTERVENTIONAL,['NA']
3529,NCT03153280,Incidence of dose limiting toxicity (DLT) within the two first cycles at each dose level.,Incidence of adverse events reported as per the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. (Safety and Tolerability).,,2022-01-13,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
3530,NCT03051802,Optimize the clinical protocol using this technology,,,2017-01-27,TERMINATED,INTERVENTIONAL,['NA']
3531,NCT01522937,The Percentage of Patients With Local Control at 1 Year Post Treatment,The Number of Patients That Experience Grade 4+ Gastrointestinal Bleeding,,2009-10,COMPLETED,INTERVENTIONAL,['PHASE2']
3532,NCT05420259,Mean Change in interleukin 6 (IL6),Change in skeletal muscle,,2022-03-21,RECRUITING,INTERVENTIONAL,['NA']
3533,NCT05361252,The incidence of postoperative complications in the two groups.,The pain scale,,2017-02-01,COMPLETED,INTERVENTIONAL,['NA']
3534,NCT01404650,Progression-free Survival (PFS),Number of Patients With Adverse Events as a Measure of Safety and Tolerability,,2011-12,COMPLETED,INTERVENTIONAL,['PHASE2']
3535,NCT01858662,Major Pathological Response Rate,Chemotherapy-associated hepatotoxicity:,,2014-01,TERMINATED,INTERVENTIONAL,['PHASE2']
3536,NCT01621451,delayed ulcer bleeding,ulcer healing rate,,2012-06,UNKNOWN,INTERVENTIONAL,['PHASE4']
3537,NCT02704143,One-year Overall Survival Rate,Median Overall Survival Will be Determined.,,2016-02,COMPLETED,INTERVENTIONAL,['NA']
3538,NCT01227018,Disease Control Rate,Number of Patients With Each Worst Grade Toxicity,Biomarker Evaluation,2010-12,TERMINATED,INTERVENTIONAL,['PHASE2']
3539,NCT05069571,Adenoma detection rate,Proportion of withdrawal overspeed,,2020-03-01,UNKNOWN,OBSERVATIONAL,['NA']
3540,NCT02015065,Number of Participants With a Clinical Activity-radiographic Response,Maximum Standardized Uptake Value (SUVmax) on Fluorodeoxyglucose Positron Emission Tomography (FDG-PET),,2013-12-14,COMPLETED,INTERVENTIONAL,['PHASE2']
3541,NCT02415101,"Complete histological response proportion, using the Chirieac grading system.",Nutritional status of patients in each study arm.,,2015-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3542,NCT02304445,Tumor response rate,Number of patients eligibility for liver transplantation,Overall survival,2015-11,WITHDRAWN,INTERVENTIONAL,['NA']
3543,NCT03380130,"Rate and type of adverse events, liver decompensation, and transient and permanent drug discontinuations due to toxicity.",Pattern of progression according to RECIST 1.1 criteria.,,2017-09-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3544,NCT04611997,3-year disease free survival rate,Total number of retrieved lymph nodes,,2020-11-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
3545,NCT01808638,"Maximum concentration (Cmax), area under the curve (AUC), time to maximum concentration (tmax), and half life (t½) of the Atu027 siRNA single strand (A-strand), and of AtuFect01 and the helper lipid DPyPE",Quality of life,,2013-03,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3546,NCT04425239,Progression-free Survival,Overall Survival (OS),Metabolomic profiling,2018-05-21,COMPLETED,INTERVENTIONAL,['PHASE2']
3547,NCT03892252,"According to the 16s rDNA sequencing results, analyze the differences in intestinal flora of colon cancer patients with different TCM syndromes and TCM constitutions before and after surgery and their correlations",,,2019-03-10,COMPLETED,OBSERVATIONAL,['NA']
3548,NCT05195294,Objective response rate (ORR),Overall survival (OS),,2022-06,NOT_YET_RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3549,NCT05966194,Incidence of Severe Oral Mucositis (SOM) through Intensity-modulated radiation therapy (IMRT),Incidence of Severe Oral Mucositis through 60 Gy of the Radiation Treatment Plan,,2024-04-02,RECRUITING,INTERVENTIONAL,['PHASE2']
3550,NCT05818072,The yield rate of intestinal metaplasia,Procedure time,,2023-03-13,RECRUITING,INTERVENTIONAL,['NA']
3551,NCT05569343,postoperative complications,Readmission,,2020-05-08,COMPLETED,OBSERVATIONAL,['NA']
3552,NCT01525706,Efficacy: Degree of Ablation,Efficacy: Cyst Resolution,,2012-09,TERMINATED,INTERVENTIONAL,['PHASE1']
3553,NCT03530267,Progression-free survival (PFS),PRO: Overall treatment utility,,2018-09-28,COMPLETED,INTERVENTIONAL,['PHASE2']
3554,NCT02497820,cancer preventive properties of enteric coated aspirin in Lynch syndrome are dose sensitive by comparing overall cumulative Lynch syndrome cancer,Overall cumulative of of new adenomas at five years,,2016-09,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE3']
3555,NCT04163887,Rate of overall complications using the comprehensive complication Index (CCI),Disease-free and overall survival at 3 years.,,2021-01-27,RECRUITING,INTERVENTIONAL,['NA']
3556,NCT00882765,Changes in microvessel density of tumor specimen after 2 weeks of treatment with genistein,"To evaluate the impact of genistein on the angiogenic factors VEGF, CXCL1, CXCL5, and CXCL8",,2009-05,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3557,NCT04715061,"Change in the concentration of different peripheral blood mononuclear cells (Natural Killer Cells, T cells and monocytes)",Heart rate variability,,2020-11-04,COMPLETED,INTERVENTIONAL,['NA']
3558,NCT01238653,The number of accurate liver surface registrations obtained in the laparoscopic environment compared to accurate liver surface registrations obtained in open procedures,,,2010-11,TERMINATED,OBSERVATIONAL,['NA']
3559,NCT03637491,Phase 2: Confirmed Objective Response (OR) Based on Investigator Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.,"Phase 2: Number of Participants With Programmed Death-Ligand 1 (PD-L1) Expression, DNA Damage Repair (DDR) Gene Alterations, and Tumor Mutational Burden (TMB) in Baseline Tumor Tissue.",,2018-08-15,TERMINATED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3560,NCT06157060,2-year recurrence-free survival rate,Correlation between ctDNA-MRD status dynamic changes and relapse,,2023-11-20,RECRUITING,OBSERVATIONAL,['NA']
3561,NCT06254521,Pathological complete response (pCR) rate,3-year local recurrence rate,Molecular pathological analysis of tumor tissue,2024-02-22,RECRUITING,INTERVENTIONAL,['PHASE2']
3562,NCT05240625,Adenoma detection rate,Withdrawal time,,2022-03-01,RECRUITING,INTERVENTIONAL,['NA']
3563,NCT01742065,FIT Completion,Any CRC Screening,,2013-01,COMPLETED,INTERVENTIONAL,['NA']
3564,NCT05643391,Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0,Evaluation of efficacy of 166Ho radioembolization in unresectable hepatocellular using metabolic assessments (FDG and choline PET/CT),"Comparison between ""pre-scout"" HBS and HBS just after ""scout dose""",2020-06-15,COMPLETED,INTERVENTIONAL,['NA']
3565,NCT02114411,Sensitivity and Specificity of the GastroPanel test for the detection of AG,,,2017-01-31,UNKNOWN,OBSERVATIONAL,['NA']
3566,NCT00005956,Safety,,,2000-02,COMPLETED,INTERVENTIONAL,['NA']
3567,NCT05176002,Safety of Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.,Efficacy of Camrelizumab in Combination With Radiotherapy for Neoadjuvant,,2021-09-23,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3568,NCT05281328,Height-adjusted total liver volume (htTLV),Adverse events (AEs),,2022-06-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3569,NCT03985644,Overall survival,Recurrence rate,,2019-07,UNKNOWN,OBSERVATIONAL,['NA']
3570,NCT05582031,Progression Free Survival at 6 months (PFS-6) as per Investigator Assessment,Frequency and Severity of Adverse Events (AEs) and Laboratory Abnormalities,,2023-04-30,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3571,NCT03311451,Safety: Incidence of Dose-related SAEs,Efficacy: Treatment,,2023-01-16,ENROLLING_BY_INVITATION,INTERVENTIONAL,['NA']
3572,NCT00220077,To determine whether specific gene expression profiles are associated with response in oesophago-gastric cancer.,Evaluation of the association of gene expression profiling and progression free survival and overall survival in patients with oesophago-gastric cancer.,,2002-06,UNKNOWN,INTERVENTIONAL,['NA']
3573,NCT05059119,Rate of associated comorbidity or intervention,,,2020-09-01,COMPLETED,OBSERVATIONAL,['NA']
3574,NCT00985400,Effect size of the exercise intervention on physical function,Effect size of the exercise intervention on symptoms and quality of life,,2010-11-05,UNKNOWN,INTERVENTIONAL,['NA']
3575,NCT04223102,16s rRNA gene sequencing to study bacterial phylogeny and taxonomy,rectal microbiota to study bacteria strains,,2020-02-18,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3576,NCT05131776,Adverse events,Progression Free Survival,,2021-11-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3577,NCT06192771,Study feasibility as measured by data fidelity for patient-reported outcomes,,,2023-12-01,RECRUITING,INTERVENTIONAL,['NA']
3578,NCT00434109,Percentage of Participants With Progression Free Survival (PFS) at 12 Months,Percentage of Participants With Overall Survival (OS) at 4 Years,,2006-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3579,NCT03019016,Chart review on PeriOperative Information,Chart review on Postoperative Information,,2016-08,COMPLETED,OBSERVATIONAL,['NA']
3580,NCT00003907,Time to Progression,Overall Survival,,1999-12-15,COMPLETED,INTERVENTIONAL,['PHASE2']
3581,NCT04534218,objective response rate,,,2020-10-16,COMPLETED,INTERVENTIONAL,['PHASE2']
3582,NCT04193553,Progression-Free Survival (PFS),Progression-Free Survival (PFS) In patients from the placebo arm who switched into the active treatment group,Pharmacokinetic properties of lenvatinib for patient in the blinded part of the study,2020-01-17,RECRUITING,INTERVENTIONAL,['PHASE2']
3583,NCT03590119,The difference in post-treatment tumor-to-non-tumor (T/N) activity concentration ratio on SPECT/CT between the intra-arterial treated liver lobe and the intravenous treated liver lobe.,The difference in kidney uptake of 177Lu-dotatate between the IA treated patients and historical controls,,2018-08-01,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3584,NCT03965546,Frequency of ARTEMIS T cell treatment-related adverse events,IFN-γ serum levels,,2019-05-30,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
3585,NCT04273061,"Overall response rate (ORR) in each tumour-defined cohort, as defined by RECIST 1.1",Duration of response (DoR) in each tumour-defined cohort,Compare the utility of iRECIST for response assessment to RECIST 1.1 in each tumour-defined cohort,2020-06-17,RECRUITING,INTERVENTIONAL,['PHASE2']
3586,NCT03645876,Objective response rate,12month and 24 month OS rate,Biomarkers and ADA,2018-11-08,TERMINATED,INTERVENTIONAL,['PHASE2']
3587,NCT02896907,Number of Participants With Adverse Events as Determined by CTCAE Version 4.03,Change in Quality of Life as Defined by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30,,2016-10-18,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
3588,NCT05262452,Percentage of subjects that were subject to surgical resection,Survival time,,2021-08-09,RECRUITING,INTERVENTIONAL,['NA']
3589,NCT00999921,Number of Participants Analysed for Reduction in Mastalgia (Cardiff Breast Pain Score).,Number of Participants Analysed for Response of Cyclical Mastalgia (Good Response Was Defined as Disappearance of Mastalgia),,2008-01,COMPLETED,INTERVENTIONAL,['PHASE4']
3590,NCT05592873,Lateral nodal recurrence,,,2014-01-01,COMPLETED,OBSERVATIONAL,['NA']
3591,NCT03530969,Participants satisfaction with Health Care Provider (HCP) training,,,2018-05-07,COMPLETED,INTERVENTIONAL,['NA']
3592,NCT04068103,"Recurrence-free survival (RFS) the ""baseline ctDNA detected"" patient subset (Phase III)",Incidence (presence or absence) of ctDNA in blood following resection of stage II colon cancer,Cost effectiveness of the use of ctDNA versus standard of care,2019-12-16,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3593,NCT04632303,Adjusted mean change in global health status/QoL score at 12 weeks,Chemotherapy dose intensity.,,2021-06-23,RECRUITING,INTERVENTIONAL,['NA']
3594,NCT02838836,"CTC/DTC numbers measured in blood, urine and bone marrow samples will be correlated with patient outcome",ctDNA characteristics will be correlated with survival data,,2016-07-01,RECRUITING,OBSERVATIONAL,['NA']
3595,NCT04300114,PFS by Blinded Independent Central Review (BICR) Using RECIST v1.1,Number of participants with treatment-emergent adverse events,,2020-08-19,TERMINATED,INTERVENTIONAL,['PHASE3']
3596,NCT01234935,Disease-free survival,Disease-free survival,,2011-01-13,COMPLETED,INTERVENTIONAL,['PHASE2']
3597,NCT03403049,Dose-limiting toxicity,The impact in terms of overall quality of life of radiation therapy as assessed by the QLQ-C30 questionnaire,,2016-04-01,COMPLETED,INTERVENTIONAL,['PHASE1']
3598,NCT03997617,"Number of patients for which a treatment recommendation for their specific cancer can be formulated, based on PFP",Number of patients for which the treatment recommendation issued by PFP were followed by the investigator,,2019-03-11,RECRUITING,INTERVENTIONAL,['NA']
3599,NCT04301986,7 Days Post-EGD Impact of Events Score (IES),Factors Influencing the Preferred Screening Modality,,2020-08-11,COMPLETED,INTERVENTIONAL,['NA']
3600,NCT02947971,Assessment of quality and performance of Compact Imaging System (CIS),,,2016-04-15,RECRUITING,INTERVENTIONAL,['NA']
3601,NCT05336617,percentage of complete colonoscopies,Quality of colonic preparation (Boston score),,2022-05-13,COMPLETED,OBSERVATIONAL,['NA']
3602,NCT03958240,Percentage of CD4 and CD8 T cells expressing PD-1,Rate of patients presenting a high Trm (Tissue resident memory) infiltrate in tumor samples,,2020-01-17,RECRUITING,INTERVENTIONAL,['NA']
3603,NCT00100321,,,,2004-12-21,TERMINATED,OBSERVATIONAL,['NA']
3604,NCT02727894,Colorectal Cancer Stage (pTNM),Colorectal Cancer and Palliative Therapy,,2013-03,COMPLETED,OBSERVATIONAL,['NA']
3605,NCT02381847,overall survival,time to distant metastasis,,2015-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
3606,NCT04239573,"Occurrence of an ""unfavorable"" outcome",Biomarker analysis from collected samples to compare the predictive performance of known and future biomarkers for dysplasia or cancer,Predictive accuracy of radiomic markers for dysplasia and pancreatic cancer,2020-06-16,RECRUITING,INTERVENTIONAL,['NA']
3607,NCT04035876,Recurrence-free survival,Adverse effect,,2019-07-16,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3608,NCT03876106,"Safety and tolerability (maximum tolerated dose, MTD) of LUT014 topically applied qd for 4 weeks in metastatic colorectal cancer (mCRC) patients with epidermal growth factor receptor inhibitor (EGFRI) induced acneiform lesions.",Functional Assessment of Cancer Therapy-EGFRI 18 (FACT-EGFRI-18) on health-related quality of life (HRQoL) questionnaire,,2019-08-21,COMPLETED,INTERVENTIONAL,['PHASE1']
3609,NCT02640898,overall survival rate,progression free survival rate,,2015-12,UNKNOWN,INTERVENTIONAL,['NA']
3610,NCT01935700,Overall Survival,Grade III Severe Adverse Events,,2013-06-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3611,NCT01448668,Overall survival time (OS).,"Number of patients with adverse events (AE) contributed to conventional oncological therapy (radio-, chemo-, targeted therapy).",,2010-09,UNKNOWN,OBSERVATIONAL,['NA']
3612,NCT01329458,evaluation of contrast enhanced ultrasound in the assessment of de novo focal liver lesions,,,2010-12,UNKNOWN,OBSERVATIONAL,['NA']
3613,NCT01896778,"Changes in tumor vascular (blood flow, blood volume)",Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,,2013-10-04,COMPLETED,INTERVENTIONAL,['NA']
3614,NCT05781074,Objective Response Rate (ORR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1,Number of participants with treatment-related adverse events as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0,,2023-03-23,RECRUITING,INTERVENTIONAL,['PHASE2']
3615,NCT01219829,Number of subjects with histological features of PanIN lesions assessed,Evaluation of Recurrence Mechanism in PDC,,2009-03-18,COMPLETED,OBSERVATIONAL,['NA']
3616,NCT01814969,• The rate of patients with downstaging after radiotherapy or radiochemotherapy to pathological response or disease with negative margins,The rate of early toxicity of neoadjuvant treatment according to the NCI CTCAE (version 4.0),,2014-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
3617,NCT03846882,Can FDG-PET / MR in combination with blood and tumor tissue biomarkers provide additional prognostic information for intermediate and high-risk rectal cancer?,How does the accumulation of FDG change in rectal cancer tissue when examined after 60 minutes vs examination after 90 minutes?,,2015-12-01,UNKNOWN,OBSERVATIONAL,['NA']
3618,NCT03961646,Diagnostic accuracy,Image quality,,2019-02-01,COMPLETED,OBSERVATIONAL,['NA']
3619,NCT05253430,Disease-free survival,Postoperative mortality,,1990-04,COMPLETED,OBSERVATIONAL,['NA']
3620,NCT01706822,The Ability to Achieve Adequate Distal Margins (Defined as >2cm [or >1cm With Clear Histologic Evaluation]) in the Low Rectum. The Reported Value Represents the Number of Participants in Whom the Criteria Was Met,Maneuverability Measured by Surgeon Usability Questionnaire. The Reported Values Represent Percentage of Cases Surgeon Agree/Strongly Agree,,2013-04,TERMINATED,INTERVENTIONAL,['PHASE4']
3621,NCT03161379,CD8 count (cells/mm^3) in the tumor microenvironment,Pathologic complete response (pCR) rate at surgical resection,,2018-02-02,COMPLETED,INTERVENTIONAL,['PHASE2']
3622,NCT03264274,Overall survival,Progression-free survival,,2017-02-06,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3623,NCT04122937,P2X7R-inflammasome activity,,,2017-03-01,COMPLETED,OBSERVATIONAL,['NA']
3624,NCT01227707,Percentage of Participants With Pathological Complete Response (pCR),TTP - Time to Event,,2005-11,COMPLETED,INTERVENTIONAL,['PHASE2']
3625,NCT01232374,3-yr overall survival,Quality of life,,2010-09,UNKNOWN,INTERVENTIONAL,['PHASE2']
3626,NCT00374036,Time until therapeutic failure : to make pass TET from 15 weeks with ECC in first line to 20 weeks with FOLFIRI in first line,"The tolerance, the quality of life, duration of hospitalization",,2005-06,COMPLETED,INTERVENTIONAL,['PHASE3']
3627,NCT04393116,Development of patients' Distress,Patient's global health status,,2017-07-11,COMPLETED,OBSERVATIONAL,['NA']
3628,NCT01320267,Successful completion of the right hemicolectomy,Postoperative Measure of Pain,,2011-12,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3629,NCT00284817,The recommended Phase II dose will be based on acceptable dose-limiting toxicity,Pharmacokinetic parameters may also be factored into the determination of a Phase II dose and; Tumor response,,2001-07,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3630,NCT04637061,Rate of 30 day-anastomotic failure (AF),Procalcitonin (PCT) measurement,,2021-01-01,UNKNOWN,OBSERVATIONAL,['NA']
3631,NCT00004870,,,,2000-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3632,NCT05638243,Sensitivity and specificity of the model in the diagnosis of colorectal cancer and adenoma,,,2022-08-20,RECRUITING,OBSERVATIONAL,['NA']
3633,NCT01123473,Progression-free survival,Concordance of diagnostic tests,,2010-12,TERMINATED,INTERVENTIONAL,['PHASE2']
3634,NCT04605185,Dose limiting toxicity(DLT),Duration of response (DOR),,2021-01-08,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
3635,NCT01727570,Six-Minute Walk Test (6MWT),,,2012-09,COMPLETED,INTERVENTIONAL,['NA']
3636,NCT03623737,pathological complete response,Number of participants with treatment-related adverse events as assessed by the NCI Common Toxicity Criteria (CTC),,2017-03-01,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3637,NCT02101580,Number of Participants with Adverse Events as a Measure of Safety and Tolerability of ADI-PEG 20 in combination with nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer,,,2014-11-17,COMPLETED,INTERVENTIONAL,['PHASE1']
3638,NCT00336141,Toxicity,Response,,2006-06,COMPLETED,INTERVENTIONAL,['PHASE1']
3639,NCT04692051,PFS,AEs,,2019-09-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
3640,NCT03416777,DNA damage,Oxidative stress,,2019-06-01,COMPLETED,INTERVENTIONAL,['NA']
3641,NCT02972372,2-year disease-free survival rate,2 year overall survival,,2016-11,UNKNOWN,INTERVENTIONAL,['NA']
3642,NCT04015466,"Development of a new diagnostic algorithm for gastric cancer that includes molecular landscape, patient history, histopathological and environmental factors, personal microbiome and immune landscape",Daily routines as assessed by a new study-specific questionnaire,,2019-06-12,UNKNOWN,OBSERVATIONAL,['NA']
3643,NCT00058149,,,,2003-03,COMPLETED,INTERVENTIONAL,['PHASE3']
3644,NCT00511862,Hepatic Progression-free Survival According to Response Evaluation Criterian in Solid Tumors (RECIST),Overall Survival,,2007-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3645,NCT03852836,Global quality of the images evaluated with a Likert score,"Performance of each sequence in the visualization of the pathology and / or an anatomical variant in the 1.5T magnetic field group, evaluated in percentage",,2019-02-26,TERMINATED,INTERVENTIONAL,['NA']
3646,NCT00233415,Efficacy of Conventional Chemoradiotherapy Followed by Stereotactic Radiosurgery,,,2003-07,COMPLETED,INTERVENTIONAL,['PHASE2']
3647,NCT03066167,Translation of scores to the Swedish language,,,2010-11,COMPLETED,OBSERVATIONAL,['NA']
3648,NCT03265483,"Blood 1,25-dihydroxyvitamin D2",,,2014-09,COMPLETED,INTERVENTIONAL,['NA']
3649,NCT01152164,To prospectively evaluate the quality of life of patients one year after rectal cancer resection,To prospectively evaluate the quality of life of patients two years after rectal cancer resection,,2008-01,UNKNOWN,OBSERVATIONAL,['NA']
3650,NCT00220155,Proportion of patients obtaining disease control in the form of tumour response or stabilisation,Progression free survival,,2004-05,COMPLETED,INTERVENTIONAL,['PHASE2']
3651,NCT00960349,"Safety of each treatment arm will be measured in terms of adverse events, vital signs, clinical chemistry, haematology, urinalysis, electrocardiogram, and physical examinations.","Pharmacokinetics will be assessed in terms of Css,max, Css,min, tmax, AUCss and AUC0-8 for cediranib, and Cmax, tmax, AUC, AUC(0-t), CL or CL/F, t½λz for capecitabine, cisplatin and TS-1. Additional PK parameters may be determined.",,2009-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3652,NCT04799080,Semmens Weinstein Monofilament Test (SWMT),Functional Assessment of Cancer Therapy-Breast (FACT-B+),,2021-03-06,COMPLETED,OBSERVATIONAL,['NA']
3653,NCT01985698,postoperative complications,locoregional recurrence rate,self reported sexual function for female patients,2013-12,COMPLETED,INTERVENTIONAL,['NA']
3654,NCT06317103,Clinical Specificity in classifying early gastric cancer (EGC) based on the depth of invasion (%),"Accuracy in classifying the depth of invasion categories (""Mucosa"" or ""Submucosa"") for early gastric cancer (%)",,2023-08-22,COMPLETED,OBSERVATIONAL,['NA']
3655,NCT01923337,"MTD, defined as the highest dose tested in which fewer than 33% of patients experience dose-limiting toxicity (DLT) attributable to the study drugs, graded using the National Cancer Institute (NCI) CTCAE version 4.0",Time to failure,,2013-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3656,NCT00002527,Disease free survival,,,1993-05,COMPLETED,INTERVENTIONAL,['PHASE3']
3657,NCT05062720,Progression free survival,Patient reported outcomes (PROs),,2021-07-29,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3658,NCT05468827,proportion of pN+ patients in which affected lymph nodes are detected only within margins of ICG distribution,feasibility of ICG mapping for colon flexure tumours,,2022-07-26,RECRUITING,INTERVENTIONAL,['NA']
3659,NCT04814030,overall response rate,,,2021-04-20,UNKNOWN,INTERVENTIONAL,['PHASE2']
3660,NCT00637247,To Evaluate and Compare the Tolerability and Toxicity of the Two Treatment Arms by Comparing Adverse Events,Progression Free Survival,,2008-04,COMPLETED,INTERVENTIONAL,['PHASE2']
3661,NCT03833466,Tumor microenvironment,Rate of pathologic complete response（pCR）,,2019-02-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
3662,NCT02794337,In-field Progression Free Survival,Toxicity Assessment,,2014-12,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3663,NCT02439008,"Analyse of immunological parameters, decription of secreted markers and nanovesicles production",Number of Participants with Adverse Events related to radiotherapy,,2015-09-16,TERMINATED,INTERVENTIONAL,['NA']
3664,NCT00630552,Safety,Time to Response,,2007-06,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3665,NCT03190265,Objective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1),Number of Participants Experiencing Grade 3 or Above Study Drug-related Adverse Events (AEs),,2017-12-14,COMPLETED,INTERVENTIONAL,['PHASE2']
3666,NCT00079274,Disease-free Survival (Arms A and D: Wild-type KRAS Patients),"Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3) (Arms A and D: Mutant KRAS Patients)",,2004-02,COMPLETED,INTERVENTIONAL,['PHASE3']
3667,NCT00600496,Safety and tolerability of twice daily oral doses of AZD6244 when administered in combination with standard doses of selected chemotherapies.,Tumor response.,,2007-12-14,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
3668,NCT00026468,,,,1999-07,WITHDRAWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3669,NCT01661686,Number of Participants With Recurrent Dysphagia.,Median Survival After SEMS Placement,,2012-07,COMPLETED,INTERVENTIONAL,['NA']
3670,NCT00796718,Percentage of Participants With Pathological Complete Response,Percentage of Participants With Adverse Events,,2008-10,COMPLETED,INTERVENTIONAL,['PHASE2']
3671,NCT00408551,Hepatic toxicity,Therapeutic efficacy based on the proportion of patients who achieve down-staging among all chemo-SIRT treated patients,,2005-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
3672,NCT01045538,"Phase 1 - maximum tolerated dose, Phase 2 - response rate",Overall survival,,2010-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3673,NCT00192075,Tumor Response by Response Evaluation Criteria In Solid Tumors (RECIST),Duration of Response,Duration of Response - A+FOLFOX4 - Avastin Subgroup,2003-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3674,NCT04426955,PFS assessed by IRC,AE,,2020-06-30,UNKNOWN,INTERVENTIONAL,['PHASE3']
3675,NCT02487017,Overall survival,Phenotypic analysis of T cells,,2015-05,UNKNOWN,INTERVENTIONAL,['PHASE2']
3676,NCT02514031,Maximum Tolerated Dose,Tolerability,,2016-03-24,TERMINATED,INTERVENTIONAL,['PHASE1']
3677,NCT01219192,MDT,PFS,,2010-08,UNKNOWN,INTERVENTIONAL,['PHASE1']
3678,NCT05660915,Rate of mortality after surgery,Incidence of postoperative complications,,2023-06-01,RECRUITING,INTERVENTIONAL,['NA']
3679,NCT03519295,Progression free survival rate (PFS),Tolerance graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] criteria v4.03,,2018-07-03,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3680,NCT00075556,Objective tumor response rate,Comparison of the conversion rate from the effects of mutilating surgery vs surgery with sphincter preservation,,2002-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
3681,NCT04627012,Overall survival (OS),Adverse events,,2018-01-01,COMPLETED,OBSERVATIONAL,['NA']
3682,NCT02186236,To validate the Trovagene urine assay,EGFR detection in plasma circulating tumor cells [CTC] and plasma cfDNA),,2014-07,COMPLETED,OBSERVATIONAL,['NA']
3683,NCT02477553,Colorectal Cancer (CRC) Screening Intention: Change From Baseline to Post-intervention,Number of Patients With High and Low Subjective Numeracy,,2015-06,COMPLETED,INTERVENTIONAL,['NA']
3684,NCT05368636,Accuracy,,,2022-06-30,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3685,NCT03449966,The percentage of remnant cancer cells in biopsy samples,pCLE findings of residual cancer cells after chemotherapy,,2018-02-20,UNKNOWN,INTERVENTIONAL,['NA']
3686,NCT03365882,Progression-free Survival(PFS),Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs.,,2017-11-27,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3687,NCT04067778,Adverse Events occurrence,Rate of Missed 2-Week Post-Procedural Assessment for Complications,,2020-11-06,COMPLETED,INTERVENTIONAL,['NA']
3688,NCT02451124,Average Methylation of Zinc Finger Protein 793 Assay,,,2015-07,COMPLETED,INTERVENTIONAL,['NA']
3689,NCT04588246,Time to Neurologic Death,Incidence of Adverse Events associated with the interventions,,2020-12-15,RECRUITING,INTERVENTIONAL,['PHASE3']
3690,NCT03588442,Liver-related disease progression,Non-hepatocellular carcinoma malignant neoplasm,,2018-07-15,UNKNOWN,OBSERVATIONAL,['NA']
3691,NCT00885248,Staging of pancreatic cancer,Diagnosis of pancreatic cancer,,2009-01,UNKNOWN,OBSERVATIONAL,['NA']
3692,NCT00099346,,,,2005-01,TERMINATED,INTERVENTIONAL,['PHASE1']
3693,NCT04803851,Disease control rate (DCR) based on RECIST v. 1 1,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,,2021-05-12,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3694,NCT02346032,Response rate,Overall survival,,2015-06-30,COMPLETED,INTERVENTIONAL,['PHASE2']
3695,NCT06217224,Evaluate the best photobiomodulation protocol for preventing oral mucositis,Hospital internment,,2022-10-17,RECRUITING,INTERVENTIONAL,['NA']
3696,NCT02894944,Number of participants with treatment-related adverse events assessed by CTCAE v4.03,Detection of adenoviral DNA in blood by PCR,,2016-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3697,NCT04680260,Recurrence Free Rate,Cost-effectiveness analysis,,2021-10-25,RECRUITING,INTERVENTIONAL,['PHASE2']
3698,NCT03765411,In-hospital Complications,Costs and Charges,,2013-01-01,COMPLETED,OBSERVATIONAL,['NA']
3699,NCT01273402,Determine the number of adverse events,Efficacy will be evaluating using CT scans and possibly PET imaging.,,2011-02,WITHDRAWN,INTERVENTIONAL,['PHASE1']
3700,NCT04006951,Proportion of patients who gave their consent to participate in the study,,,2014-10-08,RECRUITING,INTERVENTIONAL,['NA']
3701,NCT05551832,Marginal ulcer incidence,QOL,,2022-10-10,RECRUITING,INTERVENTIONAL,['PHASE3']
3702,NCT04648917,overall survival (OS),progression-free survival (PFS),,2019-05-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
3703,NCT00998751,Objective response rate according to Response Evaluation Criteria In Solid Tumors (RECIST),Progression Free Survival,,2005-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3704,NCT00339469,Biomarkers of insulin resistance and inflammation,Weight loss,,2005-08-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
3705,NCT04945733,Objective Response Rate (ORR),Number of Participants with Anti-Amivantamab Antibodies,,2021-08-30,TERMINATED,INTERVENTIONAL,['PHASE2']
3706,NCT04773080,Incidence of postoperative acute kidney injury,Increase in length of hospital stay,,2021-01-21,COMPLETED,OBSERVATIONAL,['NA']
3707,NCT04653480,Overall Response Rate,Progression Free Survival,,2021-02-01,RECRUITING,INTERVENTIONAL,['PHASE2']
3708,NCT00562068,"Incidence of infection (number of days with fever ≥ 38 degrees C, days of intravenous antibiotics, number of inpatient days, number of episodes of cytomegalovirus reactivation)",Epstein-Barr virus copy number (measured retrospectively),,2007-05,UNKNOWN,INTERVENTIONAL,['PHASE1']
3709,NCT05601323,Overall Survival,Adverse Events,,2023-01-31,RECRUITING,INTERVENTIONAL,['NA']
3710,NCT02865135,Changes in CD8+ T Cells in Peripheral Blood and Tumor Tissue,Time to Progression (TTP),,2017-03-30,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3711,NCT00028002,Rate of Disease Progression at 2 Years,"FDG-PET as Biological Marker of Metabolic Response(MR) During Imatinib Mesylate (IM) Treatment, in Patients With GIST Who Are naı¨ve to Tyrosine Kinase Inhibitor Therapy",,2002-03-31,COMPLETED,INTERVENTIONAL,['PHASE2']
3712,NCT03615326,Overall Survival (OS),Treatment Discontinuations Due to AEs,,2018-10-05,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE3']
3713,NCT04143230,Accuracy of the Simplified Screening Tool (SST) with respect to the SIAARTI/NCCN screening tool (EST),Clinical characteristics and outcomes of palliative care patients referred to an acute palliative care unit,,2017-05-23,COMPLETED,INTERVENTIONAL,['NA']
3714,NCT05322590,Objective Response Rate (ORR),Post Oxaliplatin Assessment,,2023-01-09,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3715,NCT03767660,Total venous malformation lesion load,Concentration of D-dimer in blood,,2018-07-31,UNKNOWN,INTERVENTIONAL,['PHASE4']
3716,NCT01204476,"Safety profile of cixutumumab and everolimus with octreotide acetate among patients with advanced neuroendocrine tumors, defined by the incidence of adverse events",Anti-tumor activity as determined by RECIST,Changes in molecular markers,2010-10,COMPLETED,INTERVENTIONAL,['PHASE1']
3717,NCT00744640,Response rate,Progression-free survival and overall survival,,2005-10,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3718,NCT01642875,Frequency of delayed gastric emptying,Rehospitalization rate,,2016-11,UNKNOWN,INTERVENTIONAL,['PHASE4']
3719,NCT02172690,Peritoneal Metastasis or Positive Cytology,Safety,,2014-06,UNKNOWN,INTERVENTIONAL,['NA']
3720,NCT05161585,Secondary resection rate,ctDNA clearance rate,,2021-11-01,RECRUITING,INTERVENTIONAL,['NA']
3721,NCT01045941,To determine if it is safe to administer gemcitabine to patients with pancreatic cancer one week after laparoscopic distal pancreatectomy.,To determine the if the 1-year survival in patients with pancreatic cancer is improved with administration of gemcitabine one week following laparoscopic distal pancreatectomy,,na,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3722,NCT04101292,Evaluation of the sensitivity of Bevacizumab-IRDye800 to visualize tumour tissue compared to anti-VEGF antibodies by the means of fluorescence intensity measurements,Level of accuracy of Full-field optical coherence tomography (FF-OCT) by the means of a qualitative analysis,,2021-04,WITHDRAWN,INTERVENTIONAL,['NA']
3723,NCT05167409,"Objective response rate (ORR, per RECIST v1.1) (%)",Safety and tolerability according to the NCI CTCAE v5.0,,2022-07-28,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE2']
3724,NCT04767568,correlation between the biological signature of the test and the stage of the disease in patients whose diagnosis of adenocarcinoma was identified by pathology prior to surgery.,,,2021-03-30,RECRUITING,INTERVENTIONAL,['NA']
3725,NCT05475041,Major complications,Intraoperative incidents,,2022-06-30,COMPLETED,OBSERVATIONAL,['NA']
3726,NCT00141466,Efficacy of referral of patients who are MSI positive to a clinical geneticist by surgeons.,Cost efficacy of the implementation procedures.,,2005-09,UNKNOWN,INTERVENTIONAL,['NA']
3727,NCT03001596,Overall survival(OS),Recurrence-free survival (RFS),,2017-01,COMPLETED,INTERVENTIONAL,['NA']
3728,NCT00012220,Overall Survival,Toxicity,,2001-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3729,NCT04316507,Days from decision to test to receiving genetic test results,,,2020-04-01,UNKNOWN,INTERVENTIONAL,['NA']
3730,NCT01927393,Symptom burden using the FACT-Trial Outcome Index (TOI),"Health care resource use including presence of advanced care planning, chemotherapy in the last 14 days of life, and length of time between hospice referral and death",,2014-12,WITHDRAWN,INTERVENTIONAL,['NA']
3731,NCT01486992,adverse events,disease control rate,,2011-11,UNKNOWN,INTERVENTIONAL,['PHASE2']
3732,NCT00643877,5 years disease-free survival,5 years overall survival and liver metastasis-free survival,,2008-12,UNKNOWN,INTERVENTIONAL,['PHASE3']
3733,NCT05627635,Overall response (phase II),Surgical resection (phase II),,2023-05-03,RECRUITING,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3734,NCT04297202,Major pathologic response,Safety as measured by the rate of AEs,,2019-12-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
3735,NCT01186237,urinary retention,,,2010-06,COMPLETED,INTERVENTIONAL,['NA']
3736,NCT03410732,progression-free survival,Adverse event rate,,2017-07-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
3737,NCT03922230,Hydroxymethylation level,,,2019-03-01,UNKNOWN,OBSERVATIONAL,['NA']
3738,NCT02746796,Overall survival (only Part 2),Safety will be analyzed through the incidence of laboratory abnormalities,,2016-03,COMPLETED,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3739,NCT02204124,Post-op Morbidity,Number of Participants Who Experienced Postoperative Complications,,2015-01-01,TERMINATED,INTERVENTIONAL,['NA']
3740,NCT01490996,Completion of dose escalation over 2 cycles of therapy,Efficacy in terms of disease response and survival,,2012-02,COMPLETED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3741,NCT04581005,Oxygen consumption (VO2),,,2019-08-19,UNKNOWN,INTERVENTIONAL,['NA']
3742,NCT03049345,Specificity of Sentinel Lymph Node Sampling Method,Adverse surgical events,,2016-07-01,UNKNOWN,INTERVENTIONAL,['NA']
3743,NCT01833299,Effectiveness of sorafenib combined with TACE,Time to progression,,2010-01,COMPLETED,INTERVENTIONAL,['PHASE3']
3744,NCT00005607,,,,2000-02,UNKNOWN,INTERVENTIONAL,['PHASE2']
3745,NCT03575117,Change in physical active level,Change in colorectal cancer risk and physical activity coherence,,2018-05-01,COMPLETED,INTERVENTIONAL,['NA']
3746,NCT05390684,anastomotic leak,infection,,2022-05-01,ENROLLING_BY_INVITATION,OBSERVATIONAL,['NA']
3747,NCT05293054,The rate of successful use and application of Obsidian as a supplemental procedure in the creation of rectal anastomosis with minimal invasive technique,2-year mortality,,2021-12-15,COMPLETED,OBSERVATIONAL,['NA']
3748,NCT04370418,Incidence of treatment adverse events as assessed by National Cancer Institute Common Terminology Criteria for adverse events version 4.0,assess disease local control and the response rate after short course radiotherapy concurrent with dose escalation infusion 5-fu followed by mFOLFOX and delayed surgery.,,2020-05-01,UNKNOWN,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3749,NCT01553019,Radiation Toxicity,Response rate via CA 19-9,,2011-10,COMPLETED,INTERVENTIONAL,['PHASE2']
3750,NCT00006332,,,,na,COMPLETED,INTERVENTIONAL,['PHASE2']
3751,NCT00888407,Obtain HBV Screening Test,"Knowledge and Attitudes Regarding Hepatitis B, Health and Nutrition",,2006-09,COMPLETED,INTERVENTIONAL,['NA']
3752,NCT03269955,Incidence of clinically relevant pancreatic fistula,Period of hospitalization after surgery,,2017-02-27,UNKNOWN,INTERVENTIONAL,['PHASE4']
3753,NCT02020707,Maximum tolerated dose,Incidence of adverse events (soft tissue expansion cohort),,2014-02-24,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['PHASE1']
3754,NCT05517408,Calculating the the median effective dose (ED50) of ciprofol for sedation gastrointestinal endoscopy in obese patients.,Calculating the the ED95 of ciprofol for sedation gastrointestinal endoscopy in obese patients.,,2022-09-19,RECRUITING,INTERVENTIONAL,['NA']
3755,NCT06312982,CR,immune-related adverse event rate,,2024-02-20,RECRUITING,INTERVENTIONAL,"['PHASE2', 'PHASE3']"
3756,NCT05039762,Overall complication rate,Hernia rate,,2020-09-02,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3757,NCT05410847,Conversion to negative rate,Adverse events,,2022-06-30,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE2']
3758,NCT00003441,Antitumor Activity of MGI-114,,,1998-08,COMPLETED,INTERVENTIONAL,['PHASE2']
3759,NCT03366883,Overall Survival,Rate of R0 resection,,2018-02-01,UNKNOWN,INTERVENTIONAL,['PHASE3']
3760,NCT00046995,Disease-free survival,Quality of life,,2001-05,UNKNOWN,INTERVENTIONAL,['PHASE3']
3761,NCT05553080,Evaluation of immunohistochemical staining of colorectal carcinoma by Fascin-1,,,2022-01-01,COMPLETED,OBSERVATIONAL,['NA']
3762,NCT06149923,assess ABO gene polymorphism (rs8176746) in the patients histopathologically confirmed gastric and/colorectal cancers relative to healthy controls.,,,2023-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3763,NCT02305914,Change in the Levels of fecal elastase-1,outpatient clinic and phone questionnaire,,2014-11,UNKNOWN,OBSERVATIONAL,['NA']
3764,NCT05462314,Levels of gene expression of the identified species in Gastrointestinal Malignancy,Relationship between treatment efficacy and microbiome diversity,,2022-03-29,RECRUITING,OBSERVATIONAL,['NA']
3765,NCT01498952,Phase 2: Time to Progression,Phase 1b and Phase 2: Area Under Serum Concentration-time Curve From Time Zero to Day 22 (AUC0-Day22) of MEDI-573 for Cycle 1,,2012-01-17,COMPLETED,INTERVENTIONAL,['PHASE1']
3766,NCT00510107,response rate,safety,,2007-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
3767,NCT03129074,Biomarker,Incidence of Adverse Events and changes from baseline in safety parameters,,2018-05,WITHDRAWN,INTERVENTIONAL,['PHASE2']
3768,NCT03576963,Recommended phase 2 dose (RP2D) of guadecitabine when given in combination with nivolumab,Incidence and severity of adverse events,,2020-01-30,WITHDRAWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3769,NCT02683200,"Quality of real-time image guidance provided the tri-60Co system, as defined by the treating radiation oncologist's ability to visualize the target lesion using the on-board MRI",Validity of automatically segmented contours generated by the MRI-guided tri-60Co teletherapy system through independent evaluation of images obtained,,2015-06-03,COMPLETED,INTERVENTIONAL,['EARLY_PHASE1']
3770,NCT05256459,Time the patients were diagnosed.,,,2022-05-10,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3771,NCT05794737,Detection of INHBA in Colorectal Carcinoma.,Correlation between INHBA expression in Colorectal Carcinoma and clinicopathological parameters.,,2021-01-01,RECRUITING,OBSERVATIONAL,['NA']
3772,NCT01732380,Progression-Free-Survival,Response Rate,Overall survival,2012-07,UNKNOWN,INTERVENTIONAL,['PHASE2']
3773,NCT05680077,validity,reliability,,2022-10-28,COMPLETED,OBSERVATIONAL,['NA']
3774,NCT05717998,Changes in myocardial metabolism,Blood-based biomarkers,,2021-04-02,RECRUITING,OBSERVATIONAL,['NA']
3775,NCT00325871,,,,2006-04,COMPLETED,OBSERVATIONAL,['NA']
3776,NCT04185350,Standardized uptake value,Incidence of Adverse Events,,2019-05-05,UNKNOWN,INTERVENTIONAL,['EARLY_PHASE1']
3777,NCT00992199,Metastasis in Peritoneum and peritoneal cavity,Overall survival,,2009-08,UNKNOWN,INTERVENTIONAL,['PHASE2']
3778,NCT00387842,Primary endpoint is cancer free survival at three years.,"Secondary endpoints are overall survival at three and five years, 28 day mortality and morbidity, quality of life, costs, location and rates of recurrences and pathologic anatomic characteristics of the resected specimen.",,1997-03,UNKNOWN,INTERVENTIONAL,['PHASE3']
3779,NCT00149201,overall survival,toxicity,,2002-11,COMPLETED,INTERVENTIONAL,['PHASE3']
3780,NCT05035147,Progression-free Survival (PFS),Overall survival(OS),,2021-03-25,RECRUITING,INTERVENTIONAL,['PHASE4']
3781,NCT02962219,Change in Quality of Life,,,2016-09,UNKNOWN,INTERVENTIONAL,['NA']
3782,NCT03427242,PFS,OS,,2017-11-01,UNKNOWN,INTERVENTIONAL,['PHASE2']
3783,NCT01775501,Time to Progression,Duration of Response,,2013-01,COMPLETED,INTERVENTIONAL,['PHASE2']
3784,NCT02650804,Overall Response Rate (ORR),Progression Free Survival (PFS),,2016-07-06,COMPLETED,INTERVENTIONAL,['PHASE2']
3785,NCT02026362,Time of tumor recurrence or metastasis,overall survival,,2013-07,SUSPENDED,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3786,NCT04564482,Intratumoral changes of PD-L1 expression during neoadjuvant CRT/SCPRT,Pathological therapy response,,2022-11-01,RECRUITING,INTERVENTIONAL,['NA']
3787,NCT04803890,Local tumor progression (LTP) rate,Complication rate,,2019-04-01,TERMINATED,INTERVENTIONAL,['NA']
3788,NCT02041936,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,Quality of Life on the EORTC QLQ-PAN26 and EORTC QLQ-C30,,2014-04,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,['NA']
3789,NCT01517152,Perceptions of the clarity and ease of response to a series of questions,,,2012-01-04,COMPLETED,OBSERVATIONAL,['NA']
3790,NCT01542281,Change in six minute walk test,Nutritional status,,2012-01,UNKNOWN,INTERVENTIONAL,['NA']
3791,NCT05406089,Recurrence of the hepatocellular carcinoma after hepatectomy,Surgery information,,2016-01-01,COMPLETED,OBSERVATIONAL,['NA']
3792,NCT02715362,Safety of CAR-T cell infusion mediated by TAI as measured by number of participants with adverse Events,Serum cytokine levels,,2016-03,UNKNOWN,INTERVENTIONAL,"['PHASE1', 'PHASE2']"
3793,NCT00268346,"The Number of Patients With Complete or Partial Response Rate of Single Agent ZD1839 in a Patient Population With Recurrent or Metastatic Cancer of the Esophagus or Gastroesophageal Junction, Using the RECIST 1.0 Criteria.",,,2005-10,COMPLETED,INTERVENTIONAL,['PHASE2']
3794,NCT04933227,Objective Response Rate (ORR) in the Full Analysis Set (FAS) Population,Number of Participants With Adverse Events,,2021-08-06,TERMINATED,INTERVENTIONAL,['PHASE2']
3795,NCT02642809,Tolerability of localized esophageal hypofractionated brachytherapy administered in two fractions when combined with pembrolizumab as measured by treatment related adverse events,Overall survival (OS),,2016-06-08,COMPLETED,INTERVENTIONAL,['PHASE1']
3796,NCT06158139,Neurotoxicity,Objective response rate- no bridging therapy,,2024-06,NOT_YET_RECRUITING,INTERVENTIONAL,['PHASE1']
3797,NCT04616040,Adverse events of Camrelizumab,Objective Response Rate (ORR),Correlations between biomarkers and clinical activity,2020-12-01,NOT_YET_RECRUITING,OBSERVATIONAL,['NA']
3798,NCT04989764,The disease-free survival,,,2015-01,COMPLETED,OBSERVATIONAL,['NA']
3799,NCT02848066,AUC(Area Under the Curve),Relative abundance of glycosylations,,2015-07,COMPLETED,OBSERVATIONAL,['NA']
3800,NCT04270890,To measure change in treatment volume between freebreathing and abdominal compression scans,Reported patient feedback regarding device comfort and compliance of use.,,2018-06-21,UNKNOWN,INTERVENTIONAL,['NA']
3801,NCT05625841,oral mucositis severity,microbiota level,,2022-11-25,NOT_YET_RECRUITING,INTERVENTIONAL,['NA']
3802,NCT04586491,development of oral mucositis,recovery time of oral mucositis,,2019-10-07,COMPLETED,INTERVENTIONAL,['NA']
3803,NCT00454363,Objective Response Rate (Complete and Partial Response) for Each Cohort Assessed by Response Evaluation Criteria in Solid Tumors (RECIST),Percent Change in Tumor Blood Flow Assessed by Functional CT,Plasma Trough Level of GW786034,2007-03,COMPLETED,INTERVENTIONAL,['PHASE2']
